Term IRI	Term label	Parent term IRI	Parent term label	Alternative term	Definition
http://purl.obolibrary.org/obo/PW_0002701	epigenetic regulation of gene expression pathway	http://purl.obolibrary.org/obo/PW_0001337	chromatin modification/remodeling pathway		Those metabolic reactions involved in modulating the frequency, rate or extent of gene expression through chromatin remodeling either by modifying higher order chromatin fiber structure or nucleosomal histones, cytosine methylation of DNA or RNA interference. Once established, this regulation may be maintained over many cell divisions. It can also be heritable in the absence of the instigating signal.
http://purl.obolibrary.org/obo/PW_0002702	hepoxilin biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001239	eicosanoid biosynthetic pathway		Those metabolic reactions involved in the synthesis of hepoxilins, a class of bioactive non-classic icosanoid signaling molecules with roles in the regulation of cell physiology.
http://purl.obolibrary.org/obo/PW_0002704	lipoxin biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001239	eicosanoid biosynthetic pathway		Those metabolic reactions involved in the synthesis of lipoxins. Lipoxins are non-classic eicosanoid signaling molecules that have four conjugated double bonds and are derived from arachidonic acid. They form during, then act to resolve, inflammatory responses.
http://purl.obolibrary.org/obo/PW_0002705	guanosine diphosphate mannose biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001329	guanosine diphosphate mannose metabolic pathway		Those metabolic reactions involved in the synthesis of guanosine diphosphate mannose.
http://purl.obolibrary.org/obo/PW_0002706	protein methylation pathway	http://purl.obolibrary.org/obo/PW_0002715	post-translational protein modification pathway		Those metabolic reactions involved in the addition of methyl groups to protein amino acids. A methyl group is derived from methane by the removal of a hydrogen atom.
http://purl.obolibrary.org/obo/PW_0002707	fatty acid transport pathway	http://purl.obolibrary.org/obo/PW_0000103	transport pathway		Those metabolic reactions involved in the directed movement of fatty acids into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. Fatty acids are aliphatic monocarboxylic acids liberated from naturally occurring fats and oils by hydrolysis.
http://purl.obolibrary.org/obo/PW_0002708	organic anion transport pathway	http://purl.obolibrary.org/obo/PW_0001348	ion transport pathway		Those metabolic reactions involved in the the elimination of a variety of endogenous anionic substances, xenobiotics and their metabolites from the body, mediated by families of transporters.
http://purl.obolibrary.org/obo/PW_0001803	streptomycin drug pathway	http://purl.obolibrary.org/obo/PW_0000996	anti-infective drug pathway		The pharmacokinetics and pharmacodynamics of streptomycin, a bactericidal antibiotic that inhibits bacterial protein synthesis. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002641	Toll-like receptor 1 signaling pathway	http://purl.obolibrary.org/obo/PW_0000814	Toll-like receptor signaling pathway		The series of molecular signals initiated by a ligand binding to pattern recognition receptor Toll-like receptor 1, which is expressed on monocytes.
http://purl.obolibrary.org/obo/PW_0002642	Toll-like receptor 2 signaling pathway	http://purl.obolibrary.org/obo/PW_0000814	Toll-like receptor signaling pathway		The series of molecular signals initiated by a ligand binding to pattern recognition receptor toll-like receptor 2, which is expressed constitutively on macrophages, dendritic cells, and B cells, and can be induced in some other cell types, including epithelial cells.
http://purl.obolibrary.org/obo/PW_0002643	Toll-like receptor 3 signaling pathway	http://purl.obolibrary.org/obo/PW_0000814	Toll-like receptor signaling pathway		The series of molecular signals initiated by a ligand binding to the endolysosomal pattern recognition receptor toll-like receptor 3, expressed on myeloid dendritic cells, respiratory epithelium and macrophages.
http://purl.obolibrary.org/obo/PW_0002644	Toll-like receptor 4 signaling pathway	http://purl.obolibrary.org/obo/PW_0000814	Toll-like receptor signaling pathway		The series of molecular signals initiated by a ligand binding to pattern recognition receptor toll-like receptor 4, well known for its sensitivity to bacterial lipopolysaccharides.
http://purl.obolibrary.org/obo/PW_0002645	Toll-like receptor 5 signaling pathway	http://purl.obolibrary.org/obo/PW_0000814	Toll-like receptor signaling pathway		The series of molecular signals initiated by a ligand binding to pattern recognition receptor toll-like receptor 5, the receptor for flagellin, expressed on epithelial cells as well as on macrophages and dendritic cells.
http://purl.obolibrary.org/obo/PW_0002646	Toll-like receptor 6 signaling pathway	http://purl.obolibrary.org/obo/PW_0000814	Toll-like receptor signaling pathway		The series of molecular signals initiated by a ligand binding to pattern recognition receptor toll-like receptor 6, which appears to participate in discriminating the subtle differences between dipalmitoyl and tripalmitoyl cysteinyl residues
http://purl.obolibrary.org/obo/PW_0002647	Toll-like receptor 7 signaling pathway	http://purl.obolibrary.org/obo/PW_0000814	Toll-like receptor signaling pathway		The series of molecular signals initiated by a ligand binding to the endolysosomal pattern recognition receptor toll-like receptor 7, which senses ssRNA oligonucleotides from RNA viruses.
http://purl.obolibrary.org/obo/PW_0002648	Toll-like receptor 8 signaling pathway	http://purl.obolibrary.org/obo/PW_0000814	Toll-like receptor signaling pathway		The series of molecular signals initiated by a ligand binding to the endolysosomal pattern recognition receptor toll-like receptor 8, which senses ssRNA oligonucleotides from RNA viruses.
http://purl.obolibrary.org/obo/PW_0002649	Toll-like receptor 9 signaling pathway	http://purl.obolibrary.org/obo/PW_0000814	Toll-like receptor signaling pathway		The series of molecular signals initiated by a ligand binding to the endolysosomal pattern recognition receptor toll-like receptor 9, which recognizes unmethylated CpG DNA motifs of bacterial or viral origin.
http://purl.obolibrary.org/obo/PW_0002650	Toll-like receptor TLR1:TLR2 signaling pathway	http://purl.obolibrary.org/obo/PW_0000814	Toll-like receptor signaling pathway		The series of molecular signals initiated by a ligand such as a bacterial lipoprotein or peptide binding to a cotranslationally formed heterodimeric TLR1:TLR2 complex, followed by transmission of the signal by the activated receptor, and ending with the regulation of a downstream cellular process, e.g. transcription.
http://purl.obolibrary.org/obo/PW_0002651	Toll-like receptor TLR6:TLR2 signaling pathway	http://purl.obolibrary.org/obo/PW_0000814	Toll-like receptor signaling pathway		The series of molecular signals initiated by a ligand such as a bacterial cell wall component binding to a heterodimeric TLR6:TLR2 complex, followed by transmission of the signal by the activated receptor, and ending with the regulation of a downstream cellular process, e.g. transcription.
http://purl.obolibrary.org/obo/PW_0002652	Toll-like receptor 10 signaling pathway	http://purl.obolibrary.org/obo/PW_0000814	Toll-like receptor signaling pathway		The series of molecular signals initiated by a ligand binding to pattern recognition receptor toll-like receptor 10, causing homodimerization. It is expressed as a highly N-glycosylated protein detectable in B cells and dendritic cells
http://purl.obolibrary.org/obo/PW_0000002	classic metabolic pathway	http://purl.obolibrary.org/obo/PW_0000001	pathway		The various, enzyme-controlled, series of reactions allowing for the conversion of materials, energy availability and biodegradation of xenobiotics.
http://purl.obolibrary.org/obo/PW_0000003	signaling pathway	http://purl.obolibrary.org/obo/PW_0000001	pathway		The pathways where a signal - hormone, neurotransmitter, growth factor, peptide, any molecule - triggers one or multiple cascades of events. This involves a number of molecules, including receptors, proteins, ligands, messengers, any participating molecule. A signaling pathway may be upstream or downstream of other signaling pathways. Signaling pathways control a very broad spectrum of processes as well as pathways.
http://purl.obolibrary.org/obo/PW_0000004	regulatory pathway	http://purl.obolibrary.org/obo/PW_0000001	pathway		The pathways that control the processes by which a cell or organism develops, adjusts, behaves, responds to conditions or changes in these conditions, or in any manner helps promote and maintain its efficient functioning.
http://purl.obolibrary.org/obo/PW_0000005	carbohydrate metabolic pathway	http://purl.obolibrary.org/obo/PW_0000002	classic metabolic pathway		Those metabolic reactions and pathways involved in the oxidation, breakdown and synthesis of carbohydrates in the tissue. The breakdown can be utilized by the body for energy production. The converse synthesis is used for energy storage.
http://purl.obolibrary.org/obo/PW_0000006	Ras superfamily mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000125	G protein mediated signaling pathway		The Ras superfamily consists of a diverse group of small, monomeric G proteins that function as molecular switches alternating between the GDP-inactive and the GTP-active bound state. The GTP-bound form can interact with many downstream effectors. Ras superfamily controls a broad spectrum of processes; deregulation of Ras cascades has been linked to several forms of cancer. The superfamily is structurally classified in five families.
http://purl.obolibrary.org/obo/PW_0000007	mitogen activated protein kinase signaling pathway	http://purl.obolibrary.org/obo/PW_0001194	serine/threonine-specific kinase mediated signaling pathway		The mitogen-activated protein kinase pathway groups several serine/threonine protein kinase mediated cascades in response to a number of extracellular stimuli. A characteristic feature of these cascades is the presence of at least three kinases in series leading to the activation of a multifunctional MAP kinase.
http://purl.obolibrary.org/obo/PW_0000008	Wnt signaling pathway	http://purl.obolibrary.org/obo/PW_0000656	glycoprotein signaling pathway		The secreted glycoproteins of the Wnt family regulate a wide spectrum of developmental processes and they are also playing important roles in the adult organism. Deregulation of Wnt cascades has oncogenic effects and is responsible for tumorigenesis in adults.
http://purl.obolibrary.org/obo/PW_0000009	apoptotic cell death pathway	http://purl.obolibrary.org/obo/PW_0001557	programmed cell death pathway		Apoptosis is a programmed cell death pathway that is characterized by particular morphological features such as membrane blebbing and DNA fragmentation. It can be intrinsic or extrinsic and involves the activation of caspases.
http://purl.obolibrary.org/obo/PW_0000010	lipid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000002	classic metabolic pathway		The metabolic reactions involved in the oxidation, utilization and/or synthesis of lipids in tissues.
http://purl.obolibrary.org/obo/PW_0000011	amino acid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000002	classic metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of the primary or standard 20 amino acids found in proteins. Amino acids are described as non-essential or essential depending on whether humans can or can not synthesize them, respectively. Chemically, they are classified based on the polarity of their side chain or R group, as non-polar and hydrophobic and hydrophilic and charged or polar uncharged. Amino acid metabolic pathways are also listed with their KEGG entries.
http://purl.obolibrary.org/obo/PW_0000012	nucleotide metabolic pathway	http://purl.obolibrary.org/obo/PW_0000002	classic metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of nucleotides. Nucleotides, which are the units of DNA and RNA, can also play important roles in cellular energy, enzyme regulation as well as serve as signaling molecules.
http://purl.obolibrary.org/obo/PW_0000013	disease pathway	http://purl.obolibrary.org/obo/PW_0000001	pathway		Complex human diseases encompass a spectrum of genetic and environmental attributes that together affect the normal functioning of several molecular and cellular pathways. Their combined and accumulated effect is manifested in the anomalous phenotype of the complex condition.
http://purl.obolibrary.org/obo/PW_0000014	neurodegenerative pathway	http://purl.obolibrary.org/obo/PW_0001412	nervous system disease pathway		Neurodegenerative diseases group together a number of conditions of various and many times poorly understood origins that are characterized by the progressive loss of particular neurons, the formation of particular structures such as plaques and fibrils, and protein aggregates. Proteosomal degradation, programmed cell death and oxidative stress are among a number of pathways thought to be disrupted.
http://purl.obolibrary.org/obo/PW_0000015	Alzheimer's disease pathway	http://purl.obolibrary.org/obo/PW_0000014	neurodegenerative pathway		A mostly sporadic, late-onset condition affecting the central nervous system, that is the most prevalent neurodegenerative disease and the most common form of dementia. It is characterized by the presence of amyloid plaques and fibril tangles. Possible pathways affected range from protein mis-folding and aggregation, to oxidative stress and impaired metal homeostasis.
http://purl.obolibrary.org/obo/PW_0000016	amyotrophic lateral sclerosis pathway	http://purl.obolibrary.org/obo/PW_0000014	neurodegenerative pathway		A late onset, mostly sporadic neurodegenerative disease characterized by the loss of motor neurons in the brain stem and spinal cord. Various pathways are thought to be deregulated and contribute to the condition; among them calcium and/or zinc homeostasis, apoptosis, Cdk5 and calcineurin dependent processes, and in the case of the more rare, genetically inherited form of the disease, mutations in the cytosolic Cu, Zn superoxide dismutase (SOD1) and the subsequent changes in the processes that involve SOD1.
http://purl.obolibrary.org/obo/PW_0000017	Huntington's disease pathway	http://purl.obolibrary.org/obo/PW_0000171	polyglutamine repeat pathway		An autosomal dominant neurodegenerative disease manifesting in movement, cognitive and psychiatric disorders caused by the abnormal expansion of a polyglutamine (polyQ) stretch in the Huntingtin (HTT) protein. It mostly affects the caudate-putamen striatal neurons. Other areas are also affected and undergo a size reduction. HTT is thought to be involved in several cellular pathways. Its functions are overcome by the mutant protein mHTT.
http://purl.obolibrary.org/obo/PW_0000018	Parkinson's disease pathway	http://purl.obolibrary.org/obo/PW_0000014	neurodegenerative pathway		One of the most common neurodegenerative diseases that is characterized by the loss of dopaminergic neurons in the substantia nigra and the presence of cytoplasmic inclusions called Lewy bodies in surrounding neurons. Several pathways are thought to be deregulated; for instance, imbalance of iron homeostasis is believed to contribute to the pathogenesis of the condition.
http://purl.obolibrary.org/obo/PW_0000019	prion disease pathway	http://purl.obolibrary.org/obo/PW_0000014	neurodegenerative pathway		Prion disease - any of a group of fatal, transmissible neurodegenerative diseases caused by abnormalities of prion protein metabolism, which may result from mutations in the prion protein gene or from infection with pathogenic isoforms of the protein.  Characteristics include neuronal loss, gliosis, and extensive vacuolization of the cerebral cortex. Prion diseases may be sporadic, inherited as an autosomal dominant trait, or acquired. Human diseases include Creutzfeldt-Jakob disease, Gerstmann-Strussler syndrome, fatal familial insomnia, and kuru
http://purl.obolibrary.org/obo/PW_0000020	cardiovascular system disease pathway	http://purl.obolibrary.org/obo/PW_0000013	disease pathway		Cardiovascular diseases represent a very broad spectrum of conditions that can also combine with diabetes and renal failure.
http://purl.obolibrary.org/obo/PW_0000021	hypertension pathway	http://purl.obolibrary.org/obo/PW_0000020	cardiovascular system disease pathway		Hypertension, high arterial blood pressure: various criteria for its threshold have been suggested, ranging from 140 mm Hg systolic and 90 mm Hg diastolic to as high as 200 mm Hg systolic and 110 mm Hg diastolic. Hypertension may have no known cause (essential or idiopathic h.) or be associated with other primary diseases (secondary h.).
http://purl.obolibrary.org/obo/PW_0000022	cardiomyopathy pathway	http://purl.obolibrary.org/obo/PW_0000020	cardiovascular system disease pathway		Cardiomyopathy - a general diagnostic term designating primary noninflammatory disease of the heart muscle, often of obscure or unknown etiology and not the result of ischemic, hypertensive, congenital, valvular, or pericardial disease. It is usually subdivided into dilated, hypertrophic, and restrictive cardiomyopathy (1). Cardiomyopathy is the deterioration of the cardiac muscle of the heart wall.
http://purl.obolibrary.org/obo/PW_0000023	immune response pathway	http://purl.obolibrary.org/obo/PW_0000004	regulatory pathway		The Immune response pathways mediate the defense of host cells against infection and injury. The first line of defense is provided by the phylogenetically older innate immune response. The later, more versatile response is provided by the pathways of adaptive immunity: the B cell mediated humoral and the T cell mediated cellular or cell-mediated responses.
http://purl.obolibrary.org/obo/PW_0000025	glycolysis/gluconeogenesis pathway	http://purl.obolibrary.org/obo/PW_0002655	glucose metabolic pathway		Those metabolic reactions involved in the energy-yielding conversion of glucose to pyruvate or in the formation of glucose from non-carbohydrate precursors such as pyruvate, lactate, citric acid cycle intermediates, the carbon skeleton of many amino acids. While many enzymes are shared by the two pathways, a few steps are carried out by pathway-specific enzymes. The two pathways are independently regulated.
http://purl.obolibrary.org/obo/PW_0000026	citric acid cycle pathway	http://purl.obolibrary.org/obo/PW_0000033	energy metabolic pathway		The series of chemical reactions that are central to all aerobic cells and constitute the citric acid cycle. Also known as the tricarboxylic acid cycle (TCA) or Krebs cycle, it is the center of convergence for all molecular fuels.
http://purl.obolibrary.org/obo/PW_0000027	glutamic acid/glutamate metabolic pathway	http://purl.obolibrary.org/obo/PW_0001075	hydrophilic amino acid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation glutamic acid/glutamate. Glutamate is the major excitatory neurotransmitter.
http://purl.obolibrary.org/obo/PW_0000028	alanine, aspartate and glutamate metabolic pathway	http://purl.obolibrary.org/obo/PW_0001077	amino acid metabolic pathway (KEGG)		Those metabolic reactions involved in the synthesis, utilization and/or degradation of alanine, aspartate and glutamate.
http://purl.obolibrary.org/obo/PW_0000029	fatty acid biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000058	fatty acid metabolic pathway		Acetyl-CoA, the starting material for fatty acid biosynthesis, can be derived from amino acid and lipid degradation or the oxidative decarboxylation of pyruvate. Fatty acid biosynthesis involves the condensation of C2 units; it requires seven enzymatic reactions which are carried out by the multifunctional enzyme fatty acid synthase.
http://purl.obolibrary.org/obo/PW_0000031	purine metabolic pathway	http://purl.obolibrary.org/obo/PW_0000012	nucleotide metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of purines. Purines consist of a pyrimidine ring fused to an imidazole ring. The nucleobases adenine and guanine in DNA are purines.
http://purl.obolibrary.org/obo/PW_0000032	pyrimidine metabolic pathway	http://purl.obolibrary.org/obo/PW_0000012	nucleotide metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of pyrimidines. Cytosine, thymine and uracil - the nucleobases found in nucleic acids, are pyrimidine derivatives.
http://purl.obolibrary.org/obo/PW_0000033	energy metabolic pathway	http://purl.obolibrary.org/obo/PW_0000002	classic metabolic pathway		Those metabolic reactions and pathways whose role is to release or provide energy.
http://purl.obolibrary.org/obo/PW_0000036	nitrogen metabolic pathway	http://purl.obolibrary.org/obo/PW_0000033	energy metabolic pathway		Those metabolic reactions in the nitrogen cycle carried out by various microorganisms.
http://purl.obolibrary.org/obo/PW_0000037	sulfur metabolic pathway	http://purl.obolibrary.org/obo/PW_0000033	energy metabolic pathway		Those metabolic reactions involving sulfur - a component of methionine and cysteine amino acids and of co-enzymes and vitamins. It also serves as electron donor in anaerobic respiration. Microorganisms and plants can incorporate inorganic sulfate into bioinorganic compounds; higher organisms derive them from diet.
http://purl.obolibrary.org/obo/PW_0000039	bile acid biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001304	cholesterol metabolic pathway		Those metabolic reactions involved in the biosynthesis of bile acids - any of the steroid carboxylic acids derived from cholesterol. Cholic and chenodeoxycholic acids are the primary bile acids and are formed in the liver. Secondary bile acids - deoxycholic and lithocholic - are formed from the primary bile acids through the action of intestinal bacteria. Bile acid also acts as a signal molecule via several nuclear receptors.
http://purl.obolibrary.org/obo/PW_0000040	steroid hormone biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001305	steroid hormone metabolic pathway		Those metabolic reactions involved in the synthesis of steroid hormones. All steroid hormones are derived from cholesterol. Steroid hormone metabolism is extremely complex and its molecular details are incompletely understood. De novo steroid biosynthesis is confined to very few tissues, primarily the adrenals, the gonads and the placenta.
http://purl.obolibrary.org/obo/PW_0000041	fructose and mannose metabolic pathway	http://purl.obolibrary.org/obo/PW_0000005	carbohydrate metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of fructose and mannose, as depicted in the KEGG diagram.
http://purl.obolibrary.org/obo/PW_0000042	galactose metabolic pathway	http://purl.obolibrary.org/obo/PW_0000005	carbohydrate metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of galactose - an aldohexose epimeric with glucose at the 4 carbon. Galactose is a component of lactose and other oligosaccharides, cerebrosides and gangliosides, and of various glycolipids and glycoproteins.
http://purl.obolibrary.org/obo/PW_0000043	pyruvate metabolic pathway	http://purl.obolibrary.org/obo/PW_0000556	glucose oxidation pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of pyruvate - a salt, ester, or anionic form of pyruvic acid. Pyruvate, which is the end-product of glycolysis, can be converted to lactate under anaerobic conditions, can be further oxidized via the Krebs or citrate cycle or can be converted back to glucose via gluconeogenesis.
http://purl.obolibrary.org/obo/PW_0000045	pentose phosphate pathway	http://purl.obolibrary.org/obo/PW_0002655	glucose metabolic pathway		Those metabolic reactions involved in the generation of reducing equivalents and five carbon (pentose) sugars. The oxidative phase is irreversible; the non-oxidative is reversible.
http://purl.obolibrary.org/obo/PW_0000046	inositol metabolic pathway	http://purl.obolibrary.org/obo/PW_0000005	carbohydrate metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of inositol, a cyclic sugar alcohol occurring in a number of stereoisomers of which myo-inositol is the most prominent form. myo-inositol provides a structural basis for compounds such as inositol phosphates and phosphatidylinositols, which are secondary messengers in several signaling pathways.
http://purl.obolibrary.org/obo/PW_0000047	glycine, serine and threonine metabolic pathway	http://purl.obolibrary.org/obo/PW_0001077	amino acid metabolic pathway (KEGG)		Those metabolic reactions involved in the synthesis of glycine, serine and threonine and which are intimately connected with serine being synthesized from glycine and threonine.
http://purl.obolibrary.org/obo/PW_0000048	methionine cycle/metabolic pathway	http://purl.obolibrary.org/obo/PW_0001074	hydrophobic amino acid metabolic pathway		Those metabolic reactions involved in the synthesis (remethylation), utilization and/or degradation of methionine, an essential amino acid for humans. The cycle produces S-adenosylmethionine (AdoMet),  the major methyl donor for proteins, nucleic acids, lipids and other small molecules. The cycle also produces homocysteine (Hcy) which either regenerates methionine via the  remethylation pathway or leads to the synthesis of cysteine and derivatives via the transsulfuration pathway. Homocysteine and folate metabolic pathways are intimately related to the methionine cycle.
http://purl.obolibrary.org/obo/PW_0000049	cysteine metabolic pathway	http://purl.obolibrary.org/obo/PW_0001075	hydrophilic amino acid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of cysteine, a non-essential amino acid that could be essential in certain cases. Its side chain contains a sulfhydryl group that is readily oxidized to form the cystine dimer covalently linked by a disulfide bond.
http://purl.obolibrary.org/obo/PW_0000050	arginine and proline metabolic pathway	http://purl.obolibrary.org/obo/PW_0001077	amino acid metabolic pathway (KEGG)		Those metabolic reactions involved in the synthesis, utilization and/or degradation of arginine - an essential amino acid - and proline - an amino acid that can play important roles in protein secondary structure.
http://purl.obolibrary.org/obo/PW_0000051	histidine metabolic pathway	http://purl.obolibrary.org/obo/PW_0001077	amino acid metabolic pathway (KEGG)		Those metabolic reactions involved in the synthesis, utilization and/or degradation of histidine, an essential amino acid which can act as either a proton donor or a proton acceptor. While the synthesis and degradation pathways of histidine are present in microorganisms, histidine can be acted upon by eukaryotic enzymes. Histidine is the precursor of histamine, is involved in immune responses and also acts as a neurotransmitter.
http://purl.obolibrary.org/obo/PW_0000052	tyrosine metabolic pathway	http://purl.obolibrary.org/obo/PW_0001077	amino acid metabolic pathway (KEGG)		Those metabolic reactions involved in the synthesis, utilization and/or degradation of tyrosine - a non-essential amino acid produced from phenylalanine and a precursor of thyroid hormones, catecholamines and melanin. Along with phenylalanine and tryptophan, it is one of the three aromatic amino acids.
http://purl.obolibrary.org/obo/PW_0000053	phenylalanine metabolic pathway	http://purl.obolibrary.org/obo/PW_0001077	amino acid metabolic pathway (KEGG)		Those metabolic reactions involved in the synthesis, utilization and/or degradation of phenylalanine, an essential amino acid. Along with tyrosine and tryptophan, it is one of the three aromatic amino acids.
http://purl.obolibrary.org/obo/PW_0000054	tryptophan metabolic pathway	http://purl.obolibrary.org/obo/PW_0001077	amino acid metabolic pathway (KEGG)		Those metabolic reactions that are involved in the synthesis, utilization and/or degradation of tryptophan - a dietary essential amino acid and precursor for several important compounds. Along with phenylalanine and tyrosine, it is one of the three aromatic amino acids.
http://purl.obolibrary.org/obo/PW_0000055	nucleotide sugar metabolic pathway	http://purl.obolibrary.org/obo/PW_0000005	carbohydrate metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of nucleotide sugars. Nucleotide sugars are glycosyl donors usually classified depending on the type of the nucleoside forming them. Several are used in animals and many others can be found in plants and bacteria.
http://purl.obolibrary.org/obo/PW_0000056	photosynthesis pathway	http://purl.obolibrary.org/obo/PW_0000033	energy metabolic pathway		A chemical combination caused by the action of light; specifically the formation of carbohydrates (with release of molecular oxygen) from carbon dioxide and water in the chlorophyll tissue of plants and blue-green algae under the influence of light. In bacteria, photosynthesis employs hydrogen sulfide, molecular hydrogen, and other reduced compounds in place of water, so that molecular oxygen is not released.
http://purl.obolibrary.org/obo/PW_0000057	carbon fixation pathway	http://purl.obolibrary.org/obo/PW_0000033	energy metabolic pathway		The pathway whereby photosynthetic organisms such as plants and cyanobacteria convert inorganic carbon (usually carbon dioxide) into organic compounds (usually carbohydrates).
http://purl.obolibrary.org/obo/PW_0000058	fatty acid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000010	lipid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of fatty acids - any long-chain monobasic organic acid.
http://purl.obolibrary.org/obo/PW_0000059	signaling pathway pertinent to the brain and nervous system	http://purl.obolibrary.org/obo/PW_0000003	signaling pathway		Those signaling pathways that are involved in or mediate the various aspects of nervous system and/or brain function.
http://purl.obolibrary.org/obo/PW_0000062	ascorbate and aldarate metabolic pathway	http://purl.obolibrary.org/obo/PW_0000005	carbohydrate metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of ascorbate and aldarate, as depicted in the KEGG diagram.
http://purl.obolibrary.org/obo/PW_0000063	glyoxylate and dicarboxylate metabolic pathway	http://purl.obolibrary.org/obo/PW_0000005	carbohydrate metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of glyoxylate and dicarboxylate, as depicted in the KEGG diagram.
http://purl.obolibrary.org/obo/PW_0000064	propanoate metabolic pathway	http://purl.obolibrary.org/obo/PW_0000005	carbohydrate metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of propanoate - any salt or ester of propanoic or propionic acid. Several propanoates are used in the food industry.
http://purl.obolibrary.org/obo/PW_0000065	butanoate metabolic pathway	http://purl.obolibrary.org/obo/PW_0000005	carbohydrate metabolic pathway		Those reactions involved in the synthesis, utilization and/or degradation of butanoate - an ester or salt of n-butyric acid. Various butanoates are used as ingredients in flavoring and perfumery.
http://purl.obolibrary.org/obo/PW_0000067	reductive carboxylate cycle - CO2 fixation pathway	http://purl.obolibrary.org/obo/PW_0000033	energy metabolic pathway		Those reactions involved in carbon dioxide fixation - the reductive carboxylate cycle (CO2 fixation) - the conversion of atmospheric carbon dioxide to organic carbon compounds, as in photosynthesis.
http://purl.obolibrary.org/obo/PW_0000068	methane metabolic pathway	http://purl.obolibrary.org/obo/PW_0000033	energy metabolic pathway		Those pathways used by methanotrophs and the methanogens that metabolize methane as the sole carbon source or as a byproduct.
http://purl.obolibrary.org/obo/PW_0000069	ketone bodies metabolic pathway	http://purl.obolibrary.org/obo/PW_0000058	fatty acid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization or degradation of ketone bodies. The chemicals acetoacetate, acetone and beta-hydroxybutyrate are collectively known as ketone bodies, although only the first two are ketones. They provide fuel for heart and skeletal muscle and for the brain during starvation. Excessive accumulation of these acidic chemicals leads to dangerous diabetic conditions known as ketoacidosis.
http://purl.obolibrary.org/obo/PW_0000070	C21-steroid hormone biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000040	steroid hormone biosynthetic pathway		Those metabolic reactions involved in the synthesis of C21-steroid hormones. Pregnenolone, the first C21 steroid derived from cholesterol, and progesterone, to which pregnenolone can be converted, provide the starting materials for the biosynthesis of C21, C19 and C18 steroid hormones. The C21 class includes glucocorticoids such as cortisol and mineralocorticoids such as aldosterone. Glucocorticoids and mineralocorticoids are collectively referred to as corticosteroids.
http://purl.obolibrary.org/obo/PW_0000071	valine, leucine and isoleucine degradation pathway	http://purl.obolibrary.org/obo/PW_0001077	amino acid metabolic pathway (KEGG)		Those metabolic reactions involved in the degradation of valine, leucine and isoleucine - the three dietary-essential branched amino acids.
http://purl.obolibrary.org/obo/PW_0000072	valine, leucine and isoleucine biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001077	amino acid metabolic pathway (KEGG)		Those metabolic pathways involved in the synthesis of valine, leucine and isoleucine - the three, dietary essential, branched amino acids.
http://purl.obolibrary.org/obo/PW_0000073	lysine degradation pathway	http://purl.obolibrary.org/obo/PW_0001077	amino acid metabolic pathway (KEGG)		Those metabolic reactions involved in the degradation of lysine. In mammals, lysine is metabolized to acetyl-CoA. A derivative of lysine, allysine, is used in the production of elastin and collagen.
http://purl.obolibrary.org/obo/PW_0000074	lysine biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001077	amino acid metabolic pathway (KEGG)		Those metabolic reactions involved in the biosynthesis of lysine - an essential amino acid. In plants and bacteria it is synthesized from aspartate.
http://purl.obolibrary.org/obo/PW_0000075	phenylalanine, tyrosine and tryptophan biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001077	amino acid metabolic pathway (KEGG)		Those metabolic reactions involved in the synthesis of phenylalanine, tyrosine and tryptophan and which are intimately related. Although the body can not manufacture phenylalanine on its own, phenylalanine is the precursor of tyrosine. Phenylalanine together with tryptophan governs the release of an intestinal hormone - cholecystokinin.
http://purl.obolibrary.org/obo/PW_0000076	urea cycle pathway	http://purl.obolibrary.org/obo/PW_0000011	amino acid metabolic pathway		The series of metabolic reactions, occurring in the liver, by which the ammonia derived from the breakdown of amino acids combines with carbon dioxide to form urea.
http://purl.obolibrary.org/obo/PW_0000077	beta-alanine metabolic pathway	http://purl.obolibrary.org/obo/PW_0000132	metabolic pathway of other amino acids		Those metabolic reactions involved in the synthesis, utilization and/or degradation of beta-alanine. Beta-alanine is an amino acid formed in vivo by the degradation of dihydrouracil and carnosine. Beta-alanine is not used in the synthesis of proteins but is a component of natural peptides, vitamins such as vitamin B5 and of coenzyme A. A rare genetic disorder, hyper-beta-alaninemia, has been reported.
http://purl.obolibrary.org/obo/PW_0000078	cyanoamino acid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000132	metabolic pathway of other amino acids		Those metabolic reactions involving cyanoamino acids, amino acid derivatives that contain a cyanide group.
http://purl.obolibrary.org/obo/PW_0000081	D-glutamine and D-glutamate metabolic pathway	http://purl.obolibrary.org/obo/PW_0000132	metabolic pathway of other amino acids		Those metabolic reactions involving D-glutamine and D-glutamate as depicted in the KEGG diagram. D-glutamic acid is naturally found primarily in the cell wall of certain bacteria.
http://purl.obolibrary.org/obo/PW_0000082	D-arginine and D-ornithine metabolic pathway	http://purl.obolibrary.org/obo/PW_0000132	metabolic pathway of other amino acids		Those metabolic reactions involving D-arginine and D-ornithine as depicted in the KEGG diagram.
http://purl.obolibrary.org/obo/PW_0000083	D-alanine metabolic pathway	http://purl.obolibrary.org/obo/PW_0000132	metabolic pathway of other amino acids		Those metabolic reactions involving D-alanine, the D-enantiomer of alanine. D-alanine can be found in bacterial cell walls and in some peptide antibiotics.
http://purl.obolibrary.org/obo/PW_0000085	pathway pertinent to DNA replication and repair, cell cycle, maintenance of genomic integrity, RNA and protein biosynthesis	http://purl.obolibrary.org/obo/PW_0000004	regulatory pathway		Those pathways involved in and/or controlling DNA replication, cell cycle, DNA repair and maintenance of genomic integrity, RNA and protein biosynthesis.
http://purl.obolibrary.org/obo/PW_0000086	cell cycle pathway, mitotic	http://purl.obolibrary.org/obo/PW_0001317	cell cycle pathway		The series of events, collectively known as the cell cycle, that underlie the replication of the genome and the segregation of chromosomes into daughter cells. The cycle begins with a diploid cell and produces two identical diploid cells.
http://purl.obolibrary.org/obo/PW_0000095	G1/S DNA damage checkpoint pathway	http://purl.obolibrary.org/obo/PW_0000094	cell cycle checkpoint pathway		Those pathways of DNA damage response that occur during the G1 phase.
http://purl.obolibrary.org/obo/PW_0000096	G2/M checkpoint pathway	http://purl.obolibrary.org/obo/PW_0000094	cell cycle checkpoint pathway		Those pathways that assure the genome is replicated only once per cell cycle. The checkpoints control for damaged and un-replicated DNA.
http://purl.obolibrary.org/obo/PW_0000097	mitotic spindle checkpoint pathway	http://purl.obolibrary.org/obo/PW_0000094	cell cycle checkpoint pathway		The pathway prevents cells with mis-aligned chromosomes from dividing. Defects of kinetochore function activate checkpoint proteins to initiate a cascade of events that eventually prevent separation of sister chromatids.
http://purl.obolibrary.org/obo/PW_0000099	DNA repair pathway	http://purl.obolibrary.org/obo/PW_0000085	pathway pertinent to DNA replication and repair, cell cycle, maintenance of genomic integrity, RNA and protein biosynthesis		The pathways involved in the repair of damaged DNA. The damage can involve mismatched or damaged bases, distortion of the helix or breaks in the DNA double strand. Repair of DNA lesions along with the upstream lesion detection and signaling its presence are collectively known as the DNA damage response.
http://purl.obolibrary.org/obo/PW_0000100	transcription pathway	http://purl.obolibrary.org/obo/PW_0000085	pathway pertinent to DNA replication and repair, cell cycle, maintenance of genomic integrity, RNA and protein biosynthesis		The pathways governing and/or regulating DNA transcription and gene expression. DNA transcription into coding and non-coding RNA is accomplished by one prokaryotic and several eukaryotic RNA polymerases. Transcription-coupled repair handles DNA lesions that interfere with the progression of RNA polymerases. Splicing of nascent RNA is thought to be predominantly co-transcriptional. Signaling pathways mediated by various transcription factors are involved in the regulation of gene expression.
http://purl.obolibrary.org/obo/PW_0000101	translation pathway	http://purl.obolibrary.org/obo/PW_0000085	pathway pertinent to DNA replication and repair, cell cycle, maintenance of genomic integrity, RNA and protein biosynthesis		The series of events governing the processes whereby mRNA is translated into a polypeptide chain. Post-translational modifications often accompany the formation of the final, mature protein. Translation involves initiation, elongation and termination steps and is dependent upon the availability of aminoacyl-tRNA and mature ribosomes.
http://purl.obolibrary.org/obo/PW_0000102	the extracellular signal-regulated Raf/Mek/Erk signaling pathway	http://purl.obolibrary.org/obo/PW_0000007	mitogen activated protein kinase signaling pathway		The Raf/Mek/Erk signaling pathway - a Ras activated protein kinase cascade - regulates diverse processes such as cell growth, proliferation and differentiation, in response to cytokines, hormones, growth factors.
http://purl.obolibrary.org/obo/PW_0000103	transport pathway	http://purl.obolibrary.org/obo/PW_0000004	regulatory pathway		A pathway that mediates or facilitates the movement of biochemical material, organic and inorganic substances and/or drugs.
http://purl.obolibrary.org/obo/PW_0000104	intrinsic apoptotic pathway	http://purl.obolibrary.org/obo/PW_0000009	apoptotic cell death pathway		The apoptotic pathway involving organelles, primarily the mitochondrion and endoplasmic reticulum (ER), and involving the pro- and anti-apoptotic members of the Bcl family of proteins, cytochrome C, formation of the apoptosome and activation of caspases.
http://purl.obolibrary.org/obo/PW_0000105	Rho/Rac/Cdc42 mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000006	Ras superfamily mediated signaling pathway		Members of the Ras related Rho family of proteins control diverse processes such as actin cytoskeletal rearrangements, morphogenesis of dendritic spines, gene expression. Of note is the fact that cytoskeletal rearrangements, primarily actin remodeling have a role to play in vesicular trafficking, a process regulated by Rab proteins.
http://purl.obolibrary.org/obo/PW_0000106	extrinsic apoptotic pathway	http://purl.obolibrary.org/obo/PW_0000009	apoptotic cell death pathway		The apoptotic pathway involving the death receptors-mediated route of caspase activation. Members of the tumor necrosis superfamily such as the better known Tnf-alpha (Tnf), Fas ligand or Trail elicit apoptosis via receptor-associated adapters.
http://purl.obolibrary.org/obo/PW_0000107	xenobiotics biodegradation pathway	http://purl.obolibrary.org/obo/PW_0001229	xenobiotic metabolic pathway		Those reactions involved in the breaking down of toxic chemical compounds such as oil spills, solvents, pesticides and other pollutants. These chemicals are generally resistant to degradation, but microorganisms possess enzymes that are capable of breaking them down.
http://purl.obolibrary.org/obo/PW_0000108	caprolactam degradation pathway	http://purl.obolibrary.org/obo/PW_0000107	xenobiotics biodegradation pathway		Those enzymatic reactions involved in the degradation of caprolactam - a cyclic amide of caproic acid used to produce a type of nylon.
http://purl.obolibrary.org/obo/PW_0000109	bisphenol A degradation pathway	http://purl.obolibrary.org/obo/PW_0000107	xenobiotics biodegradation pathway		Those enzymatic reactions involved in the degradation of bisphenol A, known as BPA, an important compound in the production of plastics. However, it is believed to be hazardous to humans and reports have linked several health effects to levels of BPA exposure.
http://purl.obolibrary.org/obo/PW_0000110	toluene and xylene degradation pathway	http://purl.obolibrary.org/obo/PW_0000107	xenobiotics biodegradation pathway		Those enzymatic reactions involved in the degradation of toluene and xylene. Toluene is used as organic solvent in rubber, paint, cement. Xylene represents any of three benzene derivatives used as solvent in printing, rubber, also as a cleaning agent.
http://purl.obolibrary.org/obo/PW_0000111	gamma-hexachlorocyclohexane degradation pathway	http://purl.obolibrary.org/obo/PW_0000107	xenobiotics biodegradation pathway		Those enzymatic reactions involved in the degradation of gamma-hexachlorocyclohexane,  also known as lindane, used as an insecticide and suspected to be carcinogenic.
http://purl.obolibrary.org/obo/PW_0000112	3-chloroacrylic acid degradation pathway	http://purl.obolibrary.org/obo/PW_0000107	xenobiotics biodegradation pathway		Those enzymatic reactions involved in the degradation of 3-chloroacrylic acid.
http://purl.obolibrary.org/obo/PW_0000113	atrazine degradation pathway	http://purl.obolibrary.org/obo/PW_0000107	xenobiotics biodegradation pathway		Those enzymatic reactions involved in the degradation of atrazine - a herbicide used to kill weeds.
http://purl.obolibrary.org/obo/PW_0000114	benzoate degradation pathway via hydroxylation	http://purl.obolibrary.org/obo/PW_0000282	benzoate degradation pathway		Those enzymatic reactions involved in the aerobic pathway of benzoate degradation.
http://purl.obolibrary.org/obo/PW_0000115	benzoate degradation pathway via CoA ligation	http://purl.obolibrary.org/obo/PW_0000282	benzoate degradation pathway		Those enzymatic reactions involved in the anaerobic pathway of benzoate degradation.
http://purl.obolibrary.org/obo/PW_0000116	carbazole degradation pathway	http://purl.obolibrary.org/obo/PW_0000107	xenobiotics biodegradation pathway		Those enzymatic reactions involved in the degradation of carbazole - a crystalline, slightly basic cyclic compound found in anthracene. It reacts with carbohydrates and is used for assay and analysis of carbohydrates and in making dyes.
http://purl.obolibrary.org/obo/PW_0000117	fluorene degradation pathway	http://purl.obolibrary.org/obo/PW_0000107	xenobiotics biodegradation pathway		Those enzymatic reactions involved in the degradation of fluorene - a colorless, crystalline hydrocarbon. It is obtained from coal tar and is used in making dyes.
http://purl.obolibrary.org/obo/PW_0000118	ethylbenzene degradation pathway	http://purl.obolibrary.org/obo/PW_0000107	xenobiotics biodegradation pathway		Those enzymatic reactions involved in the degradation of ethylbenzene - a liquid hydrocarbon used in the manufacture of styrene and as a solvent and diluent for dyes and paints.
http://purl.obolibrary.org/obo/PW_0000119	nitrobenzene degradation pathway	http://purl.obolibrary.org/obo/PW_0000107	xenobiotics biodegradation pathway		Those enzymatic reactions involved in the degradation of nitrobenzene - an organic compound that occurs either as yellow crystals or yellow liquid and is used in the manufacture of aniline. It is a poisonous derivative of benzene.
http://purl.obolibrary.org/obo/PW_0000120	styrene degradation pathway	http://purl.obolibrary.org/obo/PW_0000107	xenobiotics biodegradation pathway		Those enzymatic reactions involved in the degradation of styrene - an aromatic hydrocarbon that is colorless and oily. It is used in the manufacture of rubber, resins and plastics. It is a toxic, possibly carcinogenic substance.
http://purl.obolibrary.org/obo/PW_0000121	tetrachloroethene degradation pathway	http://purl.obolibrary.org/obo/PW_0000107	xenobiotics biodegradation pathway		Those enzymatic reactions involved in the degradation of tetrachloroethene (acetylene tetrachloride) - used as a solvent for fats, waxes, resins and as an intermediate in the synthesis of chlorinated hydrocarbons.
http://purl.obolibrary.org/obo/PW_0000122	Hedgehog signaling pathway	http://purl.obolibrary.org/obo/PW_0000650	signaling pathway pertinent to development		The Hedgehog signaling pathway (Hh) plays important roles in vertebrate embryogenesis, particularly in the differentiation of the neural tube, in vasculogenesis and in angiogenesis. Post-embryonically it is believed to play a homeostatic role in the maintenance of stem cells. Alteration of the pathway has been implicated in a number of human cancers.
http://purl.obolibrary.org/obo/PW_0000123	synaptic vesicle endocytosis and recycling pathway	http://purl.obolibrary.org/obo/PW_0002423	synaptic vesicle cycle pathway		The pathway of synaptic vesicle endocytosis and neurotransmitter refill following exocytosis.
http://purl.obolibrary.org/obo/PW_0000124	cellular detoxification pathway	http://purl.obolibrary.org/obo/PW_0000004	regulatory pathway		A pathway triggered by exogenous or endogenous elements, compounds or molecules that can be harmful to the system. The phase I (oxidative) and phase II (conjugative) metabolizing enzymes and the phase III transport systems and other pathways are involved in the response mechanisms resulting in processing and subsequent elimination of such elements. Others induce downstream effects such as antioxidant, cell death or inflammatory response pathways.
http://purl.obolibrary.org/obo/PW_0000125	G protein mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000003	signaling pathway		G-proteins act as signal transducers between activated receptors or other incoming signals and downstream effectors. They comprise the heterotrimeric G proteins downstream of G protein-coupled receptors (GPCRs) and the Ras superfamily of small, monomeric G proteins. They function as molecular switches, alternating between the GDP-inactive and GTP-active bound state.
http://purl.obolibrary.org/obo/PW_0000126	RNA polymerase I transcription pathway	http://purl.obolibrary.org/obo/PW_0001275	eukaryotic RNA polymerase transcription pathway		The series of events governing the synthesis of the large ribosomal RNA (rRNA) precursor in the nucleolus.
http://purl.obolibrary.org/obo/PW_0000127	RNA polymerase II transcription pathway	http://purl.obolibrary.org/obo/PW_0001275	eukaryotic RNA polymerase transcription pathway		The series of events governing the synthesis of protein-coding messenger RNA (mRNA) precursors and of transcripts of many classes of non-coding genes.
http://purl.obolibrary.org/obo/PW_0000128	RNA polymerase III transcription pathway	http://purl.obolibrary.org/obo/PW_0001275	eukaryotic RNA polymerase transcription pathway		The series of events governing the synthesis of transport/transfer RNA (tRNA) precursors, the small ribosomal rRNA and other small RNAs.
http://purl.obolibrary.org/obo/PW_0000129	base excision repair pathway	http://purl.obolibrary.org/obo/PW_0000661	single-strand DNA repair pathway		The base excision repair pathway involves the identification and removal of a damaged base followed by its replacement with the correct nucleotide and ligation of the break in the strand.
http://purl.obolibrary.org/obo/PW_0000130	nucleotide excision repair pathway	http://purl.obolibrary.org/obo/PW_0000661	single-strand DNA repair pathway		The nucleotide excision repair pathway is an important mechanism for the detection of helix-distorting base alterations. Unlike the base excision repair pathway that only removes the damaged bases, the NER pathway removes an entire lesion-containing segment. The single-strand gap thus introduced is filled in by DNA polymerase using the undamaged strand as a template. The pathway can be subdivided into two sub-pathways: transcription-coupled and global genome repair. They only differ in the lesion recognition step while the core repair component is shared.
http://purl.obolibrary.org/obo/PW_0000132	metabolic pathway of other amino acids	http://purl.obolibrary.org/obo/PW_0000002	classic metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of amino acids other than the common 20 amino acids found in protein. Some of these amino acids like carnitine or homocysteine derive from primary amino acids.
http://purl.obolibrary.org/obo/PW_0000133	selenoamino acid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000132	metabolic pathway of other amino acids		Those metabolic reactions involved in the synthesis, utilization and/or degradation of selenoamino acids - amino acids in which a selenium atom replaces a sulfur atom. Examples include selenocysteine, selenohomocysteine and selenomethionine.
http://purl.obolibrary.org/obo/PW_0000134	glutathione metabolic pathway	http://purl.obolibrary.org/obo/PW_0000135	metabolic pathway of cofactors, vitamins, nutrients		Those metabolic reactions involved in the synthesis, utilization and/or degradation of glutathione - a tripeptide that acts as an antioxidant and provides protection against reactive oxygen species. It is also used in the conjugation of xenobiotics and drugs by the phase II biotransformation enzymes.
http://purl.obolibrary.org/obo/PW_0000135	metabolic pathway of cofactors, vitamins, nutrients	http://purl.obolibrary.org/obo/PW_0000002	classic metabolic pathway		Those reactions involved in the synthesis, utilization and/or degradation of cofactors, vitamins and other nutrients. Cofactors are necessary for the proper function of certain proteins and enzymes; they can be inorganic such as the metal ions or the iron-sulfur cluster or organic. Organic compounds that are tightly bound to proteins are also referred to as prosthetic groups. Often, they are or are made from vitamins, compounds that are vital but in small amounts and which are insufficiently synthesized by the organism. Some of these molecules can also perform signaling functions.
http://purl.obolibrary.org/obo/PW_0000136	thiamine metabolic pathway	http://purl.obolibrary.org/obo/PW_0000135	metabolic pathway of cofactors, vitamins, nutrients		Those metabolic reactions involving thiamine, a water-soluble vitamin of the B complex. It is synthesized in bacteria, fungi and plants while animals obtain thiamine from food. Thiamine insufficiency results in a condition called beriberi.
http://purl.obolibrary.org/obo/PW_0000137	riboflavin metabolic pathway	http://purl.obolibrary.org/obo/PW_0000135	metabolic pathway of cofactors, vitamins, nutrients		Those metabolic reactions involving riboflavin, also known as vitamin B2 - a water-soluble vitamin. B2 occurs in several products and is a precursor for flavin coenzymes.
http://purl.obolibrary.org/obo/PW_0000138	vitamin B6 metabolic pathway	http://purl.obolibrary.org/obo/PW_0000135	metabolic pathway of cofactors, vitamins, nutrients		Those metabolic reactions involving vitamin B6 - a water-soluble vitamin that exists in several forms. Vitamin B6 is required for many enzymatic reactions as the active pyridoxal 5'-phosphate (PLP) form. A number of organisms can carry out de novo synthesis of vitamin B6; humans derive it from diet.
http://purl.obolibrary.org/obo/PW_0000139	biotin metabolic pathway	http://purl.obolibrary.org/obo/PW_0000135	metabolic pathway of cofactors, vitamins, nutrients		Those metabolic reactions involved in the synthesis, utilization and/or degradation of biotin, also known as vitamin B7 or H, a water-soluble vitamin. Biotin assists in various metabolic reactions and processes.
http://purl.obolibrary.org/obo/PW_0000140	folate metabolic pathway	http://purl.obolibrary.org/obo/PW_0000135	metabolic pathway of cofactors, vitamins, nutrients		Folate metabolism represents the various aspects of the folate cycle and the folate-mediated transfer reactions essential for several biosynthetic pathways. The folate cycle and the folate-mediated one-carbon pathways are part of folate metabolism. Folate compounds are water-soluble forms of vitamin B9.
http://purl.obolibrary.org/obo/PW_0000141	retinol metabolic pathway	http://purl.obolibrary.org/obo/PW_0001003	retinoid metabolic pathway		Those reactions involving retinol, a fat-soluble vitamin that is the dietary form of vitamin A and is important for bone growth and in vision. Precursors of retinol such as carotenoid or retinyl esters are derived from diet and are converted to retinal and retinol, respectively.
http://purl.obolibrary.org/obo/PW_0000142	ubiquinone biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000135	metabolic pathway of cofactors, vitamins, nutrients		Those metabolic reactions involved in the biosynthesis of ubiquinone, also known as coenzyme Q. Ubiquinone is a member of the mitochondrial respiratory chain and plays important roles in cellular metabolism.
http://purl.obolibrary.org/obo/PW_0000143	insulin signaling pathway	http://purl.obolibrary.org/obo/PW_0000467	peptide and protein hormone signaling pathway		Insulin, the peptide hormone secreted by pancreatic beta cells, plays essential roles in glucose and energy homeostasis. Insulin signaling activates two main intracellular pathways to regulate carbohydrate and fat metabolism and to prompt glucose absorption in insulin sensitive tissues such as skeletal muscle and adipocytes. Deregulation of the pathway has been associated with a number of conditions, primarily diabetes.
http://purl.obolibrary.org/obo/PW_0000144	ubiquitin/proteasome degradation pathway	http://purl.obolibrary.org/obo/PW_0000417	ubiquitin, ubiquitin-like/proteasome degradation pathway		The pathway for the ATP-dependent non-lysosomal proteolysis catalyzed by the 26S proteasome and for which ubiquitylation, the post-translational covalent conjugation of ubiquitin to target proteins is a key signal.
http://purl.obolibrary.org/obo/PW_0000146	glycan metabolic pathway	http://purl.obolibrary.org/obo/PW_0000005	carbohydrate metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of glycans. Glycans are a class of compounds that include oligo- and polysaccharides, simple sugars or polymeric structures of mono- or di-saccharides, respectively. The term also refers to the carbohydrate moiety of glycoproteins, proteoglycans and glycolipids.
http://purl.obolibrary.org/obo/PW_0000147	metabolic pathway of secondary metabolites	http://purl.obolibrary.org/obo/PW_0000002	classic metabolic pathway		Those reactions involved in the synthesis, utilization and/or degradation of secondary metabolites - products of cellular metabolism that are not essential for, or not directly involved in the normal growth, development or reproduction of an organism. Many of the chemicals that plants or microorganisms produce are secondary metabolites.
http://purl.obolibrary.org/obo/PW_0000151	starch and sucrose metabolic pathway	http://purl.obolibrary.org/obo/PW_0000005	carbohydrate metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of starch and sucrose, as depicted in the KEGG diagram. Starch is a polysaccharide produced by all green plants and is an important carbohydrate in the human diet. Sucrose, or the table sugar is a disaccharide of glucose and fructose that is produced by plants and cyanobacteria.
http://purl.obolibrary.org/obo/PW_0000152	amino sugar metabolic pathway	http://purl.obolibrary.org/obo/PW_0000005	carbohydrate metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of amino sugars. An amino sugar has an amino group substituent in place of a hydroxyl group. Amino sugars are important constituents of a variety of polysaccharides and glycoproteins.
http://purl.obolibrary.org/obo/PW_0000153	triacylglycerol metabolic pathway	http://purl.obolibrary.org/obo/PW_0001156	glycerolipid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of triacylglycerols - esters of glycerols with three fatty acid molecules. Triglycerides are the common form of transport and storage of fatty acids. Esters with one or two fatty acid molecules are metabolic intermediates present in small amounts.
http://purl.obolibrary.org/obo/PW_0000154	inositol phosphate metabolic pathway	http://purl.obolibrary.org/obo/PW_0000005	carbohydrate metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of inositol phosphate, which represents all of the possible phosphorylated states of inositol. Inositol phosphates have many important cellular functions.
http://purl.obolibrary.org/obo/PW_0000156	prostaglandin metabolic pathway	http://purl.obolibrary.org/obo/PW_0001240	prostanoid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of prostaglandins - a family of prostanoid eicosanoids with many regulatory functions.
http://purl.obolibrary.org/obo/PW_0000157	glycosaminoglycan metabolic pathway	http://purl.obolibrary.org/obo/PW_0000146	glycan metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of glycosaminoglycans - any of several high molecular weight linear polysaccharides of repeating disaccharide units. In many cases, the unit consists of an amino sugar and a uronic acid. When aggregating with proteins, they form proteoglycans.
http://purl.obolibrary.org/obo/PW_0000158	Ras family mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000006	Ras superfamily mediated signaling pathway		The Ras family mediated signaling pathways are primarily involved in the regulation of gene expression.
http://purl.obolibrary.org/obo/PW_0000159	Rab family mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000006	Ras superfamily mediated signaling pathway		Rab family mediated signaling pathways are involved in the regulation of intracellular vesicle trafficking. More than 60 Rab members bind to specific effectors to regulate all aspects of vesicular trafficking - from formation and transport of vesicles, to tethering and fusion with target membranes. Of note is that cytoskeletal rearrangements such as actin remodeling, a process regulated by the Rho family, have a role to play in vesicular trafficking.
http://purl.obolibrary.org/obo/PW_0000160	Ran family mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000006	Ras superfamily mediated signaling pathway		Ran family mediated signaling pathways are involved in nucleocytoplasmic trafficking.
http://purl.obolibrary.org/obo/PW_0000161	glycosylphosphatidylinositol anchor biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000146	glycan metabolic pathway		Those metabolic reactions involved in the synthesis of glycosylphosphatidylinositol (GPI) anchors. The GPI anchor allows for the attachment of cell surface proteins to the cell membrane.
http://purl.obolibrary.org/obo/PW_0000162	sphingolipid biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000197	sphingolipid metabolic pathway		Those metabolic reactions involved in the synthesis of sphingolipids. Sphingolipids are enriched in the Central Nervous System (CNS) and display multiple biological functions. They participate in tissue development, cell recognition and adhesion, and act as receptors for toxins.
http://purl.obolibrary.org/obo/PW_0000163	sphingolipid degradation pathway	http://purl.obolibrary.org/obo/PW_0000197	sphingolipid metabolic pathway		Those enzymatic reactions involved in the degradation of sphingolipids.
http://purl.obolibrary.org/obo/PW_0000164	ganglioside metabolic pathway	http://purl.obolibrary.org/obo/PW_0000733	glycosphingolipid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of gangliosides - any of a group of glycosphingolipids in which the polar head group on ceramide is a sialic acid. Their names include letters and numbers where the letters M, D and T indicate the number of sialic acid residues in the molecule - one, two or three, respectively.
http://purl.obolibrary.org/obo/PW_0000165	taurine and hypotaurine metabolic pathway	http://purl.obolibrary.org/obo/PW_0000132	metabolic pathway of other amino acids		Those metabolic reactions involved in the synthesis, utilization and/or degradation of taurine and hypotaurine.
http://purl.obolibrary.org/obo/PW_0000166	monoterpenoid biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000184	terpenoid biosynthetic pathway		Those metabolic reactions involved in the synthesis of monoterpenoids. Terpenoids are a large class of naturally-occurring organic chemicals. They are derived from five-carbon units and are modified in manifold ways.
http://purl.obolibrary.org/obo/PW_0000167	pantothenic acid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000135	metabolic pathway of cofactors, vitamins, nutrients		Those metabolic reactions involved in the synthesis, utilization and/or degradation of pantothenic acid or panthothenate, also known as vitamin B5 - a water-soluble vitamin. Vitamin B5 is the precursor to coenzyme A (CoA) which in turn, plays an essential role in fatty acids and pyruvate metabolism.
http://purl.obolibrary.org/obo/PW_0000168	growth factor signaling pathway	http://purl.obolibrary.org/obo/PW_0000003	signaling pathway		Those pathways that are triggered through the binding of a growth factor to its particular receptor. Growth factors carry out mitogenic signaling via their largely tyrosine kinase receptors.
http://purl.obolibrary.org/obo/PW_0000169	nerve growth factor signaling pathway	http://purl.obolibrary.org/obo/PW_0000571	neurotrophic factor signaling pathway		Nerve growth factor (NGF) signaling pathways control a variety of processes such as neuronal cell differentiation and axon growth. Members of the NGF family are best known for their anti-apoptotic role as mediators of neuronal cell survival.
http://purl.obolibrary.org/obo/PW_0000170	epidermal growth factor/neuregulin signaling pathway	http://purl.obolibrary.org/obo/PW_0000168	growth factor signaling pathway		Members of the EGF/neuregulin superfamily are important regulators of tissue development and repair. A characteristic feature is the presence of the EGF module, a 36-40 amino acid sequence with a disulfide-bonded three-loop structure necessary for receptor binding.
http://purl.obolibrary.org/obo/PW_0000171	polyglutamine repeat pathway	http://purl.obolibrary.org/obo/PW_0000014	neurodegenerative pathway		Inherited neurodegenerative diseases that are caused by the expansion of a polyglutamine (polyQ) tract in several, unrelated proteins. The diseases are manifested as distinct neuropathies and multiple pathways are perturbed.
http://purl.obolibrary.org/obo/PW_0000172	Kennedy's disease pathway	http://purl.obolibrary.org/obo/PW_0000171	polyglutamine repeat pathway		An inherited neurodegenerative disease caused by an expanded polyglutamine (polyQ) tract. Various pathways are disrupted and contribute to the manifestation of the condition.
http://purl.obolibrary.org/obo/PW_0000173	spinocerebellar ataxia pathway	http://purl.obolibrary.org/obo/PW_0000171	polyglutamine repeat pathway		An inherited form of neurodegenerative disease caused by an expanded polyglutamine (polyQ) tract. Several types are grouped under SCA, types 1-3, 6, 7 and 17. Various pathways are disrupted and contribute to the manifestation of the condition.
http://purl.obolibrary.org/obo/PW_0000174	metabolic syndrome X pathway	http://purl.obolibrary.org/obo/PW_0001472	metabolic disease pathway		The metabolic syndrome is a multiphenotypic condition with concurrent features of several diseases and metabolic abnormalities. Insulin resistance, obesity and hypertension are considered risk factors. Alterations in lipid, glucose and cholesterol metabolic pathways, among others, can contribute to the multifactorial metabolic syndrome and the conditions associated with it.
http://purl.obolibrary.org/obo/PW_0000176	diabetes mellitus pathway	http://purl.obolibrary.org/obo/PW_0001602	glucose metabolism disease pathway		A range of conditions with various manifestations associated with disruptions of several pathways, primarily those revolving around glucose homeostasis and insulin signaling. Organs and tissues affected include the kidney, eye, cardiovascular system and nerve tissue.
http://purl.obolibrary.org/obo/PW_0000177	diabetic nephropathy pathway	http://purl.obolibrary.org/obo/PW_0001548	diabetes complication pathway		A common complication of diabetes and a leading cause of end stage renal diseases affecting a number of pathways, particularly the thiol and anti-oxidant pathways.
http://purl.obolibrary.org/obo/PW_0000178	neurological disorder pathway	http://purl.obolibrary.org/obo/PW_0001412	nervous system disease pathway		Neurological disorders are a group of disorders that involve the central nervous system (brain, brainstem and cerebellum), the peripheral nervous system (including cranial nerves), and the autonomic nervous system (parts of which are located in both the central and peripheral nervous systems). Major branches are headache, stupor and coma, dementia, seizure, sleep disorders, trauma, infections, neoplasms, neuro-ophthalmologic diseases, movement disorders, demyelinating diseases, spinal cord disorders, and disorders of peripheral nerves, muscle and neuromuscular junctions. Many mental illnesses are believed to be neurological disorders of the central nervous system, but they are classified separately. They are not traditionally listed as neurological diseases because their causes are not definitely determined as biological, although there are good reasons to suspect that bipolar disorder and schizophrenia have neuro-chemical causes.
http://purl.obolibrary.org/obo/PW_0000179	tuberous sclerosis complex disease pathway	http://purl.obolibrary.org/obo/PW_0000178	neurological disorder pathway		An autosomal dominant condition that often leads to seizure and other neurological symptoms and that may be linked to deregulations in the mTOR signaling pathway.
http://purl.obolibrary.org/obo/PW_0000180	mTOR signaling pathway	http://purl.obolibrary.org/obo/PW_0000085	pathway pertinent to DNA replication and repair, cell cycle, maintenance of genomic integrity, RNA and protein biosynthesis		The mTOR signaling pathway regulates cellular processes such as translation, ribosome biogenesis, cell growth and autophagy and is regulated by or responds to growth factors, energy metabolites and/or levels of nutrients.
http://purl.obolibrary.org/obo/PW_0000181	pathway pertinent to protein folding, sorting, modification, translocation and degradation	http://purl.obolibrary.org/obo/PW_0000004	regulatory pathway		Those pathways that are involved in or mediate how proteins fold or are maintained in a particular folding state, are sorted for translocation or degradation, are modified to regulate their function or to target them for degradation and finally, are degraded.
http://purl.obolibrary.org/obo/PW_0000182	lysosomes based pathway of protein degradation	http://purl.obolibrary.org/obo/PW_0000325	protein degradation pathway		A protein degradation pathway that involves proteases residing in lysosomes and exhibiting optimal activity at an acidic pH (e.g., cathepsins).
http://purl.obolibrary.org/obo/PW_0000183	the proteolytic pathway involving calcium-dependent proteases	http://purl.obolibrary.org/obo/PW_0000325	protein degradation pathway		A protein degradation pathway that involves calcium-dependent proteases  (e.g., calpains) ,
http://purl.obolibrary.org/obo/PW_0000184	terpenoid biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001394	terpene and terpenoid biosynthetic pathway		Those metabolic reactions involved in the synthesis of terpenoids. The terpenoids, sometimes referred to as isoprenoids, are a class of naturally-occurring chemicals. Terpenoids are derived from five-carbon isoprene units and are assembled and modified in manifold ways. They are classified according to the number of isoprene units. The mevalonate pathway and the non-mevalonate MEP/DOXP pathway are the two biosynthetic routes. The first can branch into non-sterol and sterol-producing compounds. The second is only found in plants.
http://purl.obolibrary.org/obo/PW_0000185	limonene and pinene degradation pathway	http://purl.obolibrary.org/obo/PW_0001399	terpene degradation pathway		Those metabolic reactions involved in the degradation of limonene -  an essential oil, a monocyclic terpene, found in the peel of oranges and lemons, and pinene - a terpene found in turpentine and many essential oils, used as a solvent and in the manufacture of camphor, insecticides, and synthetic pine oil.
http://purl.obolibrary.org/obo/PW_0000186	streptomycin biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000147	metabolic pathway of secondary metabolites		Those metabolic reactions involved in the synthesis of streptomycin - the first of the aminoglycoside antibiotics to be isolated, derived from Streptomyces griseus; it is effective against a wide variety of aerobic gram-negative bacilli and some gram-positive bacteria, including mycobacteria. Its use is now limited because of the emergence of resistant strains.
http://purl.obolibrary.org/obo/PW_0000187	erythromycin biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000147	metabolic pathway of secondary metabolites		Those metabolic reactions involved in the synthesis of erythromycin - an intermediate spectrum macrolide (a chemical compound characterized by a large lactone ring containing multiple keto and hydroxyl groups) antibiotic, produced by Streptomyces erythreus, effective against most gram-positive and certain gram-negative bacteria, such as Neisseria species and Haemophilus influenzae, and against spirochetes, some rickettsias, and Entamoeba; it is also highly effective against Mycoplasma pneumoniae. It is used especially in patients allergic to penicillin and in those with penicillin-resistant infections and Legionnaires' disease; administered orally or topically.
http://purl.obolibrary.org/obo/PW_0000188	pentose and glucuronate interconversion pathway	http://purl.obolibrary.org/obo/PW_0000005	carbohydrate metabolic pathway		The series or metabolic reactions involved in the interconversions of the monosaccharide pentose and glucuronate, the salts or esters of glucuronic acid, as depicted in the KEGG diagram.
http://purl.obolibrary.org/obo/PW_0000190	porphyrin and chlorophyll metabolic pathway	http://purl.obolibrary.org/obo/PW_0000135	metabolic pathway of cofactors, vitamins, nutrients		Those reactions involved in the synthesis, utilization and/or degradation of porphyrin - any of a group of compounds containing the porphyrin structure, four pyrrole rings connected by methine bridges in a cyclic configuration, to which a variety of side chains may be attached - and chlorophyll - any of a group of green magnesium-containing porphyrin derivatives occurring in all photosynthetic organisms.
http://purl.obolibrary.org/obo/PW_0000191	keratan sulfate biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0002689	keratan sulfate metabolic pathway		Those metabolic reactions involved in the biosynthesis of keratan sulfate - a glycosaminoglycan found in the cornea, in cartilage, and in the nucleus pulposus and also as the accumulation product in Morquio's syndrome. It consists of repeating disaccharide units in specific linkage, each composed of a sulfated N-acetylglucosamine residue linked to one of galactose, which is usually sulfated. There are two forms, keratan sulfate I and keratan sulfate II, which differ in carbohydrate content and localization; the former occurs in the cornea and the latter in skeletal tissues.
http://purl.obolibrary.org/obo/PW_0000192	N-linked glycan biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000146	glycan metabolic pathway		Those metabolic reactions involved in the synthesis of N-linked glycans. A 14 residue sugar is first built on a dolichol carrier and then attached to the amide group of an asparagine of a nascent polypeptide chain. The asparagine is in a specific amino acid sequence. Subsequent processing involves removal as well as addition of various sugars and produces a wide range of N-glycan structures.
http://purl.obolibrary.org/obo/PW_0000194	O-linked glycan biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000146	glycan metabolic pathway		Those metabolic reactions involved in the synthesis of O-linked glycans. Sugars are serially added to a fully synthesized polypeptide chain. The initial step involves the transfer of N-acetylgalactosamine to the carboxy group of a serine or threonine. The location of the residue appears to be dictated by structure rather than amino acid signature.
http://purl.obolibrary.org/obo/PW_0000195	chondroitin sulfate biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0002696	chondroitin sulfate metabolic pathway		Those metabolic reactions involved in the biosynthesis of chondroitin sulfate. Chondroitin is a mucopolysaccharide occurring in sulfated form in various animal tissues (such as cartilage).
http://purl.obolibrary.org/obo/PW_0000196	globoside metabolic pathway	http://purl.obolibrary.org/obo/PW_0000733	glycosphingolipid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of globosides - glycosphingolipids containing acetylated amino sugars and simple hexoses.
http://purl.obolibrary.org/obo/PW_0000197	sphingolipid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000010	lipid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of sphingolipids - important components of animal and plant membranes. They contain a long chain amino alcohol and a ceramide core. Ceramides are also the precursors of glycolipids, also referred to as glycosphingolipids, which have attached sugar(s).
http://purl.obolibrary.org/obo/PW_0000198	p38 MAPK signaling pathway	http://purl.obolibrary.org/obo/PW_0000312	stress-regulated MAPK signaling pathway		A SAPK MAPK pathway that plays an important role in inflammation and may be involved in several forms of cancer.
http://purl.obolibrary.org/obo/PW_0000199	the Wnt/calcium signaling pathway	http://purl.obolibrary.org/obo/PW_0000597	Wnt signaling, non-canonical pathway		A Wnt mediated pathway that is involved in the regulation of cell-cell adhesion and motility.
http://purl.obolibrary.org/obo/PW_0000200	Wnt signaling, the planar cell polarity pathway	http://purl.obolibrary.org/obo/PW_0000597	Wnt signaling, non-canonical pathway		The planar cell polarity (PCP) Wnt signaling pathway plays an essential role in morphogenesis through the regulation of tissues patterning.
http://purl.obolibrary.org/obo/PW_0000201	Wnt signaling, canonical pathway	http://purl.obolibrary.org/obo/PW_0000008	Wnt signaling pathway		The Wnt signaling pathway is involved in many developmental processes. In the conventional or canonical Wnt pathway, beta-catenin is a central component required for the transcriptional control of Wnt signaling target genes.
http://purl.obolibrary.org/obo/PW_0000202	homologous recombination pathway of double-strand break repair	http://purl.obolibrary.org/obo/PW_0000663	double-strand DNA repair pathway		A specific pathway for repair of double-strand breaks. It is involved in repair of breaks induced by damaging agents or generated during meiotic recombination.
http://purl.obolibrary.org/obo/PW_0000203	non-homologous end joining pathway of double-strand break repair	http://purl.obolibrary.org/obo/PW_0000663	double-strand DNA repair pathway		A specific pathway for repair of double-strand breaks. Possibly constitutive, it is the most important pathway in mammalian cells and plays an important role in mitotically replicating cells.
http://purl.obolibrary.org/obo/PW_0000204	Notch signaling pathway	http://purl.obolibrary.org/obo/PW_0000656	glycoprotein signaling pathway		The Notch signaling pathway regulates processes involved in early embryonic development. It plays an important role in cell fate determination. Target genes of Notch have been implicated in angiogenesis, somitogenesis and gliogenesis. Deregulation of the Notch signaling pathway underlies a broad spectrum of diseases and clinical conditions.
http://purl.obolibrary.org/obo/PW_0000205	dentatorubral-pallidoluysian atrophy pathway	http://purl.obolibrary.org/obo/PW_0000171	polyglutamine repeat pathway		Dentatorubral-pallidoluysian atrophy (DRPLA) is caused by an expanded trinucleotide repeat in the atrophin-1 (ATN1) gene. A rather rare condition, it can be juvenile-, early adult- or late adult-onset.
http://purl.obolibrary.org/obo/PW_0000206	transforming growth factor-beta signaling pathway	http://purl.obolibrary.org/obo/PW_0000329	transforming growth factor-beta superfamily mediated signaling pathway		The transforming growth factor-beta (TGF-beta) signaling pathway regulates numerous cellular processes such as proliferation, differentiation, migration and cell death. The SMAD-dependent pathway represents the core signaling cascade mediated by the TGF-beta superfamily. Mutations in the TGF-beta family are responsible for a number of human diseases.
http://purl.obolibrary.org/obo/PW_0000208	type 2 diabetes mellitus pathway	http://purl.obolibrary.org/obo/PW_0000176	diabetes mellitus pathway		Diabetes mellitus is characterized by abnormally high levels of glucose in the blood. Hereditary and environmental factors are likely contributors but the exact mechanisms are not well understood. Type 2 diabetes mellitus, characterized by insulin resistance, involves alterations in insulin secretion and signaling and impaired glucose homeostasis pathways.
http://purl.obolibrary.org/obo/PW_0000209	Jak-Stat signaling pathway	http://purl.obolibrary.org/obo/PW_0001195	tyrosine-specific protein kinase mediated signaling pathway		The Jak-Stat pathway is a main intracellular cascade initiated primarily in response to cytokine and also other ligand signaling. Four Janus kinases (Jak) and seven signal transducers and activators of transcription (Stat) families of proteins mediate the action of almost 40 cytokine receptors, including the receptor for leptin. Combinations between four Jak(s) and seven Stat(s) shape the outcome of ligand- triggered signaling through the various receptors.
http://purl.obolibrary.org/obo/PW_0000211	biogenic amines and polyamines metabolic pathway	http://purl.obolibrary.org/obo/PW_0000002	classic metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of biogenic amines and polyamines. Important biogenic amines are histamine, serotonin and the catecholamines.  Spermidine and spermine are examples of important polyamines.
http://purl.obolibrary.org/obo/PW_0000212	choline metabolic pathway	http://purl.obolibrary.org/obo/PW_0000211	biogenic amines and polyamines metabolic pathway		Choline metabolism is important for the synthesis of phosphatidylcholine in mammalian cells. Its oxidation results in the production of betaine, an important methyl donor. In the brain, it is converted to the powerful neurotransmitter acetylcholine.
http://purl.obolibrary.org/obo/PW_0000213	RNA polymerase IV transcription pathway	http://purl.obolibrary.org/obo/PW_0001275	eukaryotic RNA polymerase transcription pathway		RNA polymerase IV transcription pathway is found in plants and is involved in the synthesis of small interfering RNA (siRNA).
http://purl.obolibrary.org/obo/PW_0000214	polyamine metabolic pathway	http://purl.obolibrary.org/obo/PW_0000211	biogenic amines and polyamines metabolic pathway		Polyamines play important roles in cell growth, proliferation and survival. They can be derived from diet as well as via cellular- and intestinal flora-mediated biosynthesis.
http://purl.obolibrary.org/obo/PW_0000215	RNA polymerase V transcription pathway	http://purl.obolibrary.org/obo/PW_0001275	eukaryotic RNA polymerase transcription pathway		RNA polymerase V transcription pathway operates in plants and plays a role in heterochromatin formation.
http://purl.obolibrary.org/obo/PW_0000216	spermine metabolic pathway	http://purl.obolibrary.org/obo/PW_0000214	polyamine metabolic pathway		Polyamine metabolism plays important roles in a number of cellular processes. Spermidine and spermine are formed in two consecutive reactions carried out by distinct enzymes that employ the decarboxylated form of AdoMet as an aminopropyl donor.
http://purl.obolibrary.org/obo/PW_0000217	tetrahydrobiopterin metabolic pathway	http://purl.obolibrary.org/obo/PW_0000135	metabolic pathway of cofactors, vitamins, nutrients		Tetrahydrobiopterin is a cofactor for amino acid hydroxylases involved in the synthesis of several neurotransmitters. It can be synthesized de novo from guanosine triphosphate (GTP) or recycled via a regeneration pathway.
http://purl.obolibrary.org/obo/PW_0000218	heme biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0002633	iron utilization pathway		Those metabolic reactions involved in the biosynthesis of heme - an iron-containing compound where the iron is complexed within a porphyrin heterocyclic ring. There are several kinds of heme depending on the composition of their side chain. Heme serves as a prosthetic group for several classes of proteins that include hemoglobin and myoglobin, cytochromes, peroxidases, catalases and others.
http://purl.obolibrary.org/obo/PW_0000219	nicotinamide adenine dinucleotide biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0002580	nicotinamide adenine dinucleotide metabolic pathway		Those metabolic reactions involved in the synthesis of nicotinamide adenine dinucleotide (NAD). NAD can be synthesized de novo downstream of kynurenine metabolism of tryptophan degradation, or from precursors such as nicotinamide, nicotinic acid or nicotinamide riboside, collectively known as vitamin B3 or niacin.
http://purl.obolibrary.org/obo/PW_0000220	pyridine nucleotide biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000135	metabolic pathway of cofactors, vitamins, nutrients		Those metabolic reactions involved in the biosynthesis of pyridine nucleotides, nucleotides with a pyridine derivative as a nitrogen base.
http://purl.obolibrary.org/obo/PW_0000221	heme metabolic pathway	http://purl.obolibrary.org/obo/PW_0002285	porphyrin metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of heme - an iron-containing compound where the iron is complexed within a porphyrin heterocyclic ring.
http://purl.obolibrary.org/obo/PW_0000224	N-acetylglucosamine, N-acetylmannosamine and N-acetylneuraminic acid dissimilation pathway	http://purl.obolibrary.org/obo/PW_0000152	amino sugar metabolic pathway		Those metabolic reactions leading to the decomposition of N-acetylglucosamine - an acetylated amino sugar that is an important moiety of glycoproteins, N-acetylmannosamine - the acetylated derivative of mannosamine, and N-acetylneuraminic acid - the most common form of sialic acid in mammals.
http://purl.obolibrary.org/obo/PW_0000225	citrulline degradation pathway	http://purl.obolibrary.org/obo/PW_0000132	metabolic pathway of other amino acids		Those enzymatic reactions involved in the degradation of citrulline. Citrulline, not a DNA-coded amino acid, is a product in the urea cycle.
http://purl.obolibrary.org/obo/PW_0000226	putrescine metabolic pathway	http://purl.obolibrary.org/obo/PW_0000214	polyamine metabolic pathway		Putrescine, spermidine and spermine are the only polyamines synthesized in mammalian cells. Putrescine, derived from L-ornithine, an important component of the urea cycle, is the substrate for the formation of spermidine, which is in turn the substrate for spermine formation.
http://purl.obolibrary.org/obo/PW_0000227	G protein mediated signaling pathway via Galphas family	http://purl.obolibrary.org/obo/PW_0001539	heterotrimeric G protein mediated signaling pathway		Based on sequence similarity, the Galpha genes have been grouped into four classes. Exchange of GDP to GTP promoted through binding to receptors dissociates the heterotrimeric Galpa/beta/gamma complex. GTP-bound Galpha can then interact with downstream effectors. Lipid modification of Galpha regulates membrane localization and interactions with specific effectors.
http://purl.obolibrary.org/obo/PW_0000228	G protein mediated signaling pathway via Galphai family	http://purl.obolibrary.org/obo/PW_0001539	heterotrimeric G protein mediated signaling pathway		Based on sequence similarity, the Galpha genes have been grouped into four classes. Exchange of GDP to GTP promoted through binding to receptors dissociates the heterotrimeric Galpha/beta/gamma complex. GTP-bound Galpha can then interact with downstream effectors. Lipid modification of Galpha regulates membrane localization and interactions with specific effectors.
http://purl.obolibrary.org/obo/PW_0000229	G protein mediated signaling pathway via Galphaq family	http://purl.obolibrary.org/obo/PW_0001539	heterotrimeric G protein mediated signaling pathway		Based on sequence similarity, the Galpha genes have been grouped into four classes. Exchange of GDP to GTP promoted through binding to receptors dissociates the heterotrimeric Galpha/beta/gamma complex. GTP-bound Galpha can then interact with downstream effectors. Lipid modification of Galpha regulates membrane localization and interactions with specific effectors.
http://purl.obolibrary.org/obo/PW_0000230	G protein mediated signaling pathway via Galpha12/Galpha13 family	http://purl.obolibrary.org/obo/PW_0001539	heterotrimeric G protein mediated signaling pathway		Based on sequence similarity, the Galpha genes have been grouped into four classes. Exchange of GDP to GTP promoted through binding to receptors dissociates the heterotrimeric Galpa/beta/gamma complex. GTP-bound Galpha can then interact with downstream effectors. Lipid modification of Galpha regulates membrane localization and interactions with specific effectors.
http://purl.obolibrary.org/obo/PW_0000232	phosphatidylinositol 3-kinase-Akt signaling pathway	http://purl.obolibrary.org/obo/PW_0001194	serine/threonine-specific kinase mediated signaling pathway		The phosphatidylinositol 3-kinase-Akt signaling pathway, involving PI3K class I enzymes, particularly class IA, controls various processes such as cell growth, proliferation and survival. Class IA enzymes couple to receptor tyrosine kinases or their adaptors; class IB couple to G-protein-coupled receptors mainly via Galphai. Members of the Akt family of protein kinases are activated downstream of class I PI3Ks and collectively (Akt1, 2, and 3) phosphorylate more than 70 cytoplasmic and nuclear substrates. Deregulation of the pathway has been linked to various forms of cancer.
http://purl.obolibrary.org/obo/PW_0000233	tumor necrosis factor mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000926	pro-inflammatory cytokine mediated pathway		Tumor necrosis factor (Tnf) signaling plays pivotal roles in immunity, cell proliferation, differentiation and apoptosis by activating several pathways. NF-kB is a major pathway activated by Tnf; others include JNK and P38 MAPK. Through receptor-associated adapters, Tnf elicits apoptosis via the extrinsic pathway. Deregulation of Tnf signaling has been implicated in a great number of human diseases - cerebral malaria, cancer and multiple sclerosis are a few examples.
http://purl.obolibrary.org/obo/PW_0000234	innate immune response pathway	http://purl.obolibrary.org/obo/PW_0000023	immune response pathway		The innate immune response - a universal and ancient form of host defense against infection - is a first line of response to various pathogens and also to damaged cells. It plays a role in stimulating adaptive immunity; molecules generated during innate responses act as second signals that can impact on both the magnitude and the nature of the adaptive response.
http://purl.obolibrary.org/obo/PW_0000235	adaptive immune response pathway	http://purl.obolibrary.org/obo/PW_0000023	immune response pathway		The adaptive immune response is an evolutionarily newer mechanism that provides great specificity and diversity of antigen recognition, immunological memory and specialized responses. The two types of adaptive immune response pathways are humoral and cellular or cell-mediated.
http://purl.obolibrary.org/obo/PW_0000236	tumor necrosis factor superfamily mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000828	cytokine mediated signaling pathway		Members of TNF superfamily mediate autoimmunity and inflammation, cell proliferation, survival and/or apoptosis through a number of signaling mechanisms that involve activation of nuclear factor-kappaB, of caspases and/or of mitogen-activated protein kinases (MAPK). TNF superfamily has been implicated in a wide range of human diseases including tumorigenesis, septic shock, rheumatoid arthritis and other conditions.
http://purl.obolibrary.org/obo/PW_0000237	stress response pathway	http://purl.obolibrary.org/obo/PW_0000004	regulatory pathway		The pathway(s) elicited as a physiological response to various types of insults, injuries, shocks and other situations the organism perceives as threatening.
http://purl.obolibrary.org/obo/PW_0000238	insulin-like growth factor signaling pathway	http://purl.obolibrary.org/obo/PW_0000467	peptide and protein hormone signaling pathway		Insulin-like growth factor signaling plays important roles in cell growth and proliferation. Produced primarily by the liver in response to stimulation by growth hormone (GH), the proteins activate cognate receptors to prompt intracellular signaling pathways and cell growth in a variety of tissues. Deregulation of the pathway has been associated with various conditions, including cancer.
http://purl.obolibrary.org/obo/PW_0000239	type 1 diabetes mellitus pathway	http://purl.obolibrary.org/obo/PW_0001018	immune system disease pathway		Diabetes mellitus is characterized by abnormally high levels of glucose in the blood. Hereditary and environmental factors are likely contributors but the exact mechanisms are not well understood. The type 1 diabetes mellitus pathway involves alterations in immune response pathways resulting in destruction of the insulin-producing beta cells.
http://purl.obolibrary.org/obo/PW_0000240	neuropsychiatric disease pathway	http://purl.obolibrary.org/obo/PW_0000013	disease pathway		Neuropsychiatric diseases are mental disorders due to various defects in the working of the nervous system.
http://purl.obolibrary.org/obo/PW_0000241	schizophrenia pathway	http://purl.obolibrary.org/obo/PW_0000240	neuropsychiatric disease pathway		Schizophrenia is a psychiatric diagnosis denoting a persistent, often chronic, mental illness variously affecting behavior, thinking, and emotion. The term schizophrenia comes from the Greek words schizo, (split or divide) and phrenos, (mind) and is best translated as 'shattered mind'.
http://purl.obolibrary.org/obo/PW_0000242	bipolar disorder pathway	http://purl.obolibrary.org/obo/PW_0000240	neuropsychiatric disease pathway		As categorized by the DSM-IV, bipolar disorder is a form of mood disorder characterized by a variation of mood between a phase of manic or hypomanic elation, hyperactivity and hyper imagination, and a depressive phase of inhibition, slowness to conceive ideas and move, and anxiety or sadness. Together these form what is commonly known as manic depression. Manic depression, with its two principal sub-types, bipolar disorder and major depression, was first clinically described near the end of the 19th century by psychiatrist Emil Kraepelin, who published his account of the disease in his Textbook of Psychiatry. DSM-IV is the Diagnostic and Statistical Manual of Mental Disorders, published by the American Psychiatric Association, is the handbook used most often in diagnosing mental disorders in the United States and other countries.
http://purl.obolibrary.org/obo/PW_0000243	vascular endothelial growth factor signaling pathway	http://purl.obolibrary.org/obo/PW_0000168	growth factor signaling pathway		The VEGF family plays key roles in angiogenesis and lymphangiogenesis. Through their receptors, VEGFs can initiate a diverse and complex network of signaling cascades. Deregulation of VEGF-mediated pathways, mostly through upregulation of VEGF expression, has been implicated in a number of conditions, primarily cancer.
http://purl.obolibrary.org/obo/PW_0000244	angiotensin II signaling pathway	http://purl.obolibrary.org/obo/PW_0000245	angiotensin signaling pathway		Angiotensin II signaling pathways play a critical role in the control of cardiovascular and renal homeostasis. Angiotensin II pathway can also contribute to cardiovascular diseases such as hypertension, atherosclerosis and heart failure.
http://purl.obolibrary.org/obo/PW_0000245	angiotensin signaling pathway	http://purl.obolibrary.org/obo/PW_0000467	peptide and protein hormone signaling pathway		Angiotensin peptides Ang II, Ang III, Ang IV and Ang (1-7) generated from a single precursor protein - angiotensinogen - regulate an array of physiological and pathophysiological processes.
http://purl.obolibrary.org/obo/PW_0000246	Rheb mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000158	Ras family mediated signaling pathway		The Rheb family of proteins plays an essential role in the regulation of cell growth and cell cycle. Rheb could be a mediator of the mTOR signaling pathway. The results have been shown for Drosophila but remained to be established for mammals.
http://purl.obolibrary.org/obo/PW_0000247	transforming growth factor-beta Smad independent signaling pathway	http://purl.obolibrary.org/obo/PW_0000206	transforming growth factor-beta signaling pathway		TGF-beta can activate signaling cascades other than the Smad-mediated ones, including MAPK pathways such as Erk, p38 and JNK. The mechanisms of MAPK pathway activation by TGF-beta are not well understood.
http://purl.obolibrary.org/obo/PW_0000248	isoprenoid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000010	lipid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of isoprenoids or terpenoids - a large class of organic biomolecules. Isoprenoids are precursors of sterols such as cholesterol and its derivatives and also of non-sterol molecules, many of which are used in the post-translational modification of proteins. Plant isoprenoids are among the most commonly found and have a broad range of uses and applications in plants and beyond.
http://purl.obolibrary.org/obo/PW_0000249	lipopolysaccharide biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000876	bacterial polysaccharide metabolic pathway		Those metabolic reactions involved in the biosynthesis of lipopolysaccharides, also known as lipoglycans, found in the outer membranes of Gram-negative bacteria. They are large molecules consisting of a lipid and a polysaccharide joined by a covalent bond. In host cells they act as endotoxins which are recognized by members of the Toll-like receptors to elicit strong immune responses.
http://purl.obolibrary.org/obo/PW_0000250	peptidoglycan biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000876	bacterial polysaccharide metabolic pathway		Those metabolic reactions involved in the biosynthesis of peptidoglycan - a high molecular weight polymer that forms the tough, rigid structure of bacterial cell walls. It is made up of three parts: (1) a backbone, composed of alternating N-acetylglucosamine and N-acetylmuramic acid; (2) a set of identical tetrapeptide side-chains attached to N-acetylmuramic acid; and (3) a set of identical peptide cross-bridges. The backbone is the same in all bacterial species; however, the tetrapeptide side-chains and the peptide cross-bridges vary from species to species.
http://purl.obolibrary.org/obo/PW_0000251	diterpenoid biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000184	terpenoid biosynthetic pathway		Those metabolic reactions involved in the synthesis of diterpenoids. Terpenoids are a large class of naturally-occurring organic chemicals. They are derived from five-carbon units and are modifed in manifold ways.
http://purl.obolibrary.org/obo/PW_0000253	indole and ipecac alkaloid biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000147	metabolic pathway of secondary metabolites		Those metabolic reactions involved in the synthesis of indole and ipecac. Indole is a heterocyclic compound, obtained from coal tar, and produced by the decomposition of tryptophan in the intestine, being partly responsible for the peculiar odor of the feces. It is also found in cultures of Vibrio cholerae and other bacteria; a color test for its production is used in classifying enteric bacteria. Ipecac is derived from the dried rhizome and roots of Cephaelis ipecacuanha or of C. acuminata. It is a mixture of alkaloids, primarily emetine and cephaelin.
http://purl.obolibrary.org/obo/PW_0000254	penicillins and cephalosporins biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000147	metabolic pathway of secondary metabolites		Those metabolic reactions involved in the biosynthesis of penicillin and cephalosporins. The former is the best known antibiotic which blocks the cross linking reaction in peptidoglycan synthesis, thus destroying the bacterial cell wall. The latter represents a broad class of antibiotics similar to penicillin, both chemically and in mode of action.
http://purl.obolibrary.org/obo/PW_0000255	beta-Lactam resistance pathway	http://purl.obolibrary.org/obo/PW_0000147	metabolic pathway of secondary metabolites		Those pathways that confer to an organism resistance to the action of beta-lactams - a class of broad spectrum antibiotics that are structurally and pharmacologically related to penicillins and cephalosporins.
http://purl.obolibrary.org/obo/PW_0000256	polyketides biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000147	metabolic pathway of secondary metabolites		Those metabolic reactions involved in the biosynthesis of polyketides. Polyketides are a group of secondary metabolites made by microorganisms that possess a broad range of pharmacologically important activities such as antimicrobial, antifungal, antiparasitic and antitumor.
http://purl.obolibrary.org/obo/PW_0000258	tetracycline biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000147	metabolic pathway of secondary metabolites		Those metabolic reactions involved in the synthesis of tetracyclines - any of a group of biosynthetic antibiotics. Some are isolated from certain species of Streptomyces and others are produced semisynthetically.
http://purl.obolibrary.org/obo/PW_0000259	clavulanic acid biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000147	metabolic pathway of secondary metabolites		Those metabolic reactions involved in the biosynthesis of clavulanic acid. Clavulanic acid is a beta-lactam antibiotic produced by a bacterium of the genus Streptomyces (S. clavuligerus) that is a beta-lactamase inhibitor and is usually used in the form of its clavulanate salt of potassium especially in combination with amoxicillin.
http://purl.obolibrary.org/obo/PW_0000260	puromycin biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000147	metabolic pathway of secondary metabolites		Those metabolic reactions involved in the biosynthesis of puromycin - an antibiotic produced by Streptomyces alboniger, which has been used experimentally as an antineoplastic because of its ability to inhibit protein synthesis; it also has trypanosomicidal and amebicidal activity and was formerly used in the treatment of African trypanosomiasis and amebic dysentery.
http://purl.obolibrary.org/obo/PW_0000261	neuronal secretory pathway	http://purl.obolibrary.org/obo/PW_0001251	regulatory pathway pertinent to the brain		The unique morphology of the neuron defies the classical organization of secretory pathways. The neuronal secretory pathway represents the intracellular trafficking route for proteins involved in synaptic transmission and plasticity and for lipids necessary for growth and remodeling of neurites. Neurons possess both somatic and dendritic Golgi compartments.
http://purl.obolibrary.org/obo/PW_0000262	altered metabolic pathway	http://purl.obolibrary.org/obo/PW_0000002	classic metabolic pathway		Those metabolic pathways that deviate from what their normal course should be. Aberrant metabolic pathways, alone or in combination with other pathways, underlie many conditions, disorders and/or diseases.
http://purl.obolibrary.org/obo/PW_0000263	altered regulatory pathway	http://purl.obolibrary.org/obo/PW_0000004	regulatory pathway		Those regulatory pathways that deviate from what their normal course should be. Aberrant regulatory pathways, alone or in combination with other pathways underlie many conditions, disorders and/or diseases.
http://purl.obolibrary.org/obo/PW_0000264	altered signaling pathway	http://purl.obolibrary.org/obo/PW_0000003	signaling pathway		Those signaling pathways that deviate from what their normal course should be. Aberrant signaling pathways, alone or in combination with other pathways underlie many conditions, disorders and/or diseases.
http://purl.obolibrary.org/obo/PW_0000265	Creutzfeldt-Jakob disease pathway	http://purl.obolibrary.org/obo/PW_0000019	prion disease pathway		Creutzfeldt-Jakob disease -  a rare prion disease, associated with a number of different mutations of the prion protein gene, existing in sporadic, familial (as an autosomal dominant), and infectious forms, with onset usually in middle life, and having a wide variety of clinical and pathological features. The most commonly seen are varying degrees of spongiform degeneration of neurons, neuronal loss, gliosis, and amyloid plaque formation, accompanied by rapidly progressive dementia, myoclonus, motor disturbances.
http://purl.obolibrary.org/obo/PW_0000266	Gerstmann-Strussler syndrome, Gerstmann-Strussler-Scheinker syndrome pathway	http://purl.obolibrary.org/obo/PW_0000019	prion disease pathway		Gerstmann-Strussler syndrome,   Gerstmann-Strussler-Scheinker syndrome - a group of rare prion diseases, of autosomal dominant inheritance but linked to different mutations of the prion protein gene. Common characteristics include cognitive and motor disturbances, the presence of multicentric amyloid plaques in the brain. Its manifestations include cerebellar ataxia and dementia, rigidity, tremor, memory loss and others, depending on the form of the condition.
http://purl.obolibrary.org/obo/PW_0000267	fatal familial insomnia pathway	http://purl.obolibrary.org/obo/PW_0000019	prion disease pathway		Fatal familial insomnia - an inherited prion disease, transmitted as an autosomal dominant trait, affecting primarily the ventral and dorsomedial nuclei of the thalamus and characterized by progressive insomnia, hallucinations, stupor, and coma ending in death within 6 months to 3 years of onset; autonomic and motor disturbances are also present.
http://purl.obolibrary.org/obo/PW_0000268	kuru	http://purl.obolibrary.org/obo/PW_0000019	prion disease pathway		Kuru - an infectious form of prion disease with a long incubation period, found only among the Fore and neighboring peoples of New Guinea. It is thought to be associated with ritual cannibalism. Its manifestations include truncal and limb ataxia, tremor, others; ends invariably in death. Amyloid plaques are present in about two thirds of affected individuals.
http://purl.obolibrary.org/obo/PW_0000269	protein folding pathway	http://purl.obolibrary.org/obo/PW_0001756	peptide and protein metabolic pathway		Those reactions and molecular interactions underlying the folding of a protein into its functional three-dimensional structure. Folding takes place in the cytoplasm and, in the case of secreted proteins, in the endoplasmic reticulum. Proteins are checked (quality control) for proper folding and misfolded proteins are targeted for degradation.
http://purl.obolibrary.org/obo/PW_0000270	presynaptic differentiation pathway	http://purl.obolibrary.org/obo/PW_0002422	synaptic differentiation pathway		The major events in presynaptic terminal differentiation are the formation of the active zone and the clustering of synaptic vesicles. Cytoskeletal and membrane specializations within the presynapse are necessary to for the regulated exo- and endocytosis of synaptic vesicles.
http://purl.obolibrary.org/obo/PW_0000271	postsynaptic differentiation pathway	http://purl.obolibrary.org/obo/PW_0002422	synaptic differentiation pathway		The factors and components involved in, and the elements that regulate them and together shape and modulate the formation of the postsynaptic differentiation.
http://purl.obolibrary.org/obo/PW_0000273	neuron-to-neuron signaling pathway via the electrical synapse	http://purl.obolibrary.org/obo/PW_0000272	neuron-to-neuron signaling pathways		A simpler pathway of neuron-to-neuron signaling involving the direct flow of ionic currents. It is a reciprocal pathway involving membrane-to-membrane apposition known as a gap junction.
http://purl.obolibrary.org/obo/PW_0000274	neuron-to-neuron signaling pathway via the chemical synapse	http://purl.obolibrary.org/obo/PW_0000272	neuron-to-neuron signaling pathways		A neurotransmitter-releasing pathway of neuron-to-neuron communication. It involves fusion of neurotransmitter-filled synaptic vesicles with the plasma membrane and activation of postsynaptic receptors. It also involves recycling and re-release of synaptic vesicles.
http://purl.obolibrary.org/obo/PW_0000275	cell death pathway	http://purl.obolibrary.org/obo/PW_0000004	regulatory pathway		A cell death pathway represents the particular series of events leading to the demise of a whole cell or parts of its contents. It plays an essential role in cellular and tissue homeostasis. Biochemical and morphological characteristics are used in the classification of various forms of cell death. Deregulation of cell death can contribute to the development of cancer and neurodegeneration.
http://purl.obolibrary.org/obo/PW_0000276	non-apoptotic cell death pathway	http://purl.obolibrary.org/obo/PW_0001557	programmed cell death pathway		Non-apoptotic cell death pathway refers collectively to those types of cell death whose functional and/or morphological features are different from the apoptotic cell death. Cellular autophagy is an example.
http://purl.obolibrary.org/obo/PW_0000277	cellular senescence pathway	http://purl.obolibrary.org/obo/PW_0000651	aging pathway		Cellular senescence, also known as replicative senescence, results from cells ceasing to divide. Generally, it is a state of steady cell cycle arrest induced by stresses such as DNA damage, toxins and/or oncogene activation.
http://purl.obolibrary.org/obo/PW_0000278	autophagy pathway	http://purl.obolibrary.org/obo/PW_0002402	cellular autophagy pathway		The autophagic pathway involves the sequestration of misfolded or long-lived proteins and of defective organelles within double membrane vesicles, and delivery of the cargo to lysosomes for degradation and recycling. It is also known as macroautophagy, or bulk autophagy.
http://purl.obolibrary.org/obo/PW_0000279	necrosis pathway	http://purl.obolibrary.org/obo/PW_0001558	non-programmed cell death pathway		Necrosis represents the sum of the morphological changes indicative of cell death and is caused by the progressive degradative action of enzymes; it may affect groups of cells or part of a structure or an organ. There are many causes of necrosis including injury, infection, cancer, infarction, inflammation and others. There are several distinctive morphologic patterns of necrosis.
http://purl.obolibrary.org/obo/PW_0000280	protein secretory pathway	http://purl.obolibrary.org/obo/PW_0000181	pathway pertinent to protein folding, sorting, modification, translocation and degradation		The secretory pathway is the route by which secreted proteins travel from sites of biosynthesis and folding, modification and sorting, to their final destinations. It involves ER insertion where folding and quality control of folding take place, move to Golgi and trans-Golgi Network (TGN) where sorting and final modifications take place, exit from Golgi and vesicular transport and delivery to plasma membrane and extracellular space or the endosomal system via constitutive or regulated exocytosis.
http://purl.obolibrary.org/obo/PW_0000281	endocytosis pathway	http://purl.obolibrary.org/obo/PW_0002395	cellular trafficking cycle pathway		The endocytic pathway allows for recycling of cargo delivered via the exocytic or secretory routes, uptake of nutrients, internalization of receptors and also, the engulfing of dying cells or of material foreign to the cell. Endocytosis can be subdivided into four pathways: clathrin-mediated and caveolae-mediated endocytosis, micropinocytosis and phagocytosis. Endosomes and lysosomes are central endocytic components responsible for sorting, recycling, or degradation of cargo, as necessary.
http://purl.obolibrary.org/obo/PW_0000282	benzoate degradation pathway	http://purl.obolibrary.org/obo/PW_0000107	xenobiotics biodegradation pathway		Those enzymatic reactions involved in the degradation of benzoate - a salt of benzoic acid or benzene carboxylic acid, a fungistatic compound widely used as a food preservative.
http://purl.obolibrary.org/obo/PW_0000283	altered glycan metabolic pathway	http://purl.obolibrary.org/obo/PW_0000262	altered metabolic pathway		Those metabolic pathways involving glycan that deviate from what their normal course should be. Aberrant glycan metabolic pathways, alone or in combination with other pathways, underlie various diseases.
http://purl.obolibrary.org/obo/PW_0000284	altered glycosaminoglycan pathway	http://purl.obolibrary.org/obo/PW_0000283	altered glycan metabolic pathway		Those metabolic pathways involving glycosaminoglycans that deviate from what their normal course should be. Aberrant glycosaminoglycan pathways, alone or in combination with other pathways underlie various diseases.
http://purl.obolibrary.org/obo/PW_0000285	altered heparan sulfate pathway	http://purl.obolibrary.org/obo/PW_0000524	heparan sulfate biosynthetic pathway		Those metabolic pathways involving heparan sulfate (HS) that deviate from what their normal course should be. Aberrant HS pathways, alone or in combination with other pathways may be involved in diseases. An example is the potential role of HS in Alzheimer's disease.
http://purl.obolibrary.org/obo/PW_0000286	integrin mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0001502	mechanotransduction pathway		Integrins signal bi-directionally across the plasma membrane and provide an example of mechanotransduction. Inside-out signaling modulates their interaction with ligands to regulate cell adhesion and ECM organization. Ligand binding initiates and shapes many signaling events and links to the cytoskeleton. Via protein clustering and ECM organization integrins synergize with and/or modulate various growth factor pathways. Integrin signaling regulates multiple processes including gene expression, cell proliferation, differentiation and survival.
http://purl.obolibrary.org/obo/PW_0000287	altered apoptotic cell death pathway	http://purl.obolibrary.org/obo/PW_0001559	altered programmed cell death pathway		Those apoptotic pathways that deviate from what their normal course should be. Aberrant pathways of programmed cell death, alone or in combination with other pathways underlie various diseases.
http://purl.obolibrary.org/obo/PW_0000288	altered intrinsic apoptotic pathway	http://purl.obolibrary.org/obo/PW_0000287	altered apoptotic cell death pathway		An intrinsic apoptotic pathway that deviates from what its normal course should be. Aberrant intrinsic apoptotic pathway, alone or in combination with other pathways underlies various diseases.
http://purl.obolibrary.org/obo/PW_0000289	altered cell death pathway	http://purl.obolibrary.org/obo/PW_0000275	cell death pathway		Those pathways of cell death that deviate from what their normal course should be. Aberrant pathways of cell death, alone or in combination with other pathways underlie various diseases.
http://purl.obolibrary.org/obo/PW_0000290	altered pathway pertinent to DNA replication and repair, cell cycle, maintenance of genomic integrity, RNA and protein biosynthesis	http://purl.obolibrary.org/obo/PW_0000263	altered regulatory pathway		Those pathways involved in and/or controlling DNA replication, cell cycle, DNA repair and preservation of genomic integrity, RNA and protein biosynthesis that deviate from what their normal course should be. Such aberrant pathways, alone or in combination with other pathways underlie various diseases.
http://purl.obolibrary.org/obo/PW_0000292	altered DNA repair pathway	http://purl.obolibrary.org/obo/PW_0000290	altered pathway pertinent to DNA replication and repair, cell cycle, maintenance of genomic integrity, RNA and protein biosynthesis		Those pathways of DNA repair that deviate from what their normal course should be. Aberrant pathways of DNA repair, alone or in combination with other pathways underlie various diseases.
http://purl.obolibrary.org/obo/PW_0000293	altered pathway pertinent to protein folding, sorting, modification, translocation and degradation	http://purl.obolibrary.org/obo/PW_0000263	altered regulatory pathway		Those pathways of protein folding, sorting, modification, translocation and degradation that deviate from what their normal course should be. Aberrant protein pathways, alone or in combination with other pathways underlie various diseases.
http://purl.obolibrary.org/obo/PW_0000294	altered ubiquitin/proteasome degradation pathway	http://purl.obolibrary.org/obo/PW_0000418	altered ubiquitin, ubiquitin-like degradation pathway		An ubiquitin/proteasome degradation pathway that deviates from what its normal course should be. Aberrations in the pathway have been implicated in a number of diseases. Examples include certain malignancies, disorders of the immune and inflammatory responses and neurodegeneration.
http://purl.obolibrary.org/obo/PW_0000295	altered integrin mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000671	altered cell adhesion signaling pathway		An integrin signaling pathway that deviates from what its normal course should be. Aberrant integrin signaling pathway, alone or in combination with other pathways underlies various diseases. An example is hypertrophic cardiomyopathy that involves integrins and the synergy between integrins and growth factors. Aberrant integrin signaling has also been correlated with tumor progression in several cancers.
http://purl.obolibrary.org/obo/PW_0000296	hypertrophic cardiomyopathy pathway	http://purl.obolibrary.org/obo/PW_0000022	cardiomyopathy pathway		Hypertrophic cardiomyopathy, or HCM, is a disease of the myocardium (the muscle of the heart) in which a portion of the myocardium is thickened. Many physiological and pathological conditions as well as many pathways underlie the hypertrophic response.
http://purl.obolibrary.org/obo/PW_0000297	platelet-derived growth factor signaling pathway	http://purl.obolibrary.org/obo/PW_0000650	signaling pathway pertinent to development		The PDGF signaling pathway plays an important role in the regulation of cell growth and survival.
http://purl.obolibrary.org/obo/PW_0000298	altered growth factor signaling pathway	http://purl.obolibrary.org/obo/PW_0000264	altered signaling pathway		Those growth factor mediated signaling pathways that deviate from what their normal course should be. Aberrant growth factor mediated pathways, alone or in combination with other pathways underlie various diseases.
http://purl.obolibrary.org/obo/PW_0000299	myocardial infarction pathway	http://purl.obolibrary.org/obo/PW_0000020	cardiovascular system disease pathway		Myocardial infarction, commonly known as heart attack, is a serious, sudden heart condition characterized by varying degrees of chest pain, weakness, sweating, nausea and vomiting, sometimes causing loss of consciousness. It occurs when parts of the heart muscle die because they are not supplied with enough blood.
http://purl.obolibrary.org/obo/PW_0000300	kidney disease pathway	http://purl.obolibrary.org/obo/PW_0001700	urologic disease pathway		The congenital and acquired diseases affecting the kidney.
http://purl.obolibrary.org/obo/PW_0000301	kidney failure pathway	http://purl.obolibrary.org/obo/PW_0000300	kidney disease pathway		Renal failure implies the loss of kidney function. It can be acute and rapidly progressing, or chronic with slow progression. Chronic renal failure may involve a number of kidney diseases and end-stage renal failure is the ultimate consequence.
http://purl.obolibrary.org/obo/PW_0000302	glomerulonephritis pathway	http://purl.obolibrary.org/obo/PW_0000300	kidney disease pathway		Glomerulonephritis is accompanied by inflammation of the capillary loops in the glomeruli of the kidney. It occurs in acute, subacute, and chronic forms and may be secondary to hemolytic streptococcal infection. Evidence also supports possible immune or autoimmune mechanisms.
http://purl.obolibrary.org/obo/PW_0000303	p53-dependent G1/S DNA damage checkpoint pathway	http://purl.obolibrary.org/obo/PW_0000095	G1/S DNA damage checkpoint pathway		The p53-dependent pathway of G1 arrest in response to damaged DNA.
http://purl.obolibrary.org/obo/PW_0000304	p53-independent G1/S DNA damage checkpoint pathway	http://purl.obolibrary.org/obo/PW_0000095	G1/S DNA damage checkpoint pathway		The p53-independent pathway of G1/S arrest in response to damaged DNA.
http://purl.obolibrary.org/obo/PW_0000305	altered carbohydrate metabolic pathway	http://purl.obolibrary.org/obo/PW_0000262	altered metabolic pathway		Those pathways of carbohydrate metabolism that deviate from what their normal course should be. Aberrant carbohydrate metabolic pathways, alone or in combination with other pathways, underlie various diseases.
http://purl.obolibrary.org/obo/PW_0000306	altered galactose metabolic pathway	http://purl.obolibrary.org/obo/PW_0000305	altered carbohydrate metabolic pathway		Those pathways of galactose metabolism that deviate from what their normal course should be. An aberrant galactose metabolic pathways, alone or in combination with other pathways underlies various diseases. One example is the involvement of aberrant galactose catabolism in cancer.
http://purl.obolibrary.org/obo/PW_0000307	coagulative necrosis pathway	http://purl.obolibrary.org/obo/PW_0000279	necrosis pathway		Coagulative necrosis is typically seen in hypoxic environments. Cell outlines remain after cell death and can be observed by light microscopy (e.g. myocardial infarction, infarct of the spleen).
http://purl.obolibrary.org/obo/PW_0000308	liquefactive necrosis pathway	http://purl.obolibrary.org/obo/PW_0000279	necrosis pathway		Liquefactive necrosis is associated with cellular destruction and pus formation (e.g. pneumonia).
http://purl.obolibrary.org/obo/PW_0000309	caseous necrosis pathway	http://purl.obolibrary.org/obo/PW_0000279	necrosis pathway		Caseous necrosis is a mix of coagulative necrosis and liquefactive necrosis (e.g. tuberculosis).
http://purl.obolibrary.org/obo/PW_0000310	fatty necrosis pathway	http://purl.obolibrary.org/obo/PW_0000279	necrosis pathway		Fatty necrosis results from the action of lipases on fatty tissues (e.g. acute pancreatitis).
http://purl.obolibrary.org/obo/PW_0000311	fibrinoid necrosis pathway	http://purl.obolibrary.org/obo/PW_0000279	necrosis pathway		Fibrinoid necrosis involves the deposition of fibrin and other plasma proteins in the walls of afferent renal arterioles in malignant hypertension, often accompanied by an inflammatory infiltrate within the walls and thrombosis of the vessel lumen. 
http://purl.obolibrary.org/obo/PW_0000312	stress-regulated MAPK signaling pathway	http://purl.obolibrary.org/obo/PW_0000007	mitogen activated protein kinase signaling pathway		MAPK signaling pathways that are responding to stress or injury as well as inflammatory cytokines.
http://purl.obolibrary.org/obo/PW_0000313	c-Jun N-terminal kinases MAPK signaling pathway	http://purl.obolibrary.org/obo/PW_0000312	stress-regulated MAPK signaling pathway		A stress-induced MAPK pathway that regulates an array of processes such as gene expression, cell migration, cytoskeletal organization and apoptosis.
http://purl.obolibrary.org/obo/PW_0000314	calcium/calmodulin dependent signaling pathway	http://purl.obolibrary.org/obo/PW_0001140	calcium/calcium-mediated signaling pathway		Those signaling pathways that are mediated through the binding of calmodulin - a multifunctional calcium transducer - to its target effectors.
http://purl.obolibrary.org/obo/PW_0000315	calcineurin signaling pathway	http://purl.obolibrary.org/obo/PW_0000653	serine/threonine-specific phosphatase mediated signaling pathway		Calcineurin - a calcium/calmodulin dependent serine/threonine phosphatase - plays important regulatory roles in cardiac muscle growth and differentiation, memory processes and apoptosis.
http://purl.obolibrary.org/obo/PW_0000316	calcium/calmodulin dependent kinase signaling pathway	http://purl.obolibrary.org/obo/PW_0001194	serine/threonine-specific kinase mediated signaling pathway		The multifunctional calcium/calmodulin-dependent serine/threonine kinases (CAMKs) play important regulatory roles in the cardiac, muscle, nervous and immune tissues. They are represented by CAMK2 whose Ca2+/CaM binding leads to autophosphorylation and activation and the CAMK cascades that depend on an upstream CAMK kinase (CAMKK) for phosphorylation of an 'activation loop' and subsequent activation. CAMK1 and CAMK4 are the two CAMK signaling cascades.
http://purl.obolibrary.org/obo/PW_0000317	nuclear factor of activated T-cells signaling pathway	http://purl.obolibrary.org/obo/PW_0001313	transcription pathway via transcription factor mediated signaling		Members of the NFAT family of transcription factors, once de-phosphorylated by calcineurin, translocate from the cytoplasm to the nucleus where they induce the transcription of genes involved in the immune response and cell-cell interactions. NFAT signaling is believed to play important roles in the development and function of the cardiovascular system.
http://purl.obolibrary.org/obo/PW_0000318	altered calcium/calmodulin dependent signaling pathway	http://purl.obolibrary.org/obo/PW_0001169	altered calcium/calcium-mediated signaling pathway		Those calcium/CaM dependent pathways that deviate from what their normal course should be. Aberrant calcium/CaM dependent pathways, alone or in combination with other pathways underlie many diseases. One example is the potential role disruptions within these pathways play in cardiac hypertrophy.
http://purl.obolibrary.org/obo/PW_0000319	altered calcineurin signaling pathway	http://purl.obolibrary.org/obo/PW_0001197	altered serine/threonine-specific phosphatase mediated signaling pathway		A calcineurin signaling pathway that deviates from what its normal course should be. Aberrant calcineurin pathway, alone or in combination with other pathways underlie various diseases. One example is the role a constitutively active calcineurin plays in cardiac hypertrophy, via the NFAT pathway.
http://purl.obolibrary.org/obo/PW_0000320	novobiocin biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000147	metabolic pathway of secondary metabolites		Those metabolic reactions involved in the synthesis of novobiocin, an aminocoumarin antibiotic. It is also known as albamycin or cathomycin and is produced by an actinomycete of the order Actinobacteria.
http://purl.obolibrary.org/obo/PW_0000321	altered Hedgehog signaling pathway	http://purl.obolibrary.org/obo/PW_0000673	altered signaling pathway pertinent to development		A Hedgehog signaling pathway that deviates from what its normal course should be. Aberrant Hedgehog signaling pathway has been involved in a number of human cancers.
http://purl.obolibrary.org/obo/PW_0000322	ephrin - ephrin receptor bidirectional signaling axis	http://purl.obolibrary.org/obo/PW_0000332	cell-cell signaling pathway		Ephrins and their receptors constitute a bidirectional signaling pathway transducing forward signals through the receptors and reverse signals through the ephrins that influence the behavior of both interacting cells. The Eph/ephrin axis plays important roles in cell morphology, adhesion and migration. Its disruption has been implicated in several human cancers.
http://purl.obolibrary.org/obo/PW_0000323	altered ephrin - ephrin receptor bidirectional signaling pathway	http://purl.obolibrary.org/obo/PW_0000336	altered cell-cell signaling pathway		An Eph/ephrin bidirectional axis that deviates from what its normal course should be. Aberrant Eph/ephrins axis has been implicated in a number of human cancers.
http://purl.obolibrary.org/obo/PW_0000324	altered Notch signaling pathway	http://purl.obolibrary.org/obo/PW_0000673	altered signaling pathway pertinent to development		A Notch signaling pathway that deviates from what its normal course should be. Aberrant Notch signaling pathway has been implicated in a number of human cancers.
http://purl.obolibrary.org/obo/PW_0000325	protein degradation pathway	http://purl.obolibrary.org/obo/PW_0000181	pathway pertinent to protein folding, sorting, modification, translocation and degradation		Those pathways involved in the degradation of proteins.
http://purl.obolibrary.org/obo/PW_0000327	protein disulphide bond formation pathway	http://purl.obolibrary.org/obo/PW_0000269	protein folding pathway		The pathways involved in the formation, reduction and isomerization of disulphide bonds in proteins. Disulphide bonds are essential for the stability of proteins that are secreted or are localized to organelles of the secretory pathway.
http://purl.obolibrary.org/obo/PW_0000328	fibroblast growth factor signaling pathway	http://purl.obolibrary.org/obo/PW_0000168	growth factor signaling pathway		The family of fibroblast growth factors (FGF) comprises 22 ligands classified into seven phylogenetic subfamilies and three groups by mode of action: the intracellular intracrine and the extracellular paracrine or canonical and endocrine or hormone-like groups. The paracrine subfamilies signal via the fibroblast growth factor receptors (FGFR), receptor tyrosine kinases (RTK). The endocrine subfamily is FGFR-dependent but the affinity towards the receptors is low and it relies on the Klotho family of transmembrane proteins. The intracrine subfamily is FGFR-independent. Overall, the pathway plays important roles during embryonic and postnatal development, neuromodulation, mineral metabolism and homeostasis. Deregulation of the pathway has been associated with neoplastic and metabolic diseases.
http://purl.obolibrary.org/obo/PW_0000329	transforming growth factor-beta superfamily mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000168	growth factor signaling pathway		The TGF-beta superfamily of growth factors regulates a broad spectrum of processes such as angiogenesis, embryonic development, cell differentiation, proliferation and wound healing. Binding to two types of serine/threonine receptors and activation of Smad proteins is a common theme. However, ligand-receptor interaction and the identity of the activated Smad protein(s) appear to be member-specific.
http://purl.obolibrary.org/obo/PW_0000330	Bone morphogenetic proteins signaling pathway	http://purl.obolibrary.org/obo/PW_0000650	signaling pathway pertinent to development		The bone morphogenetic proteins (BMP) are related to TGF-beta and activins and are members of the TGF-beta superfamily. The BMP signaling pathway plays important roles in induction and patterning of the mesoderm. BMP pathway cross-talks to other pathways such as TGF-beta, Wnt, MAPK, Notch, JAK-STAT and others.
http://purl.obolibrary.org/obo/PW_0000331	activin signaling pathway	http://purl.obolibrary.org/obo/PW_0000650	signaling pathway pertinent to development		Activins are members of the TGF-beta superfamily of growth factors. The pathway plays important roles in embryonic development, inflammation and reproductive biology. Deregulation of activin signaling contributes to a number of pathological conditions.
http://purl.obolibrary.org/obo/PW_0000332	cell-cell signaling pathway	http://purl.obolibrary.org/obo/PW_0000648	cell adhesion signaling pathway		The cell-cell signaling pathway conveys information between cells using cell adhesion molecules.
http://purl.obolibrary.org/obo/PW_0000333	cadherin mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000332	cell-cell signaling pathway		Cadherins represent a large protein superfamily with many and important roles in cell adhesion and signaling. Cadherins are characterized by the presence of the extracellular cadherin, calcium-binding repeat. The number and structural similarities of repeats across families vary.
http://purl.obolibrary.org/obo/PW_0000335	altered transforming growth factor-beta superfamily mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000329	transforming growth factor-beta superfamily mediated signaling pathway		Those TGF-beta superfamily mediated signaling pathways that deviate from what their normal course should be. Alone or in combination with other pathways they underlie many conditions such as pulmonary hypertension and various types of cancer.
http://purl.obolibrary.org/obo/PW_0000336	altered cell-cell signaling pathway	http://purl.obolibrary.org/obo/PW_0000671	altered cell adhesion signaling pathway		Those cell-cell signaling pathways that deviate from what their normal course should be.
http://purl.obolibrary.org/obo/PW_0000337	selectin signaling pathway	http://purl.obolibrary.org/obo/PW_0000332	cell-cell signaling pathway		Selectins represent a small family of lectin-like adhesion receptors that mediate cell-cell interactions via calcium-dependent recognition of sialylated glycans. The exact role of this signaling pathway is not well known.
http://purl.obolibrary.org/obo/PW_0000340	altered Notch signaling pathway involving the main players	http://purl.obolibrary.org/obo/PW_0000324	altered Notch signaling pathway		An altered Notch signaling pathway due to mutation(s) in the main players. They include receptor(s), ligand(s), and members of the CSL complex.
http://purl.obolibrary.org/obo/PW_0000341	altered Notch signaling pathway involving the macromolecules modifying the main players	http://purl.obolibrary.org/obo/PW_0000324	altered Notch signaling pathway		An altered Notch signaling pathway due to mutation(s) in the enzymes, macromolecules that act upon the main players. They include proteases, elements of the proteo- and glucosaminoglycan metabolic pathways, ubiquitin ligases, other proteins that modulate availability, sensitivity, endocytosis of ligands/receptors.
http://purl.obolibrary.org/obo/PW_0000342	altered Notch signaling pathway involving target gene(s)	http://purl.obolibrary.org/obo/PW_0000324	altered Notch signaling pathway		An altered Notch signaling pathway due to mutation(s) in the target gene(s). They may include members of the HES and HERP families of basic helix-loop-helix (bHLH) transcriptional repressors.
http://purl.obolibrary.org/obo/PW_0000343	altered Notch signaling pathway involving promoters	http://purl.obolibrary.org/obo/PW_0000324	altered Notch signaling pathway		An altered Notch signaling pathway due to mutation(s) in the promoters of target gene(s).
http://purl.obolibrary.org/obo/PW_0000346	CADASIL pathway	http://purl.obolibrary.org/obo/PW_0000345	cerebral arterial diseases pathway		CADASIL - cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy - a disease of the small cerebral arteries characterized by subcortical stroke and vascular dementia. It is associated with mutations in the Notch3 gene. More than fifty mutations are clustered within the first EGF repeats and involve the gain or loss of a cysteine.
http://purl.obolibrary.org/obo/PW_0000349	Alagille syndrome pathway	http://purl.obolibrary.org/obo/PW_0000348	congenital heart defects pathway		Alagille syndrome is a developmental disease characterized by defects in heart, as well as liver, skeleton and eye. Abnormalities of the central nervous system are also found. The disease is associated with mutations across the entire Jag1 gene.
http://purl.obolibrary.org/obo/PW_0000350	altered vascular endothelial growth factor signaling pathway	http://purl.obolibrary.org/obo/PW_0001538	altered cardiovascular system homeostasis pathway		A VEGF mediated pathway that deviates from what its normal course should be. Aberrant VEGF mediated pathways have been implicated in a number of human cancers. Upregulation of VEGF expression is associated with cancer and tumor growth.
http://purl.obolibrary.org/obo/PW_0000351	altered vascular endothelial growth factor signaling pathway involving the main players	http://purl.obolibrary.org/obo/PW_0000350	altered vascular endothelial growth factor signaling pathway		An altered VEGF signaling pathway due to mutation(s) in the main players. They include the various VEGF molecules and VEGF receptors.
http://purl.obolibrary.org/obo/PW_0000352	altered vascular endothelial growth factor signaling pathway involving the macromolecules modifying the main players	http://purl.obolibrary.org/obo/PW_0000350	altered vascular endothelial growth factor signaling pathway		An altered VEGF signaling pathway due to mutation(s) in the enzymes that process VEGF, such as the plasmin and furin-like proteases.
http://purl.obolibrary.org/obo/PW_0000353	altered vascular endothelial growth factor signaling pathway involving proteins affecting its expression	http://purl.obolibrary.org/obo/PW_0000350	altered vascular endothelial growth factor signaling pathway		An altered VEGF signaling pathway due to mutation(s), any activity change in the proteins that regulate VEGF expression. They include transcription factors such as the hypoxia-inducible factor and the many proteins impacting on the stability and/or activity of these factors.
http://purl.obolibrary.org/obo/PW_0000354	glycerophospholipid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000010	lipid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of glycerophospholipids, also known as phospholipids. They are key components of membranes and some are also involved in signaling.
http://purl.obolibrary.org/obo/PW_0000355	homeostasis pathway	http://purl.obolibrary.org/obo/PW_0000004	regulatory pathway		Those pathways involved in the maintenance of the internal environment of an organism, the adequate levels of substances and nutrients, the stability of normal body states and the feedback regulatory mechanisms that control them.
http://purl.obolibrary.org/obo/PW_0000356	oxygen homeostasis pathway	http://purl.obolibrary.org/obo/PW_0001692	inorganic chemical homeostasis pathway		The pathways involved in responding to changes in and maintenance of adequate oxygen levels.
http://purl.obolibrary.org/obo/PW_0000357	energy homeostasis pathway	http://purl.obolibrary.org/obo/PW_0000355	homeostasis pathway		Those pathways involved in the balance between energy uptake and energy expenditure. Disturbance of this equilibrium has been linked to various conditions including obesity.
http://purl.obolibrary.org/obo/PW_0000358	altered homeostasis pathway	http://purl.obolibrary.org/obo/PW_0000355	homeostasis pathway		Those homeostatic pathways that deviate from what their normal course should be. Aberrant homeostatic pathways, alone or in combination with other pathways, underlie many conditions, disorders and/or diseases.
http://purl.obolibrary.org/obo/PW_0000359	altered energy homeostasis pathway	http://purl.obolibrary.org/obo/PW_0000358	altered homeostasis pathway		Those pathways of energy homeostasis that deviate from what their normal course should be. Obesity in particular has been associated with disturbances in the control of energy balance.
http://purl.obolibrary.org/obo/PW_0000360	hypoxia inducible factor pathway	http://purl.obolibrary.org/obo/PW_0001313	transcription pathway via transcription factor mediated signaling		The hypoxia inducible transcription factor is activated in response to hypoxic conditions to promote the expression of many genes that play important roles in glucose and energy metabolism, angiogenesis and erythropoiesis.
http://purl.obolibrary.org/obo/PW_0000363	leptin system pathway	http://purl.obolibrary.org/obo/PW_0000467	peptide and protein hormone signaling pathway		Leptin acts on two populations of hypothalamic neurons that express orexigenic (feeding inducing) and anorexigenic genes, respectively. Leptin reduces the expression of genes from the former and enhances the expression of genes from the latter neurons. The leptin mediated response acts primarily via Jak-dependent activation of STAT.
http://purl.obolibrary.org/obo/PW_0000365	melanocortin system pathway	http://purl.obolibrary.org/obo/PW_0000467	peptide and protein hormone signaling pathway		The melanocortin dependent system is involved in a diverse number of pathways such as pigmentation, steroidogenesis, sexual function, energy homeostasis. Its implication in energy homeostasis is of particular interest as alterations of this system have been associated with obesity.
http://purl.obolibrary.org/obo/PW_0000366	altered melanocortin system pathway	http://purl.obolibrary.org/obo/PW_0000511	altered peptide and protein hormone signaling pathway		A melanocortin dependent system pathway that deviates from what its normal course should be. Mutations in the prohormone gene PMOC and the modifying enzyme PC1 are linked to obesity. Mutations in MC2R receptor and its accessory protein MRAP have been associated with type 1 and 2 familial glucocorticoid deficiency, respectively.
http://purl.obolibrary.org/obo/PW_0000367	altered Jak-Stat signaling pathway	http://purl.obolibrary.org/obo/PW_0001543	altered signaling pathway pertinent to immunity		Jak-Stat signaling pathways that deviate from what their normal course should be.
http://purl.obolibrary.org/obo/PW_0000368	Non-Stat, Jak dependent pathway	http://purl.obolibrary.org/obo/PW_0001195	tyrosine-specific protein kinase mediated signaling pathway		Those pathways dependent on activation by JAK kinases but independent of Stat proteins.
http://purl.obolibrary.org/obo/PW_0000369	nuclear factor, erythroid 2 like 2 signaling pathway	http://purl.obolibrary.org/obo/PW_0001313	transcription pathway via transcription factor mediated signaling		Nuclear factor, 2 like 2 (Nfe2l2, also known as Nrf2) signaling pathway is one of the most important regulator of antioxidant and/or electrophilic stress responses. Upon activation, Nfe2l2 induces the expression of antioxidant, xenobiotic metabolism, and cytoprotective genes, among others. Deregulation of the pathway has been associated with various conditions, including neurodegeneration and cancer.
http://purl.obolibrary.org/obo/PW_0000370	aryl hydrocarbon receptor signaling pathway	http://purl.obolibrary.org/obo/PW_0001371	basic helix-loop-helix signaling pathway		The aryl hydrocarbon receptor (AhR) is a transcription factor whose ligands include a variety of aromatic hydrocarbons and which regulates the expression of phase I and phase II drug- and xenobiotic-metabolizing enzymes. Phase I enzymes convert otherwise inactive hydrocarbons into active metabolites with potential carcinogenic effects, thus rendering AhR a player in tumor initiation.
http://purl.obolibrary.org/obo/PW_0000371	calcium homeostasis pathway	http://purl.obolibrary.org/obo/PW_0000589	metal homeostasis pathway		The maintenance of adequate intracellular calcium levels are crucial in order to assure the availability of this important ion and, at the same time prevent against the damage its high concentration can cause. Pumps and exchangers move the calcium ions into organelles or outside the cell, channels of many types allow for its transient flow inside the cell. Calcium transport, which maintains and controls the calcium gradient, and calcium signaling, which the gradient promotes, are inextricably connected in the fabric of calcium homeostasis.
http://purl.obolibrary.org/obo/PW_0000372	altered calcium homeostasis pathway	http://purl.obolibrary.org/obo/PW_0001832	altered metal homeostasis pathway		Dysfunction of calcium homeostasis has been implicated in several human neural, neurodegenerative and cardiac conditions.
http://purl.obolibrary.org/obo/PW_0000373	glutathione conjugation pathway	http://purl.obolibrary.org/obo/PW_0000858	phase II biotransformation pathway		The glutathione conjugation of endogenous and exogenous electrophilic compounds represents a major pathway phase II biotransformation. The glutathione conjugates may either be excreted or undergo further processing.
http://purl.obolibrary.org/obo/PW_0000374	alternate pathways of glutathione conjugates processing	http://purl.obolibrary.org/obo/PW_0000373	glutathione conjugation pathway		Pathways of glutathione conjugates processing other than the mercapturic acid pathway.
http://purl.obolibrary.org/obo/PW_0000375	phase I biotransformation pathway via cytochrome P450	http://purl.obolibrary.org/obo/PW_0000857	phase I biotransformation pathway		The major phase I biotransformation pathway for the activation of endogenous and exogenous substances carried out by members of the cytochrome P450 superfamily.
http://purl.obolibrary.org/obo/PW_0000376	cytochrome P450-independent phase I biotransformation pathway	http://purl.obolibrary.org/obo/PW_0000857	phase I biotransformation pathway		A minor phase I biotransformation pathway for the activation of endogenous and exogenous substances carried by flavin-containing monooxygenases.
http://purl.obolibrary.org/obo/PW_0000377	glutathione conjugates processing - the mercapturic acid pathway	http://purl.obolibrary.org/obo/PW_0000373	glutathione conjugation pathway		The mercapturic acid pathway of glutathione conjugates processing involves the sequential cleavage of glutamyl and glycine residues of glutathione followed by cysteine N-acetylation.
http://purl.obolibrary.org/obo/PW_0000378	oxidative stress response pathway	http://purl.obolibrary.org/obo/PW_0000237	stress response pathway		Oxidative stress occurs when the redox balance between pro- and anti-oxidants is upset due to an increase in endogenous or exogenous pro-oxidant stimuli. The response triggers the upregulation of antioxidant and detoxification systems. Oxidants can also act as second messengers to trigger a variety of cellular signaling pathways.
http://purl.obolibrary.org/obo/PW_0000379	endoplasmic reticulum stress  - the unfolded protein response pathway	http://purl.obolibrary.org/obo/PW_0000237	stress response pathway		Inhibition of protein folding or its disruption by mutant proteins in the endoplasmic reticulum triggers a signal transduction response known as the unfolded protein response (UPR). The UPR increases the biosynthetic capacity while decreasing the biosynthetic burden of the secretory pathway through up- and downregulation of gene expression.
http://purl.obolibrary.org/obo/PW_0000380	transport pathway for the elimination of drugs, endogenous or exogenous compounds and metabolites	http://purl.obolibrary.org/obo/PW_0001229	xenobiotic metabolic pathway		Drugs, endogenous and/or exogenous compounds processed through the phase I and II of  bioactivation, biotransformation pathways are eliminated via phase III transport pathway carried out by several transporter families.
http://purl.obolibrary.org/obo/PW_0000383	multispecific organic anion transporter mediated transport pathway	http://purl.obolibrary.org/obo/PW_0000380	transport pathway for the elimination of drugs, endogenous or exogenous compounds and metabolites		Those metabolic reactions involved in the the elimination of a variety of endogenous anionic substances, xenobiotics and their metabolites from the body, mediated by families of multi-specific transporters.
http://purl.obolibrary.org/obo/PW_0000384	G2/M DNA damage checkpoint pathway	http://purl.obolibrary.org/obo/PW_0000096	G2/M checkpoint pathway		The G2/M checkpoint pathways assure the genome is replicated only once per cell cycle. The checkpoints control for damaged and un-replicated DNA. Various DNA damage checkpoints lead to inhibition of the cyclin-dependent kinases that regulate the next cell cycle point.
http://purl.obolibrary.org/obo/PW_0000385	G2/M DNA replication checkpoint pathway	http://purl.obolibrary.org/obo/PW_0000096	G2/M checkpoint pathway		Those pathways that assure the genome is replicated only once per cell cycle. The checkpoints control for damaged and un-replicated DNA. Un-replicated DNA signals to block the cell cycle from proceeding. The mechanism by which the cell detects un-replicated DNA is not known.
http://purl.obolibrary.org/obo/PW_0000386	Rap1 mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000158	Ras family mediated signaling pathway		A very close relative of Ras, the Rap1 mediated pathway appears to control diverse processes such as modulation of growth and differentiation, secretion, integrin-linked cell adhesion and morphogenesis.
http://purl.obolibrary.org/obo/PW_0000387	Arf family mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000006	Ras superfamily mediated signaling pathway		Arf family mediated signaling pathways are involved in the regulation of intracellular vesicle trafficking. In particular they appear to control early events such as vesicle budding.
http://purl.obolibrary.org/obo/PW_0000388	Reelin signaling pathway	http://purl.obolibrary.org/obo/PW_0000656	glycoprotein signaling pathway		The reelin signaling pathway regulates neuronal positioning and may also play a role in synaptic plasticity. The reelin gene appears to be downregulated in schizophrenic brains but the link between the reelin pathway and the disease remains to be established.
http://purl.obolibrary.org/obo/PW_0000392	altered Ras mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0001540	altered Ras family mediated signaling pathway		A Ras mediated signaling pathway that deviates from what its normal course should be. Aberrant Ras mediated signaling pathways have been implicated in a number of human cancers and deregulation of Ras has been reported even in the absence of mutations.
http://purl.obolibrary.org/obo/PW_0000394	dopamine signaling pathway	http://purl.obolibrary.org/obo/PW_0001162	chemical compound signaling pathway		Dopamine signaling plays important roles in processes such as motivation, learning and movement. It also plays several roles in the periphery as a modulator of renal, cardiovascular and endocrine systems. Dopamine signals to a family of at least 5 receptors that are classified into two subfamilies that couple to distinct G proteins to elicit diverse downstream events. Deregulation of the pathway has been implicated in several neuropsychiatric and neurological disorders.
http://purl.obolibrary.org/obo/PW_0000396	spermidine metabolic pathway	http://purl.obolibrary.org/obo/PW_0000214	polyamine metabolic pathway		Polyamine metabolism plays important roles in a number of cellular processes. Spermidine and spermine are formed in two consecutive reactions carried out by distinct enzymes that employ the decarboxylated form of AdoMet as an aminopropyl donor.
http://purl.obolibrary.org/obo/PW_0000397	cobalamin metabolic pathway	http://purl.obolibrary.org/obo/PW_0000135	metabolic pathway of cofactors, vitamins, nutrients		Those metabolic reactions involved in the synthesis, utilization and/or degradation of cobalamin, known as vitamin B12 - a water-soluble vitamin. Cobalamin has important roles in a number of metabolic pathways. There are several related compounds whose synthesis occurs in bacteria but whose conversion can be carried out in higher organisms.
http://purl.obolibrary.org/obo/PW_0000398	homocysteine metabolic pathway	http://purl.obolibrary.org/obo/PW_0000132	metabolic pathway of other amino acids		Homocysteine (Hcy) metabolism is at the intersection of two pathways: the remethylation pathway that regenerates methionine and thus the methionine cycle and the transsulfuration pathway that gives rise to cysteine and derivatives. The Hcy pathway also engages choline, folate and vitamin metabolism and links to the metabolism of other amino acids and compounds.
http://purl.obolibrary.org/obo/PW_0000402	altered metabolic pathway of other amino acids	http://purl.obolibrary.org/obo/PW_0000262	altered metabolic pathway		Those metabolic pathways of amino acids other than the common amino acids that deviate from what their normal course should be. Aberrant metabolic pathways of other amino acids, alone or in combination with other pathways, underlie various diseases.
http://purl.obolibrary.org/obo/PW_0000403	altered amino acid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000262	altered metabolic pathway		Those pathways of amino acid metabolism that deviate from what their normal course should be. Aberrant amino acid metabolic pathways, alone or in combination with other pathways, underlie various diseases.
http://purl.obolibrary.org/obo/PW_0000404	creatine metabolic pathway	http://purl.obolibrary.org/obo/PW_0000132	metabolic pathway of other amino acids		Those metabolic reactions involved in the synthesis, utilization and/or degradation of creatine. Officially methyl guanidino-acetic acid formed from arginine and glycine and the methyl group of methionine, creatine supplies energy to muscle cells.
http://purl.obolibrary.org/obo/PW_0000405	synaptic vesicle exocytosis - neurotransmitter release pathway	http://purl.obolibrary.org/obo/PW_0002423	synaptic vesicle cycle pathway		Release of neurotransmitters is mediated through the exocytosis of neurotransmitter-filled synaptic vesicles. Synaptic vesicle trafficking cycle is composed of a number of steps that culminate in calcium-triggered fusion and release.
http://purl.obolibrary.org/obo/PW_0000407	neurotransmitter metabolic pathway	http://purl.obolibrary.org/obo/PW_0000406	metabolic pathway pertinent to the brain		Those metabolic reactions involved in the synthesis, utilization and/or degradation of neurotransmitters, substances that are released on excitation from the axon terminal of a presynaptic neuron and cross the synaptic cleft to excite or inhibit a target cell.
http://purl.obolibrary.org/obo/PW_0000408	acetylcholine metabolic pathway	http://purl.obolibrary.org/obo/PW_0000436	amine neurotransmitter metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of acetylcholine - an ester of choline and acetic acid that acts as a neurotransmitter in both the peripheral nervous system and the central nervous system.
http://purl.obolibrary.org/obo/PW_0000409	dopamine metabolic pathway	http://purl.obolibrary.org/obo/PW_0000443	catecholamine metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of dopamine, a neuromodulatory molecule that acts as a neurotransmitter and a neurohormone. Dopamine has multiple functions in the brain.
http://purl.obolibrary.org/obo/PW_0000410	serotonin metabolic pathway	http://purl.obolibrary.org/obo/PW_0000444	indoleamine and related compounds metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of serotonin - an amine neurotransmitter that is believed to play important roles in a number of conditions such as depression, bipolar disorder and anxiety.
http://purl.obolibrary.org/obo/PW_0000411	histamine metabolic pathway	http://purl.obolibrary.org/obo/PW_0000444	indoleamine and related compounds metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of histamine - a biogenic amine that acts as a neurotransmitter and is also involved in local immune responses.
http://purl.obolibrary.org/obo/PW_0000412	gamma-aminobutyric acid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000446	inhibitory neurotransmitter metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of gamma-aminobutyric acid (GABA), the central nervous system's main inhibitory neurotransmitter, involved in reducing neuronal excitability throughout the system.
http://purl.obolibrary.org/obo/PW_0000413	heme degradation pathway	http://purl.obolibrary.org/obo/PW_0000221	heme metabolic pathway		Those metabolic reactions involved in the degradation of heme - an iron-containing compound where the iron is complexed within a porphyrin heterocyclic ring, There are several kinds of hemes depending on the composition of their side chain. Heme serves as a prosthetic group for a number of proteins.
http://purl.obolibrary.org/obo/PW_0000414	protein degradation pathway via the 'core' 20S proteasome pathway	http://purl.obolibrary.org/obo/PW_0000325	protein degradation pathway		The 'core' 20S proteasome degrades oxidized and/or unfolded proteins in an ATP and ubiquitin independent manner. The association with the 19S regulatory cap yields the 26S proteasome which has substrate selectivity and ATP and ubiquitin-dependent activity.
http://purl.obolibrary.org/obo/PW_0000415	proteasome degradation pathway involving cullin-dependent ubiquitin ligases	http://purl.obolibrary.org/obo/PW_0000144	ubiquitin/proteasome degradation pathway		A proteasome degradation pathway mediated by cullins. Cullins are components of E3 ligase complexes and substrates for Nedd8 - a ubiquitin-like molecule. Neddylation is thought to modulate the activity of cullins.
http://purl.obolibrary.org/obo/PW_0000416	sumoylation pathway	http://purl.obolibrary.org/obo/PW_0000433	protein modification pathway via conjugation with ubiquitin and ubiqutin-like molecules		A pathway of protein modification via conjugation with SUMO (small ubiquitin-related modifier). SUMOylation does not target proteins to the proteasome, rather it targets proteins to particular cellular compartments.
http://purl.obolibrary.org/obo/PW_0000417	ubiquitin, ubiquitin-like/proteasome degradation pathway	http://purl.obolibrary.org/obo/PW_0000325	protein degradation pathway		The pathway for the ATP-dependent non-lysosomal proteolysis catalyzed by the 26S proteasome and for which ubiquitination, the post-translational covalent conjugation of ubiquitin, or ubiquitin-like, to target proteins is a key signal.
http://purl.obolibrary.org/obo/PW_0000419	water transport pathway	http://purl.obolibrary.org/obo/PW_0000103	transport pathway		The pathways by which water flows into and out of the cell and into and out of sub-cellular compartments for multi-cellular organisms, mediated by members of the aquaporin family of water channels (WCP). The 13 members identified in mammals are grouped into three subfamilies: aquaporins, selective for water; aquaglyceroporins, permeable to both water and small molecules; superaquaporins, the sub-cellular aquaporins. WCPs belong to the superfamily of major intrinsic proteins (MIPs).
http://purl.obolibrary.org/obo/PW_0000421	altered mitogen activated protein kinase pathway	http://purl.obolibrary.org/obo/PW_0001199	altered serine/threonine-specific kinase mediated signaling pathway		A mitogen activated protein kinase pathway that deviates from what its normal course should be. Altered MAPK pathways have been linked to a spectrum of conditions.
http://purl.obolibrary.org/obo/PW_0000423	surfactant homeostasis pathway	http://purl.obolibrary.org/obo/PW_0000355	homeostasis pathway		The processes and pathways involved in maintaining steady-state levels of surfactants, surface-active agents that reduce the surface tension of liquids.
http://purl.obolibrary.org/obo/PW_0000424	altered surfactant homeostasis pathway	http://purl.obolibrary.org/obo/PW_0000423	surfactant homeostasis pathway		A surfactant homeostatic pathway that deviates from what its normal course should be. Mutations in surfactant proteins and in ABCA3 - a member of the ABC transporters have been implicated in the altered pathway and associated with conditions such as Respiratory Distress Syndrome (RDS) in newborns and lung diseases in infants.
http://purl.obolibrary.org/obo/PW_0000425	diabetic retinopathy pathway	http://purl.obolibrary.org/obo/PW_0001549	diabetic angiopathy pathway		High glucose-mediated oxidative stress effects on the expression of vascular endothelial growth factor and insulin-like growth factor, triggering of polyol metabolic pathway and activation of protein kinase c (PKC) signaling are thought to play a role in the pathophysiology of diabetic retinopathy.
http://purl.obolibrary.org/obo/PW_0000426	protein sorting pathway	http://purl.obolibrary.org/obo/PW_0000181	pathway pertinent to protein folding, sorting, modification, translocation and degradation		In the secretory pathway, protein sorting, mainly in trans-Golgi Network (TGN), but also in other compartments, underlies cargo recognition by various carriers to assure the specificity of final localization.
http://purl.obolibrary.org/obo/PW_0000427	molybdenum cofactor biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000135	metabolic pathway of cofactors, vitamins, nutrients		Molybdenum cofactor is a complex between molybdopterin and an oxide of molybdenum and is required for the activity of several enzymes.
http://purl.obolibrary.org/obo/PW_0000432	protein modification pathway	http://purl.obolibrary.org/obo/PW_0000181	pathway pertinent to protein folding, sorting, modification, translocation and degradation		The protein modification pathway exerts a central role in the regulation of protein function and the pathways these functions impinge upon. It is also used to target proteins for degradation. In the more specialized aspect of protein modification in the secretory pathway, it involves the final modification of glycoproteins and glycosaminoglycans as well as processing of proteins to their mature forms.
http://purl.obolibrary.org/obo/PW_0000433	protein modification pathway via conjugation with ubiquitin and ubiqutin-like molecules	http://purl.obolibrary.org/obo/PW_0002715	post-translational protein modification pathway		Conjugation of proteins with ubiquitin and ubiquitin-like molecules proceeds via a cascade-like, enzyme-driven mechanism with diverse functionality.
http://purl.obolibrary.org/obo/PW_0000434	ubiquitination pathway	http://purl.obolibrary.org/obo/PW_0000433	protein modification pathway via conjugation with ubiquitin and ubiqutin-like molecules		A pathway of protein modification via conjugation with ubiquitin. Ubiquitination is well known for targeting proteins for degradation. However, ubiquitination is also used as a tag that modulates the signaling outcomes of modified substrates.
http://purl.obolibrary.org/obo/PW_0000435	neddylation pathway	http://purl.obolibrary.org/obo/PW_0000433	protein modification pathway via conjugation with ubiquitin and ubiqutin-like molecules		A pathway of protein modification via conjugation with Nedd8 - a ubiquitin-like protein. All Nedd8 targets appear to be members of the cullin family. Cullins participate in the assembly of various E3 ligase complexes. The neddylation pathway is important for embryogenesis and cell cycle control in metazoa, embryonic development in animals.
http://purl.obolibrary.org/obo/PW_0000436	amine neurotransmitter metabolic pathway	http://purl.obolibrary.org/obo/PW_0000407	neurotransmitter metabolic pathway		The prominent examples of biogenic amines are histamine, serotonin, the catecholamine and the choline derived acetylcholine, all acting as neurotransmitters involved in a wide range of processes.
http://purl.obolibrary.org/obo/PW_0000438	alanine metabolic pathway	http://purl.obolibrary.org/obo/PW_0001074	hydrophobic amino acid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of alanine. Alanine is a non-essential amino acid with roles in glucose and protein metabolism.
http://purl.obolibrary.org/obo/PW_0000439	aspartic acid/aspartate metabolic pathway	http://purl.obolibrary.org/obo/PW_0001075	hydrophilic amino acid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of aspartic acid/aspartate. Aspartic acid is a non-essential amino acid with roles in glucose, protein and nucleotide metabolism. In the brain, it can act as a neurotransmitter.
http://purl.obolibrary.org/obo/PW_0000440	glycine metabolic pathway	http://purl.obolibrary.org/obo/PW_0001074	hydrophobic amino acid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of glycine, a non-essential amino acid. Glycine has the simplest amino acid structure with a hydrogen atom as its side chain. It is the major inhibitory neurotransmitter.
http://purl.obolibrary.org/obo/PW_0000441	epinephrine metabolic pathway	http://purl.obolibrary.org/obo/PW_0000443	catecholamine metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of epinephrine - a catecholamine derived from the amino acids phenylalanine and tyrosine. It acts as a hormone and a neurotransmitter.
http://purl.obolibrary.org/obo/PW_0000442	norepinephrine metabolic pathway	http://purl.obolibrary.org/obo/PW_0000443	catecholamine metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of norepinephrine - a catecholamine derived from the amino acid tyrosine. It acts as a hormone and a neurotransmitter.
http://purl.obolibrary.org/obo/PW_0000443	catecholamine metabolic pathway	http://purl.obolibrary.org/obo/PW_0000436	amine neurotransmitter metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of catecholamines - chemical compounds derived from tyrosine. Epinephrine, norepinephrine and dopamine are among the most abundant and are produced primarily from the adrenal medulla and the postganglionic fibers of the sympathetic nervous system.
http://purl.obolibrary.org/obo/PW_0000444	indoleamine and related compounds metabolic pathway	http://purl.obolibrary.org/obo/PW_0000436	amine neurotransmitter metabolic pathway		Any of a number of indole derivatives containing an amine group.
http://purl.obolibrary.org/obo/PW_0000448	neuropeptide Y metabolic pathway	http://purl.obolibrary.org/obo/PW_0000447	peptide neurotransmitter metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of neuropeptide Y.
http://purl.obolibrary.org/obo/PW_0000449	enkephalin metabolic pathway	http://purl.obolibrary.org/obo/PW_0000447	peptide neurotransmitter metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of enkephalin, a pentapeptide involved in the regulation of nociception.
http://purl.obolibrary.org/obo/PW_0000450	neurotensin metabolic pathway	http://purl.obolibrary.org/obo/PW_0000447	peptide neurotransmitter metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of neurotensin.
http://purl.obolibrary.org/obo/PW_0000451	beta-endorphin metabolic pathway	http://purl.obolibrary.org/obo/PW_0000447	peptide neurotransmitter metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of beta-endorphine - a peptide neurotransmitter that may play a role in depression.
http://purl.obolibrary.org/obo/PW_0000452	substance P metabolic pathway	http://purl.obolibrary.org/obo/PW_0000447	peptide neurotransmitter metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of substance P - a  short-chain polypeptide that acts as a neurotransmitter and a neuromodulator.
http://purl.obolibrary.org/obo/PW_0000453	isoprenoid biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000248	isoprenoid metabolic pathway		Those metabolic reactions involved in the synthesis of an isoprenoid. Isoprenoids are precursors of both sterols and non-sterol derivatives.
http://purl.obolibrary.org/obo/PW_0000454	cholesterol biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001304	cholesterol metabolic pathway		Those metabolic reactions involved in the synthesis of cholesterol, an essential sterol component of mammalian cell membrane. Cholesterol is the precursor of all steroid hormones.
http://purl.obolibrary.org/obo/PW_0000455	excitatory synaptic transmission pathway	http://purl.obolibrary.org/obo/PW_0000274	neuron-to-neuron signaling pathway via the chemical synapse		Synaptic transmission, or neurotransmission is the pathway of neuron-to-neuron signaling via the chemical synapse and mediated by neurotransmitters. Their effect can be excitatory or inhibitory and many neurotransmitters can exert either effect. The major excitatory neurotransmitter is the amino acid glutamate.
http://purl.obolibrary.org/obo/PW_0000456	Inhibitory synaptic transmission pathway	http://purl.obolibrary.org/obo/PW_0000274	neuron-to-neuron signaling pathway via the chemical synapse		Synaptic transmission, or neurotransmission is the pathway of neuron-to-neuron signaling via the chemical synapse and mediated by neurotransmitters. Their effect can be excitatory or inhibitory and many neurotransmitters can exert either effect. The major inhibitory neurotransmitter is gamma-aminobutyric acid (GABA).
http://purl.obolibrary.org/obo/PW_0000457	angiotensin III signaling pathway	http://purl.obolibrary.org/obo/PW_0000245	angiotensin signaling pathway		Angiotensin III is derived from angiotensin II through the action of aminopeptidase A and in turn is cleaved by aminopeptidase N to generate angiotensin IV. Angiotensin III appears to function in a manner similar to angiotensin II. It plays a role in vasoconstriction and the control of arterial blood pressure. Angiotensin III may be the effective angiotensin peptide in the central nervous system.
http://purl.obolibrary.org/obo/PW_0000458	angiotensin IV signaling pathway	http://purl.obolibrary.org/obo/PW_0000245	angiotensin signaling pathway		Angiotensin IV is derived from angiotensin III through the action of aminopeptidase N. The receptor for angiotensin IV has been shown to be the insulin-regulated membrane aminopeptidase. Studies suggest that angiotensin IV signaling activates a number of intracellular second messenger systems and plays a role in vascular remodeling and memory.
http://purl.obolibrary.org/obo/PW_0000459	apelin signaling pathway	http://purl.obolibrary.org/obo/PW_0000467	peptide and protein hormone signaling pathway		The apelin signaling pathway plays a role in the vascular, cardiac, bone and digestive systems as well as in the brain.
http://purl.obolibrary.org/obo/PW_0000460	arachidonic acid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000058	fatty acid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or conversion of arachidonic acid - a polyunsaturated, omega-6 fatty acid. It is a precursor in the production of eicosanoids and can also be converted to other metabolites, collectively known as the arachidonic acid cascade.
http://purl.obolibrary.org/obo/PW_0000461	cyclooxygenase mediated pathway of arachidonic acid metabolism	http://purl.obolibrary.org/obo/PW_0000460	arachidonic acid metabolic pathway		The cyclooxygenase pathway is one of the three major routes of arachidonic acid oxygenation.
http://purl.obolibrary.org/obo/PW_0000462	lipoxygenase mediated pathway of arachidonic acid metabolism	http://purl.obolibrary.org/obo/PW_0000460	arachidonic acid metabolic pathway		Lipoxygenase pathway is one of three major routes of arachidonic acid oxygenation
http://purl.obolibrary.org/obo/PW_0000463	cytochrome P450 monooxygenase mediated pathway of arachidonic acid metabolism	http://purl.obolibrary.org/obo/PW_0000460	arachidonic acid metabolic pathway		Cytochrome P450 monooxygenase pathway is one the three major routes of arachidonic acid oxygenation.
http://purl.obolibrary.org/obo/PW_0000464	leukotriene metabolic pathway	http://purl.obolibrary.org/obo/PW_0000485	eicosanoid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of leukotrienes - a class of eicosanoids whose effects include vasoconstriction and bronchoconstriction.
http://purl.obolibrary.org/obo/PW_0000465	hormone signaling pathway	http://purl.obolibrary.org/obo/PW_0000003	signaling pathway		Hormones are a class of molecules that are used as messengers between cells and serve as signals to the target cell. Vertebrate hormones belong to three classes: amine and amino acid derived, peptide and protein hormones, and lipid and phospholipid derived hormones.
http://purl.obolibrary.org/obo/PW_0000468	steroid hormone signaling pathway	http://purl.obolibrary.org/obo/PW_0000469	lipid hormone signaling pathway		steroid hormones - steroids that act as hormones - can be grouped into several categories depending on the receptor to which they bind.
http://purl.obolibrary.org/obo/PW_0000469	lipid hormone signaling pathway	http://purl.obolibrary.org/obo/PW_0000465	hormone signaling pathway		The main categories of lipid hormones are the eicosanoids derived from arachidonic acid metabolism and the cholesterol derived steroid hormones. The signaling they initiate plays important roles in metabolism, inflammation and immunity, in the cardiovascular, nervous, renal and reproductive systems.
http://purl.obolibrary.org/obo/PW_0000470	natriuretic peptide signaling pathway	http://purl.obolibrary.org/obo/PW_0000467	peptide and protein hormone signaling pathway		The natriuretic peptide family consists of three peptide hormones of diverse roles in cardiovascular as well as neuroendocrine and renal functions.
http://purl.obolibrary.org/obo/PW_0000471	atrial natriuretic peptide signaling pathway	http://purl.obolibrary.org/obo/PW_0000470	natriuretic peptide signaling pathway		Atrial natriuretic peptide hormone pathway plays important roles in the regulation of body fluid volume and blood pressure.
http://purl.obolibrary.org/obo/PW_0000472	brain natriuretic peptide signaling pathway	http://purl.obolibrary.org/obo/PW_0000470	natriuretic peptide signaling pathway		brain natriuretic peptide signaling pathway appears to elicit cardiovascular, renal and endocrine functions similar to those elicited by the atrial natriuretic peptide.
http://purl.obolibrary.org/obo/PW_0000473	C-type natriuretic peptide signaling pathway	http://purl.obolibrary.org/obo/PW_0000470	natriuretic peptide signaling pathway		The role of the C-type signaling pathway is not well established. The receptor for the C-type natriuretic peptide, unlike the receptors for the other two types of peptides, is non-guanylyl cyclase receptor that appears to couple to adenylyl cyclase inhibition/phospholipase C activation via Gi family of G-protein.
http://purl.obolibrary.org/obo/PW_0000478	tissue factor pathway inhibitor	http://purl.obolibrary.org/obo/PW_0000477	natural anticoagulant pathway		Tissue factor pathway inhibitor isoforms alpha and beta are the main anticoagulants targeting the extrinsic coagulation cascade factors F7a and F7a-dependent F10a.
http://purl.obolibrary.org/obo/PW_0000479	heparin-antithrombin pathway	http://purl.obolibrary.org/obo/PW_0000477	natural anticoagulant pathway		Antithrombin (AT) affects the activity of many coagulation factors in the intrinsic and common coagulation cascade. Heparin, though not essential, is an important AT cofactor. increasing the activity of AT by ~1,000-fold.
http://purl.obolibrary.org/obo/PW_0000480	protein C anticoagulant pathway	http://purl.obolibrary.org/obo/PW_0000477	natural anticoagulant pathway		Activated protein C, with the aid of protein S, inhibits F8a and F5a - the important cofactors of the intrinsic tenase and thrombinase complexes, respectively, of coagulation cascade.
http://purl.obolibrary.org/obo/PW_0000482	lipoprotein metabolic pathway	http://purl.obolibrary.org/obo/PW_0000010	lipid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of lipoproteins - any of the protein-lipid complexes. In the blood, lipoproteins carry fats essential for the cell. Genetic variability and environmental (nongenetic) factors contribute to alterations in the homeostasis of lipid metabolic pathways and constitute cardiovascular disease risk.
http://purl.obolibrary.org/obo/PW_0000483	altered lipid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000262	altered metabolic pathway		Those lipid metabolic pathways that deviate from what their normal course should be. Aberrant lipid metabolic pathways, alone or in combination with other pathways underlie a number of diseases.
http://purl.obolibrary.org/obo/PW_0000484	altered lipoprotein metabolic pathway	http://purl.obolibrary.org/obo/PW_0000483	altered lipid metabolic pathway		Those lipoprotein metabolic pathways that deviate from what their normal course should be. Aberrant lipoprotein metabolic pathways, alone or in combination with other pathways underlie several diseases.
http://purl.obolibrary.org/obo/PW_0000485	eicosanoid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000010	lipid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of eicosanoids. Eicosanoids are derived from omega-6 or omega-3 fatty acids and derivatives. Examples include the leukotriene and the prostanoid classes, the latter represented by several families. Eicosanoids play important roles in the immune and vascular systems.
http://purl.obolibrary.org/obo/PW_0000486	class I major histocompatibility complex pathway	http://purl.obolibrary.org/obo/PW_0000825	antigen processing and presentation pathway		Peptides generated from proteolytic degradation of cytosolic proteins are translocated to the ER where they associate with class I MHC molecules. Peptide-class I MHC complexes move through the Golgi and are transported to the cell surface to be recognized by CD8+ T cells.
http://purl.obolibrary.org/obo/PW_0000487	class II major histocompatibility complex pathway	http://purl.obolibrary.org/obo/PW_0000825	antigen processing and presentation pathway		Peptides generated from enzymatic degradation of proteins internalized in late endosomes or lysosomes bind to class II MHC molecules. Peptide-class II MHC complexes are delivered to the cell surface to be recognized by CD4+ T cells.
http://purl.obolibrary.org/obo/PW_0000489	angiopoietin signaling pathway	http://purl.obolibrary.org/obo/PW_0000168	growth factor signaling pathway		Angiopoietin signaling pathway is involved in the regulation of angiogenic remodeling. Recent studies suggest that the pathway may also be involved in lymphangiogenesis and possibly in the development of hematopoietic system.
http://purl.obolibrary.org/obo/PW_0000490	transforming growth factor-beta Smad dependent signaling pathway	http://purl.obolibrary.org/obo/PW_0000650	signaling pathway pertinent to development		Transforming growth factor-beta (TGF-beta) signaling is one of the best characterized modules of the Tgf-b superfamily pathways. Binding to the type II receptor leads to activation of the type I receptor and subsequent activation of the Smad pathway. Nuclear translocation of Smad(s) and interaction with transcription factors leads to activation or repression of many genes.
http://purl.obolibrary.org/obo/PW_0000491	vasopressin signaling pathway	http://purl.obolibrary.org/obo/PW_0000467	peptide and protein hormone signaling pathway		The hormone vasopressin plays central roles in cardiovascular and water homeostasis by signaling via two receptor types, G-protein coupled receptors coupling to particular G alpha subunits of heterotrimeric G proteins.
http://purl.obolibrary.org/obo/PW_0000492	renin-angiotensin cascade pathway	http://purl.obolibrary.org/obo/PW_0001757	peptide and protein hormone metabolic pathway		The renin-angiotensin cascade (RAS) generates a number of bioactive peptides with diverse physiological and pathophysiological functions. RAS exerts vasoconstriction, vasodilation or vascular remodeling, cell proliferation or anti-proliferation effects, depending on which angiotensin peptide generates the signaling. Some of these features are also shared by the kallikrein-kinin system (KKS); the two systems can interact and cross-talk.
http://purl.obolibrary.org/obo/PW_0000493	corticotropin-releasing hormone signaling pathway	http://purl.obolibrary.org/obo/PW_0000467	peptide and protein hormone signaling pathway		Corticotropin-releasing hormone is secreted by the hypothalamus in response to stress or fear and signaling through its receptors stimulates secretion of corticotropic (adrenocorticotropic, ACTH) hormone by the anterior pituitary. ACTH is one of the cleavage products of pro-opiomelanocortin (POMC).
http://purl.obolibrary.org/obo/PW_0000494	oxytocin signaling pathway	http://purl.obolibrary.org/obo/PW_0000467	peptide and protein hormone signaling pathway		The peptide hormone oxytocin plays a central role in parturition, lactation and sexual behavior.
http://purl.obolibrary.org/obo/PW_0000495	Gas6 - Axl signaling axis	http://purl.obolibrary.org/obo/PW_0000168	growth factor signaling pathway		Gas6, a vitamin K-dependent growth factor signals through the Axl subfamily of tyrosine kinase receptors. The Gas6-Axl axis appears to be involved in growth and survival of various cell types as well as in tissue remodeling and regeneration. Deregulation of the axis is involved in a number of conditions, particularly renal.
http://purl.obolibrary.org/obo/PW_0000498	reverse cholesterol transport pathway	http://purl.obolibrary.org/obo/PW_0001346	cholesterol transport pathway		Reverse cholesterol transport (RCT) is the pathway by which cholesterol from extrahepatic cells/tissue is transported to the liver for excretion. The pathway may prevent the development of atherosclerosis by reducing the accumulation of cholesterol in the walls of arteries.
http://purl.obolibrary.org/obo/PW_0000499	nuclear factor kappa B signaling pathway	http://purl.obolibrary.org/obo/PW_0001313	transcription pathway via transcription factor mediated signaling		NF-kB signaling plays an essential role in the mammalian immune system. The classical/canonical pathway, downstream but not exclusively of tumor necrosis factor/receptor 1 signaling, is regarded as a paradigm of NF-kB signaling. The classical and the non-classical pathway downstream of a subset of Tnf receptor superfamily, share similar sets of core components, albeit in distinct ways. Collectively they regulate the expression of a vast array of genes.
http://purl.obolibrary.org/obo/PW_0000501	thyroid hormone signaling pathway	http://purl.obolibrary.org/obo/PW_0000500	tyrosine-based hormone signaling pathway		Thyroid hormone (TH) signaling pathway plays important roles in glucose and lipid metabolism. The TH receptors are nuclear receptors that once activated act as transcription factors. Low levels of TH stimulate the release of thyrotropin-releasing hormone (TRH) from the hypothalamus, in turn stimulating the secretion of thyroid-stimulating hormone (TSH) from the pituitary whose signaling then triggers TH production. TRH, TSH and TH signaling pathways are part of the hypothalamic-pituitary-thyroid (HPT) axis for which TH itself provides a negative regulatory loop.
http://purl.obolibrary.org/obo/PW_0000503	classical complement pathway	http://purl.obolibrary.org/obo/PW_0000502	complement system pathway		The classical complement pathway is one of the three biochemical pathways of the complement system. It is activated by antigen-bound antibodies.
http://purl.obolibrary.org/obo/PW_0000504	lectin complement pathway	http://purl.obolibrary.org/obo/PW_0000502	complement system pathway		The lectin pathway is one of the three biochemical pathways of the complement system. It is activated by microbial polysaccharides binding to circulating lectins.
http://purl.obolibrary.org/obo/PW_0000505	alternative complement pathway	http://purl.obolibrary.org/obo/PW_0000502	complement system pathway		The alternative pathway is one of the three biochemical pathways of the complement system. Stable activation of the alternative pathway occurs on microbial cell surfaces.
http://purl.obolibrary.org/obo/PW_0000506	endothelin signaling pathway	http://purl.obolibrary.org/obo/PW_0000467	peptide and protein hormone signaling pathway		Endothelins represent a family of three vasoconstrictor peptides that play a role in several intracellular signaling pathways and have been associated with hypertension, heart failure and myocardial infarction.
http://purl.obolibrary.org/obo/PW_0000507	estrogen signaling pathway	http://purl.obolibrary.org/obo/PW_0001313	transcription pathway via transcription factor mediated signaling		Estrogens are C18 steroid hormones that constitute the females sex hormones. Estrogens signal via the estrogen receptor which, once activated, drives the expression of target genes.
http://purl.obolibrary.org/obo/PW_0000509	altered hormone signaling pathway	http://purl.obolibrary.org/obo/PW_0000465	hormone signaling pathway		A hormone signaling pathway that deviates from what its normal course should be.
http://purl.obolibrary.org/obo/PW_0000512	Interleukin mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000828	cytokine mediated signaling pathway		Signaling by interleukin family members plays various roles in the immune response.
http://purl.obolibrary.org/obo/PW_0000513	interleukin-10 family mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000512	Interleukin mediated signaling pathway		The interleukin-10 family comprises several interleukins, including members of the interferon type III also known as interferon lambda or interferon-like type, that carry out various immunomodulatory functions.
http://purl.obolibrary.org/obo/PW_0000514	interleukin-6 family mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000512	Interleukin mediated signaling pathway		The interleukin-6 family includes several members involved in a wide range of biological processes such as immune regulation, inflammation, hematopoiesis and oncogenesis. All members share a common signal transducer, gp130, which activates Jak-Stat and Raf/Mek/Erk signaling pathways.
http://purl.obolibrary.org/obo/PW_0000515	Interleukin-10 signaling pathway	http://purl.obolibrary.org/obo/PW_0000513	interleukin-10 family mediated signaling pathway		Interleukin-10 signaling is involved in various immunomodulatory functions. It promotes the release of immune mediators and antigen presentation, exerting important anti-inflammatory effects that may primarily characterize this family member. Signaling by Il-10 and the other members of the family activate the intracellular Jak-Stat cascade.
http://purl.obolibrary.org/obo/PW_0000516	interleukin-6 signaling pathway	http://purl.obolibrary.org/obo/PW_0000926	pro-inflammatory cytokine mediated pathway		Interleukin-6 signaling is involved in a wide range of biological processes such as immune regulation, inflammation, hematopoiesis and oncogenesis. A signal transducer common to all family members, gp130 activates Jak-Stat and Raf/Mek/Erk signaling pathways.
http://purl.obolibrary.org/obo/PW_0000517	arterial occlusive disease pathway	http://purl.obolibrary.org/obo/PW_0000020	cardiovascular system disease pathway		A pathway leading to a general or specific artery occlusion.
http://purl.obolibrary.org/obo/PW_0000518	atherosclerosis pathway	http://purl.obolibrary.org/obo/PW_0000517	arterial occlusive disease pathway		A pathway leading to the thickening of medium and large arteries. While lipoprotein related pathways are of interest, monogenic conditions such as those linked to mutations in the laminin gene may also provide clues regarding atherosclerosis pathways.
http://purl.obolibrary.org/obo/PW_0000519	1,1,1-trichloro-2,2-bis(4-chlorophenyl)ethane degradation pathway	http://purl.obolibrary.org/obo/PW_0000107	xenobiotics biodegradation pathway		Those enzymatic reactions involved in the degradation of DDT - a chlorinated organic insecticide and environmental pollutant. Although it is banned in the United States, it is still widely used in developing countries.
http://purl.obolibrary.org/obo/PW_0000520	2,4-dichlorobenzoate degradation pathway	http://purl.obolibrary.org/obo/PW_0000107	xenobiotics biodegradation pathway		Those enzymatic reactions involved in the degradation of 2,4-dichlorobenzoate - a key intermediate in the aerobic degradation of over 200 polychlorinated biphenyls.
http://purl.obolibrary.org/obo/PW_0000521	1,2-dichloroethane degradation pathway	http://purl.obolibrary.org/obo/PW_0000107	xenobiotics biodegradation pathway		Those enzymatic reactions involved in the degradation of 1,2-dichloroethane - a moderately reactive alkylating compound.
http://purl.obolibrary.org/obo/PW_0000522	flavonoid biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000147	metabolic pathway of secondary metabolites		Those enzymatic reactions involved in the biosynthesis of flavonoids - a class of plant secondary metabolites generally known for their antioxidant activity.
http://purl.obolibrary.org/obo/PW_0000523	linoleic acid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000058	fatty acid metabolic pathway		Those enzymatic reactions involved in the synthesis, utilization or degradation of linoleic acid - an unsaturated omega-6 fatty acid. Linoleic acid is an essential fatty acid that humans and other animals cannot synthesize and must obtain from diet.
http://purl.obolibrary.org/obo/PW_0000524	heparan sulfate biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0002691	heparan sulfate metabolic pathway		Those metabolic reactions involved in the biosynthesis of heparan sulfate. Heparan sulfate is a glycosaminoglycan occurring in the cell membrane of most cells. It consists of repeating disaccharide units in specific linkage, each composed of a glucosamine residue linked to a uronic acid, either glucuronic acid or L-iduronic acid, which may be sulfated.
http://purl.obolibrary.org/obo/PW_0000526	kallikrein-kinin cascade pathway	http://purl.obolibrary.org/obo/PW_0001756	peptide and protein metabolic pathway		The kallikrein-kinin system (KKS) cascade generates several bioactive kinins with roles in vasodilation, release of inflammatory mediators and stimulation of sensory neurons. Kinins also play a role in the renal handling of sodium and water metabolism. In the latter case, the system parallels renin-angiotensin (RAS); the two systems can cross-talk.
http://purl.obolibrary.org/obo/PW_0000527	angiotensin II signaling pathway via AT1 receptor	http://purl.obolibrary.org/obo/PW_0000244	angiotensin II signaling pathway		Angiotensin II signaling through the angiotensin type 1 receptor (AT1) activates downstream signaling pathways and elicits a broad range of physiological responses. It is involved in the regulation of blood pressure and volume, water and electrolyte balance and exerts a potent vasoconstrictive effect.
http://purl.obolibrary.org/obo/PW_0000528	angiotensin II signaling pathway via AT2 receptor	http://purl.obolibrary.org/obo/PW_0000244	angiotensin II signaling pathway		Angiotensin II signaling through the angiotensin type 2 receptor (AT2) is less well understood and rather controversial. It appears to counteract AT1 receptor function and promote apoptosis. Alternatively, it may complement the effects of AT1 receptor with deleterious consequences in cardiac pathologies. AT2 receptor appears to function in a G-protein dependent as well as independent manner.
http://purl.obolibrary.org/obo/PW_0000529	angiotensin (1-7) signaling pathway	http://purl.obolibrary.org/obo/PW_0000245	angiotensin signaling pathway		Angiotensin (1-7) is derived from angiotensin II through the action of angiotensin converting enzyme 2 (ACE2) or from angiotensin I through the action of neutral endopeptidase (NEP). Angiotensin (1-7) signaling appears to have a vasodilatory effect but the exact action of this peptide in humans remains to be established.
http://purl.obolibrary.org/obo/PW_0000530	angiotensin III signaling pathway via AT1 receptor	http://purl.obolibrary.org/obo/PW_0000457	angiotensin III signaling pathway		Angiotensin III, like angiotensin II, binds to the type 1 and 2 receptors and triggers downstream signaling pathways. In rats, angiotensin III signaling through the receptor type 1 (AT1) can modulate noradrenergic transmission via phospholipase C activation.
http://purl.obolibrary.org/obo/PW_0000531	angiotensin III signaling pathway via AT2 receptor	http://purl.obolibrary.org/obo/PW_0000457	angiotensin III signaling pathway		The role of angiotensin type 2 receptor is less well understood. In rats, angiotensin III can mediate natriuresis through the activation of receptor type 2.
http://purl.obolibrary.org/obo/PW_0000532	glycogen biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000557	glucose storage pathway		Those metabolic reactions leading to the biosynthesis of glycogen, a highly branched polysaccharide. Glycogen is the storage form of glucose in the cell; it represents an energy reserve that can be mobilized when and where there is a need for glucose.
http://purl.obolibrary.org/obo/PW_0000533	glycogen metabolic pathway	http://purl.obolibrary.org/obo/PW_0000005	carbohydrate metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of glycogen, a highly branched polysaccharide that constitutes the major form of glucose storage in the cell.
http://purl.obolibrary.org/obo/PW_0000534	glycogen degradation pathway	http://purl.obolibrary.org/obo/PW_0000685	glucose biosynthesis pathway		Those metabolic reactions involved in the breakdown of glycogen to glucose-6-phosphate. Glucose-6-phosphate can then be dephosphorylated to glucose or it can be utilized via glycolysis for energy production; an alternative pathway of G6P utilization is the oxidative phase of the pentose phosphate shunt. A small percentage of glucose-6-phosphate can be converted to hexosamines.
http://purl.obolibrary.org/obo/PW_0000535	protein transport pathway	http://purl.obolibrary.org/obo/PW_0000103	transport pathway		The pathway that mediates the transport of proteins to their proper destination and the trafficking of proteins between organelles. Notable examples are the nucleocytoplasmic shuttling and the mitochondrial protein import pathways.
http://purl.obolibrary.org/obo/PW_0000536	constitutive protein secretory pathway	http://purl.obolibrary.org/obo/PW_0000636	protein exocytosis pathway		In the constitutive secretory pathway, common to all cell types, newly synthesized proteins are sorted into transport vesicles and targeted to their destination in the absence of a signal.
http://purl.obolibrary.org/obo/PW_0000537	regulated protein secretory pathway	http://purl.obolibrary.org/obo/PW_0000636	protein exocytosis pathway		In the regulated secretory pathway, secreted proteins are sorted into secretory vesicles which are stored intracellularly and move to the final destination upon receiving a signal. It is a salient feature of endocrine and neuroendocrine cells.
http://purl.obolibrary.org/obo/PW_0000538	nuclear protein transport pathway	http://purl.obolibrary.org/obo/PW_0000535	protein transport pathway		The import-export cycle that underlies the shuttling of proteins between the cytoplasm and the nucleus.
http://purl.obolibrary.org/obo/PW_0000539	ghrelin system pathway	http://purl.obolibrary.org/obo/PW_0000467	peptide and protein hormone signaling pathway		Ghrelin is an appetite-stimulating hormone secreted primarily from the stomach in response to fasting that can downregulate energy expenditure and lead to weight increase.
http://purl.obolibrary.org/obo/PW_0000540	obesity pathway	http://purl.obolibrary.org/obo/PW_0001601	nutritional disorder pathway		Obesity, usually defined as 20% or more excess body weight, constitutes a major public health problem and an independent risk factor for a number of conditions such as hypertension and diabetes. Deregulation of energy homeostasis, of various metabolic and signaling pathways, genetic and environmental aspects, all can contribute to the development of an obese state.
http://purl.obolibrary.org/obo/PW_0000542	adenosine monophosphate-activated protein kinase (AMPK) signaling pathway	http://purl.obolibrary.org/obo/PW_0000541	signaling pathway involving second messengers		AMPK senses changes in cellular energy as an ATP/AMP ratio. AMP binding allosterically activates AMPK; subsequent phosphorylation events lead to repression of energy consuming pathways. One target of AMPK is the mTOR signaling pathway. AMPK activates the inhibitory Tsc2 while inhibiting the mTorc1 complex.
http://purl.obolibrary.org/obo/PW_0000543	protein kinase A (PKA) signaling pathway	http://purl.obolibrary.org/obo/PW_0001194	serine/threonine-specific kinase mediated signaling pathway		Protein kinase A (PKA) signaling is a widely used intracellular pathway and the major route for channeling the cAMP signal. cAMP is regulated by adenylyl cyclases that produce it and phosphodiesterases that hydrolyze it. Compartmentalization of PKA signaling is mediated by the AKAP family of scaffold proteins that bring together the kinase, cAMP modulators and sometimes the targets.
http://purl.obolibrary.org/obo/PW_0000544	altered reverse cholesterol transport pathway	http://purl.obolibrary.org/obo/PW_0001347	altered cholesterol transport pathway		An impaired pathway of reverse cholesterol transport and efflux can pose a risk for the development of cardiovascular disease. This varies in severity and manifestation depending on which gene in the pathway is affected.
http://purl.obolibrary.org/obo/PW_0000546	mRNA decay pathway	http://purl.obolibrary.org/obo/PW_0001161	RNA degradation pathway		The pathways of mRNA quality control whereby erroneous mRNA is degraded in the nucleus or cytoplasm, or normal mRNA accumulated in the nucleus is degraded.
http://purl.obolibrary.org/obo/PW_0000547	exosome mediated RNA decay pathway	http://purl.obolibrary.org/obo/PW_0001641	rRNA decay pathway		The nuclear exosome pathway degrades erroneous mRNA as well as normal mRNA that has accumulated in the nucleus. The nucleolar exosome is  involved in the processing of rRNA.
http://purl.obolibrary.org/obo/PW_0000548	nonsense-mediated mRNA decay pathway	http://purl.obolibrary.org/obo/PW_0000546	mRNA decay pathway		The nonsense-mediated decay pathway (NMD) degrades mRNA that contains a premature translation termination codon (PTC) and is one of the best characterized systems in eukaryotes.
http://purl.obolibrary.org/obo/PW_0000549	nonstop mRNA decay pathway	http://purl.obolibrary.org/obo/PW_0000546	mRNA decay pathway		The nonstop mRNA decay pathway degrades mRNA that lacks a translation termination codon.
http://purl.obolibrary.org/obo/PW_0000550	Staufen-mediated mRNA decay pathway	http://purl.obolibrary.org/obo/PW_0000546	mRNA decay pathway		Staufen-mediated mRNA decay pathway (SMD) is a rather novel pathway identified in mammals. Staufen (Stau1) is thought to be involved in mRNA localization and it has recently been shown to be involved in mRNA decay. It shares some of the features of the nonsense-mediated mRNA decay pathway (NMD) but does not require components essential for NMD.
http://purl.obolibrary.org/obo/PW_0000551	altered mRNA decay pathway	http://purl.obolibrary.org/obo/PW_0000546	mRNA decay pathway		An mRNA decay pathway that deviates from what its normal course should be. An aberrant mRNA decay pathway would lead to the translation of erroneous mRNA with potentially serious consequences.
http://purl.obolibrary.org/obo/PW_0000552	brassinosteroid biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000147	metabolic pathway of secondary metabolites		Those metabolic reactions involved in the biosynthesis of brassinosteroids or brassins, a group of plant hormones released in response to low oxygen and sugar, or to root stresses.
http://purl.obolibrary.org/obo/PW_0000553	glucose homeostasis pathway	http://purl.obolibrary.org/obo/PW_0001691	organic chemical homeostasis pathway		Those pathways involved in the balanced maintenance of glucose levels, transport and processing as demanded by the needs of the cells, tissues and organs. Glucose is an important and the most efficient fuel source. Disruption of glucose homeostasis underlies many complex disorders.
http://purl.obolibrary.org/obo/PW_0000554	glucose transport pathway	http://purl.obolibrary.org/obo/PW_0000575	sugar transport pathway		Glucose diffusion into cells requires specific transporter proteins. Two families of hexose transporters facilitate glucose transport down its concentration gradient.
http://purl.obolibrary.org/obo/PW_0000555	glucose utilization pathway	http://purl.obolibrary.org/obo/PW_0002655	glucose metabolic pathway		The various pathways thereby glucose is oxidized to produce energy, is converted to other molecules or is stored for further use.
http://purl.obolibrary.org/obo/PW_0000556	glucose oxidation pathway	http://purl.obolibrary.org/obo/PW_0000555	glucose utilization pathway		The various pathways thereby glucose is converted to other compounds to yield primarily ATP. The final oxidation of glucose to carbon dioxide and water produces a net of 38 molecules of ATP per molecule of glucose.
http://purl.obolibrary.org/obo/PW_0000557	glucose storage pathway	http://purl.obolibrary.org/obo/PW_0000555	glucose utilization pathway		Glycogen is the major form of glucose storage. Excess glucose is converted into glycogen - a highly branched polysaccharide. When glucose is rapidly needed, glycogen can be broken down via glycogenolysis.
http://purl.obolibrary.org/obo/PW_0000559	hexosamine biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000570	hexosamine metabolic pathway		The formation of nucleotide hexosamines, primarily UDP-N-acetylglucosamine, constitutes the final step in the hexosamine biosynthetic pathway which provides substrates for the O-linked glycosylation of proteins. Glycoproteins that are either secreted from the cell or inserted into the plasma membrane undergo N-linked glycosylation. The O-linked glycosylation of nuclear and/or cytosolic proteins confers a signaling dimension to the hexosamine biosynthetic pathway.
http://purl.obolibrary.org/obo/PW_0000560	facilitative sugar transporter mediated glucose transport pathway	http://purl.obolibrary.org/obo/PW_0000554	glucose transport pathway		The GLUT family contains 14 members in mammals which can be grouped into 3 classes based on sequence similarities. The members of group I (best characterized) and of group III transporters facilitate glucose transport.
http://purl.obolibrary.org/obo/PW_0000561	sodium-glucose cotransporter mediated glucose transport pathway	http://purl.obolibrary.org/obo/PW_0000554	glucose transport pathway		The sodium-glucose or the sodium-dependent glucose cotransporters are characterized by the presence of 14 transmembrane alpha-helices. The N- and C-termini are responsible for permeating sodium and sugar, respectively.
http://purl.obolibrary.org/obo/PW_0000562	growth hormone signaling pathway	http://purl.obolibrary.org/obo/PW_0000467	peptide and protein hormone signaling pathway		The growth hormone signaling pathway is an important regulator of postnatal development. However, despite many years of research, the molecular mechanisms underlying its many actions are incompletely understood. It is believed that its actions involve direct and indirect routes. An example of the latter is the role the pathway plays in stimulating the production of insulin-like growth factor.
http://purl.obolibrary.org/obo/PW_0000563	adiponectin signaling pathway	http://purl.obolibrary.org/obo/PW_0000467	peptide and protein hormone signaling pathway		Adiponectin signaling, by a hormone secreted by the adipose tissue, impacts on metabolic pathways such as glucose and lipid metabolism, possibly via activation of the AMPK pathway. Its deregulation has been linked to obesity, cardiovascular diseases, diabetes and metabolic syndrome.
http://purl.obolibrary.org/obo/PW_0000564	androgen signaling pathway	http://purl.obolibrary.org/obo/PW_0001313	transcription pathway via transcription factor mediated signaling		Androgens are C19 steroids that constitutes the male sex hormones. They are also the precursors of female sex hormones, the estrogens. Testosterone and its more potent metabolite, dihydrotestosterone bind to androgen receptors to then translocate to the nucleus and activate the transcription of target genes. Many regulators, both activators and repressors, have been identified. Upregulation of receptor activity has been implicated in prostate cancer.
http://purl.obolibrary.org/obo/PW_0000565	eicosanoid signaling pathway	http://purl.obolibrary.org/obo/PW_0000959	lipid signaling pathway		Eicosanoids, derived from omega-3 or omega-6 fatty acids, are represented by the leukotriene and prostanoid classes of which the latter is represented by several families. Some can act as endogenous ligands for members of the peroxisomal proliferator-activated nuclear receptors (PPARs). Once activated, PPARs heterodimerize with the retinoid X receptor (RXR) and modulate the expression of target genes.
http://purl.obolibrary.org/obo/PW_0000566	corticosteroid signaling pathway	http://purl.obolibrary.org/obo/PW_0000468	steroid hormone signaling pathway		Corticosteroids group together glucocorticoids and mineralocorticoids, C21-steroid hormones derived from cholesterol. They control a wide range of physiological and cellular responses. Synthetic drugs mimicking their effects are used in the treatment of many conditions. Side effects, long-term use and/or natural deficiencies have been associated with various disorders.
http://purl.obolibrary.org/obo/PW_0000567	sex steroids signaling pathway	http://purl.obolibrary.org/obo/PW_0000468	steroid hormone signaling pathway		Sex steroid mediated signaling pathways have important roles in the development and/or maintenance of sex-specific characteristics or attributes.
http://purl.obolibrary.org/obo/PW_0000568	aldosterone signaling pathway	http://purl.obolibrary.org/obo/PW_0001313	transcription pathway via transcription factor mediated signaling		Aldosterone signaling through the mineralocorticoid receptor plays an important role in the balance of fluids and electrolytes in the body. Its biosynthesis is primarily regulated by the renin-angiotensin system and potassium ions concentration.
http://purl.obolibrary.org/obo/PW_0000569	cortisol signaling pathway	http://purl.obolibrary.org/obo/PW_0001313	transcription pathway via transcription factor mediated signaling		Cortisol, also known as hydrocortisone, is the most important glucocorticoid. Cortisol signaling, via binding to the glucocorticoid receptor present in almost every animal cell, is essential for many cellular and physiological functions.
http://purl.obolibrary.org/obo/PW_0000570	hexosamine metabolic pathway	http://purl.obolibrary.org/obo/PW_0000152	amino sugar metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of hexosamines, amino sugars created by adding an amino group to a hexose. Hexosamines, particularly N-acetylglucosamine, are used to modify proteins.
http://purl.obolibrary.org/obo/PW_0000571	neurotrophic factor signaling pathway	http://purl.obolibrary.org/obo/PW_0000168	growth factor signaling pathway		Signaling pathways activated by members of the neurotrophic family of growth factors are involved in differentiation of progenitor cells, survival and differentiation of neural cells. They exert their effects by engaging specific tropomyosin-related kinase (Trk) receptors.
http://purl.obolibrary.org/obo/PW_0000572	brain-derived neurotrophic factor signaling pathway	http://purl.obolibrary.org/obo/PW_0000571	neurotrophic factor signaling pathway		The brain-derived neurotrophic factor (BDNF) signaling pathway plays important roles in the growth, differentiation and survival of neurons, particularly the striatal neurons. BDNF signals via the tropomyosin-related kinase receptor type B (TrkB) to activate PKC, PI3K-AKT and MAPK/ERK intracellular pathways. Impaired BDNF signaling contributes to the pathogenesis of conditions such as Huntington Disease (HD) and psychiatric disorders. Upregulation, on the other hand, is associated with several malignancies.
http://purl.obolibrary.org/obo/PW_0000573	pentose phosphate pathway - oxidative phase	http://purl.obolibrary.org/obo/PW_0000556	glucose oxidation pathway		The oxidative (linear) phase of the pentose phosphate pathway involves the oxidation and decarboxylation of glucose-6-phosphate to produce the 5 carbon sugar ribulose-5-phosphate with the generation of NADPH.
http://purl.obolibrary.org/obo/PW_0000575	sugar transport pathway	http://purl.obolibrary.org/obo/PW_0000103	transport pathway		Those pathways that mediate the transport of sugars across the cell membrane. Transport of glucose, one of the major energy sources in the cell, is an important aspect of the sugar transport pathway.
http://purl.obolibrary.org/obo/PW_0000576	facilitative sugar transporter mediated sugar transport pathway	http://purl.obolibrary.org/obo/PW_0000575	sugar transport pathway		The GLUT family contains 14 members in mammals which can be grouped into 3 classes based on sequence similarities. These transporters are characterized by the presence of 12 transmembrane alpha helices. Of the 14 members of the GLUT family, 11 have been shown to be involved in sugar transport pathway.
http://purl.obolibrary.org/obo/PW_0000577	cytokine and chemokine mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000003	signaling pathway		Cytokines are small proteins released by the cell and acting as intercellular mediators. Chemokines are a subset of cytokine that can attract and activate leukocytes. They are characterized by a small size and the presence of four cysteines whose location is important for their structural folding. Cytokines or chemokines binding to cognate receptors triggers numerous downstream signaling cascades.
http://purl.obolibrary.org/obo/PW_0000578	scatter factor/hepatocyte growth factor signaling pathway	http://purl.obolibrary.org/obo/PW_0000168	growth factor signaling pathway		Scatter factor/hepatocyte growth factor signaling impacts on various biological processes such as proliferation and survival, morphogenesis and motility. SF/HGF and its receptor c-Met have also been implicated in tumor growth and angiogenesis.
http://purl.obolibrary.org/obo/PW_0000579	somatostatin signaling pathway	http://purl.obolibrary.org/obo/PW_0000467	peptide and protein hormone signaling pathway		Somatostatin signaling through its receptors regulates processes such as proliferation, secretion and motility via inhibition of growth hormone and factor. The potential anti-tumor activity of somatostatin has led to the development and clinical use of its analogs.
http://purl.obolibrary.org/obo/PW_0000583	orexin/hypocretin signaling pathway	http://purl.obolibrary.org/obo/PW_0000467	peptide and protein hormone signaling pathway		The orexin/hypocretin signaling appears to play a role in the stimulation of food intake. Alterations of the system are associated with the narcolepsy sleep disorder.
http://purl.obolibrary.org/obo/PW_0000584	altered orexin/hypocretin signaling pathway	http://purl.obolibrary.org/obo/PW_0000583	orexin/hypocretin signaling pathway		An orexin/hypocretin signaling pathway that deviates from what its normal course should be. Alterations in orexin/hypocretin signaling pathway have been linked to narcolepsy. It may also play a role in obesity.
http://purl.obolibrary.org/obo/PW_0000585	orexin/hypocretin signaling pathway via orexin/hypocretin receptor 1	http://purl.obolibrary.org/obo/PW_0000583	orexin/hypocretin signaling pathway		Orexin/hypocretin signaling through receptor 1 couples to Galphaq class of G proteins. Orexin/hypocretin receptor 1 primarily binds orexin A. Orexin A and B are derived from prepro-orexin precursor.
http://purl.obolibrary.org/obo/PW_0000586	orexin/hypocretin signaling pathway via orexin/hypocretin receptor 2	http://purl.obolibrary.org/obo/PW_0000583	orexin/hypocretin signaling pathway		Orexin/hypocretin signaling through receptor 2 couples to Galphaq and the inhibitory Galphai classes of G proteins. Orexin/hypocretin receptor 2 binds both orexin A and B derived from the prepro-orexin precursor.
http://purl.obolibrary.org/obo/PW_0000587	narcolepsy pathway	http://purl.obolibrary.org/obo/PW_0000178	neurological disorder pathway		Narcolepsy is a neurological condition characterized by excessive day sleep, an inability to maintain awake states. Dysfunction of the orexin/hypocretin signaling pathway has been linked to this condition.
http://purl.obolibrary.org/obo/PW_0000588	altered adiponectin signaling pathway	http://purl.obolibrary.org/obo/PW_0000563	adiponectin signaling pathway		An adiponectin signaling pathway that deviates from what its normal course should be. Deregulation of adiponectin signaling have been linked to obesity, cardiovascular diseases, diabetes and metabolic syndrome.
http://purl.obolibrary.org/obo/PW_0000589	metal homeostasis pathway	http://purl.obolibrary.org/obo/PW_0001692	inorganic chemical homeostasis pathway		Those pathways involved in the proper balance of metal ion levels, uptake and transport, utilization and storage as demanded by the needs of cells, tissues and organs. Disruption of metal ion homeostasis can have toxic and harmful consequences.
http://purl.obolibrary.org/obo/PW_0000590	iron homeostasis pathway	http://purl.obolibrary.org/obo/PW_0000589	metal homeostasis pathway		Those pathways involved in the proper balance of iron levels, uptake and transport, utilization and storage as needed by cells, tissues and organs. Iron is essential for many life processes but its reactivity makes it potentially dangerous.
http://purl.obolibrary.org/obo/PW_0000591	iron transport pathway	http://purl.obolibrary.org/obo/PW_0000593	metal ion transport pathway		The uptake and efflux routes of iron transport. Several systems mediate uptake of recycled and dietary iron. One system is involved in the efflux.
http://purl.obolibrary.org/obo/PW_0000593	metal ion transport pathway	http://purl.obolibrary.org/obo/PW_0001348	ion transport pathway		Those pathways that mediate the uptake and transport of metal ions. Metal ion transport pathways are important aspects of metal ion homeostasis.
http://purl.obolibrary.org/obo/PW_0000594	altered glucose homeostasis pathway	http://purl.obolibrary.org/obo/PW_0000553	glucose homeostasis pathway		The pathways involved in the balanced maintenance of glucose levels, transport and processing as demanded by the needs of the cells, tissues and organs assure the maintenance of glucose homeostasis. Disruption in these pathways alter glucose homeostasis and underlie many complex disorders - type 2 diabetes and its associated complications is one example.
http://purl.obolibrary.org/obo/PW_0000595	phosphatidylinositol 3-kinase signaling pathway	http://purl.obolibrary.org/obo/PW_0000541	signaling pathway involving second messengers		Phosphatidylinositol kinases represent a family of lipid kinases that phosphorylate the 3' position of the inositol ring in target substrates. They are grouped into three classes: class I, further subdivided into subclass A and B, class II and class III. By far the best known and characterized is class I, particularly IA that signals downstream of receptor tyrosine kinases and engages the Akt family of kinases.
http://purl.obolibrary.org/obo/PW_0000596	altered insulin signaling pathway	http://purl.obolibrary.org/obo/PW_0000594	altered glucose homeostasis pathway		An insulin signaling pathway that deviates from what its normal course should be. Deregulation of insulin signaling can have profound health consequences due to its potential to alter glucose and energy homeostasis.
http://purl.obolibrary.org/obo/PW_0000597	Wnt signaling, non-canonical pathway	http://purl.obolibrary.org/obo/PW_0000008	Wnt signaling pathway		The non-canonical Wnt signaling pathway groups the various Wnt signaling routes that are beta-catenin-independent.
http://purl.obolibrary.org/obo/PW_0000598	altered Wnt signaling pathway	http://purl.obolibrary.org/obo/PW_0000673	altered signaling pathway pertinent to development		A Wnt signaling pathway that deviates from what its normal course should be. Deregulation of Wnt signaling has been implicated in several cancers as well as diseases other than cancer.
http://purl.obolibrary.org/obo/PW_0000599	altered Wnt signaling, canonical pathway	http://purl.obolibrary.org/obo/PW_0000598	altered Wnt signaling pathway		A canonical Wnt signaling pathway that deviates from what its normal course should be. Mutations in core components of the canonical pathway have been implicated in several types of cancer as well as diseases other than cancer.
http://purl.obolibrary.org/obo/PW_0000600	altered Wnt signaling, non-canonical pathway	http://purl.obolibrary.org/obo/PW_0000598	altered Wnt signaling pathway		A non-canonical Wnt signaling pathway that deviates from what its normal course should be. Deregulation of the beta-catenin independent pathway appears to play a role in the biology of tumors.
http://purl.obolibrary.org/obo/PW_0000602	altered extracellular signal-regulated Raf/Mek/Erk signaling pathway	http://purl.obolibrary.org/obo/PW_0000421	altered mitogen activated protein kinase pathway		A Raf/Mek/Erk signaling pathway that deviates from what its normal course should be. Aberrant Raf/Mek/Erk signaling has been implicated in many types of cancer.
http://purl.obolibrary.org/obo/PW_0000603	Erk5 MAPK signaling pathway	http://purl.obolibrary.org/obo/PW_0000007	mitogen activated protein kinase signaling pathway		The Erk5 pathway, also known as the big MAP kinase, is activated by various stresses but not by inflammatory cytokines. In HeLa and PC12 cells, the pathway can be activated by growth factors.
http://purl.obolibrary.org/obo/PW_0000605	cancer pathway	http://purl.obolibrary.org/obo/PW_0000013	disease pathway		Cancer, or malignant neoplasm, represents a category of diseases characterized by uncontrolled cell growth and avoidance of apoptosis, invasion and metastasis.  Deregulation of many pathways - signaling, regulatory, metabolic and combination of them, have been implicated in susceptibility to or development of these conditions. Generally, cancer is classified according to the tissue or organ affected.
http://purl.obolibrary.org/obo/PW_0000606	urogenital cancer pathway	http://purl.obolibrary.org/obo/PW_0000605	cancer pathway		Urogenital cancer groups those malignancies that affect the urinary system and reproductive organs. Deregulation of several pathways along with genetic damage accumulated over time can lead to the development of these conditions.
http://purl.obolibrary.org/obo/PW_0000607	ovarian cancer pathway	http://purl.obolibrary.org/obo/PW_0000606	urogenital cancer pathway		Ovarian cancer is a leading cause of cancer deaths in women. Several susceptibility genes have been identified and they have a role to play in pathways involved in or regulating proliferation, DNA repair and apoptosis.
http://purl.obolibrary.org/obo/PW_0000608	cervical cancer pathway	http://purl.obolibrary.org/obo/PW_0000606	urogenital cancer pathway		Cervical cancer affects the cervical area and human papilloma virus (HPV) infection plays a major role in the pathogenesis of the condition. A number of HPV proteins interact with and affect the function of several host proteins that play a role in apoptoptic pathway and/or those involved in cell proliferation.
http://purl.obolibrary.org/obo/PW_0000609	prostate cancer pathway	http://purl.obolibrary.org/obo/PW_0000606	urogenital cancer pathway		Prostate cancer is a frequent form of cancer in men over the age of fifty. It is usually asymptomatic but when in an advanced stage, it may spread to other parts of the body, causing symptoms others than those sometimes observed. Several susceptibility as well as defective genes have been identified.
http://purl.obolibrary.org/obo/PW_0000610	urinary bladder cancer pathway	http://purl.obolibrary.org/obo/PW_0000606	urogenital cancer pathway		Bladder cancer groups several types of malignant tumors of the urinary bladder. It is more prevalent in men than in women and combines both risk factors such as tobacco and exposure to certain carcinogens and genetic factors. Mutations in genes involved in a number of signaling pathways have been implicated in the development of these conditions.
http://purl.obolibrary.org/obo/PW_0000611	endometrial cancer pathway	http://purl.obolibrary.org/obo/PW_0000606	urogenital cancer pathway		Endometrial cancer affects the lining of the uterus, or endometrium. Hormonal and genetic alterations play a role in the development of this carcinoma type. Mutations in genes acting in several pathways have been associated with the condition and its types.
http://purl.obolibrary.org/obo/PW_0000612	colorectal cancer pathway	http://purl.obolibrary.org/obo/PW_0000627	gastrointestinal cancer pathway		Colorectal cancer are malignant tumors of the colon and rectum. Both risk factors usually relating to life style such as physical exercise or use of tobacco and genetics contribute to the development of the condition. Mutations in the components of canonical Wnt and Smad-dependent TGF-beta signaling and of DNA mismatch repair pathways  have been associated with the pathogenesis of colorectal cancer pathway.
http://purl.obolibrary.org/obo/PW_0000613	altered transforming growth factor-beta signaling pathway	http://purl.obolibrary.org/obo/PW_0000335	altered transforming growth factor-beta superfamily mediated signaling pathway		A trasforming growth factor-beta (TGF-beta) signaling pathway that deviates from what its normal course should be. Altered Tgf-b signaling, primarily the well characterized SMAD dependent pathway, has been implicated in numerous conditions.
http://purl.obolibrary.org/obo/PW_0000614	altered transforming growth factor-beta Smad dependent signaling pathway	http://purl.obolibrary.org/obo/PW_0000673	altered signaling pathway pertinent to development		A transfoming growth factor-beta Smad dependent signaling pathway that deviates from what its normal course should be. Altered TGF-beta Smad dependent signaling has been implicated in vascular conditions and tumorigenesis.
http://purl.obolibrary.org/obo/PW_0000615	altered bone morphogenetic protein signaling pathway	http://purl.obolibrary.org/obo/PW_0000673	altered signaling pathway pertinent to development		A bone morphogenetic protein (BMP) signaling pathway that deviates from what its normal course should be. Altered BMP signaling has been implicated in cardiovascular condition, pulmonary hypertension, the juvenile polyposis syndrome (JPS).
http://purl.obolibrary.org/obo/PW_0000616	altered tumor necrosis factor superfamily mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000617	altered cytokine mediated signaling pathway		Those tumor necrosis factor superfamily mediated pathways that deviate from what their normal course should be. Altered tumor necrosis factor superfamily pathways have been implicated in a spectrum of conditions ranging from septic shock and tumorigenesis to diabetes, rheumatoid arthritis and various inflammatory diseases.
http://purl.obolibrary.org/obo/PW_0000617	altered cytokine mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000828	cytokine mediated signaling pathway		A cytokine mediated signaling pathway that deviates from what its normal course should be. Aberrant cytokine signaling pathway, alone or in combination with other pathways underlie various diseases.
http://purl.obolibrary.org/obo/PW_0000618	altered tumor necrosis factor mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000680	altered extrinsic apoptotic pathway		A tumor necrosis factor (Tnf) signaling pathway that deviates from what its normal course should be. Altered Tnf signaling has been implicated in many human diseases - cerebral malaria, cancer, multiple sclerosis - are a few examples.
http://purl.obolibrary.org/obo/PW_0000619	altered nuclear factor kappa B signaling pathway	http://purl.obolibrary.org/obo/PW_0001543	altered signaling pathway pertinent to immunity		A nuclear factor kappa B (NF-kB) signaling pathway that deviates from what its normal course should be. Altered NF-kB signaling has been implicated in a number of conditions including immunodeficiency, inflammation and several forms of cancer.
http://purl.obolibrary.org/obo/PW_0000620	altered signaling pathway involving second messengers	http://purl.obolibrary.org/obo/PW_0000541	signaling pathway involving second messengers		Those signaling pathways involving second messengers that deviate from what their normal course should be. Deregulation of these pathways can have far reaching consequences.
http://purl.obolibrary.org/obo/PW_0000622	altered phosphatidylinositol 3-kinase-Akt signaling pathway	http://purl.obolibrary.org/obo/PW_0001199	altered serine/threonine-specific kinase mediated signaling pathway		A phosphatidylinositol 3-kinase-Akt signaling pathway that deviates from what its normal course should be. Altered phosphatidylinositol 3-kinase-Akt signaling pathway has been implicated in several forms of cancer. The components of the pathway are attractive targets for the development of therapeutics.
http://purl.obolibrary.org/obo/PW_0000623	altered scatter factor/hepatocyte growth factor signaling pathway	http://purl.obolibrary.org/obo/PW_0000578	scatter factor/hepatocyte growth factor signaling pathway		A scatter factor/hepatocyte growth factor signaling pathway that deviates from what its normal course should be. Aberrant Hgf signaling via Met receptor has been implicated in numerous forms of cancer.
http://purl.obolibrary.org/obo/PW_0000624	breast cancer pathway	http://purl.obolibrary.org/obo/PW_0000605	cancer pathway		Breast cancer or neoplasm is the most common cancer among women and the second worldwide after lung cancer. Deregulated pathways such estrogen or PI3K-Akt signaling have been implicated in breast cancer. In many cases, the disease is estrogen-dependent and it is possible that dysregulation of miRNA may correlate with the expression of estrogen receptor. Mutations in a number of other genes such as Brca1, 2 and 3 or p53 have also been associated with breast cancer.
http://purl.obolibrary.org/obo/PW_0000625	digestive system cancer pathway	http://purl.obolibrary.org/obo/PW_0000605	cancer pathway		A general term grouping neoplastic pathways of the biliary tract, liver, pancreas and the gastrointestinal system.
http://purl.obolibrary.org/obo/PW_0000626	pancreatic cancer pathway	http://purl.obolibrary.org/obo/PW_0000700	endocrine gland cancer pathway		Pancreatic cancer, a malignant tumor of the pancreas, has both genetic and predisposing factors. Deregulated pathways, such as TGF-B, PI3K-Akt or RAF/MEK/ERK, have been implicated in the development of pancreatic cancer.
http://purl.obolibrary.org/obo/PW_0000627	gastrointestinal cancer pathway	http://purl.obolibrary.org/obo/PW_0000625	digestive system cancer pathway		A general term grouping neoplastic pathways of the esophagus, gastric or stomach and intestinal system.
http://purl.obolibrary.org/obo/PW_0000629	gastric cancer pathway	http://purl.obolibrary.org/obo/PW_0000627	gastrointestinal cancer pathway		Gastric cancer is the fourth most common form of cancer worldwide and has a high death rate. Deregulated pathways, such as Wnt, PI3K-Akt or RAF/MEK/ERK, have been implicated in the development of gastric cancer.
http://purl.obolibrary.org/obo/PW_0000631	head and neck cancer pathway	http://purl.obolibrary.org/obo/PW_0000605	cancer pathway		A general term grouping neoplastic pathways of the upper aerodigestive system. Deregulated pathways, such as TGF-B, PI3K-Akt or epidermal growth factor (EGF) signaling, have been implicated in the of head and neck cancer.
http://purl.obolibrary.org/obo/PW_0000633	skin cancer pathway	http://purl.obolibrary.org/obo/PW_0000605	cancer pathway		A general term grouping together neoplastic pathways of the sweat and sebaceous gland or of neuroectodermal and neuroendocrine origins.
http://purl.obolibrary.org/obo/PW_0000634	altered Wnt signaling, the planar cell polarity pathway	http://purl.obolibrary.org/obo/PW_0000600	altered Wnt signaling, non-canonical pathway		A planar cell polarity Wnt signaling pathway that deviates from what its normal course should be. Altered planar cell polarity Wnt signaling has been implicated in a number of conditions including gastric and pancreatic cancer.
http://purl.obolibrary.org/obo/PW_0000637	protein modification pathway in the secretory pathway	http://purl.obolibrary.org/obo/PW_0002715	post-translational protein modification pathway		In the secretory pathway, the protein modification pathway involves the appropriate modification of glycoproteins and proteoglycans. It also provides for processing of the pro-forms of proteins into their mature form.
http://purl.obolibrary.org/obo/PW_0000638	Endoplasmic Reticulum-associated degradation pathway	http://purl.obolibrary.org/obo/PW_0000325	protein degradation pathway		In the endoplasmic reticulum, correctly-folded proteins are targeted for further export whereas misfolded proteins are retained and targeted for degradation.
http://purl.obolibrary.org/obo/PW_0000639	insulin responsive facilitative sugar transporter mediated glucose transport pathway	http://purl.obolibrary.org/obo/PW_0000560	facilitative sugar transporter mediated glucose transport pathway		The GLUT family contains 14 members in mammals which can be grouped into 3 classes based on sequence similarities. The members of group I (best characterized) and of group III transporters facilitate glucose transport. Of the three members of group I, Slc2a4 (Glut4), is involved in insulin-mediated uptake of glucose in the heart, skeletal muscle and adipose tissue. The response - central to glucose homeostasis - brings together several signaling and trafficking events.
http://purl.obolibrary.org/obo/PW_0000640	glycolysis pathway	http://purl.obolibrary.org/obo/PW_0000556	glucose oxidation pathway		The glycolytic pathway converts the six-carbon glucose to two three-carbon pyruvate molecules. The ten reactions of glycolysis can be subdivided into an energy-consuming 'stage I' and an energy-generating 'stage II'. The net energy yield is two molecules of ATP. Pyruvate can be further oxidized via the citrate cycle, converted to lactose under anaerobic conditions or back to glucose via gluconeogenesis.
http://purl.obolibrary.org/obo/PW_0000641	gluconeogenesis pathway	http://purl.obolibrary.org/obo/PW_0000685	glucose biosynthesis pathway		The gluconeogenic pathway involves the synthesis of glucose from noncarbohydrate precursors. They include the glycolysis products pyruvate and lactate, citric acid cycle intermediates and the carbon skeletons of many amino acids.
http://purl.obolibrary.org/obo/PW_0000642	fatty acid degradation pathway	http://purl.obolibrary.org/obo/PW_0000058	fatty acid metabolic pathway		Fatty acid degradation occurs primarily via beta oxidation in the mitochondrion. It also occurs via alpha degradation in peroxisomes and omega degradation which is an alternative pathway. Other pathways include the degradation of branched-chain, unsaturated and odd-chain fatty acids.
http://purl.obolibrary.org/obo/PW_0000643	altered glycogen metabolic pathway	http://purl.obolibrary.org/obo/PW_0000533	glycogen metabolic pathway		A glycogen metabolic pathway that deviates from what its normal course should be. Aberrant glycogen metabolism has been associated with several glycogen storage diseases.
http://purl.obolibrary.org/obo/PW_0000644	altered glycogen biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000643	altered glycogen metabolic pathway		A glycogen biosynthetic pathway that deviates from what its normal course should be. Aberrant glycogen metabolism has been associated with several glycogen storage diseases.
http://purl.obolibrary.org/obo/PW_0000645	altered glycogen degradation pathway	http://purl.obolibrary.org/obo/PW_0000643	altered glycogen metabolic pathway		A glycogen degradation pathway that deviates from what its normal course should be. Aberrant glycogen metabolism has been associated with several glycogen storage diseases.
http://purl.obolibrary.org/obo/PW_0000646	cell-extracellular matrix signaling pathway	http://purl.obolibrary.org/obo/PW_0000648	cell adhesion signaling pathway		Cell-extracellular matrix signaling pathway conveys information between cells and components of the extracellular matrix using cell adhesion molecules.
http://purl.obolibrary.org/obo/PW_0000647	forkhead signaling pathway	http://purl.obolibrary.org/obo/PW_0001313	transcription pathway via transcription factor mediated signaling		Forkhead proteins represent a large family of transcription factors that regulate the expression of genes involved in cell growth, proliferation and survival as well as organ development and speech acquisition.
http://purl.obolibrary.org/obo/PW_0000648	cell adhesion signaling pathway	http://purl.obolibrary.org/obo/PW_0000003	signaling pathway		Cell adhesion signaling pathway conveys information between cells or between cells and the extracellular matrix (ECM) using cell adhesion molecules (CAMs). While many CAMs appear to be specialized for either cell-cell or cell-ECM communication, integrin family of receptors mediates both types of signaling.
http://purl.obolibrary.org/obo/PW_0000650	signaling pathway pertinent to development	http://purl.obolibrary.org/obo/PW_0000003	signaling pathway		Those signaling pathways that are involved in or mediate the various aspects of development.
http://purl.obolibrary.org/obo/PW_0000651	aging pathway	http://purl.obolibrary.org/obo/PW_0000004	regulatory pathway		Aging or the overall deteriorating change of function can be at the cellular level as well as the whole organism level. Cellular aging or senescence underlies organismal aging.
http://purl.obolibrary.org/obo/PW_0000652	phosphatase mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000003	signaling pathway		Phosphatases are essential components of biological pathways. Phosphorylaton by protein kinases and dephosphorylation by protein phosphatases exert major regulatory roles. In addition, they can also initiate signaling cascades.
http://purl.obolibrary.org/obo/PW_0000653	serine/threonine-specific phosphatase mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000652	phosphatase mediated signaling pathway		Serine/threonine-specific phosphatase mediated signaling presents an interesting case. If the number of tyrosine kinases and of tyrosine phosphatases is similar (~100 in mammals), serine/threonine kinases have diversified to some 400 members in the course of evolution while the serine/threonine phosphatases count to about 25. The functional versatility is conferred through the diversity of regulatory subunits with which they interact. The holoenzyme dictates the role the protein complex plays in signaling pathways.
http://purl.obolibrary.org/obo/PW_0000654	tyrosine-specific phosphatase mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000652	phosphatase mediated signaling pathway		The protein tyrosine phosphatase superfamily exerts essential roles in signaling pathways. The coordinated interplay of tyrosine kinase mediated phosphorylation and tyrosine phosphatase mediated dephosphorylation of substrates shapes the functional topology of signaling networks. The PTP superfamily is composed of four families.
http://purl.obolibrary.org/obo/PW_0000655	glycoconjugated protein signaling pathway	http://purl.obolibrary.org/obo/PW_0000003	signaling pathway		Those signaling pathways mediated or initiated by oligosaccharide or polysaccharide linked proteins.
http://purl.obolibrary.org/obo/PW_0000656	glycoprotein signaling pathway	http://purl.obolibrary.org/obo/PW_0000655	glycoconjugated protein signaling pathway		Those pathways initiated or mediated by glycoproteins. Glycoproteins have oligosaccharides attached to their amino acid side chains via N- or O-glycosylation. Glycoproteins represent a large category of proteins encompassing a wide range of functionalities.
http://purl.obolibrary.org/obo/PW_0000657	proteoglycan signaling pathway	http://purl.obolibrary.org/obo/PW_0000655	glycoconjugated protein signaling pathway		Those pathways initiated or mediated by proteoglycans - heavily glycosylated proteins that have glycosaminoglycan (GAG) chain(s) linked to their protein cores. GAGs are long unbranched polysaccharides of repeating disaccharide units. Proteoglycans are categorized by the nature of the GAG chain or by their size.
http://purl.obolibrary.org/obo/PW_0000658	glypican signaling pathway	http://purl.obolibrary.org/obo/PW_0000657	proteoglycan signaling pathway		Glypicans are heparan sulfate proteoglycans represented by six families in mammals. They impact on a number of signaling pathways; the effect on signaling can be either inhibitory or stimulatory, depending on the context. They also appear to integrate directional cues important for neuronal migration, axon guidance and synapse formation.
http://purl.obolibrary.org/obo/PW_0000659	syndecan signaling pathway	http://purl.obolibrary.org/obo/PW_0000657	proteoglycan signaling pathway		Syndecan family of proteoglycans appears to be involved in cell-adhesion, particularly cell-extracellular matrix (ECM) signaling and to integrate with the integrin pathway. They also appear to integrate directional cues important for neuronal migration, axon guidance and synapse formation.
http://purl.obolibrary.org/obo/PW_0000661	single-strand DNA repair pathway	http://purl.obolibrary.org/obo/PW_0000099	DNA repair pathway		A DNA repair pathway responsible for removing one or several damaged nucleotides or of  nucleotide mismatched during DNA replication in one of the DNA strands. Several excision pathways are available for correcting single-strand damage.
http://purl.obolibrary.org/obo/PW_0000662	mismatch repair pathway	http://purl.obolibrary.org/obo/PW_0000661	single-strand DNA repair pathway		The mismatch repair pathway assures the maintenance of normal Watson-Crick base pairing. Bases incorrectly matched during DNA replication are removed and replaced with the correct ones.
http://purl.obolibrary.org/obo/PW_0000663	double-strand DNA repair pathway	http://purl.obolibrary.org/obo/PW_0000099	DNA repair pathway		A pathway dealing with repair of double-strand breaks of the DNA or of strand damage such as interstrand cross-links.
http://purl.obolibrary.org/obo/PW_0000666	altered single-strand DNA repair pathway	http://purl.obolibrary.org/obo/PW_0000661	single-strand DNA repair pathway		A single-strand DNA repair pathway that deviates from what its normal course should be. Aberrant single-strand repair pathways have been linked to several diseases.
http://purl.obolibrary.org/obo/PW_0000667	altered double-strand DNA repair pathway	http://purl.obolibrary.org/obo/PW_0000663	double-strand DNA repair pathway		Defective repair pathway(s) of double-strand breaks can lead to chromosomal rearrangements, genomic instability and oncogenic activation.
http://purl.obolibrary.org/obo/PW_0000668	altered mismatch repair pathway	http://purl.obolibrary.org/obo/PW_0000666	altered single-strand DNA repair pathway		A mismatch repair pathway that deviates from what its normal course should be. Mutations in several genes in the pathway have been implicated in cases of colorectal cancer, primarily the inherited forms. To a lesser extent they are found in other types of cancer, such as type 1 endometrial cancer.
http://purl.obolibrary.org/obo/PW_0000669	altered glycoprotein signaling pathway	http://purl.obolibrary.org/obo/PW_0000670	altered glycoconjugated protein signaling pathway		A glycoprotein signaling pathway that deviates from what its normal course should be.
http://purl.obolibrary.org/obo/PW_0000670	altered glycoconjugated protein signaling pathway	http://purl.obolibrary.org/obo/PW_0000655	glycoconjugated protein signaling pathway		A glycoconjugated protein signaling pathway that deviates from what its normal course should be.
http://purl.obolibrary.org/obo/PW_0000676	glucagon signaling pathway	http://purl.obolibrary.org/obo/PW_0000467	peptide and protein hormone signaling pathway		Glucagon signaling responds to low levels of circulating glucose to stimulate its release. The action of glucagon signaling is counter-regulatory to the action of insulin and it plays an essential role in glucose homeostasis.
http://purl.obolibrary.org/obo/PW_0000677	altered insulin secretion pathway	http://purl.obolibrary.org/obo/PW_0000674	insulin secretion pathway		An insulin secretion pathway that deviates from what its normal course should be. Altered insulin secretion has been associated with type 2 diabetes mellitus. Multiple defects are thought to underle malfunctions of insulin secretion; the exact molecular mechanisms are only partially understood.
http://purl.obolibrary.org/obo/PW_0000678	altered glucagon secretion pathway	http://purl.obolibrary.org/obo/PW_0000675	glucagon secretion pathway		A glucagon secretion pathway that deviates from what its normal course should be. Elevated serum glucagon has been observed in patients with type 2 diabetes. The pathway of glucagon secretion is not well understood and this complicates the understanding of how the pathway may falter.
http://purl.obolibrary.org/obo/PW_0000679	altered glucagon signaling pathway	http://purl.obolibrary.org/obo/PW_0000676	glucagon signaling pathway		A glucagon signaling pathway that deviates from what its normal course should be. Glucagon signaling counteracts the signaling of insulin and the potential exists that an alteration of glucagon signaling has a role to play in diabetes type 2. Serum glucagon is elevated in patients with the disease; the mechanisms leading to and the consequences of elevated glucagon remain to be established.
http://purl.obolibrary.org/obo/PW_0000681	FasL mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000236	tumor necrosis factor superfamily mediated signaling pathway		Fas ligand binding to its receptor triggers a conformational change that allows the receptor to assemble a signaling complex known as DISC, followed by recruitment of pro-caspase-8 and activation of caspase-3 and -7. It is believed that Fas-mediated signaling to elicit apoptosis follows two routes.
http://purl.obolibrary.org/obo/PW_0000682	Trail mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000236	tumor necrosis factor superfamily mediated signaling pathway		Trail-mediated signaling leads to apoptosis via assembly of the DISC complex (Death-Inducing Signaling Complex) downstream of its receptors.
http://purl.obolibrary.org/obo/PW_0000683	integrin mediated cell-cell signaling pathway	http://purl.obolibrary.org/obo/PW_0000332	cell-cell signaling pathway		A cell-cell signaling pathway mediated by integrins, a family of receptors that convey both 'outside-in' and 'inside-out' signals.
http://purl.obolibrary.org/obo/PW_0000684	integrin mediated cell-extracellular matrix signaling pathway	http://purl.obolibrary.org/obo/PW_0000646	cell-extracellular matrix signaling pathway		A cell-extracellular matrix signaling pathway mediated by integrins, a family of receptors that convey both 'outside-in' and 'inside-out' signals.
http://purl.obolibrary.org/obo/PW_0000685	glucose biosynthesis pathway	http://purl.obolibrary.org/obo/PW_0002655	glucose metabolic pathway		The metabolic pathways for generating glucose to meet the body's glucose needs. Gluconeogenesis in the liver and to some extent in kidney is the major pathway of glucose production; glycogenolysis is another route for generating glucose in these tissues.
http://purl.obolibrary.org/obo/PW_0000686	altered vasopressin signaling pathway	http://purl.obolibrary.org/obo/PW_0001538	altered cardiovascular system homeostasis pathway		A vasopressin signaling pathway that deviates from what its normal course should be. Altered vasopressin signaling manifests clinically as problems associated with water and sodium balance.
http://purl.obolibrary.org/obo/PW_0000687	altered sugar transport pathway	http://purl.obolibrary.org/obo/PW_0000575	sugar transport pathway		A sugar transport pathway that deviates from what its normal course should be. Alterations in sugar transport, particularly glucose, can potentially have very harmful consequences.
http://purl.obolibrary.org/obo/PW_0000688	altered facilitative sugar transporter mediated sugar transport pathway	http://purl.obolibrary.org/obo/PW_0000687	altered sugar transport pathway		A facilitative sugar transporter mediated sugar transport pathway that deviates from what its normal course should be. Alterations in sugar transport, particularly glucose, can potentially have very harmful consequences.
http://purl.obolibrary.org/obo/PW_0000689	altered glucose transport pathway	http://purl.obolibrary.org/obo/PW_0000687	altered sugar transport pathway		A glucose transport pathway that deviates from what its normal course should be. Alterations in glucose transport can potentially have very harmful consequences.
http://purl.obolibrary.org/obo/PW_0000690	altered facilitative sugar transporter mediated glucose transport pathway	http://purl.obolibrary.org/obo/PW_0000689	altered glucose transport pathway		A facilitative sugar transporter mediated glucose transport pathway that deviates from what its normal course should be. Alterations in glucose transport can potentially have very harmful consequences.
http://purl.obolibrary.org/obo/PW_0000691	altered sodium-glucose cotransporter mediated glucose transport pathway	http://purl.obolibrary.org/obo/PW_0000689	altered glucose transport pathway		A sodium-glucose cotransporter mediated glucose transport pathway that deviates from what its normal course should be. Alterations in glucose transport can potentially have very harmful consequences.
http://purl.obolibrary.org/obo/PW_0000692	altered insulin responsive facilitative sugar transporter mediated glucose transport pathway	http://purl.obolibrary.org/obo/PW_0000690	altered facilitative sugar transporter mediated glucose transport pathway		An insulin responsive facilitative sugar transporter mediated glucose transport pathway that deviates from what its normal course should be. Alterations in the pathway can manifest in insulin resistance, a hallmark of type 2 diabetes.
http://purl.obolibrary.org/obo/PW_0000693	biphenyl degradation pathway	http://purl.obolibrary.org/obo/PW_0000107	xenobiotics biodegradation pathway		Those enzymatic reactions involved in the degradation of biphenyl, an aromatic hydrocarbon used as a starting material for the production of polychlorinated biphenyls or as an intermediate for the production of a variety of organic compounds.
http://purl.obolibrary.org/obo/PW_0000694	geraniol degradation pathway	http://purl.obolibrary.org/obo/PW_0000107	xenobiotics biodegradation pathway		Those enzymatic reactions involved in the degradation of geraniol, a monoterpenoid and an alcohol, used in perfumes and in flavors.
http://purl.obolibrary.org/obo/PW_0000696	zeatin biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000147	metabolic pathway of secondary metabolites		Those metabolic reactions involved in the synthesis of zeatin - a plant hormone derived from adenine. It induces plant growth and has been reported to have anti-aging effects on human skin fibroblasts.
http://purl.obolibrary.org/obo/PW_0000697	carotenoid biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000147	metabolic pathway of secondary metabolites		Those metabolic reactions involved in the synthesis of carotenoids, organic pigments found in plants and other photosynthetic organisms. Some can act as antioxidants.
http://purl.obolibrary.org/obo/PW_0000698	thyroid cancer pathway	http://purl.obolibrary.org/obo/PW_0000700	endocrine gland cancer pathway		Thyroid cancer refers to one of several types of malignant tumors of the thyroid gland of which papillary thyroid cancer is the most frequent, accounting for almost 80% of all cases. The other types include follicular, medullary and anaplastic.
http://purl.obolibrary.org/obo/PW_0000699	parathyroid cancer pathway	http://purl.obolibrary.org/obo/PW_0000631	head and neck cancer pathway		Parathyroid cancer is a rare type of cancer whose causes are unknown. There are four parathyroid glands, each of the two lobes of the thyroid gland houses two.
http://purl.obolibrary.org/obo/PW_0000700	endocrine gland cancer pathway	http://purl.obolibrary.org/obo/PW_0000605	cancer pathway		A general term grouping neoplastic pathways of the adrenal gland, ovaries and pancreas, pituitary and thyroid.
http://purl.obolibrary.org/obo/PW_0000701	thoracic cancer pathway	http://purl.obolibrary.org/obo/PW_0000605	cancer pathway		A general term grouping neoplastic pathways of the heart, respiratory tract and thymus.
http://purl.obolibrary.org/obo/PW_0000703	lung cancer pathway	http://purl.obolibrary.org/obo/PW_0000702	respiratory tract cancer pathway		Lung cancer is one of the most common causes of cancer-related death in men but is also very common in women. The main types are represented by small cell and non-small cell lung carcinomas. The former tends to respond better to chemotherapy; the latter is at times treated surgically.
http://purl.obolibrary.org/obo/PW_0000704	lung small cell carcinoma pathway	http://purl.obolibrary.org/obo/PW_0000703	lung cancer pathway		Small cell lung cancer is an aggressive type of lung cancer. Several pathways appear to be deregulated and they include the intrinsic apoptotic pathway, PI3K-Akt signaling and changes in oncogene transcription factors such as Myc and p53.
http://purl.obolibrary.org/obo/PW_0000705	lung non-small cell carcinoma pathway	http://purl.obolibrary.org/obo/PW_0000703	lung cancer pathway		Non-small cell lung carcinoma groups together several non-small cell lung carcinomas. The main types are represented by squamous cell, adeno- and large-cell carcinoma. Alterations in Ras and epidermal growth factor signaling, among others, have been implicated in the condition.
http://purl.obolibrary.org/obo/PW_0000706	leukemia pathway	http://purl.obolibrary.org/obo/PW_0000605	cancer pathway		Leukemia is a cancer of the blood or bone marrow. The term covers a broad spectrum of conditions subdivided by proliferation type - acute and chronic, and by cell type - myeloid and lymphocytic leukemia.
http://purl.obolibrary.org/obo/PW_0000707	myeloid leukemia pathway	http://purl.obolibrary.org/obo/PW_0000706	leukemia pathway		Myeloid leukemia affects cells of the myeloid lineage and their precursors and in turn is subdivided by proliferation type.
http://purl.obolibrary.org/obo/PW_0000708	lymphoid leukemia pathway	http://purl.obolibrary.org/obo/PW_0000706	leukemia pathway		Lymphoid leukemia affects lymphoid tissues and there are increase numbers of circulating lymphoblasts and lymphocytes.
http://purl.obolibrary.org/obo/PW_0000709	acute myeloid leukemia pathway	http://purl.obolibrary.org/obo/PW_0000707	myeloid leukemia pathway		Acute myeloid leukemia is a common type of leukemia among adults. Abnormal cells are present inside the bone marrow that grow very vast and replace healthy blood cells. Several signaling pathways are disrupted and/or constitutively activated.
http://purl.obolibrary.org/obo/PW_0000710	chronic myeloid leukemia pathway	http://purl.obolibrary.org/obo/PW_0000707	myeloid leukemia pathway		Chronic myeloid leukemia, a slowly progressing condition, is a type of leukemia where too many white blood cells are made in the bone marrow.
http://purl.obolibrary.org/obo/PW_0000711	glioma pathway	http://purl.obolibrary.org/obo/PW_0001550	nervous system and nerve tissue cancer pathway		Gliomas are tumors of the brain categorized by the type of cell they are associated with, their location and grade. Several pathways appear to be deregulated via amplifications, overexpression, mutations or loss.
http://purl.obolibrary.org/obo/PW_0000712	vasopressin signaling pathway via receptor type 1	http://purl.obolibrary.org/obo/PW_0000491	vasopressin signaling pathway		Vasopressin signaling via receptor type 1 couples to Gq alpha subunit leading to stimulation of phospholipase C beta, subsequent generation of second messengers and increase in intracellular calcium resulting in vasoconstriction.
http://purl.obolibrary.org/obo/PW_0000713	vasopressin signaling pathway via receptor type 2	http://purl.obolibrary.org/obo/PW_0000491	vasopressin signaling pathway		Vasopressin signaling via receptor type 2 plays a central role in water homeostasis by regulating the translocation of Aqp2 channel. The receptor couples to Gs alpha subunit leading to activation of adenylyl cyclase, production of cyclic AMP and triggering of protein kinase A (PKA) signaling pathway. PKA regulates both the translocation and the expression of the channel.
http://purl.obolibrary.org/obo/PW_0000714	altered vasopressin signaling pathway via receptor type 1	http://purl.obolibrary.org/obo/PW_0000712	vasopressin signaling pathway via receptor type 1		A vasopressin, receptor type 1 mediated signaling pathway, that deviates from what its normal course should be. Alterations in this pathway might relate to septic shock.
http://purl.obolibrary.org/obo/PW_0000715	altered vasopressin signaling pathway via receptor type 2	http://purl.obolibrary.org/obo/PW_0000713	vasopressin signaling pathway via receptor type 2		A vasopressin, receptor type 2 mediated signaling pathway, that deviates from what its normal course should be. Alterations in the pathway have been associated with Nephrogenic Diabetes Insipidus (NDI) caused by mutations in the receptor or, more rarely, in aquaporin channel 2.
http://purl.obolibrary.org/obo/PW_0000716	transcription factor mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000003	signaling pathway		Transcription factors mediated signaling are components of transcription that, by controlling the expression of target genes, impact upon a wide range of processes.
http://purl.obolibrary.org/obo/PW_0000717	forkhead class O signaling pathway	http://purl.obolibrary.org/obo/PW_0000647	forkhead signaling pathway		The signaling pathway mediated by the FoxO subgroup of forkhead family of transcription factors regulates cell cycle and survival via the expression of its target genes. FoxO pathway is negatively regulated by PI3K-Akt pathway downstream of insulin signaling. It is positively regulated by the Jnk pathway of stress activated MAPK cascade.
http://purl.obolibrary.org/obo/PW_0000718	p53 signaling pathway	http://purl.obolibrary.org/obo/PW_0001313	transcription pathway via transcription factor mediated signaling		p53 transcription factor is a tumor suppressor frequently mutated in cancer. p53 is at the hub of many signaling and regulatory pathways. In response to various stresses, it promotes apoptosis, cell cycle arrest and other defense pathways via transcription dependent as well as independent routes. A key regulator of p53 is Mdm2. Mdm2 is a transcriptional target of p53 thus providing a negative feedback loop.
http://purl.obolibrary.org/obo/PW_0000719	altered transcription factor mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000716	transcription factor mediated signaling pathway		A transcription factor mediated signaling pathway that deviates from what its normal course should be. Deregulation of such pathways has been linked to cancer and various other diseases.
http://purl.obolibrary.org/obo/PW_0000720	altered p53 signaling pathway	http://purl.obolibrary.org/obo/PW_0001545	altered stress response pathway		A p53 signaling pathway that deviates from what its normal course should be. Due to its central role at the intersection of many cellular pathways, disturbance of p53 network can have far-reaching negative consequences. The tumor suppressor Tp53 gene is frequently mutated in cancer.
http://purl.obolibrary.org/obo/PW_0000721	nicotine drug pathway	http://purl.obolibrary.org/obo/PW_0000923	nervous system drug pathway		The pharmacokinetics and pharmacodynamics pathway of nicotine, an alkaloid found in tobacco and other plants. It is an agonist of nicotinic acetylcholine receptors and exerts stimulatory roles. It is also responsible for tobacco dependence.  Prolonged exposure and high levels of nicotine can have toxic effects. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000722	warfarin drug pathway	http://purl.obolibrary.org/obo/PW_0002325	vitamin K antagonist drug pathway		The pharmacokinetics and pharmacodynamics pathway of warfarin. Warfarin is used as anticoagulant that antagonizes the vitamin K dependent clotting pathway. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000723	anti-diabetic drug pathway	http://purl.obolibrary.org/obo/PW_0000921	alimentary tract and metabolism drug pathway		The pharmacokinetics and pharmacodynamics of anti-diabetic drugs such as repaglinide, nateglinide and sulfonylurea - inhibitors of ATP-dependent potassium channel. By blocking the channel they stimulate insulin secretion to lower blood glucose level. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000724	statin drug pathway	http://purl.obolibrary.org/obo/PW_0000920	cardiovascular system drug pathway		The pharmacokinetics and pharmacodynamics pathway of statin. Statins are a class of drugs used to lower cholesterol. They act as inhibitors of HMG-CoA reductase, the enzyme that catalyzes an early rate-limiting step in cholesterol biosynthesis. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000725	potassium channel inhibitors pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0000723	anti-diabetic drug pathway		The pathway of anti-diabetic drugs-target interaction and of the biochemical or physiological responses to them. Repaglinide, nateglinide and sulfonylurea are used as inhibitors of ATP-dependent potassium channel. By blocking the channel they stimulate insulin secretion to lower blood glucose level. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000726	repaglinide pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0000723	anti-diabetic drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of repaglinide. The drug is used as an inhibitor of ATP-dependent potassium channel. By blocking the channel it stimulates insulin secretion to lower blood glucose level. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0000727	nateglinide pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0000723	anti-diabetic drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of nateglinide. The drug is used as an inhibitor of ATP-dependent potassium channel. By blocking the channel it stimulates insulin secretion to lower blood glucose level. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0000728	statin pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0000724	statin drug pathway		The pathway of statins-target interaction and of the biochemical or physiological responses to drug. Statins are a class of drugs used to lower cholesterol. They act as inhibitors of HMG-CoA reductase, the enzyme that catalyzes an early rate-limiting step in cholesterol biosynthesis. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000729	statin pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0000724	statin drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of statin. Statins are a class of drugs used to lower cholesterol. They act as inhibitors of HMG-CoA reductase, the enzyme that catalyzes an early rate-limiting step in cholesterol biosynthesis. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0000730	warfarin pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0000722	warfarin drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of warfarin. Warfarin is used as anticoagulant that antagonizes the vitamin K dependent clotting pathway. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0000731	warfarin pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0000722	warfarin drug pathway		The pathway of warfarin-target interaction and of the biochemical or physiological responses to drug. Warfarin is used as anticoagulant that antagonizes the vitamin K dependent clotting pathway. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000732	thromboxane metabolic pathway	http://purl.obolibrary.org/obo/PW_0001240	prostanoid metabolic pathway		Those metabolic reactions involving thromboxanes - a family of prostanoid eicosanoids whose effects include vasoconstriction and platelet aggregation.
http://purl.obolibrary.org/obo/PW_0000733	glycosphingolipid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000197	sphingolipid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of glycosphingolipids - glycolipids with sugar(s) attached to the ceramide core. Based on the sequences of the core carbohydrate residues, they are classified into a number of series such as lacto- and neolacto-, globo-, ganglio- or muco-series.
http://purl.obolibrary.org/obo/PW_0000734	cerebroside metabolic pathway	http://purl.obolibrary.org/obo/PW_0000733	glycosphingolipid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of cerebroside, sphingolipids in which the sugar is a monosaccharide.
http://purl.obolibrary.org/obo/PW_0000735	altered sphingolipid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000483	altered lipid metabolic pathway		A sphingolipid metabolic pathway that deviates from what its normal course should be. Altered sphingolipid metabolism has been associated with several lysosomal storage diseases and most appear to be fatal.
http://purl.obolibrary.org/obo/PW_0000736	triacylglycerol biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000153	triacylglycerol metabolic pathway		The de novo synthesis of triacylglycerol, the common form of fatty acid transport and storage. Most triacylglycerols are synthesized in the liver and stored in the adipose tissue.
http://purl.obolibrary.org/obo/PW_0000737	triacylglycerol degradation pathway	http://purl.obolibrary.org/obo/PW_0000153	triacylglycerol metabolic pathway		Those enzymatic reactions involved in the degradation of triacylglycerols when energy reserves are low, such as in the fasting state, during exercise or in response to stress. Triacylglycerols are the common form of fatty acid transport and storage.
http://purl.obolibrary.org/obo/PW_0000738	fatty acid beta degradation pathway	http://purl.obolibrary.org/obo/PW_0000642	fatty acid degradation pathway		Fatty acid degradation via beta oxidation, the most common fatty acid degradation pathway, occurs in four reactions resulting in the formation of acetyl-CoA and a fatty acyl-CoA two carbon shorter than the one that began the cycle. Acetyl-CoA can undergo further oxidation via the Krebs cycle or can be converted to ketone bodies.
http://purl.obolibrary.org/obo/PW_0000739	fatty acid alpha degradation pathway	http://purl.obolibrary.org/obo/PW_0000642	fatty acid degradation pathway		The degradation of branched-chain fatty acids is carried out by the alpha oxidation pathway. In humans, this pathway occurs in peroxisomes.
http://purl.obolibrary.org/obo/PW_0000740	unsaturated fatty acid degradation pathway	http://purl.obolibrary.org/obo/PW_0000642	fatty acid degradation pathway		The pathway of unsaturated fatty acids requires additional enzymes.
http://purl.obolibrary.org/obo/PW_0000741	altered ganglioside metabolic pathway	http://purl.obolibrary.org/obo/PW_0000742	altered glycosphingolipid metabolic pathway		A ganglioside metabolic pathway that deviates from what its normal course should be. For instance, Tay-Sachs disease is caused by a deficiency in the enzyme that degrades ganglioside GM2. This and other conditions involving impaired sphingolipid metabolism are collectively known as sphingolipid storage disease.
http://purl.obolibrary.org/obo/PW_0000742	altered glycosphingolipid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000735	altered sphingolipid metabolic pathway		A glycoshingolipid metabolic pathway that deviates from what its normal course should be. Altered glycosphingolipid metabolism has been associated with several lysosomal storage diseases and most appear to be fatal.
http://purl.obolibrary.org/obo/PW_0000743	galactocerebroside metabolic pathway	http://purl.obolibrary.org/obo/PW_0000734	cerebroside metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of galactocerebroside, a cerebroside in which the monosaccharide is galactose.
http://purl.obolibrary.org/obo/PW_0000744	glucocerebroside metabolic pathway	http://purl.obolibrary.org/obo/PW_0000734	cerebroside metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of glucocerebroside, a cerebroside in which the monosaccharide is glucose.
http://purl.obolibrary.org/obo/PW_0000745	sphingomyelin metabolic pathway	http://purl.obolibrary.org/obo/PW_0000197	sphingolipid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of sphingomyelin - a sphingolipid found abundantly in the myelin sheath of nerve cells.
http://purl.obolibrary.org/obo/PW_0000746	altered sphingomyelin metabolic pathway	http://purl.obolibrary.org/obo/PW_0000745	sphingomyelin metabolic pathway		A sphingomyelin metabolic pathway that deviates from what its normal course should be. For instance, Niemann-Pick disease is caused by a deficiency in the enzyme that degrades sphingomyelin. This and other conditions involving impaired sphingolipid metabolism are collectively known as sphingolipid storage disease.
http://purl.obolibrary.org/obo/PW_0000747	altered galactocerebroside metabolic pathway	http://purl.obolibrary.org/obo/PW_0000748	altered cerebroside metabolic pathway		A galactocerebroside metabolic pathway that deviates from what its normal course should be. For instance, Krabbe's disease is caused by a deficiency in the enzyme that degrades galactocerebroside. This and other conditions involving impaired sphingolipid metabolism are collectively known as sphingolipid storage disease.
http://purl.obolibrary.org/obo/PW_0000748	altered cerebroside metabolic pathway	http://purl.obolibrary.org/obo/PW_0000742	altered glycosphingolipid metabolic pathway		A cerebroside metabolic pathway that deviates from what its normal course should be. Altered cerebroside metabolism has been associated with several lysosomal storage diseases and most appear to be fatal.
http://purl.obolibrary.org/obo/PW_0000749	altered glucocerebroside metabolic pathway	http://purl.obolibrary.org/obo/PW_0000748	altered cerebroside metabolic pathway		A glucocerebroside metabolic pathway that deviates from what its normal course should be. For instance, Gaucher's disease is caused by a deficiency in the enzyme that degrades glucocerebroside. This and other conditions involving impaired sphingolipid metabolism are collectively known as sphingolipid storage disease.
http://purl.obolibrary.org/obo/PW_0000750	altered isoprenoid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000483	altered lipid metabolic pathway		An isoprenoid metabolic pathway that deviates from what its normal course should be. Aberrant isoprenoid metabolism, as evidenced in alterations in cholesterol metabolism, has been associated with a variety of conditions.
http://purl.obolibrary.org/obo/PW_0000751	altered isoprenoid biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000750	altered isoprenoid metabolic pathway		An isoprenoid biosynthetic pathway that deviates from what its normal course should be. Aberrant isoprenoid biosynthetic pathway, as evidenced in altered cholesterol biosynthesis has been associated with several conditions.
http://purl.obolibrary.org/obo/PW_0000752	altered cholesterol biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001306	altered steroid biosynthetic pathway		A cholesterol biosynthetic pathway that deviates from what its normal course should be. Aberrant cholesterol biosynthesis involves defects in enzymes of both early and later steps leading to several disorders.
http://purl.obolibrary.org/obo/PW_0000753	sterol regulatory element-binding protein signaling pathway	http://purl.obolibrary.org/obo/PW_0001371	basic helix-loop-helix signaling pathway		The sterol regulatory element-binding protein (SREBP) pathway has important roles in the control of lipid and cholesterol metabolism. SREBPs are sterol-regulated transcription factors that belong to the bHLH family.
http://purl.obolibrary.org/obo/PW_0000754	drug pathway	http://purl.obolibrary.org/obo/PW_0000001	pathway		The pharmacokinetics and the pharmacodynamics pathway elicited by the administration of specific drugs. The systems involved in drug processing and responses are also those handling exogenous, xenobiotic compounds in the cellular detoxification pathway. The distinction between a random encounter with a foreign compound and the processing of a substance administered for treatment along with the importance of genetic variation for the individual responses to particular drugs warrant their separate consideration.
http://purl.obolibrary.org/obo/PW_0000755	benzodiazepine drug pathway	http://purl.obolibrary.org/obo/PW_0002295	antiepileptic drug pathway		The pharmacokinetics and pharmacodynamics pathway of benzodiazepines, a class of drugs acting upon the central nervous system. The drugs are administered as sedatives and also as antiepileptics. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000756	benzodiazepine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0000755	benzodiazepine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of benzodiazepines. Benzodiazepine represent a class of drugs used as sedatives. They act as ligands for the GABA-A receptor to stimulate its inhibitory activity. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0000757	benzodiazepine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0000755	benzodiazepine drug pathway		The pathway of benzodiazepine-target interaction and of the biochemical or physiological responses to drug. Benzodiazepines are a class of drugs used as sedatives. They act as ligands for the GABA-A receptor to stimulate its inhibitory activity. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000758	gemcitabine pathway	http://purl.obolibrary.org/obo/PW_0002367	antineoplastic drug pathway		The pharmacokinetics and pharmacodynamics pathway of gemcitabine, a cytidine analogue that is administered as a prodrug for the treatment of certain types of cancer. The diphosphate form is an inhibitor of ribonucleotide reductases, essential enzymes of deoxyribonucleotide synthesis. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000759	gemcitabine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0000758	gemcitabine pathway		The pathway of processing - absorption, distribution, metabolism or elimination of gemcitabine. Gemcitabine is a cytidine analogue administered as a prodrug for the treatment of certain cancers. The diphosphate form is an inhibitor of ribonucleotide reductases, essential enzymes of deoxyribonucleotide synthesis. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0000760	gemcitabine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0000758	gemcitabine pathway		The pathway of gemcitabine-target interaction and of the biochemical or physiological responses to drug. Gemcitabine is a cytidine analogue that is administered as a prodrug for the treatment of certain types of cancer. The diphosphate form is an inhibitor of ribonucleotide reductases, essential enzymes of deoxyribonucleotide synthesis. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000761	celecoxib drug pathway	http://purl.obolibrary.org/obo/PW_0001170	musculo-skeletal system drug pathway		The pharmacokinetics and pharmacodynamics pathway of celecoxib, a selective cyclooxygenase 2 inhibitor used for the treatment of osteoarthritis and rheumatoid arthritis. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000762	celecoxib pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0000761	celecoxib drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination of celecoxib - a selective inhibitor of cyclooxygenase 2 used for the treatment of osteoarthritis and rheumatoid arthritis. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0000763	celecoxib pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0000761	celecoxib drug pathway		The pathway of celecoxib-target interaction and of the biochemical or physiological responses to drug. Celecoxib is a selective inhibitor of cyclooxygenase 2 used for the treatment of osteoarthritis and rheumatoid arthritis. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000764	ifosfamide drug pathway	http://purl.obolibrary.org/obo/PW_0002367	antineoplastic drug pathway		The pharmacokinetics and pharmacodynamics pathway of ifosfamide, am antitumor agent used in the treatment of certain cancers. It is administered as a prodrug that has to be converted to the active form. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000765	ifosfamide pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0000764	ifosfamide drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination of ifosfamide, a prodrug used against solid tumors. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0000766	ifosfamide pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0000764	ifosfamide drug pathway		The pathway of ifosfamide-target interaction and of the biochemical or physiological responses to drug. Ifosfamide is administered as a prodrug and is widely used as an alkylating agent for the treatment of certain cancers. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000767	omeprazole drug pathway	http://purl.obolibrary.org/obo/PW_0000918	proton pump inhibitor drug pathway		The pharmacokinetics and pharmacodynamics pathway of omeprazole, a proton pump inhibitor. Omeprazole is the representative compound of a class of such inhibitors that are administered for the treatment of acid-related disorders. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000768	omeprazole pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0000767	omeprazole drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination of omeprazole, a representative compound of a class of proton pump inhibitors. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0000769	omeprazole pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0000767	omeprazole drug pathway		The pathway of omeprazole-target interaction and of the biochemical or physiological responses to drug. Omeprazole is a representative compound of a class of proton pump inhibitors used in the treatment of acid-related disorders. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000770	C19-steroid hormone biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000040	steroid hormone biosynthetic pathway		Those metabolic reactions involved in the synthesis of C19-steroid hormones. Pregnenolone, a C21 steroid derived from cholesterol, and progesterone, to which pregnenolone can be converted, provide the starting material for the C21, C19 and C18 steroid hormones. The C19 class is represented by androgens such as testosterone.
http://purl.obolibrary.org/obo/PW_0000771	mineralocorticoid biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000070	C21-steroid hormone biosynthetic pathway		Mineralocorticoids are a group of C21 steroid hormones synthesized by the adrenal cortex and so named because of their effects on the concentration of sodium as well as potassium and chloride. The group is best exemplified by aldosterone.
http://purl.obolibrary.org/obo/PW_0000772	glucocorticoid biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000070	C21-steroid hormone biosynthetic pathway		Those metabolic reactions involved in the synthesis of glucocorticoids, a group of C21 steroid hormones synthesized by the adrenal cortex and so named because of their effects on glucose metabolism. They also play a role in developmental processes and the immune system. The group is best exemplified by cortisol.
http://purl.obolibrary.org/obo/PW_0000773	aldosterone biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000771	mineralocorticoid biosynthetic pathway		Those metabolic reactions involved in the synthesis of aldosterone, a C21 mineralocorticoid produced in the outer zone, the zona glomerulosa, of the adrenal cortex from cholesterol as the precursor. It plays important roles in the regulation of water and salt balance.
http://purl.obolibrary.org/obo/PW_0000774	cortisol biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000772	glucocorticoid biosynthetic pathway		Those metabolic reactions involved in the synthesis of cortisol, a C21 glucocorticoid produced in the middle zone, the zona fasciculata, of the adrenal cortex from cholesterol as the precursor. It plays important roles in the metabolism of carbohydrates and other nutrients.
http://purl.obolibrary.org/obo/PW_0000775	altered epidermal growth factor/neuregulin signaling pathway	http://purl.obolibrary.org/obo/PW_0000298	altered growth factor signaling pathway		An epidermal growth factor/neuregulin signaling pathway that deviates from what its normal course should be. Deregulation of the pathway, mostly as upregulation due to the increased expression or amplification of ligands and/or receptors, or mutations leading to such increases, has been linked to numerous forms of cancer, such as pancreatic, lung, endometrial and breast.
http://purl.obolibrary.org/obo/PW_0000776	ketone bodies biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000069	ketone bodies metabolic pathway		Those metabolic reactions involved in the synthesis of acetoacetate and beta-hydroxybutyrate, also known as ketone bodies, although only acetoacetate is a ketone. Generally, the acetyl-CoA derived from fatty acid oxidation enters the citrate cycle. In the liver, a substantial fraction of acetyl-CoA is converted to ketone bodies which are then released into the bloodstream to supply peripheral tissues.
http://purl.obolibrary.org/obo/PW_0000777	ketone bodies degradation pathway	http://purl.obolibrary.org/obo/PW_0000069	ketone bodies metabolic pathway		Those metabolic reactions that convert acetoacetate and beta-hydroxybutyrate back to acetyl-CoA, which then can enter the citrate cycle for energy production. Ketone bodies are synthesized in the liver and released into the bloodstream to supply fuel to peripheral tissues, heart and skeletal muscle in particular and during starvation, the brain.
http://purl.obolibrary.org/obo/PW_0000778	testosterone biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000770	C19-steroid hormone biosynthetic pathway		Those metabolic reactions involved in the synthesis of testosterone, a C19-steroid hormone secreted primarily in the testes and ovaries and to a lesser extend by the adrenal glands.
http://purl.obolibrary.org/obo/PW_0000779	dehydroepiandrosterone biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000770	C19-steroid hormone biosynthetic pathway		Those metabolic reactions involved in the synthesis of dehydroepiandrosterone, a C19 steroid hormone produced in the adrenal cortex and a primary precursor of estrogens.
http://purl.obolibrary.org/obo/PW_0000780	C18-steroid hormone biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000040	steroid hormone biosynthetic pathway		Those metabolic reactions involved in the synthesis of C18-steroid hormones. Pregnenolone, a C21 steroid derived from cholesterol, and progesterone, to which pregnenolone can be converted, provide the starting material for the C21, C19 and C18 steroid hormones. The C18 class is represented by estrogens. The major natural estrogens are beta-estradiol - the primary estrogen, the estrone of menopause and the estriol of pregnancy.
http://purl.obolibrary.org/obo/PW_0000781	estradiol biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000780	C18-steroid hormone biosynthetic pathway		Those metabolic reactions involved in the synthesis of estradiol, the major C18 steroid hormone. The term generally refers to the 17 beta isomer, the most potent form of estrogen.
http://purl.obolibrary.org/obo/PW_0000782	glucocorticoid signaling pathway	http://purl.obolibrary.org/obo/PW_0000566	corticosteroid signaling pathway		Glucocorticoids, C21-steroid hormones, initiate signaling by binding to their specific nuclear receptor to regulate metabolism, development and immune response. The major glucocorticoid is cortisol.
http://purl.obolibrary.org/obo/PW_0000783	mineralocorticoid signaling pathway	http://purl.obolibrary.org/obo/PW_0000566	corticosteroid signaling pathway		Mineralocorticoids, C21 steroid hormones, initiate signaling by binding to their cognate receptor to regulate water and mineral levels. The main endogenous mineralocorticoid is aldosterone.
http://purl.obolibrary.org/obo/PW_0000784	altered androgen signaling pathway	http://purl.obolibrary.org/obo/PW_0001314	altered transcription pathway via transcription factor mediated signaling		An androgen signaling pathway that deviates from what its normal course should be. Altered androgen signaling, due to upregulation of the androgen receptor, has been implicated in prostate cancer.
http://purl.obolibrary.org/obo/PW_0000788	glucose-dependent insulinotropic peptide signaling pathway	http://purl.obolibrary.org/obo/PW_0000467	peptide and protein hormone signaling pathway		Glucose-dependent insulinotropic peptide signaling plays an important role in promoting insulin secretion. Gip is secreted from the K intestinal cells in response to nutrient ingestion. It signals via a G-protein coupled receptor to increase calcium and cAMP and activate downstream signaling pathways.
http://purl.obolibrary.org/obo/PW_0000789	glucagon-like peptide-1 signaling pathway	http://purl.obolibrary.org/obo/PW_0000467	peptide and protein hormone signaling pathway		Glucagon-like peptide-1 signaling pathway plays an important role in promoting insulin secretion. GLp-1 is secreted from the L intestinal cells in response to nutrient ingestion. It signals via a G-protein coupled receptor to increase calcium and cAMP and activate numerous downstream signaling pathways.
http://purl.obolibrary.org/obo/PW_0000790	epinephrine signaling pathway	http://purl.obolibrary.org/obo/PW_0001162	chemical compound signaling pathway		Epinephrine acts as a hormone and a neurotransmitter. It promotes various actions by signaling via various adrenergic receptors, G-protein coupled receptor type. The alpha receptor 1 and 2 couple to the Galphaq and Galphai subunits of heterotrimeric G proteins, respectively. The three beta receptors couple to the Galphas subunit.
http://purl.obolibrary.org/obo/PW_0000791	norepinephrine signaling pathway	http://purl.obolibrary.org/obo/PW_0001162	chemical compound signaling pathway		Norepinephrine acts as a hormone and a neurotransmitter. It promotes various actions by signaling via various adrenergic receptors, G-protein coupled receptor type. The alpha receptor 1 and 2 couple to the Galphaq and Galphai subunits of heterotrimeric G proteins, respectively. The three beta receptors couple to the Galphas subunit.
http://purl.obolibrary.org/obo/PW_0000792	epinephrine signaling pathway via adrenergic receptor alpha 1	http://purl.obolibrary.org/obo/PW_0000790	epinephrine signaling pathway		Epinephrine acts as a hormone and a neurotransmitter. It promotes various actions by signaling via various adrenergic receptors, G-protein coupled receptor type. The alpha 1 receptors couple to the Galphaq subunit.
http://purl.obolibrary.org/obo/PW_0000793	epinephrine signaling pathway via adrenergic receptor alpha 2	http://purl.obolibrary.org/obo/PW_0000790	epinephrine signaling pathway		Epinephrine acts as a hormone and a neurotransmitter. It promotes various actions by signaling via various adrenergic receptors, of the G-protein coupled receptor type. The alpha 2 receptors couple to the Galphai subunit.
http://purl.obolibrary.org/obo/PW_0000794	epinephrine signaling pathway via adrenergic receptor beta	http://purl.obolibrary.org/obo/PW_0000790	epinephrine signaling pathway		Epinephrine acts as a hormone and a neurotransmitter. It promotes various actions by signaling via various adrenergic receptors, G-protein coupled receptor type. The beta receptors couple to the Galphas subunit. Beta 2 receptor may also couple to Galphai.
http://purl.obolibrary.org/obo/PW_0000795	norepinephrine signaling pathway via adrenergic receptor alpha 1	http://purl.obolibrary.org/obo/PW_0000791	norepinephrine signaling pathway		Norepinephrine acts as a hormone and a neurotransmitter. It promotes various actions by signaling via various adrenergic receptors, G-protein coupled receptor type. The alpha 1 receptors couple to the Galphaq subunit.
http://purl.obolibrary.org/obo/PW_0000796	norepinephrine signaling pathway via adrenergic receptor alpha 2	http://purl.obolibrary.org/obo/PW_0000791	norepinephrine signaling pathway		Norepinephrine acts as a hormone and a neurotransmitter. It promotes various actions by signaling via various adrenergic receptors, G-protein coupled receptor type. The alpha 2 receptors couple to the Galphai subunit.
http://purl.obolibrary.org/obo/PW_0000797	norepinephrine signaling pathway via adrenergic receptor beta	http://purl.obolibrary.org/obo/PW_0000791	norepinephrine signaling pathway		Norepinephrine acts as a hormone and a neurotransmitter. It promotes various actions by signaling via various adrenergic receptors, G-protein coupled receptor type. The beta receptors couple to the Galphas subunit. Beta 2 receptor may also couple to Galphai.
http://purl.obolibrary.org/obo/PW_0000798	catecholamine signaling pathway	http://purl.obolibrary.org/obo/PW_0000466	amine and amino acid-derived hormone signaling pathway		Catecholamines act as hormones and neurotransmitters. The major catecholamines are dopamine, epinephrine and norepinephrine. They are derived from tyrosine and are not to be confused with tyrosine-based hormones.
http://purl.obolibrary.org/obo/PW_0000799	adrenergic beta receptor drug pathway - beta-agonist and beta-blocker	http://purl.obolibrary.org/obo/PW_0000924	respiratory system drug pathway		The pharmacokinetics and pharmacodynamics pathway of adrenergic beta receptors drugs - beta-agonists and blockers. Adrenergic beta receptors, in response to epinephrine or norepinephrine couple to the Gs alpha subunit of heterotrimeric G protein to elicit several responses. Beta-agonists are used to stimulate while beta-blocker antagonists are used to inhibit these responses, as necessary. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000800	adrenergic beta receptor agonist and beta-blocker pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0000799	adrenergic beta receptor drug pathway - beta-agonist and beta-blocker		The pathway of processing - absorption, distribution, metabolism or elimination - of beta adrenergic receptor drugs. The beta-agonists are used to stimulate while the beta-blockers are used to inhibit the action of adrenergic beta receptors, as necessary. Adrenergic beta receptors are G-protein coupled receptors that in response to epinephrine or norepinephrine elicit various sympathetic responses important for proper cardiac function and in the case of beta2 receptor, smooth muscle relaxation and bronchodilation. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0000801	adrenergic beta receptor agonist and beta-blocker pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0000799	adrenergic beta receptor drug pathway - beta-agonist and beta-blocker		The pathway of beta adrenergic drug-target interactions and of the biochemical or physiological responses to drug. The beta-agonists are used to stimulate while the beta-blockers are used to inhibit the action of adrenergic beta receptors, as necessary. Adrenergic beta receptors are G-protein coupled receptors that in response to epinephrine or norepinephrine elicit various sympathetic responses important for proper cardiac function and in the case of beta2 receptor, smooth muscle relaxation and bronchodilation. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000802	dopamine biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001235	catecholamine biosynthetic pathway		Those metabolic reactions involved in the synthesis of dopamine.
http://purl.obolibrary.org/obo/PW_0000803	epinephrine biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001235	catecholamine biosynthetic pathway		Those metabolic reactions involved in the biosynthesis of epinephrine. Epinephrine is primarily synthesized in adrenal chromaffin cells in response to specific stresses that activate the sympatho-adreno-medullary system.
http://purl.obolibrary.org/obo/PW_0000804	norepinephrine biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001235	catecholamine biosynthetic pathway		Those metabolic reactions involved in the biosynthesis of norepinephrine. Norepinephrine is primarily synthesized in sympathetic neurons in response to stresses such as cold or pain.
http://purl.obolibrary.org/obo/PW_0000805	altered Trail mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000682	Trail mediated signaling pathway		A Trail mediated signaling pathway that deviates from what its normal course should be. Mutations with the death domain of the receptors or deletions within the region containing the receptor genes have been reported for certain types of lymphomas.
http://purl.obolibrary.org/obo/PW_0000806	altered FasL mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000681	FasL mediated signaling pathway		A FasL mediated signaling pathway that deviates from what its normal course should be.
http://purl.obolibrary.org/obo/PW_0000807	altered transcription pathway	http://purl.obolibrary.org/obo/PW_0000290	altered pathway pertinent to DNA replication and repair, cell cycle, maintenance of genomic integrity, RNA and protein biosynthesis		A transcription pathway that deviates from what its normal course should be. Aberrant transcription can have devastating consequences. Altered signaling mediated by various transcription factors has been implicated in a spectrum of human diseases.
http://purl.obolibrary.org/obo/PW_0000808	microRNA pathway	http://purl.obolibrary.org/obo/PW_0000809	small non-coding RNA pathway		MicroRNAs (miRNAs) are a large family of small RNAs involved in the post-transcriptional regulation of gene expression. The biogenesis and function of miRNA is subject to complex control. Deregulation of miRNA expression has been linked to many diseases including cancer.
http://purl.obolibrary.org/obo/PW_0000809	small non-coding RNA pathway	http://purl.obolibrary.org/obo/PW_0001334	non-coding RNA pathway		The small non-coding RNA pathways have emerged as potent regulators of gene expression. Three major classes have been identified of which the microRNA (miRNA) system is the better understood one.
http://purl.obolibrary.org/obo/PW_0000811	Piwi-interacting RNA pathway	http://purl.obolibrary.org/obo/PW_0000809	small non-coding RNA pathway		Piwi-RNA (piRNAs) are believed to play a role in gene silencing, particularly the silencing of transposons as many
http://purl.obolibrary.org/obo/PW_0000812	altered small non-coding RNA pathway	http://purl.obolibrary.org/obo/PW_0000809	small non-coding RNA pathway		A small non-coding RNA pathway that deviates from what its normal course should. For instance, alterations in miRNA pathway have been associated with many diseases including various types of cancer.
http://purl.obolibrary.org/obo/PW_0000813	altered microRNA pathway	http://purl.obolibrary.org/obo/PW_0000812	altered small non-coding RNA pathway		A microRNA pathway that deviates from what its normal course should be. An altered miRNA pathway has been implicated in many diseases including various forms of cancer.
http://purl.obolibrary.org/obo/PW_0000814	Toll-like receptor signaling pathway	http://purl.obolibrary.org/obo/PW_0000925	pattern recognition receptor mediated signaling pathway		Toll-like receptors represent a large and the better understood family of pattern recognition receptors that sense an array of exogenous structures, and recent evidence shows they can also recognize defective endogenous molecules. The intracellular signaling cascades they set in motion lead to the expression of inflammatory mediators.
http://purl.obolibrary.org/obo/PW_0000815	C-type lectin receptor signaling pathway	http://purl.obolibrary.org/obo/PW_0000925	pattern recognition receptor mediated signaling pathway		C-type lectin receptors represent one of four classes of pattern recognition receptors. The intracellular signaling cascades they set in motion lead to the expression of inflammatory mediators.
http://purl.obolibrary.org/obo/PW_0000816	Retinoic acid-inducible gene (RIG) I-like receptor signaling pathway	http://purl.obolibrary.org/obo/PW_0000925	pattern recognition receptor mediated signaling pathway		This family of pattern recognition receptors are cytoplasmic proteins that recognize exogenous cytoplasmic DNA. The signaling cascades they set in motion lead to the expression of inflammatory mediators.
http://purl.obolibrary.org/obo/PW_0000817	NOD-like receptor signaling pathway	http://purl.obolibrary.org/obo/PW_0000925	pattern recognition receptor mediated signaling pathway		NOD-like receptors are cytosolic proteins that recognize components of bacterial peptidoglycans. The signaling cascades they set in motion lead to the expression of inflammatory mediators.
http://purl.obolibrary.org/obo/PW_0000818	signaling pathway pertinent to immunity	http://purl.obolibrary.org/obo/PW_0000003	signaling pathway		Those signaling pathways that are involved in or mediate the various aspects of immune responses.
http://purl.obolibrary.org/obo/PW_0000821	T cell receptor signaling pathway	http://purl.obolibrary.org/obo/PW_0000820	signaling pathway in the adaptive immune response		T cell receptor (TCR) signaling in developing thymocytes is important for the establishment of CD4 and CD8 lineages. Mature T cells express either CD4 or CD8 co-receptors which are essential for the interaction with peptide-bound class II or class I MHC complexes to elicit CD4 T helper (Th) or CD8 cytotoxic T lymphocyte responses, respectively. In either case, T cell-initiated signaling activates the expression of genes whose products mediate these responses.
http://purl.obolibrary.org/obo/PW_0000822	B cell receptor signaling pathway	http://purl.obolibrary.org/obo/PW_0000820	signaling pathway in the adaptive immune response		Antigen recognition by B cell receptors initiates signaling cascades that activate the expression of genes whose products are important for B cell functional responses.
http://purl.obolibrary.org/obo/PW_0000823	humoral immunity pathway	http://purl.obolibrary.org/obo/PW_0000235	adaptive immune response pathway		Humoral immunity is mediated by antibodies secreted by the B cell lymphocytes. Antibodies recognize antigens of extracellular microbes and act to neutralize and eliminate them. Activation of B cells can occur in a T cell dependent or independent manner.
http://purl.obolibrary.org/obo/PW_0000824	cell-mediated immunity pathway	http://purl.obolibrary.org/obo/PW_0000235	adaptive immune response pathway		Cell-mediated immune response pathways are carried out by T cell lymphocytes. T cells receptors recognize peptides bound to a major histocompatibility complex (MHC) on the antigen presenting cell. Depending on whether the co-receptor is CD4 or CD8, the receptors will interact with MHC class II or class I to elicit distinct responses against intracellular pathogens.
http://purl.obolibrary.org/obo/PW_0000826	T cell receptor signaling pathway in CD4+ T cells	http://purl.obolibrary.org/obo/PW_0000821	T cell receptor signaling pathway		T cells that express the CD4 co-receptor, also called T helper cells, recognize class II MHC presented antigens derived from internalized microbes to initiate a signaling cascade that results in enhanced microbicidal capacity of phagocytes. T helper cells can be further subdivided into subsets of CD4+ T cells based on the distinct cytokines they produce and effector functions they perform.
http://purl.obolibrary.org/obo/PW_0000827	T cell receptor signaling pathway in CD8+ T cells	http://purl.obolibrary.org/obo/PW_0000821	T cell receptor signaling pathway		T cells that express the CD8 co-receptor, also called cytotoxic or cytolytic T cells, recognize class I MHC presented antigens derived from cytosolic proteins to initiate a signaling cascade that results in killing of the target cell.
http://purl.obolibrary.org/obo/PW_0000828	cytokine mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000818	signaling pathway pertinent to immunity		Cytokine-initiated signaling pathways play important roles in innate and adaptive immunity, as well as cell proliferation and apoptosis.
http://purl.obolibrary.org/obo/PW_0000829	chemokine mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000818	signaling pathway pertinent to immunity		Chemokine-initiated pathways play important roles in innate and adaptive immunity. They are also involved in development and tissue maintenance. The presence and localization of four cysteines is important for structural folding and is also the basis for chemokine classification. The spacing between the first two cysteine residues divides the family members into four groups. Most mammalian chemokines belong to the CC and CXC families. Chemokines signal via G-protein-coupled receptors to engage distinct G-protein signaling and downstream cascades.
http://purl.obolibrary.org/obo/PW_0000830	CXC chemokine mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000829	chemokine mediated signaling pathway		The CXC family members are characterized by the presence of two cysteine resides separated by one amino acid. CXC and CC are the two most prominent families. This family of chemokines is also subdivided into two subgroups: the one with the ELR motif - ELR (+) and the one without - ELR(-), respectively. Generally, ELR(+) and ELR(-) members bind to distinct chemokine, G-coupled protein, receptors. The effects of their signaling is for the most part angiogenic or angiostatic, respectively.
http://purl.obolibrary.org/obo/PW_0000831	CC chemokine mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000829	chemokine mediated signaling pathway		The CC family members are characterized by the presence of two adjacent cysteine residues. The CC and the CXC family are the two most prominent families. Chemokines signal via G-protein coupled receptors to engage distinct G protein signaling and downstream cascades.
http://purl.obolibrary.org/obo/PW_0000832	C chemokine mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000829	chemokine mediated signaling pathway		The C family of chemokine is small and its members have two rather than four cysteines residues. Chemokines signal via G-protein coupled receptors to engage distinct G protein signaling and downstream cascades.
http://purl.obolibrary.org/obo/PW_0000833	CX3C chemokine mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000829	chemokine mediated signaling pathway		The CX3X family of chemokine is small and characterized by the presence of three residues separating the first two cysteines. Currently, only one member is known in mammals. Chemokines signal via G-protein coupled receptors to engage distinct G protein signaling and downstream cascades.
http://purl.obolibrary.org/obo/PW_0000834	bile acid transport pathway	http://purl.obolibrary.org/obo/PW_0000103	transport pathway		Bile acid absorption by the intestinal epithelium and hepatic recycling collectively group the transport pathway of the important molecules of cholesterol catabolism.
http://purl.obolibrary.org/obo/PW_0000835	anti-estrogen drug pathway	http://purl.obolibrary.org/obo/PW_0002367	antineoplastic drug pathway		Breast cancer is a major cause of death among Western women and many breast tumors are estrogen-dependent. Pharmacologically two major therapies have been developed: one targets the estrogen receptors via antagonists and selective modulators (SERM) and the second targets estrogen synthesis via aromatase inhibitors.
http://purl.obolibrary.org/obo/PW_0000836	aromatase inhibitor pathway	http://purl.obolibrary.org/obo/PW_0000835	anti-estrogen drug pathway		Aromatase inhibitors block the last step of estrogen biosynthesis. They can be classified into first-, second- and third-generation drugs. Depending on whether they inactivate the aromatase complex irreversibly or reversibly, they can be further subdivided into type I and II, respectively. Currently, third generation drugs are being used.
http://purl.obolibrary.org/obo/PW_0000837	tamoxifen drug pathway	http://purl.obolibrary.org/obo/PW_0000835	anti-estrogen drug pathway		The pharmacokinetics and pharmacodynamics pathway of tamoxifen - one of the most widely used anti-estrogen drug that targets the estrogen receptor. The drug is a modulator than acts as an antagonist in breast cancer cells but can be an agonist in bone and the cardiovascular system. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000838	tamoxifen pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0000837	tamoxifen drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of tamoxifen - a SERM anti-estrogen drug. Genetic variations can result in changes in the availability of the drug. For instance, variation in CYP2D6, an important enzyme for the production of a primary drug metabolite, impacts on the available concentration of the drug.
http://purl.obolibrary.org/obo/PW_0000839	tamoxifen pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0000837	tamoxifen drug pathway		The pathway of tamoxifen-target interaction and of the biochemical or physiological responses to drug. In breast cancer cells, tamoxifen binding antagonizes estrogen binding and the subsequent conformational changes necessary for co-activators recruitment. It may also prompt the recruitment of co-repressor. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000840	protein kinase C (PKC) signaling pathway	http://purl.obolibrary.org/obo/PW_0001194	serine/threonine-specific kinase mediated signaling pathway		Protein kinase C constitutes a family of serine/threonine kinases activated by diacylglycerol (DAG) and calcium whose signal transduction plays important roles in many cellular processes. Ligand-activated G protein-coupled receptors, via the Galphaq pathway, stimulate phospholipase C, which cleaves PIP2 into DAG and IP3. IP3 promotes calcium release.
http://purl.obolibrary.org/obo/PW_0000841	acetylcholine signaling pathway	http://purl.obolibrary.org/obo/PW_0001162	chemical compound signaling pathway		Acetylcholine signaling plays important roles in the central and peripheral nervous systems and exerts both excitatory and inhibitory effects. It is synthesized from acetyl-CoA and choline by choline O-acetyltransferase.
http://purl.obolibrary.org/obo/PW_0000842	acetylcholine signaling pathway via nicotinic acetylcholine receptor	http://purl.obolibrary.org/obo/PW_0000841	acetylcholine signaling pathway		Activation of the pentameric ionotropic nicotinic acetylcholine receptor leads to membrane depolarization and subsequent excitatory transmission. A salient feature of presynaptic signaling is promoting the release of various neurotransmitters depending on the neuron expressing the receptors.
http://purl.obolibrary.org/obo/PW_0000843	acetylcholine signaling pathway via muscarinic acetylcholine receptor	http://purl.obolibrary.org/obo/PW_0000841	acetylcholine signaling pathway		Acetylcholine signaling via the metabotropic muscarinic receptors exerts important roles in the central and peripheral nervous system, the autonomic nervous system and also in non-neuronal cells. The five G protein-coupled receptors can be classified according to the G proteins they engage. Receptors M1, M3 and M5 predominantly couple to Galphaq whereas receptors M2 and M4 predominantly couple to Galphai-mediated pathways. The signaling effects can be either excitatory or inhibitory.
http://purl.obolibrary.org/obo/PW_0000844	glutamate signaling pathway	http://purl.obolibrary.org/obo/PW_0000455	excitatory synaptic transmission pathway		Glutamate signaling via the ionotropic AMPA or NMDA and several metabotropic receptors plays important roles in the modulation of synaptic plasticity, long term depression or potentiation, and in learning and memory.
http://purl.obolibrary.org/obo/PW_0000845	glutamate signaling pathway via NMDA receptor	http://purl.obolibrary.org/obo/PW_0000844	glutamate signaling pathway		Glutamate signaling via the ionotropic NMDA glutamate receptor plays important roles in synaptic plasticity and in learning and memory. The receptor is ligand-gated and voltage-dependent and requires glycine as a co-agonist.
http://purl.obolibrary.org/obo/PW_0000846	glutamate signaling pathway via AMPA receptor	http://purl.obolibrary.org/obo/PW_0000844	glutamate signaling pathway		Glutamate signaling via the ionotropic AMPA receptor plays important roles in long-term potentiation (LTP). The AMPA receptors are both receptors and cation channels.
http://purl.obolibrary.org/obo/PW_0000847	glutamate signaling pathway via metabotropic glutamate receptor	http://purl.obolibrary.org/obo/PW_0000844	glutamate signaling pathway		Glutamate signaling via the various metabotropic, G protein-coupled receptors plays important roles in both the central and peripheral nervous systems. Based on their structure and physiological function, the receptors have been classified into three groups. Group I receptors couple to Galphaq, group II and III couple to Galphai
http://purl.obolibrary.org/obo/PW_0000848	gamma-aminobutyric acid signaling pathway	http://purl.obolibrary.org/obo/PW_0000456	Inhibitory synaptic transmission pathway		Gamma-aminobutyric acid signals at inhibitory synapses via the type A receptor, which is part of a ligand-gated ion channel, and the type B receptors, which are metabotropic G protein-coupled receptors.
http://purl.obolibrary.org/obo/PW_0000851	dopamine signaling pathway via D1 family of receptors	http://purl.obolibrary.org/obo/PW_0000394	dopamine signaling pathway		Dopamine signaling via D1-like receptors engages the Galphas family of G proteins leading to activation of adenylyl cyclases and increase in intracellular cAMP. Dopamine receptors 1 and 5 belong to this family.
http://purl.obolibrary.org/obo/PW_0000852	dopamine signaling pathway via D2 family of receptors	http://purl.obolibrary.org/obo/PW_0000394	dopamine signaling pathway		Dopamine signaling via D2-like family of receptors engages the Galphai family of G proteins leading to inhibition of adenylyl cyclases and reduction of intracellular cAMP. Dopamine receptors 2, 3 and 4 belong to this family.
http://purl.obolibrary.org/obo/PW_0000853	histamine signaling pathway, neuronal	http://purl.obolibrary.org/obo/PW_0002120	histamine signaling pathway		Histamine signaling is important for the central and to some extent the peripheral nervous systems and is also involved in the immune responses. Histamine signaling engages four G-protein coupled receptors (GPCR). In the brain, it involves receptors H1 and H3 that couple to Galphaq and Galphai, respectively.
http://purl.obolibrary.org/obo/PW_0000854	serotonin signaling pathway	http://purl.obolibrary.org/obo/PW_0001162	chemical compound signaling pathway		Serotonin signaling exerts many roles, from regulation of appetite, mood and sleep to involvement in learning and memory and in muscle contraction. Serotonin signals via several receptors known as 5-hydroxytryptamine or 5-HT receptors. With one exception, 5-HT receptors are G protein-coupled receptors engaging distinct G protein signaling to elicit distinct, both inhibitory and excitatory responses.
http://purl.obolibrary.org/obo/PW_0000855	acetylcholine signaling pathway via muscarinic acetylcholine receptors engaging G alphaq protein family	http://purl.obolibrary.org/obo/PW_0000843	acetylcholine signaling pathway via muscarinic acetylcholine receptor		Acetylcholine signaling via receptor type M1, M3 and M5 primarily engages G alphaq protein family resulting in activation of phospholipase C and mobilization of intracellular calcium. The receptors are expressed in various areas of the brain and the cell membrane of effector tissues.
http://purl.obolibrary.org/obo/PW_0000856	acetylcholine signaling pathway via muscarinic acetylcholine receptors engaging G alphai protein family	http://purl.obolibrary.org/obo/PW_0000843	acetylcholine signaling pathway via muscarinic acetylcholine receptor		Acetylcholine signaling via receptor type M2 and M4 primarily engages G alphai protein family resulting in inhibition of adenylate cyclases and reduction of intracellular cAMP. The receptors are expressed in various areas of the brain and the cell membrane of effector tissues. A special feature is their role as autoreceptors at the presynapse of cholinergic neurons.
http://purl.obolibrary.org/obo/PW_0000857	phase I biotransformation pathway	http://purl.obolibrary.org/obo/PW_0001229	xenobiotic metabolic pathway		The phase I biotransformation pathway involves the conversion of exogenous substances to more polar metabolites. Members of the cytochrome P450 superfamily and to a lesser extent, flavin-containing monooxygenases mediate the reactions.
http://purl.obolibrary.org/obo/PW_0000858	phase II biotransformation pathway	http://purl.obolibrary.org/obo/PW_0001229	xenobiotic metabolic pathway		The phase II biotransformation pathway involves the conjugation of phase I products to various hydrophilic moieties that renders them more suitable for excretion. Various enzyme superfamilies are involved in carrying out the specific conjugation of metabolites.
http://purl.obolibrary.org/obo/PW_0000859	glucuronidation conjugation pathway	http://purl.obolibrary.org/obo/PW_0000858	phase II biotransformation pathway		Glucuronidation of phase I products by members of the UDP-glucuronosyltranferase superfamily represents the major phase II conjugation pathway.
http://purl.obolibrary.org/obo/PW_0000860	sulfonation conjugation pathway	http://purl.obolibrary.org/obo/PW_0000858	phase II biotransformation pathway		The sulfonation of phase I products by members of the sulfotransferase family represents a major route of phase II biotransformation, second to the glucuronidation pathway.
http://purl.obolibrary.org/obo/PW_0000861	pyrimidine biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000032	pyrimidine metabolic pathway		Those enzymatic reactions involved in the synthesis of pyrimidine nucleotides. A major route for pyrimidine synthesis is the de novo pathway. However, an alternate pathway, the salvage pathway, converts nucleosides generated by DNA or RNA breakdown back to nucleotide monophosphates which can then re-enter the biosynthetic pathway.
http://purl.obolibrary.org/obo/PW_0000862	de novo pyrimidine biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000861	pyrimidine biosynthetic pathway		In the de novo biosynthetic pathway, pyrimidines are synthesized from simple precursors. Six reactions carried out by three enzymes in higher eukaryotes result in the formation of UMP, the precursor of all other pyrimidine nucleotides.
http://purl.obolibrary.org/obo/PW_0000863	pyrimidine salvage pathway	http://purl.obolibrary.org/obo/PW_0000861	pyrimidine biosynthetic pathway		The salvage pathway of pyrimidine biosynthesis, mostly used in resting and differentiated cells, allows for the synthesis of pyrimidines from intermediates derived from DNA and RNA degradation pathways.
http://purl.obolibrary.org/obo/PW_0000864	pyrimidine degradation pathway	http://purl.obolibrary.org/obo/PW_0000032	pyrimidine metabolic pathway		Those enzymatic reactions involved in the degradation of pyrimidines.
http://purl.obolibrary.org/obo/PW_0000865	purine biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000031	purine metabolic pathway		Those enzymatic reactions involved in the synthesis of purine nucleotides. A major route for purine synthesis is the novo pathway. However, an alternate pathway, the salvage pathway, can also be used.
http://purl.obolibrary.org/obo/PW_0000866	purine degradation pathway	http://purl.obolibrary.org/obo/PW_0000031	purine metabolic pathway		Those enzymatic reactions involved in the degradation pathway of purines. Several enzymes are involved in the breakdown of adenine and guanine to uric acid. Primates, birds and other animal excrete uric acid. In other species uric acid is further metabolized to allantoin.
http://purl.obolibrary.org/obo/PW_0000867	de novo purine biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000865	purine biosynthetic pathway		De novo purine biosynthesis requires ten enzymatic reactions to produce inosine monophosphate (IMP). Both adenine and guanine are then derived from IMP via several reactions. Purines are synthesized as nucleosides, i.e., as bases attached to ribose. Purines can also be created synthetically.
http://purl.obolibrary.org/obo/PW_0000868	purine salvage pathway	http://purl.obolibrary.org/obo/PW_0000865	purine biosynthetic pathway		The salvage pathway of purine biosynthesis allows for the synthesis of purines from intermediates derived from DNA and RNA degradation pathways. This is important because some tissues are unable to synthesize purines de novo.
http://purl.obolibrary.org/obo/PW_0000869	gefitinib drug pathway	http://purl.obolibrary.org/obo/PW_0002367	antineoplastic drug pathway		The pharmacokinetics and pharmacodynamics pathway of gefitinib. Gefitinib is the first selective inhibitor of EGFR whose mutations within the tyrosine kinase domain have been associated with hyperactive epidermal growth factor signaling in non-small cell lung cancers. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000870	gefitinib pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0000869	gefitinib drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of gefitinib. Gefitinib is the first selective inhibitor of EGFR whose mutations within the tyrosine kinase domain have been associated with hyperactive epidermal growth factor signaling in non-small cell lung cancers. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0000871	gefitinib pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0000869	gefitinib drug pathway		The pathway of gefitinib-target interactions and of the biochemical or physiological responses to drug. Gefitinib is the first selective inhibitor of EGFR whose mutations within the tyrosine kinase domain have been associated with hyperactive epidermal growth factor signaling in non-small cell lung cancers. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000872	erlotinib drug pathway	http://purl.obolibrary.org/obo/PW_0002367	antineoplastic drug pathway		The pharmacokinetics and pharmacodynamics pathway of erlotinib. Erlotinib is the second (after gefitinib) selective inhibitor of EGFR whose mutations within the tyrosine kinase domain have been associated with hyperactive epidermal growth factor signaling in non-small cell lung cancers. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000873	erlotinib pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0000872	erlotinib drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of erlotinib. Erlotinib is the second (after gefitinib) selective inhibitor of EGFR whose mutations within the tyrosine kinase domain have been associated with hyperactive epidermal growth factor signaling in non-small cell lung cancers. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0000874	erlotinib pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0000872	erlotinib drug pathway		The pathway of erlotinib-target interaction and of the biochemical or physiological responses to drug. Erlotinib is the second (after gefitinib) selective inhibitor of EGFR whose mutations within the tyrosine kinase domain have been associated with hyperactive epidermal growth factor signaling in non-small cell lung cancers. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000875	deoxyribonucleotide metabolic pathway	http://purl.obolibrary.org/obo/PW_0000012	nucleotide metabolic pathway		Deoxyribonucleotide synthesis occurs via the de novo pathway mediated by ribonucleotide reductase or via the salvage pathway. The de novo pathway is responsible for the bulk of dNTP during the S phase of the cell cycle, whereas the salvage pathway mostly operates in the quiescent state of the cell. Several cytosolic and mitochondrial enzymes are responsible for the initial steps of the salvage pathway in the two compartments and for the reverse reactions that control the size of the dNTP pool.
http://purl.obolibrary.org/obo/PW_0000876	bacterial polysaccharide metabolic pathway	http://purl.obolibrary.org/obo/PW_0000146	glycan metabolic pathway		Those metabolic reaction involved in the synthesis, utilization and/or degradation of polysaccharides that are components of bacterial cell wall. They may also act as virulence factors.
http://purl.obolibrary.org/obo/PW_0000877	cytosine monophosphate metabolic pathway	http://purl.obolibrary.org/obo/PW_0000055	nucleotide sugar metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of cytosine monophosphate, the only nucleotide sugar in the monophosphate form.
http://purl.obolibrary.org/obo/PW_0000878	phosphatidylcholine biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001307	phosphatidylcholine metabolic pathway		Phosphatidylcholine is the predominant phospholipid of eukaryotic membranes. Of the three known biosynthetic pathways, two are found in eukaryotes and one, the CDP-choline pathway, is the best characterized.
http://purl.obolibrary.org/obo/PW_0000879	altered cortisol signaling pathway	http://purl.obolibrary.org/obo/PW_0001314	altered transcription pathway via transcription factor mediated signaling		A cortisol signaling pathway that deviates from what its normal course should be. Mutations in the glucocorticoid receptor have been associated with rare, sporadic or familial, glucocorticoid resistance.
http://purl.obolibrary.org/obo/PW_0000882	interleukin-1 family mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000512	Interleukin mediated signaling pathway		Interleukin-1 family mediated signaling plays important roles in innate and adaptive immune responses. The best characterized member of the family is interleukin-1, followed by interleukin-18 and the more recently identified interleukin-33. Other family members are less well characterized.
http://purl.obolibrary.org/obo/PW_0000883	interleukin-1 signaling pathway	http://purl.obolibrary.org/obo/PW_0000926	pro-inflammatory cytokine mediated pathway		Interleukin-1 signaling, primarily via interleukin-1beta, plays important roles in innate and adaptive immune responses. Binding of the processed cytokine to its receptor allows for the recruitment of several accessory and adaptor proteins leading to the activation of NF-kappaB and MAPK signaling cascades. A natural receptor antagonist and a decoy receptor act as regulators of interleukin-1alpha and beta.
http://purl.obolibrary.org/obo/PW_0000884	interleukin-18 signaling pathway	http://purl.obolibrary.org/obo/PW_0000882	interleukin-1 family mediated signaling pathway		Interleukin-18 signaling plays important roles in innate and adaptive immunity. In the central nervous system (CNS), Il-18 and its receptors have been shown to play a role in neuroinflammatory and neurodegenerative processes as well as behavior and homeostasis. In addition, Il-18 may be a mediator of inflammation in rheumatoid arthritis.
http://purl.obolibrary.org/obo/PW_0000885	interleukin-33 signaling pathway	http://purl.obolibrary.org/obo/PW_0000882	interleukin-1 family mediated signaling pathway		Interleukin-33 is the most recently discovered member of the interleukin-1 family. As with the other members of the family, signaling by interleukin-33 plays important roles in inflammation and immunity and may be critical for the development of inflammatory and immune diseases.
http://purl.obolibrary.org/obo/PW_0000888	interleukin-22 signaling pathway	http://purl.obolibrary.org/obo/PW_0000513	interleukin-10 family mediated signaling pathway		Interleukin-22 signaling triggers the Jak-Stat intracellular cascade resulting in the activation of various T helper (Th) cells.
http://purl.obolibrary.org/obo/PW_0000894	interferon mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000828	cytokine mediated signaling pathway		The interferons represent a subset of cytokines whose signaling is involved in various aspects of innate and adaptive immunity. Based on the type of receptors they employ, interferons have been classified into type I and II. A third type, the lambda interferons, are members of the interleukin 10 family.
http://purl.obolibrary.org/obo/PW_0000895	type I interferon signaling pathway	http://purl.obolibrary.org/obo/PW_0000894	interferon mediated signaling pathway		Type I interferon, which includes all but one of the seven known human genes, binds to distinct receptors that activate the Jak-Stat signaling pathway.
http://purl.obolibrary.org/obo/PW_0000896	type II interferon signaling pathway	http://purl.obolibrary.org/obo/PW_0000894	interferon mediated signaling pathway		Type II interferon, of which there is only one in humans, binds to distinct receptors that activate the Jak-Stat signaling pathway. It is known as interferon gamma signaling.
http://purl.obolibrary.org/obo/PW_0000897	interleukin-17 family mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000512	Interleukin mediated signaling pathway		The interleukin-17 family-mediated signaling plays important roles in inflammation and in the development of autoimmunity as well as in the host defense against fungal and bacterial infections.
http://purl.obolibrary.org/obo/PW_0000898	interleukin-17E signaling pathway	http://purl.obolibrary.org/obo/PW_0000897	interleukin-17 family mediated signaling pathway		Interleukin-17E signaling, also known as interleukin-25, induces the production of Th2 cell cytokine leading to enhancement of Th2 cell responses.
http://purl.obolibrary.org/obo/PW_0000899	interleukin-17A signaling pathway	http://purl.obolibrary.org/obo/PW_0000897	interleukin-17 family mediated signaling pathway		Of the six family members of the interleukin-17 family, interleukin-17A is the founding member and the better-characterized system. While interleukin-17A binds the same receptor as interleukin-17F and can also heterodimerize with it, its signaling elicits distinct and broader responses.
http://purl.obolibrary.org/obo/PW_0000900	interleukin-17F signaling pathway	http://purl.obolibrary.org/obo/PW_0000897	interleukin-17 family mediated signaling pathway		Interleukin-17F binds the same receptor as interleukin-17A and can also heterodimerize with it. However, its signaling while sharing features of interleukin-17A pathway also elicits distinct responses.
http://purl.obolibrary.org/obo/PW_0000901	altered interleukin mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000617	altered cytokine mediated signaling pathway		An interleukin mediated signaling pathway that deviates from what its normal course should be. Aberrant interleukin signaling pathway, alone or in combination with other pathways underlie various diseases.
http://purl.obolibrary.org/obo/PW_0000903	leukemia inhibitory factor signaling pathway	http://purl.obolibrary.org/obo/PW_0000514	interleukin-6 family mediated signaling pathway		Leukemia inhibitory factor, an interleukin-6 family member, inhibits cell differentiation, affecting cell growth.
http://purl.obolibrary.org/obo/PW_0000905	oncostatin M signaling pathway	http://purl.obolibrary.org/obo/PW_0000514	interleukin-6 family mediated signaling pathway		Oncostatin M, an interleukin-6 family member, has roles in bone formation and destruction, and has activities affecting inflammation, development and hematopoiesis.
http://purl.obolibrary.org/obo/PW_0000906	interleukin-2 family mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000512	Interleukin mediated signaling pathway		The interleukin-2 family of cytokines, also known as the gamma(c) family because of the shared gamma(c) receptor, play crucial roles in the regulation of T cells.
http://purl.obolibrary.org/obo/PW_0000907	interleukin-2 signaling pathway	http://purl.obolibrary.org/obo/PW_0000906	interleukin-2 family mediated signaling pathway		Interleukin-2 is the prototypical member of the interleukin-2 family of cytokines. The signaling pathway initiated by Il-2 and the other family members activates the Jak-Stat intracellular cascade to regulate T cell, innate and adaptive immune responses.
http://purl.obolibrary.org/obo/PW_0000908	interleukin-7 signaling pathway	http://purl.obolibrary.org/obo/PW_0000906	interleukin-2 family mediated signaling pathway		Interleukin-7, an interleukin-2 family member, is secreted by several cell types and is involved in leukemia progression.
http://purl.obolibrary.org/obo/PW_0000909	interleukin-9 signaling pathway	http://purl.obolibrary.org/obo/PW_0000906	interleukin-2 family mediated signaling pathway		Interleukin-9, an interleukin-2 family member, is produced by a variety of cell types; it stimulates hematopoietic cell proliferation and prevents apoptosis.
http://purl.obolibrary.org/obo/PW_0000910	interleukin-15 signaling pathway	http://purl.obolibrary.org/obo/PW_0000906	interleukin-2 family mediated signaling pathway		Interleukin-15, an interleukin-2 family member, induces natural killer cell proliferation and plays roles in adaptive and innate immunity.
http://purl.obolibrary.org/obo/PW_0000911	interleukin-21 signaling pathway	http://purl.obolibrary.org/obo/PW_0000906	interleukin-2 family mediated signaling pathway		Interleukin-21, an interleukin-2 family member, induces proliferation of immune system cells and has roles in cancer, allergies and viral infections.
http://purl.obolibrary.org/obo/PW_0000912	interleukin-4 signaling pathway	http://purl.obolibrary.org/obo/PW_0000906	interleukin-2 family mediated signaling pathway		Interleukin-4 is a member of the interleukin 2 family of cytokines whose signaling is important for the differentiation of naive T helper cells.
http://purl.obolibrary.org/obo/PW_0000913	interleukin-12 family mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000512	Interleukin mediated signaling pathway		Interleukin-12 family members are heterodimeric cytokines produced by antigen-presenting cells. The signaling they initiate triggers the Jak-Stat intracellular cascade and plays important roles in the regulation of T helper (Th) cell differentiation.
http://purl.obolibrary.org/obo/PW_0000914	interleukin-12 signaling pathway	http://purl.obolibrary.org/obo/PW_0000913	interleukin-12 family mediated signaling pathway		Interleukin-12 signaling activates the Jak-Stat intracellular cascade and promotes the differentiation and proliferation of Th1 cells and the production of interferon-gamma.
http://purl.obolibrary.org/obo/PW_0000915	interleukin-23 signaling pathway	http://purl.obolibrary.org/obo/PW_0000913	interleukin-12 family mediated signaling pathway		Interleukin-23, an interleukin-12 family member, is a heterodimeric, inflammatory cytokine important in T helper cell effector cytokine secretion and proliferation; it also stimulates angiogenesis.
http://purl.obolibrary.org/obo/PW_0000916	interleukin-27 signaling pathway	http://purl.obolibrary.org/obo/PW_0000913	interleukin-12 family mediated signaling pathway		Interleukin-27, an interleukin-12 family member, it induces various T cell populations to differentiate and stimulates them to produce interleukin-10.
http://purl.obolibrary.org/obo/PW_0000917	interleukin-35 signaling pathway	http://purl.obolibrary.org/obo/PW_0000913	interleukin-12 family mediated signaling pathway		Interleukin-35, an interleukin-12 family member, plays a role in suppressing the immune system; it obstructs development of certain T cell subsets by restricting early cell proliferation.
http://purl.obolibrary.org/obo/PW_0000918	proton pump inhibitor drug pathway	http://purl.obolibrary.org/obo/PW_0000921	alimentary tract and metabolism drug pathway		The pharmacokinetics and pharmacodynamics of proton pump inhibitor (PPI), a class of compounds that block the acid secretion from parietal cells in the stomach. A representative PPI compound is omeprazole. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000919	antineoplastic and immunomodulatory drug pathway	http://purl.obolibrary.org/obo/PW_0000754	drug pathway		The pharmacokinetics and pharmacodynamics of compounds used as antineoplastic or as immunomodulatory agents. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000920	cardiovascular system drug pathway	http://purl.obolibrary.org/obo/PW_0000754	drug pathway		The pharmacokinetics and pharmacodynamics of compounds used for the treatment of various cardiovascular conditions. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000921	alimentary tract and metabolism drug pathway	http://purl.obolibrary.org/obo/PW_0000754	drug pathway		The pharmacokinetics and pharmacodynamics of compounds used for the treatment of alimentary tract and metabolism-related conditions. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000922	blood and blood forming organs drug pathway	http://purl.obolibrary.org/obo/PW_0000754	drug pathway		The pharmacokinetics and pharmacodynamics of compounds used for the treatment of conditions associated with blood and blood forming organs. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000923	nervous system drug pathway	http://purl.obolibrary.org/obo/PW_0000754	drug pathway		The pharmacokinetics and pharmacodynamics of compounds used for the treatment of conditions associated with the nervous system. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000924	respiratory system drug pathway	http://purl.obolibrary.org/obo/PW_0000754	drug pathway		The pharmacokinetics and pharmacodynamics of compounds used for the treatment of conditions associated with the respiratory system. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000925	pattern recognition receptor mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000819	signaling pathway in the innate immune response		Pattern recognition receptors (PRR) respond to a diverse array of exogenous molecules and also several endogenous ones. PRR's 'sensing' of pathogen-associated molecular patterns (PAMP) or damage-associated (DAMP) prompts signaling cascades leading to the expression of pro-inflammatory genes.
http://purl.obolibrary.org/obo/PW_0000926	pro-inflammatory cytokine mediated pathway	http://purl.obolibrary.org/obo/PW_0000024	inflammatory response pathway		An early response of the innate immunity is the secretion of cytokines critical for the acute inflammatory response. The major pro-inflammatory cytokines are tumor necrosis factor alpha and the interleukins 1 and 6.
http://purl.obolibrary.org/obo/PW_0000927	anti-tumor necrosis factor drug pathway	http://purl.obolibrary.org/obo/PW_0002369	immunosuppressant drug pathway		Tumor necrosis factor (TNF) inhibitors are used in the treatment of rheumatoid arthritis. The inhibitors are recombinant proteins that bind the soluble and membrane-associated TNF and inhibit the effects of this pro-inflammatory cytokine.
http://purl.obolibrary.org/obo/PW_0000928	tocilizumab drug pathway	http://purl.obolibrary.org/obo/PW_0002369	immunosuppressant drug pathway		Tocilizumab is a humanized anti-interleukin 6 (Il-6) receptor antibody used in the treatment of patients with rheumatoid arthritis, Castleman's disease or juvenile idiopathic arthritis. Tocilizumab binds to the soluble and membrane associated interleukin-6 receptor and competitively blocks binding of interleukin-6 to its receptor(s) and inhibits the effects of this potent cytokine.
http://purl.obolibrary.org/obo/PW_0000929	anakinra drug pathway	http://purl.obolibrary.org/obo/PW_0002369	immunosuppressant drug pathway		Anakinra is a recombinant, non-glycosylated version of the human interleukin-1 (Il-1) receptor antagonist used for the treatment of inflammation associated with rheumatoid arthritis. Like the natural antagonist, anakinra competitively inhibits binding of interleukin-1 to its receptor and the subsequent effects of this potent pro-inflammatory cytokine.
http://purl.obolibrary.org/obo/PW_0000930	methotrexate drug pathway	http://purl.obolibrary.org/obo/PW_0002369	immunosuppressant drug pathway		The pharmacokinetics and pharmacodynamics of methotrexate (MTX), a polyglutamatable antifolate used in the treatment of cancers and autoimmune diseases. The impact of MTX on cancer and rheumatoid arthritis is thought to arise through distinct mechanisms and pharmacodynamics pathways. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000931	methotrexate pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0000930	methotrexate drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of methotrexate (MTX), a folate analogue used in the treatment of cancers and autoimmune diseases. Genetic variations can result in changes in the availability of the drug and It is believed that variability in MTX pharmacokinetics is linked to genetic variations in transporter proteins.
http://purl.obolibrary.org/obo/PW_0000932	methotrexate pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0000930	methotrexate drug pathway		The pathway of methotrexate-target interaction and of the biochemical or physiological responses to drug. The impact of MTX on cancer and rheumatoid arthritis is thought to arise through distinct mechanisms and pharmacodynamics pathways. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000933	tumor necrosis factor member 14 signaling pathway	http://purl.obolibrary.org/obo/PW_0000236	tumor necrosis factor superfamily mediated signaling pathway		Tumor necrosis factor member 14, also known as Light, binds the lymphotoxin beta receptor and the tumor necrosis receptor member 14 known as Hvem of the tumor necrosis receptor superfamily to elicit important responses for the dendritic (DC) and T cells of the immune system.
http://purl.obolibrary.org/obo/PW_0000934	tumor necrosis factor member 13 signaling pathway	http://purl.obolibrary.org/obo/PW_0000236	tumor necrosis factor superfamily mediated signaling pathway		Tumor necrosis factor member 13 also known as April, binds the tumor necrosis factor receptor member 13B known as Taci and receptor member 17 known as Bcma of the tumor necrosis factor receptor superfamily to elicit important responses for the B cells of the immune system.
http://purl.obolibrary.org/obo/PW_0000935	tumor necrosis factor member 13b signaling pathway	http://purl.obolibrary.org/obo/PW_0000236	tumor necrosis factor superfamily mediated signaling pathway		The tumor necrosis factor member 13b known as Baff binds to three receptors of the tumor necrosis factor receptor superfamily - the receptor member 13B known as Taci and member 17 known as Bcma to which member 13 of the ligand superfamily also binds, and additionally to member 13C of the receptor superfamily to elicit important responses for the B cells of the immune system.
http://purl.obolibrary.org/obo/PW_0000936	chemokine (C-C motif) ligand 1 signaling pathway	http://purl.obolibrary.org/obo/PW_0000831	CC chemokine mediated signaling pathway		Chemokine ligand 1 signaling engages the chemokine (C-C motif) receptor 8 (Ccr8) and together with other CC chemokines is classified as a member of the allergenic subgroup.
http://purl.obolibrary.org/obo/PW_0000937	chemokine (C-C motif) ligand 2 signaling pathway	http://purl.obolibrary.org/obo/PW_0000831	CC chemokine mediated signaling pathway		Chemokine ligand 2 signaling engages the chemokine (C-C motif) receptor 2 (Ccr2) and together with other CC chemokines it is classified as a member of the allergenic subgroup.
http://purl.obolibrary.org/obo/PW_0000938	chemokine (C-C motif) ligand 3 signaling pathway	http://purl.obolibrary.org/obo/PW_0000831	CC chemokine mediated signaling pathway		Chemokine ligand 3 signaling pathway engages chemokine (C-C motif) receptors 2 and 5 (Ccr2 and Ccr5) and together with other chemokines is classified as a member of the pro-inflammatory subgroup.
http://purl.obolibrary.org/obo/PW_0000939	chemokine (C-C motif) ligand 4 signaling pathway	http://purl.obolibrary.org/obo/PW_0000831	CC chemokine mediated signaling pathway		Chemokine ligand 4 signaling engages the chemokine (C-C motif) receptor 5 (Ccr5) and together with other chemokines is classified as a member of the pro-inflammatory subgroup.
http://purl.obolibrary.org/obo/PW_0000940	chemokine (C-C motif) ligand 5 signaling pathway	http://purl.obolibrary.org/obo/PW_0000831	CC chemokine mediated signaling pathway		Chemokine ligand 5 signaling engages chemokine (C-C motif) receptors 1, 3 and 5 (Ccr1, Ccr3 and Ccr5) and together with other chemokines it is classified as a member of the pro-inflammatory subgroup.
http://purl.obolibrary.org/obo/PW_0000941	chemokine (C-C motif) ligand 6 signaling pathway	http://purl.obolibrary.org/obo/PW_0000831	CC chemokine mediated signaling pathway		Chemokine ligand 6 signaling is known to act in rodents and does not appear to have a human equivalent. Ccl6, together with other chemokines is classified as a member of the pro-inflammatory subgroup.
http://purl.obolibrary.org/obo/PW_0000942	chemokine (C-C motif) ligand 7 signaling pathway	http://purl.obolibrary.org/obo/PW_0000831	CC chemokine mediated signaling pathway		Chemokine ligand 7 signaling engages chemokine (C-C) motif receptors 1, 2, and 3 (Ccr1, Ccr2, Ccr3) and together with other chemokines is classified as a member of the allergenic subgroup.
http://purl.obolibrary.org/obo/PW_0000943	chemokine (C-C motif) ligand 8 signaling pathway	http://purl.obolibrary.org/obo/PW_0000831	CC chemokine mediated signaling pathway		Chemokine ligand 8 signaling engages chemokine (C-C motif) receptors 3 and 5 (Ccr3 and Ccr5) and together with other chemokines is classified as a member of the allergenic subgroup.
http://purl.obolibrary.org/obo/PW_0000944	chemokine (C-C motif) ligand 11 signaling pathway	http://purl.obolibrary.org/obo/PW_0000831	CC chemokine mediated signaling pathway		Chemokine ligand 11 signaling engages the chemokine (C-C motif) receptor 3 (Ccr3) and together with other chemokines is classified as a member of the allergenic subgroup.
http://purl.obolibrary.org/obo/PW_0000945	chemokine (C-C motif) ligand 12 signaling pathway	http://purl.obolibrary.org/obo/PW_0000831	CC chemokine mediated signaling pathway		Chemokine ligand 12 signaling is known to act in rodents and does not appear to have a human equivalent. Ccl12, together with other chemokines is classified as a member of the allergenic subgroup.
http://purl.obolibrary.org/obo/PW_0000946	chemokine (C-C motif) ligand 13 signaling pathway	http://purl.obolibrary.org/obo/PW_0000831	CC chemokine mediated signaling pathway		Chemokine ligand 13 signaling engages chemokine (C-C motif) receptors 2 and 3 (Ccr2 and Ccr3) and together with other chemokines is classified as a member of the allergenic subgroup.
http://purl.obolibrary.org/obo/PW_0000947	chemokine (C-C motif) ligand 17 signaling pathway	http://purl.obolibrary.org/obo/PW_0000831	CC chemokine mediated signaling pathway		Chemokine ligand 17 signaling engages the chemokine (C-C motif) receptor 4 (Ccr4) and together with other chemokines is classified as a member of the developmental subgroup.
http://purl.obolibrary.org/obo/PW_0000948	chemokine (C-C motif) ligand 22 signaling pathway	http://purl.obolibrary.org/obo/PW_0000831	CC chemokine mediated signaling pathway		Chemokine ligand 22 signaling engages the chemokine (C-C motif) receptor 4 (Ccr4) and together with other chemokines is classified as member of the developmental subgroup.
http://purl.obolibrary.org/obo/PW_0000949	chemokine (C-C motif) ligand 25 signaling pathway	http://purl.obolibrary.org/obo/PW_0000831	CC chemokine mediated signaling pathway		Chemokine ligand 25 signaling engages the chemokine (C-C motif) receptor 9 (Ccr9) and together with other chemokines is classified as a member of the developmental subgroup.
http://purl.obolibrary.org/obo/PW_0000950	chemokine (C-C motif) ligand 24 signaling pathway	http://purl.obolibrary.org/obo/PW_0000831	CC chemokine mediated signaling pathway		Chemokine ligand 24 signaling engages the chemokine (C-C motif) receptor 3 (Ccr3) and together with other chemokines is classified as member of the allergenic subgroup.
http://purl.obolibrary.org/obo/PW_0000951	chemokine (C-C motif) ligand 26 signaling pathway	http://purl.obolibrary.org/obo/PW_0000831	CC chemokine mediated signaling pathway		Chemokine ligand 26 signaling engages the chemokine (C-C motif) receptor 3 (Ccr3) and together with other chemokines is classified as member of the allergenic subgroup.
http://purl.obolibrary.org/obo/PW_0000952	chemokine (C-C motif) ligand 14 signaling pathway	http://purl.obolibrary.org/obo/PW_0000831	CC chemokine mediated signaling pathway		Chemokine ligand 14 signaling engages chemokine (C-C motif) receptors 1 and 5 (Ccr1 and Ccr5) and together with other chemokines is classified as a member of the HCC (hemofiltrate CC chemokine) subgroup.
http://purl.obolibrary.org/obo/PW_0000953	chemokine (C-C motif) ligand 15 signaling pathway	http://purl.obolibrary.org/obo/PW_0000831	CC chemokine mediated signaling pathway		Chemokine ligand 15 signaling engages chemokine (C-C motif) receptors 1 and 3 (Ccr1 and Ccr3) and together with other chemokines is classified as a member of the HCC (hemofiltrate CC chemokine) subgroup.
http://purl.obolibrary.org/obo/PW_0000954	chemokine (C-C motif) ligand 16 signaling pathway	http://purl.obolibrary.org/obo/PW_0000831	CC chemokine mediated signaling pathway		Chemokine ligand 16 signaling engages chemokine (C-C motif) receptors 1 and 2 (Ccr1 and Ccr2) and together with other chemokines is classified as a member of the HCC (hemofiltrate CC chemokine) subgroup.
http://purl.obolibrary.org/obo/PW_0000955	chemokine (C-C motif) ligand 23 signaling pathway	http://purl.obolibrary.org/obo/PW_0000831	CC chemokine mediated signaling pathway		Chemokine ligand 23 signaling engages the chemokine (C-C motif) receptor 1 (Ccr1) and together with other chemokines is classified as a member of the HCC (hemofiltrate CC chemokine) subgroup.
http://purl.obolibrary.org/obo/PW_0000956	chemokine (C-C motif) ligand 27 signaling pathway	http://purl.obolibrary.org/obo/PW_0000831	CC chemokine mediated signaling pathway		Chemokine ligand 27 signaling engages chemokine (C-C motif) receptor 10 (Ccr10) and does not appear to be a member of any of the chemokines subgroups.
http://purl.obolibrary.org/obo/PW_0000957	chemokine (C-X-C motif) ligand 1 signaling pathway	http://purl.obolibrary.org/obo/PW_0000971	CXC chemokine ELR(+) subgroup mediated signaling pathway		Chemokine (C-X-C) ligand 1belongs to the growth-related oncogene (GRO) subgroup whose signaling engages receptor 2 and promotes chemotaxis of neutrophils.
http://purl.obolibrary.org/obo/PW_0000958	forkhead class A signaling pathway	http://purl.obolibrary.org/obo/PW_0000647	forkhead signaling pathway		The signaling pathway mediated by the FoxA subgroup of forkhead family of transcription factors plays important roles in development and in modulating steroid hormone signaling. Three FoxA genes carry out overlapping yet distinct functions. FOXA1 appears to modulate steroid receptor activity in breast and prostate cancer.
http://purl.obolibrary.org/obo/PW_0000960	sphingosine 1-phosphate signaling pathway	http://purl.obolibrary.org/obo/PW_0000959	lipid signaling pathway		Sphingosine 1-phosphate (S1P), a sphingolipid metabolite, can signal intracellularly as a second messenger or extracellularly as a ligand for five G-protein-coupled receptors. The S1P pathway plays important roles in processes such as cell migration, proliferation and survival. The five receptors engage similar G-proteins but their expression varies.
http://purl.obolibrary.org/obo/PW_0000961	ceramide signaling pathway	http://purl.obolibrary.org/obo/PW_0000959	lipid signaling pathway		Ceramide signaling can act as a lipid second messenger or as a mediator of various cellular signaling pathways by promoting receptor clustering. The pathway plays important roles in apoptosis.
http://purl.obolibrary.org/obo/PW_0000962	visual phototransduction pathway	http://purl.obolibrary.org/obo/PW_0001536	sensory system signaling pathway		The signaling pathway initiated by light-induced isomerization of 11-cis retinal and subsequent activation of its photoreceptors in rods and cones.
http://purl.obolibrary.org/obo/PW_0000963	phosphatidylinositol 3-kinase class I signaling pathway	http://purl.obolibrary.org/obo/PW_0000595	phosphatidylinositol 3-kinase signaling pathway		Phosphatidylinositol kinases represent a family of lipid kinases that phosphorylate the 3' position of the inositol ring in target substrates. They are grouped into three classes: class I further subdivided into subclass A and B, class II and class III. By far the best known and characterized is class I, particularly IA that signals downstream of receptor tyrosine kinases and engages the Akt family of kinases.
http://purl.obolibrary.org/obo/PW_0000965	phosphatidylinositol 3-kinase class II signaling pathway	http://purl.obolibrary.org/obo/PW_0000595	phosphatidylinositol 3-kinase signaling pathway		Phosphatidylinositol kinases represent a family of lipid kinases that phosphorylate the 3' position of the inositol ring in target substrates. They are grouped into three classes: class I further subdivided into subclass A and B, class II and class III. By far the best known and characterized is class I, particularly IA that signals downstream of receptor tyrosine kinases and engages the Akt family of kinases.
http://purl.obolibrary.org/obo/PW_0000966	phosphatidylinositol 3-kinase class III signaling pathway	http://purl.obolibrary.org/obo/PW_0000595	phosphatidylinositol 3-kinase signaling pathway		Phosphatidylinositol kinases represent a family of lipid kinases that phosphorylate the 3' position of the inositol ring in target substrates. They are grouped into three classes: class I further subdivided into subclass A and B, class II and class III. By far the best known and characterized is class I, particularly IA that signals downstream of receptor tyrosine kinases and engages the Akt family of kinases.
http://purl.obolibrary.org/obo/PW_0000967	interleukin-3/interleukin-5/GM-CSF mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000512	Interleukin mediated signaling pathway		The interleukin-3, interleukin 5 and granulocyte-macrophage colony-stimulating factor family of hemopoietic cytokines mediate overlapping and distinct signals. Collectively they regulate the production and activation of hemopoietic cells.
http://purl.obolibrary.org/obo/PW_0000968	interleukin-3 signaling pathway	http://purl.obolibrary.org/obo/PW_0000967	interleukin-3/interleukin-5/GM-CSF mediated signaling pathway		Interleukin-3 signaling plays important roles in the function of hematopoietic cells.
http://purl.obolibrary.org/obo/PW_0000969	interleukin-5 signaling pathway	http://purl.obolibrary.org/obo/PW_0000967	interleukin-3/interleukin-5/GM-CSF mediated signaling pathway		Interleukin-5 signaling plays important roles in the function of hematopoietic cells.
http://purl.obolibrary.org/obo/PW_0000970	granulocyte-macrophage colony-stimulating factor signaling pathway	http://purl.obolibrary.org/obo/PW_0000967	interleukin-3/interleukin-5/GM-CSF mediated signaling pathway		GM-CSF signaling, like the other hemopoietic cytokines, is involved in the production and activation of hemopoietic cells. The GM-CSF pathway acts on monocytes, macrophages and granulocytes and is also involved in the regulation of T and dendritic cell functions.
http://purl.obolibrary.org/obo/PW_0000971	CXC chemokine ELR(+) subgroup mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000830	CXC chemokine mediated signaling pathway		The CXC chemokine ELR(+) subgroup mediated signaling primarily engages receptor 2 to promote angiogenic effects.
http://purl.obolibrary.org/obo/PW_0000972	CXC chemokine ELR(-) subgroup mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000830	CXC chemokine mediated signaling pathway		CXC chemokine (ELR-) subgroup mediated signaling primarily engages receptor 3 to promote angiostatic effects.
http://purl.obolibrary.org/obo/PW_0000973	chemokine (C-X-C motif) ligand 2 signaling pathway	http://purl.obolibrary.org/obo/PW_0000971	CXC chemokine ELR(+) subgroup mediated signaling pathway		Chemokine (C-X-C) ligand 2 belongs to the growth-related oncogene (GRO) subgroup whose signaling engages receptor 2 to promote chemotaxis of neutrophils.
http://purl.obolibrary.org/obo/PW_0000974	chemokine (C-X-C motif) ligand 3 signaling pathway	http://purl.obolibrary.org/obo/PW_0000971	CXC chemokine ELR(+) subgroup mediated signaling pathway		Chemokine (C-X-C) ligand 3 belongs to the growth-related oncogene (GRO) subgroup whose signaling engages receptor 2 to promote chemotaxis of neutrophils.
http://purl.obolibrary.org/obo/PW_0000975	chemokine (C-X-C motif) ligand 5 signaling pathway	http://purl.obolibrary.org/obo/PW_0000971	CXC chemokine ELR(+) subgroup mediated signaling pathway		Chemokine (C-X-C) ligand 5 signaling engages receptor 2 to exert potent chemotactic functions in neutrophil activation.
http://purl.obolibrary.org/obo/PW_0000976	chemokine (C-X-C motif) ligand 6 signaling pathway	http://purl.obolibrary.org/obo/PW_0000971	CXC chemokine ELR(+) subgroup mediated signaling pathway		Chemokine (C-X-C0) ligand 6 engages receptors 1 and 2 to promote chemoattraction of neutrophils and angiogenic effects, respectively.
http://purl.obolibrary.org/obo/PW_0000978	chemokine (C-X-C motif) ligand 8 signaling pathway	http://purl.obolibrary.org/obo/PW_0000971	CXC chemokine ELR(+) subgroup mediated signaling pathway		Chemokine (C-X-C) ligand 8, also known as interleukin-8 (Il-8), although a chemokine, engages receptor 1 and 2 to promote angiogenic effects.
http://purl.obolibrary.org/obo/PW_0000979	chemokine (C-X-C motif) ligand 4 signaling pathway	http://purl.obolibrary.org/obo/PW_0000972	CXC chemokine ELR(-) subgroup mediated signaling pathway		Chemokine (C-X-C) ligand 4 signaling engages receptor 3 to promote angiostatic effects.
http://purl.obolibrary.org/obo/PW_0000980	chemokine (C-X-C motif) ligand 9 signaling pathway	http://purl.obolibrary.org/obo/PW_0000972	CXC chemokine ELR(-) subgroup mediated signaling pathway		Chemokine (C-X-C) ligand 9 engages receptor 3 to promote angiostatic effects.
http://purl.obolibrary.org/obo/PW_0000981	chemokine (C-X-C motif) ligand 10 signaling pathway	http://purl.obolibrary.org/obo/PW_0000972	CXC chemokine ELR(-) subgroup mediated signaling pathway		Chemokine (C-X-C) ligand 10 signaling engages receptor 3 to promote angiostatic effects.
http://purl.obolibrary.org/obo/PW_0000982	chemokine (C-X-C motif) ligand 11 signaling pathway	http://purl.obolibrary.org/obo/PW_0000972	CXC chemokine ELR(-) subgroup mediated signaling pathway		Chemokine (C-X-C) ligand 11 signaling engages receptor 3 to promote angiostatic effects.
http://purl.obolibrary.org/obo/PW_0000983	chemokine (C-X-C motif) ligand 12 signaling pathway	http://purl.obolibrary.org/obo/PW_0000972	CXC chemokine ELR(-) subgroup mediated signaling pathway		Chemokine (C-X-C motif) ligand 12, a member of the intercrine chemokine family, has roles in many cell functions, including inflammation, immune surveillance, embryogenesis and tumor growth.
http://purl.obolibrary.org/obo/PW_0000987	erythropoietin signaling pathway	http://purl.obolibrary.org/obo/PW_0000828	cytokine mediated signaling pathway		Erythropoietin (EPO) signaling is crucial for the production of blood cell or erythropoiesis and also plays important roles in wound healing and responses to neural injury. EPO is a glycoprotein hormone and also a cytokine whose receptor belongs to type I cytokine receptor. The pathway engages the Jak-Stat intracellular cascade.
http://purl.obolibrary.org/obo/PW_0000988	classical cadherin signaling pathway	http://purl.obolibrary.org/obo/PW_0000333	cadherin mediated signaling pathway		Classical cadherins, such as E- or N-cadherin are single-span transmembrane proteins with five extracellular cadherin repeats and a conserved cytoplasmic tail. Their interaction with many cytoskeletal and signaling molecules underlies the calcium-dependent cell-cell adhesion and signaling. While E- and N-cadherin share some of the interacting partners, they have different localization and impact on distinct cellular events.
http://purl.obolibrary.org/obo/PW_0000989	desmosomal cadherin signaling pathway	http://purl.obolibrary.org/obo/PW_0000333	cadherin mediated signaling pathway		Desmosomal cadherins, which can be further subdivided into two subgroups, possess the five cadherin repeats but have distinct cytoplasmic tails.
http://purl.obolibrary.org/obo/PW_0000990	protocadherin signaling pathway	http://purl.obolibrary.org/obo/PW_0000333	cadherin mediated signaling pathway		Protocadherin represent a very large family which can be further subdivided into two groups. The protocadherin are predominantly expressed in the nervous system. They have up to seven cadherin repeats but distinct and even divergent cytoplasmic regions.
http://purl.obolibrary.org/obo/PW_0000991	atypical cadherin signaling pathway	http://purl.obolibrary.org/obo/PW_0000333	cadherin mediated signaling pathway		The atypical, or unconventional group includes the seven transmembrane (7TM), GPCR-like cadherins with up to nine cadherin repeats along with EGF-like and laminin motifs, the large FAT and the t-Cadherin proteins.
http://purl.obolibrary.org/obo/PW_0000992	E-cadherin signaling pathway	http://purl.obolibrary.org/obo/PW_0000988	classical cadherin signaling pathway		E-cadherin or the epithelial cadherin encoded by the Cdh1 gene, is a member of the classical cadherin family and among the best studied cadherin pathway. Deregulation of the pathway has been associated with several forms of cancer.
http://purl.obolibrary.org/obo/PW_0000993	N-cadherin signaling pathway	http://purl.obolibrary.org/obo/PW_0000988	classical cadherin signaling pathway		N-cadherin, or neuronal cadherin, is predominantly expressed in the brain. The pathway plays important roles in learning and memory.
http://purl.obolibrary.org/obo/PW_0000996	anti-infective drug pathway	http://purl.obolibrary.org/obo/PW_0000754	drug pathway		The pharmacokinetics and pharmacodynamics of compounds used as anti-infective agents. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0000998	adenosine signaling pathway	http://purl.obolibrary.org/obo/PW_0000997	nucleoside and nucleotide mediated signaling pathway		Adenosine signaling is involved in the regulation of several physiological processes. It uses four receptors of the GPCR family that activate the Gaphas or Galphai types of G proteins to increase or decrease the levels of cAMP. The adenosine receptors are a class of purinergic or purinoreceptors.
http://purl.obolibrary.org/obo/PW_0000999	adenosine triphosphate signaling pathway	http://purl.obolibrary.org/obo/PW_0000997	nucleoside and nucleotide mediated signaling pathway		Adenosine triphosphate (ATP) extracellular signaling activates the P2X ligand-gated ion channels that are permeable to sodium, potassium and calcium ions. There are several P2X subtypes that are involved in a range of physiological processes. ATP along with other nucleotide also engages a class of metabotropic purinergic receptors known as P2Y that couple to either the Galphaq or to G alphai subunit of heterotrimeric G proteins. ATP is the sole ligand of P2Y 11 receptor.
http://purl.obolibrary.org/obo/PW_0001000	nucleotide signaling via the purinergic P2Y receptors.	http://purl.obolibrary.org/obo/PW_0000997	nucleoside and nucleotide mediated signaling pathway		The P2Y receptors are a class of purinergic or purinoreceptors, Gprotein-coupled receptors that respond to ADP, ATP, UDP, UTP and UDP-glucose to activate either the Galphaq or the Galphai mediated signal transduction pathways.
http://purl.obolibrary.org/obo/PW_0001002	copper homeostasis pathway	http://purl.obolibrary.org/obo/PW_0000589	metal homeostasis pathway		Those pathways involved in the proper balance of copper levels, uptake and transport, utilization and storage as needed by cells, tissues and organs. Copper is a cofactor in proteins mediating electron transfer reactions and is required by plants as a micronutrient.
http://purl.obolibrary.org/obo/PW_0001003	retinoid metabolic pathway	http://purl.obolibrary.org/obo/PW_0002665	fat-soluble vitamin metabolic pathway		Those metabolic reactions involving the fat-soluble vitamin A and its metabolites. Vitamin A, retinol and vitamin A activities of metabolites such as retinal and retinoic acids are essential for visual transduction as well as for neuro and immune system functions and epithelial differentiation. Plants and microorganisms can synthesize vitamin A de novo while higher organisms derive it from diet as precursors of carotenoids or retinyl esters.
http://purl.obolibrary.org/obo/PW_0001004	retinoic acid metabolic pathway	http://purl.obolibrary.org/obo/PW_0001003	retinoid metabolic pathway		The reactions involved in deriving retinoic acid (RA) from retinal and its further processing to more polar derivatives. Retinoic acid engages several retinoic acid receptors; its actions are important for neurological and immune system functions and for energy balance. Deregulation of proper RA activity has been associated with obesity and cancer.
http://purl.obolibrary.org/obo/PW_0001005	retinoid cycle metabolic pathway	http://purl.obolibrary.org/obo/PW_0001003	retinoid metabolic pathway		The series of reactions involved in the regeneration of the visual chromophore 11-cis retinal from the all-trans retinal released from the light -activated rhodopsin.
http://purl.obolibrary.org/obo/PW_0001006	vitamin homeostasis	http://purl.obolibrary.org/obo/PW_0001691	organic chemical homeostasis pathway		Those pathways involved in the proper balance of vitamin levels, uptake and transport, utilization and storage, as demanded by the needs of cells tissues and organs. Disruption of vitamin homeostasis can have harmful consequences. Collectively they represent a class of organic chemicals that the organism cannot synthesize or does not in adequate quantities.
http://purl.obolibrary.org/obo/PW_0001007	vitamin A homeostasis	http://purl.obolibrary.org/obo/PW_0001006	vitamin homeostasis		The pathways involved in the balanced maintenance of vitamin A and vitamin A metabolites uptake and transport, utilization and storage, as demanded by the needs of cells, tissues and organs. 11-cis retinal is the visual chromophore while retinoic acid signaling through its nuclear receptors transcription factors exerts the rest and manifold functions of vitamin A.
http://purl.obolibrary.org/obo/PW_0001008	photosignal transduction pathway	http://purl.obolibrary.org/obo/PW_0000003	signaling pathway		The series of reactions within a cell required to convert absorbed photons into molecular signals.
http://purl.obolibrary.org/obo/PW_0001009	ascorbic acid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000135	metabolic pathway of cofactors, vitamins, nutrients		Those metabolic reactions involving ascorbic acid, known as vitamin C, a water-soluble vitamin. Vitamin C is an essential antioxidant that is derived from glucose. Unlike many animals, humans do not have the ability to produce it.
http://purl.obolibrary.org/obo/PW_0001010	niacin metabolic pathway	http://purl.obolibrary.org/obo/PW_0000135	metabolic pathway of cofactors, vitamins, nutrients		Those metabolic reactions involving niacin, also known as nicotinate, vitamin B3 or vitamin PP - a water-soluble vitamin. Niacin represents an essential nutrient and is also a precursor of NAD through a salvage pathway. Niacin is among the few vitamins humans can synthesize.
http://purl.obolibrary.org/obo/PW_0001011	vitamin D metabolic pathway	http://purl.obolibrary.org/obo/PW_0002665	fat-soluble vitamin metabolic pathway		Those metabolic reactions involving vitamin D - a fat-soluble vitamin. Vitamin D represents a group of fat-soluble compounds that can be synthesized from cholesterol and exposure to sunlight. In view of the latter source, it is not considered a true vitamin. One of its metabolites, calcitriol, acts in a hormone-like manner as a signaling molecule.
http://purl.obolibrary.org/obo/PW_0001012	vitamin and vitamin metabolites signaling pathway	http://purl.obolibrary.org/obo/PW_0000003	signaling pathway		Vitamin and metabolites of vitamin in addition to representing important nutrients and aid in cellular metabolism can also, in a hormone-like manner, acts as signaling molecules.
http://purl.obolibrary.org/obo/PW_0001013	vitamin D signaling pathway	http://purl.obolibrary.org/obo/PW_0001313	transcription pathway via transcription factor mediated signaling		The active vitamin D metabolite plays important roles in cell growth and differentiation and in immunity. Its receptor is a transcription factor nuclear receptor.
http://purl.obolibrary.org/obo/PW_0001014	retinoic acid signaling pathway	http://purl.obolibrary.org/obo/PW_0001313	transcription pathway via transcription factor mediated signaling		Retinoic acid, a vitamin A-derived metabolite, plays important roles in development and cell differentiation. All-trans retinoic acid (RA) binds to nuclear RA (RARs) and X (RXRs) receptor subtypes that once activated act as transcription factors.
http://purl.obolibrary.org/obo/PW_0001015	vitamin E metabolic pathway	http://purl.obolibrary.org/obo/PW_0002665	fat-soluble vitamin metabolic pathway		Those metabolic reactions involving vitamin E - a fat-soluble vitamin which represents a class of chemical compounds known as tocopherols. The alpha- and gamma-tocopherols appear to be the main dietary forms. Vitamin E is best known for its antioxidant properties.
http://purl.obolibrary.org/obo/PW_0001016	vitamin K metabolic pathway	http://purl.obolibrary.org/obo/PW_0002665	fat-soluble vitamin metabolic pathway		Those metabolic reactions involving vitamin K - a fat-soluble vitamin which represents a group of related compounds. The K1 form is found in plants; other forms are synthesized by bacteria, including species present in the microflora of the human gut. Vitamin K is an essential cofactor in the modification reaction of vitamin K-dependent proteins.
http://purl.obolibrary.org/obo/PW_0001017	renal cell carcinoma pathway	http://purl.obolibrary.org/obo/PW_0000606	urogenital cancer pathway		Renal cell cancer, although representing a small percentage of human neoplasms, has one of the highest rates of mortality amongst genitourinary cancers. Several mutated genes and associated altered pathways have been implicated in the condition but many more remain to be elucidated.
http://purl.obolibrary.org/obo/PW_0001018	immune system disease pathway	http://purl.obolibrary.org/obo/PW_0000013	disease pathway		Altered immune system responses can be grouped into four categories: malignancy, immunodeficiency, hypersensitivity and autoimmunity.
http://purl.obolibrary.org/obo/PW_0001019	rheumatoid arthritis pathway	http://purl.obolibrary.org/obo/PW_0001440	arthritis pathway		Rheumatoid arthritis is an autoimmune condition characterized by persistent inflammation. Several pro-inflammatory cytokines and chemokines are over-activated.
http://purl.obolibrary.org/obo/PW_0001020	basal cell carcinoma pathway	http://purl.obolibrary.org/obo/PW_0000633	skin cancer pathway		Basal cell carcinoma is the most common form of skin cancer that is mostly sporadic. Hedgehog signaling pathway via sonic hedgehog appears to be constitutively active. Mutations in Tp53 are also frequent.
http://purl.obolibrary.org/obo/PW_0001021	melanoma pathway	http://purl.obolibrary.org/obo/PW_0000633	skin cancer pathway		Melanoma is a form of skin cancer which, despite being less common than other forms of skin malignancies, can be dangerous if not detected earlier, and accounts for the highest percentage of skin cancer related deaths. Oncogenic Nras and other mutations in downstream pathways appear to be associated with it.
http://purl.obolibrary.org/obo/PW_0001022	asthma pathway	http://purl.obolibrary.org/obo/PW_0001308	respiratory system disease pathway		Asthma, a complex condition with many phenotypic manifestations, is primarily characterized by inflammation of the airways. Environmental and genetic factors contribute to it through complex and incompletely understood interactions.
http://purl.obolibrary.org/obo/PW_0001023	systemic lupus erythematosus pathway	http://purl.obolibrary.org/obo/PW_0001018	immune system disease pathway		Systemic lupus erythematosus (SLE) is an autoimmune condition that can affect many parts of the body and which, although treatable, does not have a cure. Activation of complement and deregulations of immune regulatory and signaling pathways contribute in ways that are incompletely understood.
http://purl.obolibrary.org/obo/PW_0001024	autoimmune thyroiditis pathway	http://purl.obolibrary.org/obo/PW_0001018	immune system disease pathway		Autoimmune thyroid disease (AITD) groups several conditions that are generally relatively mild but that can progress to serious symptoms.
http://purl.obolibrary.org/obo/PW_0001025	allograft rejection pathway	http://purl.obolibrary.org/obo/PW_0001018	immune system disease pathway		Allograft or transplant rejection results from the recipient's autoimmune response to non-self antigens.
http://purl.obolibrary.org/obo/PW_0001026	graft-versus-host disease pathway	http://purl.obolibrary.org/obo/PW_0001018	immune system disease pathway		Graft-versus-host disease (GVHD) is a complication following transplantation of cells, tissues or organs from a genetically non-identical donor in which the donor T cells attack the host cells. Several pro-inflammatory pathways are activated as a result of damage in the host tissue induced by the procedure. GVHD is commonly associated with stem cell or bone marrow transplant.
http://purl.obolibrary.org/obo/PW_0001027	primary immunodeficiency pathway	http://purl.obolibrary.org/obo/PW_0001018	immune system disease pathway		Primary immunodeficiency groups disorders that result from the immune system malfunctioning that affect both cell-mediated and humoral immunity pathways.
http://purl.obolibrary.org/obo/PW_0001028	infectious disease pathway	http://purl.obolibrary.org/obo/PW_0000013	disease pathway		Infectious diseases are caused by pathogens that have gained access to the host organism and have managed to avoid the host defense mechanisms while taking over some of the host pathways.
http://purl.obolibrary.org/obo/PW_0001030	cocaine addiction pathway	http://purl.obolibrary.org/obo/PW_0001029	substance dependence pathway		Prolonged use of cocaine results in cardiovascular and brain damage. Cocaine is thought to bind to the dopamine reuptake transporter thus blocking the reuptake of dopamine into nerve terminals. The resulting higher concentration of dopamine in synapses leads to overactivation of dopamine receptors such as D1 and of signaling pathways downstream of it overall believed to be critical in mediating the behavioral responses to cocaine.
http://purl.obolibrary.org/obo/PW_0001031	amphetamine addiction pathway	http://purl.obolibrary.org/obo/PW_0001029	substance dependence pathway		Amphetamine is believed to promote an elevation in extracellular dopamine. Higher and high levels of the drug lead to overactivation of transcription factors and cofactors.
http://purl.obolibrary.org/obo/PW_0001032	morphine addiction pathway	http://purl.obolibrary.org/obo/PW_0001029	substance dependence pathway		Morphine, an effective pain killer drug, can also be extremely addictive. Activation of dopamine neurons and reduction of inhibitory synaptic transmission might be associated with the effects or morphine. Changes in neuronal responses and communication may underlie the addictive behavior.
http://purl.obolibrary.org/obo/PW_0001033	nicotine addiction pathway	http://purl.obolibrary.org/obo/PW_0001029	substance dependence pathway		Nicotine, like the other addictive substances, impacts on the dopaminergic and mesolimbic reward circuitries. Nicotine is also a ligand for the nicotinic acetylcholine receptors which are ligand-gated ion channels.
http://purl.obolibrary.org/obo/PW_0001034	alcoholism pathway	http://purl.obolibrary.org/obo/PW_0001029	substance dependence pathway		The mechanisms of alcohol dependence, or alcoholism, are not well understood. Like in the case of other substances of abuse, alcohol may lead to stimulation of dopamine release and overactivation of dopamine-related circuitries.
http://purl.obolibrary.org/obo/PW_0001035	arrhythmogenic right ventricular cardiomyopathy pathway	http://purl.obolibrary.org/obo/PW_0000022	cardiomyopathy pathway		Arrhythmogenic right ventricular cardiomyopathy (ARVC) represents an inherited heart muscle condition leading to arrhythmia and heart failure that could results in death. Mutations in several genes and disruption of associated pathways have been implicated in the condition.
http://purl.obolibrary.org/obo/PW_0001036	dilated cardiomyopathy pathway	http://purl.obolibrary.org/obo/PW_0000022	cardiomyopathy pathway		Dilated cardiomyopathy (DCM) is a condition in which the heart is weakened and enlarged resulting in inefficient blood pumping. Although mostly occurring in adults, it can also affect children.
http://purl.obolibrary.org/obo/PW_0001037	myocarditis pathway	http://purl.obolibrary.org/obo/PW_0000022	cardiomyopathy pathway		Myocarditis is a condition associated with inflammation of the heart muscle that can have both infectious and non-infectious etiologies, with the former being the primary cause. Viral proteins, once inside the host cells, interfere with the function of host gene and they can either avoid or appropriate host pathways.
http://purl.obolibrary.org/obo/PW_0001038	maturity-onset diabetes of the young pathway	http://purl.obolibrary.org/obo/PW_0000176	diabetes mellitus pathway		Maturity onset diabetes of the young (MODY) represents any of a number of hereditary, monogenic forms of diabetes caused by mutations in several genes.
http://purl.obolibrary.org/obo/PW_0001039	Vibrio cholerae infection pathway	http://purl.obolibrary.org/obo/PW_0001028	infectious disease pathway		Vibrio cholerae disease is an infection of the small intestine resulting in dehydration and electrolyte imbalance which in some cases can cause death. Cholera toxin, is one the main virulence factors of the Gram-negative Vibrio cholerae bacterium which, together with other virulence factors can invade the host.
http://purl.obolibrary.org/obo/PW_0001040	Salmonella infection pathway	http://purl.obolibrary.org/obo/PW_0001028	infectious disease pathway		Salmonella, a Gram-negative bacterium of which  many species exist, in humans can cause gastroenteritis or the more severe typhoid fever. Salmonella enters the host via the digestive tract; bacteria that escape the host defense machinery can survive and replicate in Salmonella-containing vacuole (SCV) whose maturation they control.
http://purl.obolibrary.org/obo/PW_0001041	pathogenic Escherichia coli infection pathway	http://purl.obolibrary.org/obo/PW_0001028	infectious disease pathway		The pathogenic Escherichia coli strains EPEC and EHEC (enteropathogenic and enterohemorrhagic E. coli, respectively) can cause severe food poisoning in humans. The non-pathogenic strains are part of the gut normal flora with beneficial contributions for the host.
http://purl.obolibrary.org/obo/PW_0001042	Shigella infection pathway	http://purl.obolibrary.org/obo/PW_0001028	infectious disease pathway		Shigella, a Gram-negative bacterium that is related to Salmonella and to Escherichia coli, is a disease causing agent in humans and primates. Shigellosis, also known as bacillary dysentery or Marlow syndrome is due to colonization of the intestinal epithelium and the subsequent evasion of the host defense machinery and use of host intracellular pathways by the bacteria.
http://purl.obolibrary.org/obo/PW_0001043	Bordetella pertussis infection pathway	http://purl.obolibrary.org/obo/PW_0001028	infectious disease pathway		The Gram-negative Bordetella pertusis is the causative agent of pertussis or whooping cough. One of its main virulence factors, pertussis toxin blocks the interaction of Galphai subunit of heterotrimeric G protein with its partner receptors. This results in unrestrained adenylyl cyclase activity and subsequent increased concentration of cAMP which affects normal intracellular signaling.
http://purl.obolibrary.org/obo/PW_0001044	Legionella infection pathway	http://purl.obolibrary.org/obo/PW_0001028	infectious disease pathway		Legionella, a pathogenic Gram-negative bacterium that includes species such as legionella pneumophila, causes several respiratory infections of which Legionnaires' disease is potentially fatal. L. pneumophila can grow within lung macrophages and is known to subvert several host pathways.
http://purl.obolibrary.org/obo/PW_0001045	Staphylococcus aureus infection pathway	http://purl.obolibrary.org/obo/PW_0001028	infectious disease pathway		Staphylococcus aureus, a Gram-positive bacteria of which there are many species, usually colonizes the skin and mucous membranes of humans and other organisms and are mostly harmless. However, they can also cause a range of infections of which some can be extremely severe.
http://purl.obolibrary.org/obo/PW_0001046	tuberculosis pathway	http://purl.obolibrary.org/obo/PW_0001028	infectious disease pathway		Mycobacterium tuberculosis is the causative agent of most forms of tuberculosis. Once in the lung, the bacteria interfere with a number of intracellular pathways and processes.
http://purl.obolibrary.org/obo/PW_0001047	Leishmaniasis pathway	http://purl.obolibrary.org/obo/PW_0001028	infectious disease pathway		Leishmania is a protozoan parasite and a number of its species can infect mammals, including humans. While cutaneous leishmaniasis is the most common form, others such as visceral or mucosal have also been reported. The infection results in alterations in a number of host signaling pathways.
http://purl.obolibrary.org/obo/PW_0001048	trypanosomiasis pathway	http://purl.obolibrary.org/obo/PW_0001028	infectious disease pathway		Trypanosoma is a protozoan parasite of which T brucei and cruzi are responsible for causing the sleeping sickness and Chagas disease, respectively. Several host signaling and regulatory pathways are altered in the infection.
http://purl.obolibrary.org/obo/PW_0001049	sleeping sickness pathway	http://purl.obolibrary.org/obo/PW_0001048	trypanosomiasis pathway		Trypanosoma brucei, a protozoan parasite, is the causative agent of sleeping sickness, also known as the African trypanosomiasis, as its vector is the tsetse fly common to sub-Saharan Africa. Several pro-inflammatory cytokines are overactivated. The neurological damage the infection causes is irreversible and the disease is fatal.
http://purl.obolibrary.org/obo/PW_0001050	Chagas disease pathway	http://purl.obolibrary.org/obo/PW_0001048	trypanosomiasis pathway		Trypanosoma cruzi is the causative agent of the Chagas disease, also known as the American trypanosomiasis, as it occurs primarily in poor areas of the Americas, mostly Central and South America. Infection interferes with a number of intracellular pathways and it appears to activate calcium signaling.
http://purl.obolibrary.org/obo/PW_0001051	malaria pathway	http://purl.obolibrary.org/obo/PW_0001028	infectious disease pathway		Several species of the protozoan parasite Plasmodium can infect humans and cause malaria. Severe malaria, which is primarily caused by Plasmodium falciparum, can lead to death and the fatalities are mostly children. Deregulated induction of cytokines appears to play a role in the infection.
http://purl.obolibrary.org/obo/PW_0001052	toxoplasmosis pathway	http://purl.obolibrary.org/obo/PW_0001028	infectious disease pathway		Toxoplasma gondii, whose hosts include various warm-blooded species including humans, is the causative agent of toxoplasmosis. The infection interferes with a number of host pathways; in its most severe manifestations it can be fatal.
http://purl.obolibrary.org/obo/PW_0001053	Entamoebiasis pathway	http://purl.obolibrary.org/obo/PW_0001028	infectious disease pathway		Entamoeba histolyca is a protozoan parasite that is the causative agent of amoebiasis which affects the intestinal tissue leading to severe dysentery and ulcerations. It can also infect other tissues such as the liver and to a lesser extent the brain, lungs and spleen.
http://purl.obolibrary.org/obo/PW_0001054	influenza A pathway	http://purl.obolibrary.org/obo/PW_0001028	infectious disease pathway		The influenza A virus is the causative agent of seasonal epidemics and occasional pandemics of influenza which affects the respiratory system.
http://purl.obolibrary.org/obo/PW_0001055	hepatitis C pathway	http://purl.obolibrary.org/obo/PW_0001028	infectious disease pathway		The hepatitis C virus is the causative agent of hepatitis C, a chronic liver disease in humans. The virus interferes with several signaling and regulatory pathways in the host cells.
http://purl.obolibrary.org/obo/PW_0001058	measles pathway	http://purl.obolibrary.org/obo/PW_0001028	infectious disease pathway		The measles virus (MV) of the genus Morbillivirus is the causative agent of the condition that bears its name. The condition causes immunosuppression and several MV proteins are thought to interfere with the normal host immune responses.
http://purl.obolibrary.org/obo/PW_0001059	oxidative phosphorylation pathway	http://purl.obolibrary.org/obo/PW_0000033	energy metabolic pathway		Oxidative phosphorylation is the coupling of the electron transport chain and the ATP biosynthetic pathways. The electron transfer chain generates an electrochemical gradient that drives the phosphorylation of ADP. Under certain circumstances the two may be uncoupled.
http://purl.obolibrary.org/obo/PW_0001060	primary bile acid biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000039	bile acid biosynthetic pathway		Primary bile acids, cholic and  chenodeoxycholic acids, are derived from cholesterol in the liver. Upon conjugation with glycine or taurine they can be secreted into the intestine.
http://purl.obolibrary.org/obo/PW_0001061	secondary bile acid biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000039	bile acid biosynthetic pathway		Secondary bile acids, deoxycholic and lithocholic acids, are synthesized from the primary ones by intestinal bacteria. like the primary bile acids, they need to be conjugated to glycine or taurine prior to secretion.
http://purl.obolibrary.org/obo/PW_0001062	lacto-series glycosphingolipid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000733	glycosphingolipid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of lacto-series type of glycosphingolipids.
http://purl.obolibrary.org/obo/PW_0001063	lipoic acid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000135	metabolic pathway of cofactors, vitamins, nutrients		The metabolic reactions involving lipoic acid, a compound derived from octanoic acid that contains two sulfur centers. Lipoic acid is a co-factor for the pyruvate dehydrogenase complex responsible for the irreversible decarboxylation of pyruvate to acetyl-CoA.
http://purl.obolibrary.org/obo/PW_0001064	phosphonate and phosphinate metabolic pathway	http://purl.obolibrary.org/obo/PW_0000132	metabolic pathway of other amino acids		Those metabolic reactions involving phosphonate and phosphinate, organic compounds that contain carbon-phosphorus bonds and which can be synthesized by bacteria and protists.
http://purl.obolibrary.org/obo/PW_0001065	interstrand cross link repair pathway	http://purl.obolibrary.org/obo/PW_0000663	double-strand DNA repair pathway		Interstrand cross links (ICL) of DNA can be induced by both endogenous and exogenous ligands. ICL if not repaired will lead to cell death. The ICL repair pathway, also known as the Fanconi anemia pathway, is the cellular response to this type of DNA damage.
http://purl.obolibrary.org/obo/PW_0001067	altered ribosome biogenesis pathway	http://purl.obolibrary.org/obo/PW_0001068	altered translation pathway		Alterations in the pathway result in specific phenotypes collectively known as ribosomopathies.
http://purl.obolibrary.org/obo/PW_0001069	gonadotropin-releasing hormone signaling pathway	http://purl.obolibrary.org/obo/PW_0000467	peptide and protein hormone signaling pathway		Gonadotropin-releasing hormone signaling pathway induces the synthesis and secretion of luteinizing and follicle-stimulating hormones from the pituitary.
http://purl.obolibrary.org/obo/PW_0001070	luteinizing hormone signaling pathway	http://purl.obolibrary.org/obo/PW_0000467	peptide and protein hormone signaling pathway		Lutenizing hormone signaling is important for the normal development and function of the ovaries and testes. It acts synergistically with the follicle-stimulating hormone.
http://purl.obolibrary.org/obo/PW_0001071	follicle-stimulating hormone signaling pathway	http://purl.obolibrary.org/obo/PW_0000467	peptide and protein hormone signaling pathway		Follicle-stimulating hormone signaling is important for the normal development and function of the ovaries and testes. It acts synergistically with the lutenizing hormone.
http://purl.obolibrary.org/obo/PW_0001073	spliceosome pathway	http://purl.obolibrary.org/obo/PW_0001580	lncRNA maturation pathway		The spliceosome is a multimegadalton ribonucleoprotein complex that removes the exons to produce the mature mRNA, including several mature mRNAs from a single RNA transcript via alternative splicing. A complex assembly/disassembly  pathway mediates the two chemical steps of a splicing event.  lncRNAs are also frequently spliced.
http://purl.obolibrary.org/obo/PW_0001074	hydrophobic amino acid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000011	amino acid metabolic pathway		Those metabolic reactions involving hydrophobic, uncharged amino acids. Hydrophobic amino acids include alanine, valine, isoleucine, leucine and methionine with hydrocarbon side chains and the phenylalanine, tyrosine and tryptophan with bulky, aromatic side chains.
http://purl.obolibrary.org/obo/PW_0001075	hydrophilic amino acid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000011	amino acid metabolic pathway		Those metabolic reactions involving hydrophilic, polar amino acids. The hydrophilic amino acids include the negatively charged (acidic) aspartic acid and glutamic acid whose salts are glutamate and aspartate, respectively, the positively charged (basic) lysine and arginine and the uncharged polar asparagine, cysteine, glutamine, serine and threonine. Histidine, whose side chain contains an imidazole can shift from positively charged to neutral.
http://purl.obolibrary.org/obo/PW_0001077	amino acid metabolic pathway (KEGG)	http://purl.obolibrary.org/obo/PW_0000011	amino acid metabolic pathway		Those metabolic reactions involving amino acids as listed in the Kyoto Encyclopedia of Genes and Genomes (KEGG).
http://purl.obolibrary.org/obo/PW_0001079	proline metabolic pathway	http://purl.obolibrary.org/obo/PW_0001074	hydrophobic amino acid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of proline, a non-essential amino acid that could be essential in certain cases. Its side chain bends to form a ring and its rigidity limits the folding abilities of proteins around proline residues.
http://purl.obolibrary.org/obo/PW_0001080	valine metabolic pathway	http://purl.obolibrary.org/obo/PW_0001074	hydrophobic amino acid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of valine, an essential amino acid. Valine, along with leucine and isoleucine is a branched-chain amino acid.
http://purl.obolibrary.org/obo/PW_0001081	lysine metabolic pathway	http://purl.obolibrary.org/obo/PW_0001075	hydrophilic amino acid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of lysine, an essential amino acid.
http://purl.obolibrary.org/obo/PW_0001082	arginine metabolic pathway	http://purl.obolibrary.org/obo/PW_0001075	hydrophilic amino acid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of arginine, a non-essential amino acid that could be essential in certain cases.
http://purl.obolibrary.org/obo/PW_0001083	asparagine metabolic pathway	http://purl.obolibrary.org/obo/PW_0001075	hydrophilic amino acid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of asparagine, a non-essential amino acid.
http://purl.obolibrary.org/obo/PW_0001084	serine metabolic pathway	http://purl.obolibrary.org/obo/PW_0001075	hydrophilic amino acid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of serine, a non-essential amino acid that could be essential in certain cases.
http://purl.obolibrary.org/obo/PW_0001085	threonine metabolic pathway	http://purl.obolibrary.org/obo/PW_0001075	hydrophilic amino acid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of threonine, an essential amino acid.
http://purl.obolibrary.org/obo/PW_0001086	glutamine metabolic pathway	http://purl.obolibrary.org/obo/PW_0001075	hydrophilic amino acid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of glutamine, a non-essential amino acid that could be essential in certain cases.
http://purl.obolibrary.org/obo/PW_0001087	isoleucine metabolic pathway	http://purl.obolibrary.org/obo/PW_0001074	hydrophobic amino acid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of isoleucine, an essential, branched-chain amino acid.
http://purl.obolibrary.org/obo/PW_0001088	leucine metabolic pathway	http://purl.obolibrary.org/obo/PW_0001074	hydrophobic amino acid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of leucine, an essential, branched-chain amino acid.
http://purl.obolibrary.org/obo/PW_0001089	serotonin signaling pathway via receptors engaging G alphai protein family	http://purl.obolibrary.org/obo/PW_0000854	serotonin signaling pathway		Serotonin signaling via receptor family 1 and 5 primarily engages G alphai protein family resulting in inhibition of adenylate cyclases and reduction of intracellular cAMP. There are five receptors subtypes in family 1 and one in the human family 5.
http://purl.obolibrary.org/obo/PW_0001090	serotonin signaling pathway via receptors engaging G alphaq protein family	http://purl.obolibrary.org/obo/PW_0000854	serotonin signaling pathway		Serotonin signaling via receptor family 2 engages G alphaq protein family resulting in activation of phospholipase C, mobilization of calcium ions and production of inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). There are three receptors subtypes in family 2.
http://purl.obolibrary.org/obo/PW_0001091	serotonin signaling pathway via receptors engaging G alphas protein family	http://purl.obolibrary.org/obo/PW_0000854	serotonin signaling pathway		Serotonin signaling via receptor family 4, 6, and 7 engages G alphas protein family resulting in activation of adenylyl cyclases and increased concentration of cAMP. There are seven receptor subtypes in family 4 and only one in families 6 and 7.
http://purl.obolibrary.org/obo/PW_0001092	serotonin signaling via receptor family 3	http://purl.obolibrary.org/obo/PW_0000854	serotonin signaling pathway		Serotonin family 3 receptor is a ligand-gated Na+/K+ channel with two receptor subtypes and their heterodimerization is believed to be necessary for their function. Serotonin signaling results in depolarization of plasma membrane.
http://purl.obolibrary.org/obo/PW_0001093	bile acid signaling pathway	http://purl.obolibrary.org/obo/PW_0001313	transcription pathway via transcription factor mediated signaling		Bile acid binds to and activates several nuclear receptors such as the farnesoid X and liver X receptors as well as a cell surface G-protein- coupled receptor.
http://purl.obolibrary.org/obo/PW_0001094	altered estrogen signaling pathway	http://purl.obolibrary.org/obo/PW_0001314	altered transcription pathway via transcription factor mediated signaling		Disregulated estrogen signaling is associated with the growth and development of breast cancers; estrogen mediated transcription is constitutively active in more than 50% of cases.
http://purl.obolibrary.org/obo/PW_0001095	zidovudine drug pathway	http://purl.obolibrary.org/obo/PW_0000996	anti-infective drug pathway		The pharmacokinetics and pharmacodynamics pathway of zidovudine, an anti-viral drug used for the treatment of HIV infection. It belongs to the family of nucleoside analog reverse transcriptase inhibitors. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001096	zidovudine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001095	zidovudine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of zidovudine, a drug used for the treatment of HIV. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001097	zidovudine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001095	zidovudine drug pathway		The pathway of zidovudine-target interaction and of the biochemical or physiological responses to drug. Zidovudine is a drug used for the treatment of HIV infection. Zidovudine, in its active triphosphate form, inhibits HIV-1 reverse transcriptase activity. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001098	tramadol drug pathway	http://purl.obolibrary.org/obo/PW_0002443	opioid drug pathway		The pharmacokinetics and pharmacodynamics pathway of tramadol, an analgesic used for the treatment of moderate to moderately severe pain. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001099	tramadol pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001098	tramadol drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of tramadol, an analgesic used in the treatment of pain. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001100	tramadol pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001098	tramadol drug pathway		The pathway of tramadol-target interaction and of the biochemical or physiological responses to drug. Tramadol is an analgesic used for the treatment of pain. The drug and its o-desmethyl metabolite are weak, but selective opiate receptor 3 (OP3) agonists. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001101	viral carcinogenesis pathway	http://purl.obolibrary.org/obo/PW_0000605	cancer pathway		A number of human viruses have been shown to be associated/contribute to approximately 10 to 15% of cancers. The viral particles encode oncogenes whose escape from the host defense system impacts on many cellular pathways and promotes tumor development.
http://purl.obolibrary.org/obo/PW_0001102	altered hypoxia inducible factor pathway	http://purl.obolibrary.org/obo/PW_0001314	altered transcription pathway via transcription factor mediated signaling		A hypoxia inducible pathway that deviates from what its normal course should be. Mutations in the von Hippel-Lindau (Vhl), the E3 ubiquitin ligase which targets Hif alpha for degradation under normoxic conditions, lead to a constitutively active pathway regardless the levels of oxygen. Mutations in Vhl and a number of other genes have been implicated in renal cancers.
http://purl.obolibrary.org/obo/PW_0001103	acid-base homeostasis pathway	http://purl.obolibrary.org/obo/PW_0000355	homeostasis pathway		The pathways that respond to and control the levels of protons, bicarbonate, carbon dioxide and ammonia in cells. Several sensing pathways, i.e., prompting intracellular signaling cascades and transport have been identified as critical players. The kidneys play a major role along with the respiratory system.
http://purl.obolibrary.org/obo/PW_0001104	pH sensing signaling pathway	http://purl.obolibrary.org/obo/PW_0001105	acid and base sensing signaling pathway		The pathway that respond to increases or decreases in protons, or pH levels and whose signaling aim at restoring systemic acid-base balance. Several G-protein coupled receptor  (GPCRs) and ion channel mediated signaling have been reported in the literature.
http://purl.obolibrary.org/obo/PW_0001105	acid and base sensing signaling pathway	http://purl.obolibrary.org/obo/PW_0000003	signaling pathway		The signaling pathway elicited by changes in pH and bicarbonate levels.
http://purl.obolibrary.org/obo/PW_0001106	bicarbonate sensing signaling pathway	http://purl.obolibrary.org/obo/PW_0001105	acid and base sensing signaling pathway		The signaling pathway elicited by increased levels of bicarbonate. Bicarbonate results from the instantaneous dissociation of carbonic acid, the end product of carbonic anhydrase hydration of exogenous or metabolically produced carbon dioxide.
http://purl.obolibrary.org/obo/PW_0001107	sorafenib drug pathway	http://purl.obolibrary.org/obo/PW_0002367	antineoplastic drug pathway		The pharmacokinetics and pharmacodynamics pathway of sorafenib, a multikinase inhibitor used in the treatment of cancer, in particular for advanced renal cell carcinoma.  The drug binds to the intracytoplasmic domain of tyrosine kinase receptors blocking the downstream signaling cascade. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001108	sorafenib pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001107	sorafenib drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of sorafenib. The drug was the first oral multikinase inhibitor approved for the treatment of renal cell carcinoma. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001109	sorafenib pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001107	sorafenib drug pathway		The pathway of sorafenib-target interaction and of the biochemical or physiological responses to drug. Sorafenib is the first multikinase inhibitor approved for the treatment of renal cell carcinoma.  The drug binds to the intracytoplasmic domain of tyrosine kinase receptors blocking the downstream signaling cascade. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001110	sunitinib drug pathway	http://purl.obolibrary.org/obo/PW_0002367	antineoplastic drug pathway		The pharmacokinetics and pharmacodynamics pathway of sunitinib, a multikinase inhibitor used in the treatment of cancer, in particular for advanced renal cell carcinoma. The drug binds to the intracytoplasmic domain of tyrosine kinase receptors blocking the downstream signaling cascade. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001113	sunitinib pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001110	sunitinib drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of sunitinib. The drug is a multikinase inhibitor approved for the treatment of renal cell carcinoma. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001114	sunitinib pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001110	sunitinib drug pathway		The pathway of sunitinib-target interaction and of the biochemical or physiological responses to drug. Sunitinib is a multikinase inhibitor approved for the treatment of renal cell carcinoma. The drug binds to the intracytoplasmic domain of tyrosine kinase receptors blocking the downstream signaling cascade. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001115	non-visual phototransduction pathway	http://purl.obolibrary.org/obo/PW_0001008	photosignal transduction pathway		A signaling cascade triggered by light in the visible and red spectrum whose sensor appears to be cytochrome c oxidase, the terminal enzyme of the electron transfer chain, and which relies on a retrograde mitochondrion-to-nucleus pathway that translates in the upregulation of various genes. Unlike the visual phototransduction, this pathway does not require vitamin A metabolites.
http://purl.obolibrary.org/obo/PW_0001117	retinol mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0001116	vitamin A and metabolites signaling pathway		A signaling pathway mediated by a signaling complex for which retinol or vitamin A appears to be an essential docking molecule and redox sensor. The pathway may play an important role in regulating the tricarboxylic acid cycle through the pyruvate dehydrogenase complex by mechanisms that are still to be elucidated.
http://purl.obolibrary.org/obo/PW_0001119	altered citric acid cycle pathway	http://purl.obolibrary.org/obo/PW_0001118	altered energy metabolic pathway		Defects in components of the citrate cycle have been shown to relate to several types of cancer. For instance, mutations in fumarate hydratase are associated with renal cancer, in succinate dehydrogenase in renal as well as paragangliomas and pheochromocytomas. Mutations in isocitrate dehydrogenase have also been implicated in several types of cancer. Defects in this central metabolic network result in unwanted activation of hypoxia inducible factor whose target genes are involved in angiogenesis, erythropoiesis, glycolysis, among others.
http://purl.obolibrary.org/obo/PW_0001120	bevacizumab drug pathway	http://purl.obolibrary.org/obo/PW_0002370	monoclonal antibody drug pathway		The pharmacokinetics and pharmacodynamics pathway of bevacizumab, a humanized monoclonal antibody that inhibits VEGF activity. It is used for the treatment of several types of advanced cancers. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001121	bevacizumab pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001120	bevacizumab drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of bevacizumab, a VEGF inhibitor used in the treatment of several types of  tumors. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001122	bevacizumab pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001120	bevacizumab drug pathway		The pathway of bevacizumab-target interaction and of the biochemical or physiological responses to drug. The drug is an inhibitor of VEGF and is used in the treatment of several types of cancers such as for instance renal cell carcinoma. VEGF is a target of hypoxia inducible factor pathway, which is constitutively active in the condition.  Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001123	axitinib drug pathway	http://purl.obolibrary.org/obo/PW_0002367	antineoplastic drug pathway		The pharmacokinetics and pharmacodynamics pathway of axitinib, a receptor tyrosine kinase inhibitor used in the treatment of renal cell carcinoma as well as other tumors. Angiogenic factors such as vascular endothelial or platelet derived growth factors are direct and indirect targets of hypoxia inducible factor pathway, constitutively active in renal cell carcinoma. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001124	axitinib pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001123	axitinib drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of axitinib, a receptor tyrosine kinase inhibitor used in the treatment of renal cell carcinoma and other tumors. Axitinib is a selective second generation inhibitor of vascular endothelial growth factor receptors 1, 2 and 3. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001125	axitinib pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001123	axitinib drug pathway		The pathway of axitinib-target interaction and of the biochemical or physiological responses to drug. Axitinib is a receptor tyrosine kinase inhibitor used in the treatment of renal cell carcinoma as well as other tumors. Axitinib is a selective second generation inhibitor of vascular endothelial growth factor receptors 1, 2 and 3. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001126	everolimus drug pathway	http://purl.obolibrary.org/obo/PW_0002369	immunosuppressant drug pathway		The pharmacokinetics and pharmacodynamics pathway of everolimus, an inhibitor of mTOR pathway used in the treatment of several types of tumors, including renal cell carcinoma. Hypoxia inducible factor (HIF) pathway is constitutively active in the disease; mTOR regulates the translation of HIF-alpha gene. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001127	everolimus pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001126	everolimus drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of everolimus, an inhibitor of mTOR pathway used in the treatment of renal cell carcinoma and other tumors. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001128	everolimus pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001126	everolimus drug pathway		The pathway of everolimus-target interactions and of the biochemical or physiological responses to drug. The drug is an inhibitor of mTOR pathway and is used in the treatment of renal cell carcinoma and other types of tumors. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001129	temsirolimus drug pathway	http://purl.obolibrary.org/obo/PW_0002367	antineoplastic drug pathway		The pharmacokinetics and pharmacodynamics pathway of temsirolimus, an inhibitor of mTOR pathway used in the treatment of renal cell carcinoma and other types of tumors. Hypoxia inducible factor (HIF) pathway is constitutively active in renal cell carcinoma; HIF-alpha translation is under the control of mTOR pathway. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001130	temsirolimus pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001129	temsirolimus drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of temsirolimus, an inhibitor of mTOR pathway used in the treatment of renal cell carcinoma and other tumors. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001131	temsirolimus pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001129	temsirolimus drug pathway		The pathway of temsirolimus-target interaction and of the biochemical or physiological responses to drug. The drug is an inhibitor of mTOR pathway and is used in the treatment of renal cell carcinoma and other types of tumors. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001132	pazopanib drug pathway	http://purl.obolibrary.org/obo/PW_0002367	antineoplastic drug pathway		The pharmacokinetics and pharmacodynamics pathway of pazopanib, a receptor tyrosine kinase inhibitor used in the treatment of renal cell carcinoma as well as other tumors. Angiogenic factors such as vascular endothelial or platelet derived growth factors are direct and indirect targets of hypoxia inducible factor pathway, constitutively active in renal cell carcinoma. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001133	pazopanib pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001132	pazopanib drug pathway		he pathway of processing - absorption, distribution, metabolism or elimination - of pazopanib. The drug is a multikinase inhibitor approved for the treatment of renal cell carcinoma. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001134	pazopanib pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001132	pazopanib drug pathway		The pathway of pazopanib-target interaction and of the biochemical or physiological responses to drug. Pazopanib is a selective multikinase inhibitor approved for the treatment or renal cell carcinoma. The drug binds to the intracytoplasmic domain of tyrosine kinase receptors blocking the downstream signaling cascade. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001135	parathyroid hormone signaling pathway	http://purl.obolibrary.org/obo/PW_0001180	parathyroid hormone family signaling pathway		Parathyroid hormone (PTH) signaling is important for calcium and phosphate homeostasis in bone and kidney. It acts to increase the concentration of calcium in the blood, has both anabolic and catabolic effects in the bone and regulates calcium and phosphate reabsorption in the kidney. It also plays important roles in vitamin D metabolism.
http://purl.obolibrary.org/obo/PW_0001136	fatty acid elongation pathway	http://purl.obolibrary.org/obo/PW_0000029	fatty acid biosynthetic pathway		The C16 palmitate product of the fatty acid biosynthetic pathway can be esterifed to triacylglycerol or converted to longer chain saturated and unsaturated fatty acid molecules by elongases and desaturases, depending on the needs of the cell. The elongation pathway takes place in the endoplasmic reticulum or in the mitochondrion. Longer chain fatty acids are present in certain specialized tissues; for instance, myelin contains large amounts of C22 and C24 molecules.
http://purl.obolibrary.org/obo/PW_0001137	unsaturated fatty acid biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000029	fatty acid biosynthetic pathway		The C16 palmitate product of the fatty acid biosynthetic pathway can be esterifed to triacylglycerol or converted to longer chain saturated and unsaturated fatty acid molecules by elongases and desaturases, depending on the needs of the cell. Unsaturated fatty acids are essential membrane components.
http://purl.obolibrary.org/obo/PW_0001138	ether lipid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000010	lipid metabolic pathway		Those metabolic reactions involving ether lipids, lipid molecules in which one or several of the carbons on glycerol has an ether linkage to an alkyl chain. Ether lipids are constituents of cell membrane; some metabolites could act as signaling second messengers or carry out antioxidant functions.
http://purl.obolibrary.org/obo/PW_0001139	calcium transport pathway	http://purl.obolibrary.org/obo/PW_0000593	metal ion transport pathway		Calcium is pumped into organelles or out of the cell by pumps and exchangers to maintain the low calcium concentration necessary for cell viability. Many type of channels, some calcium-selective, others of lower selectivity or calcium-permeant, allow for the flow of calcium from external sources or internal stores into the cell to initiate many signaling events. The movement of calcium ions, which controls and maintains the calcium gradient, and calcium signaling, which the gradient promotes, are inextricably connected in the fabric of calcium homeostasis.
http://purl.obolibrary.org/obo/PW_0001140	calcium/calcium-mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000003	signaling pathway		Calcium signaling impacts on a large and diverse spectrum of cellular processes such as gene expression and cell death, proliferation, muscle contraction and energy metabolism, learning, memory and synaptic plasticity. Calcium acts in signal transduction as a first as well as a second messenger. Calcium transport, which controls and maintains the calcium gradient, and calcium signaling, which the gradient promotes, are inextricably connected in the fabric of calcium homeostasis.
http://purl.obolibrary.org/obo/PW_0001141	calcium signaling pathway via the calcium-sensing receptor	http://purl.obolibrary.org/obo/PW_0001140	calcium/calcium-mediated signaling pathway		Calcium signaling through the calcium-sensing receptor inhibits the secretion of parathyroid hormone in the parathyroid glands and controls calcium absorption and water balance in the kidneys. Calcium is considered the main physiological agonist but other cations and various agonists can activate the receptor. The G protein coupled receptor (GPCR) is believed to engage several types of Galpha proteins and to have many other interacting partners. The pathway leads to activation of MAPK cascades, particularly the one mediated by Erk1/2. Casr signaling is cell specific; many of its molecular details are not fully understood. Many mutations, both inactivating and activating the receptor, have been identified.
http://purl.obolibrary.org/obo/PW_0001142	clathrin-mediated endocytosis pathway	http://purl.obolibrary.org/obo/PW_0000281	endocytosis pathway		The clathrin-mediated endocytosis pathway involves clathrin-coated vesicles used for the engulfment of material.
http://purl.obolibrary.org/obo/PW_0001143	caveolae-mediated endocytosis pathway	http://purl.obolibrary.org/obo/PW_0000281	endocytosis pathway		Caveolar endocytosis is a ligand-triggered uptake mechanism functioning in parallel with the clathrin-mediated pathway.
http://purl.obolibrary.org/obo/PW_0001144	micropinocytosis pathway	http://purl.obolibrary.org/obo/PW_0000281	endocytosis pathway		The incorporation of macromolecules or other chemical substances into cells by membrane invagination and the pinching off of relatively small vesicles.
http://purl.obolibrary.org/obo/PW_0001145	phagocytosis pathway	http://purl.obolibrary.org/obo/PW_0000281	endocytosis pathway		The phagocytosis pathway is used for the removal of unwanted material such as dying cells and also of foreign material. As such it is also part of the immune response. Various receptors on the surface of a phagocytic cell will recognize/bind material and induce signaling cascades.
http://purl.obolibrary.org/obo/PW_0001146	Fc gamma receptor mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0001150	Fc receptor mediated signaling pathway		The signaling cascade initiated by an activated Fc gamma receptor. Fc receptors are classified by the type of antibody they recognize; thus, Fc gamma receptors bind IgG, the most common type of antibody. Fc gamma receptors belong to the immunoglobulin superfamily.
http://purl.obolibrary.org/obo/PW_0001148	hepatitis B virus infection pathway	http://purl.obolibrary.org/obo/PW_0001028	infectious disease pathway		Hepatitis B virus (HBV) is the causative agent of hepatitis B, an inflammatory condition of the liver affecting people in parts of Asia and Africa. The virus interferes with a number of regulatory and signaling pathways in the host.
http://purl.obolibrary.org/obo/PW_0001149	human T-lymphotropic virus type 1 infection pathway	http://purl.obolibrary.org/obo/PW_0001028	infectious disease pathway		The human T-lymphotropic virus type 1 (HTLV-1) is a pathogenic retrovirus causing a type of cancer known as adult T-cell leukemia and lymphoma and a demyelinating condition referred to as HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP). A viral regulatory protein known as Tax, which is a transcriptional co-factor, interferes with a number of signaling pathways in the host.
http://purl.obolibrary.org/obo/PW_0001150	Fc receptor mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000820	signaling pathway in the adaptive immune response		Fc receptors mediated signaling exerts important regulatory and modulatory roles in immunity. Fc receptors are classified by the type of antibody they recognize. They are widely expressed on immune system cells and a number of other cell types. With one exception, they mediate activating signaling cascades.
http://purl.obolibrary.org/obo/PW_0001151	Fc epsilon receptor mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0001150	Fc receptor mediated signaling pathway		The signaling cascade initiated by an activated Fc epsilon receptor. Fc receptors are classified by the type of antibody they recognize; thus, Fc epsilon receptors bind IgE antibody.
http://purl.obolibrary.org/obo/PW_0001152	steroid biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001303	steroid metabolic pathway		Those metabolic reactions involved in the synthesis of steroids. Notable examples include cholesterol and steroid hormones.
http://purl.obolibrary.org/obo/PW_0001153	caffeine metabolic pathway	http://purl.obolibrary.org/obo/PW_0000147	metabolic pathway of secondary metabolites		Those metabolic reactions involved in the synthesis, utilization and/or degradation of caffeine, a xanthine alkaloid found in the seeds, leaves, and fruit of certain plants that humans use as a stimulant.
http://purl.obolibrary.org/obo/PW_0001154	glycosaminoglycan degradation pathway	http://purl.obolibrary.org/obo/PW_0000157	glycosaminoglycan metabolic pathway		Those metabolic reactions involved in the degradation of glycosaminoglycans.
http://purl.obolibrary.org/obo/PW_0001155	butirosin and neomycin biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000147	metabolic pathway of secondary metabolites		Those metabolic reactions involved in the synthesis of butirosin and neomycin -aminoglycoside antibiotics produced by Bacillus circulans and Streptomyces fradiae, respectively.
http://purl.obolibrary.org/obo/PW_0001156	glycerolipid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000010	lipid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of glycerolipids, which are composed of mono-, di-, and tri-substituted glycerols. Triacylglycerol, or triglyceride, is the best known example.
http://purl.obolibrary.org/obo/PW_0001158	alpha-linolenic acid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000058	fatty acid metabolic pathway		Those enzymatic reactions involved in the synthesis, utilization or degradation of alpha-linolenic acid - an unsaturated omega-3 fatty acid. Alpha-linolenic acid is an essential fatty acid that humans and other animals cannot synthesize and must obtain from diet.
http://purl.obolibrary.org/obo/PW_0001160	RNA transport pathway	http://purl.obolibrary.org/obo/PW_0000103	transport pathway		The pathway whereby various RNA molecules synthesized in the nucleus are exported to the cytoplasm to be further processed such as protein-coding mRNA or to fulfill particular functions.
http://purl.obolibrary.org/obo/PW_0001161	RNA degradation pathway	http://purl.obolibrary.org/obo/PW_0001567	RNA processing pathway		The turnover of RNA molecules produced by the three eukaryotic polymerases and those resulting from their processing and/or assembly. It includes the degradation of defective molecules, of excess molecules, or of defective components by the RNA surveillance or decay pathway.
http://purl.obolibrary.org/obo/PW_0001162	chemical compound signaling pathway	http://purl.obolibrary.org/obo/PW_0000003	signaling pathway		The signaling pathway initiated by a chemical entity. It could be an organic or inorganic molecule.
http://purl.obolibrary.org/obo/PW_0001163	cannabinoid signaling pathway	http://purl.obolibrary.org/obo/PW_0001162	chemical compound signaling pathway		Cannabinoids are a class of rather diverse chemical compounds of which some, like endocannabinoids, are naturally produced by the body in humans and other animals, while others are found in plants or are synthesized. Signaling is mediated by the cannabinoid receptors that are G-protein-coupled (GPCR) receptors. The endogenous cannabinoids are lipids and the signaling route is referred to as retrograde as it travels 'backwards' from the postsynaptic to the presynaptic cell.
http://purl.obolibrary.org/obo/PW_0001164	endocannabinoid signaling pathway	http://purl.obolibrary.org/obo/PW_0001163	cannabinoid signaling pathway		The signaling pathway initiated by the endogenous cannabinoids that activate the G-protein-coupled (GPCR) cannabinoid receptors and utilize a retrograde route from the postsynaptic to the presynaptic neuron.
http://purl.obolibrary.org/obo/PW_0001167	parathyroid hormone-like hormone signaling pathway	http://purl.obolibrary.org/obo/PW_0001180	parathyroid hormone family signaling pathway		Parathyroid hormone related peptide (PTHLH) signaling exerts pleiotropic roles, unlike the related parathyroid hormone whose specific role is in calcium and phosphate homeostasis. Initially identified as a  molecule produced by certain cancers, it is now known that it is important for normal physiological functions, mostly related to development and organogenesis.
http://purl.obolibrary.org/obo/PW_0001168	altered calcium signaling pathway via the calcium-sensing receptor	http://purl.obolibrary.org/obo/PW_0001169	altered calcium/calcium-mediated signaling pathway		Altered calcium signaling due to mutations in the calcium-sensing receptor has been associated with a number of conditions. To date, more than 250 mutations have been identified of which more than half reside in the extracellular part of the receptor.
http://purl.obolibrary.org/obo/PW_0001170	musculo-skeletal system drug pathway	http://purl.obolibrary.org/obo/PW_0000754	drug pathway		The pharmacokinetics and pharmacodynamics of compounds used for the treatment of conditions associated with the musculo-skeletal system. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001171	tuberoinfundibular 39 residues peptide signaling pathway	http://purl.obolibrary.org/obo/PW_0001180	parathyroid hormone family signaling pathway		Tuberoinfundibular peptide of 39 residues (Tip39) is encoded by the parathyroid hormone 2 gene, weakly homologous to parathyroid hormone (PTH) and parathyroid hormone-like hormone (PTHrP). Tip39 is an endogenous ligand for the parathyroid hormone receptor 2, a G protein coupled receptor (GPCR), initially considered an orphan receptor. Signaling, mostly in the brain but also in the pancreas, testis and renal tissues, appears to involve elevation in cAMP.
http://purl.obolibrary.org/obo/PW_0001172	altered fibroblast growth factor signaling pathway	http://purl.obolibrary.org/obo/PW_0000328	fibroblast growth factor signaling pathway		Fibroblast growth factor (FGF) signaling involves more than 20 proteins involved in embryonic and postnatal development and for some members, also acting as hormones in the adult. Deregulation of the pathway has been implicated in a number of neoplastic and metabolic conditions.
http://purl.obolibrary.org/obo/PW_0001173	intracrine fibroblast growth factor signaling pathway	http://purl.obolibrary.org/obo/PW_0000328	fibroblast growth factor signaling pathway		The fibroblast growth factors (FGF)  also known as FGF homologous factors belong to the phylogenetic subfamily FGF11/12/13/14. They signal intracellularly and independent of fibroblast growth factor receptors (FGFR). The pathway plays important neuromodulatory roles. Deregulation of the pathway has been associated with several neurodegenerative disorders.
http://purl.obolibrary.org/obo/PW_0001174	paracrine fibroblast growth factor signaling pathway	http://purl.obolibrary.org/obo/PW_0000650	signaling pathway pertinent to development		Paracrine fibroblast growth factors (FGF) are represented by five phylogenetic subfamilies whose signaling, also referred to as canonical, is involved in the well known role of FGF in embryonic and postnatal development. Deregulation of the pathway has been associated with several conditions.
http://purl.obolibrary.org/obo/PW_0001175	endocrine fibroblast growth factor signaling pathway	http://purl.obolibrary.org/obo/PW_0000328	fibroblast growth factor signaling pathway		The endocrine fibroblast growth factors (FGF) also known as hormone-like belong to the 15/19/21/23 phylogenetic subfamily, also referred to as FGF19 subfamily. They have low affinity for the fibroblast growth factor receptors (FGFR) and rely on the Klotho family members to bind the receptors under physiological conditions. In particular, FGF23 signaling via Klotho, also known as the FGF23/Klotho axis plays a central role in vitamin D metabolism and renal phosphate homeostasis. Deregulation of the pathway has been associated with several conditions.
http://purl.obolibrary.org/obo/PW_0001176	altered endocrine fibroblast growth factor signaling pathway	http://purl.obolibrary.org/obo/PW_0001175	endocrine fibroblast growth factor signaling pathway		Deregulation of endocrine fibroblast growth factor signaling pathway has been associated with several paraneoplastic and metabolic diseases that include renal failure, Cushing's syndrome, type 2 diabetes and obesity, among others.
http://purl.obolibrary.org/obo/PW_0001177	altered intracrine fibroblast growth factor signaling pathway	http://purl.obolibrary.org/obo/PW_0001173	intracrine fibroblast growth factor signaling pathway		Deregulation of the intracrine fibroblast growth factor signaling pathway has been associated with several neurodegenerative disorders and also with mental retardation.
http://purl.obolibrary.org/obo/PW_0001178	altered paracrine fibroblast growth factor signaling pathway	http://purl.obolibrary.org/obo/PW_0001174	paracrine fibroblast growth factor signaling pathway		Deregulation of the paracrine fibroblast growth factor signaling pathway has been associated with several congenital disorders.
http://purl.obolibrary.org/obo/PW_0001179	fibroblast growth factor 23 signaling pathway	http://purl.obolibrary.org/obo/PW_0001175	endocrine fibroblast growth factor signaling pathway		Fibroblast growth factor 23 signaling, a member of the endocrine subfamily of fibroblast growth factor family plays important roles in phosphate homeostasis. It is also important in vitamin D metabolism. The pathway is also referred to as the FGF23-Klotho axis, Klotho representing the obligatory co-receptor family for this subfamily with low affinity for the FGF receptors.
http://purl.obolibrary.org/obo/PW_0001180	parathyroid hormone family signaling pathway	http://purl.obolibrary.org/obo/PW_0000467	peptide and protein hormone signaling pathway		The parathyroid hormone family consists of parathyroid hormone and parathyroid hormone-like hormone that employ the same parathyroid hormone receptor type 1, a G-protein coupled receptor (GPCR) of family B of GPCRs. Despite signaling through the same receptor, the two hormones elicit distinct functions. Receptor type 2 has been considered an orphan receptor, but a specific ligand has been identified, a 39 residues peptide with weaker amino acid sequence similarity to the two hormones.
http://purl.obolibrary.org/obo/PW_0001182	phosphate homeostasis pathway	http://purl.obolibrary.org/obo/PW_0001692	inorganic chemical homeostasis pathway		Phosphate is an essential element with many important roles in biology, from skeletal development and integrity to metabolism and cellular signaling. The greatest amount of phosphate is found in bone and teeth. The major regulator of phosphate homeostasis is  the kidney. Maintenance of proper phosphate levels is assured by an interplay of transport and signaling pathways. Sodium phosphate co-transporters, primarily type 2 and 3 and parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) signaling are essential components.
http://purl.obolibrary.org/obo/PW_0001183	phosphate transport pathway	http://purl.obolibrary.org/obo/PW_0000103	transport pathway		The pathway that assures the proper transport of phosphate in the body. The kidney plays a major role in the filtration and reabsorption of phosphate while bone is a principal form of storage. Several types of sodium phosphate cotransporters are involved; the role of type 2 and 3 has been established. Renal phosphate transport is under the control of parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) signaling.
http://purl.obolibrary.org/obo/PW_0001185	calcium/calmodulin dependent kinase 2 signaling pathway	http://purl.obolibrary.org/obo/PW_0000316	calcium/calmodulin dependent kinase signaling pathway		Calcium/calmodulin dependent kinase 2 (CAMK2) signaling plays important roles in excitation-contraction coupling in the heart and long-term potentiation (LPT) and memory in the brain.
http://purl.obolibrary.org/obo/PW_0001186	calcium/calmodulin dependent kinase signaling cascade	http://purl.obolibrary.org/obo/PW_0000316	calcium/calmodulin dependent kinase signaling pathway		The calcium/calmodulin dependent kinase signaling cascade require an upstream CAMK kinase (CAMKK) for activating phosphorylation.
http://purl.obolibrary.org/obo/PW_0001189	altered folate metabolic pathway	http://purl.obolibrary.org/obo/PW_0000429	altered metabolic pathway of cofactors, vitamins, nutrients		A folate metabolic pathway that deviates from what its normal course should be. Impairment of folate cycle and/or folate mediated one-carbon pathways is associated with an increased risk for several conditions and developmental anomalies.
http://purl.obolibrary.org/obo/PW_0001191	altered methionine cycle/metabolic pathway	http://purl.obolibrary.org/obo/PW_0001190	altered hydrophobic amino acid metabolic pathway		A methionine cycle/metabolic pathway that deviates from what its normal course should be. Impaired methionine metabolism and/or altered levels of S-adenosylmethionine (AdoMet) have been associated with hepatocellular carcinoma and alcoholic liver disease.
http://purl.obolibrary.org/obo/PW_0001192	altered homocysteine metabolic pathway	http://purl.obolibrary.org/obo/PW_0000402	altered metabolic pathway of other amino acids		A homocysteine metabolic pathway that deviates from what its normal course should be. Enzyme and/or vitamin deficiencies or defects in folate metabolism can give rise to the abnormal levels of homocysteine in homocysteinuria or  hyperhomocystenemia and the consequences related to them.
http://purl.obolibrary.org/obo/PW_0001193	kinase mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000003	signaling pathway		Kinases are essential components of biological pathways. Phosphorylaton by protein kinases and dephosphorylation by protein phosphatases exert major regulatory roles. In addition, they can also initiate intracellular signaling cascades. Kinases represent a significant fraction of eukaryotic genes and prominent amongst them are the serine/threonine kinases.
http://purl.obolibrary.org/obo/PW_0001194	serine/threonine-specific kinase mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0001193	kinase mediated signaling pathway		Serine/threonine-specific kinase mediated signaling include essential intracellular pathways such as those involving the mitogen-activated (MAPK), Akt (also known as Pkb), protein kinase A and protein kinase C, to name a few. Serine/threonine-specific kinases represent the largest class.
http://purl.obolibrary.org/obo/PW_0001195	tyrosine-specific protein kinase mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0001193	kinase mediated signaling pathway		The non-receptor tyrosine-specific kinases are represented by members of Src, Jak, Syk  and other families. Some, such as Jak, function as initiators of  intracellular pathways, others are components of several pathways. Tyrosine-specific kinases are also represented by receptor tyrosine kinases activated by growth factors and hormones.  These kinases are components of the pathways the specific growth factors and hormones initiate.
http://purl.obolibrary.org/obo/PW_0001200	thyroid-stimulating hormone signaling pathway	http://purl.obolibrary.org/obo/PW_0000467	peptide and protein hormone signaling pathway		Thyroid-stimulating hormone (TSH) signaling stimulates the secretion of thyroid hormone. Its own secretion is dependent upon activation of thyrotropin-releasing hormone (TRH) in the hypothalamus by low levels of thyroid hormone (TH). TRH, TSH and TH signaling pathways are part of the hypothalamic-pituitary-thyroid (HPT) axis for which TH itself provides a negative regulatory loop.
http://purl.obolibrary.org/obo/PW_0001201	thyrotropin-releasing hormone signaling pathway	http://purl.obolibrary.org/obo/PW_0000467	peptide and protein hormone signaling pathway		Thyrotropin-releasing hormone (TRH or TRF) signaling stimulates the production of thyroid-stimulating hormone (TSH) from the pituitary, which in turn stimulates the thyroid to produce thyroid hormone (TH). TRH, TSH and TH signaling pathways are part of the hypothalamic-pituitary-thyroid (HPT) axis for which TH itself provides a negative regulatory loop.
http://purl.obolibrary.org/obo/PW_0001202	genito-urinary system and sex hormones drug pathway	http://purl.obolibrary.org/obo/PW_0000754	drug pathway		The pharmacokinetics and pharmacodynamics of compounds used for the treatment of genito-urinary system conditions or as sex hormones derivatives and analogs. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001203	systemic hormones drug pathway	http://purl.obolibrary.org/obo/PW_0000754	drug pathway		The pharmacokinetics and pharmacodynamics of hormonal preparations that may contain natural hormones or are synthetic hormonal analogs and their derivatives. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001204	thyromimetics drug pathway	http://purl.obolibrary.org/obo/PW_0001203	systemic hormones drug pathway		The pharmacokinetics and pharmacodynamics of thyroid hormone analogs, many of which have tissue specific thyroid hormone action.
http://purl.obolibrary.org/obo/PW_0001205	sobetirome drug pathway	http://purl.obolibrary.org/obo/PW_0001204	thyromimetics drug pathway		Sobetirome, also known as GC-1, is a one of the best characterized thyromimetics with high affinity for the beta thyroid receptor. It has been shown to reduce LDL cholesterol in animal model studies.
http://purl.obolibrary.org/obo/PW_0001206	eprotirome drug pathway	http://purl.obolibrary.org/obo/PW_0001204	thyromimetics drug pathway		Eprotirome is a thyromimetics that in addition for being selective for the beta tyrosine receptor is also highly liver-selective with minimal uptake in non-hepatic tissues. In overweight and hypercholesterolemic patients, its administration lead to lowering of total and LDL-cholesterol while stimulating bile acid biosynthesis.
http://purl.obolibrary.org/obo/PW_0001210	plevitrexed drug pathway	http://purl.obolibrary.org/obo/PW_0002367	antineoplastic drug pathway		The pharmacokinetics and pharmacodynamics of plevitrexed, a non-polyglutamatable antifolate quinazoline derivative and thymidylate synthase inhibitor used in the treatment of cancers. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001211	plevitrexed pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001210	plevitrexed drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of plevitrexed, an antifolate used in the treatment of cancer. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001212	plevitrexed pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001210	plevitrexed drug pathway		The pathway of plevitrexed-target interactions and of the biochemical or physiological responses to drug. The drug is an antifolate that targets thymidylate synthase and is used in the treatment of several cancers. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001213	pemetrexed drug pathway	http://purl.obolibrary.org/obo/PW_0002367	antineoplastic drug pathway		The pharmacokinetics and pharmacodynamics of permetrexed, an antifolate originally designed as a thymidylate synthase inhibitor but which also has inhibitory effects on other enzymes involved in the folate cycle and/or folate mediated one-carbon transfer reactions. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001214	pemetrexed pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001213	pemetrexed drug pathway		The pathway of pemetrexed-target interactions and of the biochemical or physiological responses to drug. The drug is an antifolate that targets thymidylate synthase and other enzymes of the folate cycle and folate mediated one-carbon transfer reactions and is used in the treatment of several cancers. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001215	pemetrexed pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001213	pemetrexed drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of pemetrexed, an antifolate used in the treatment of cancer. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001216	pralatrexate drug pathway	http://purl.obolibrary.org/obo/PW_0002367	antineoplastic drug pathway		The pharmacokinetics and pharmacodynamics of pralatrexate, a polyglutamatable antifolate used as an inhibitor of dihydrofolate reductase (DHFR) enzyme of folate cycle. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001217	pralatrexate pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001216	pralatrexate drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of pralatrexed, an antifolate used in the treatment of cancer. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001218	pralatrexate pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001216	pralatrexate drug pathway		The pathway of pralatrexed-target interactions and of the biochemical or physiological responses to drug. The drug is an antifolate that targets dihydrofolate reductase (DHFR) and is used in the treatment of some cancers. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001219	hydrogen sulfide mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0001221	gasotransmitter mediated signaling pathway		Hydrogen sulfide can act as a signaling molecule with roles in the heart, brain and smooth muscle.
http://purl.obolibrary.org/obo/PW_0001220	nitric oxide mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0001764	radical mediated signaling pathway		Nitric oxide (NO) signaling, well known for its vasodilation effects, exerts multiple roles that include the immune and nervous system.
http://purl.obolibrary.org/obo/PW_0001221	gasotransmitter mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0001162	chemical compound signaling pathway		Those signaling pathway elicited by gases such as carbon monoxide, nitric oxide or hydrogen sulfide.
http://purl.obolibrary.org/obo/PW_0001224	irinotecan drug pathway	http://purl.obolibrary.org/obo/PW_0002367	antineoplastic drug pathway		The pharmacokinetics and pharmacodynamics of irinotecan an inhibitor of DNA topoisomerase I used in the treatment of several types of cancer. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001225	irinotecan pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001224	irinotecan drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of irinotecan, a drug used in the treatment of several types of cancer. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001226	irinotecan pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001224	irinotecan drug pathway		The pathway of irinotecan-target interactions and of the biochemical or physiological responses to drug. Irinotecan is a DNA topoisomerase I inhibitor used in the treatment of several types of cancer. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001227	Stem Cell Factor signaling pathway	http://purl.obolibrary.org/obo/PW_0000168	growth factor signaling pathway		The Stem Cell Factor (SCF) signaling pathway plays important roles in cell migration, proliferation and survival. SCF activates the KIT receptor tyrosine kinase which then prompts several intracellular signaling pathways. Deregulation of the pathway has been associated with several conditions including cancer.
http://purl.obolibrary.org/obo/PW_0001228	ACE inhibitor drug pathway	http://purl.obolibrary.org/obo/PW_0001789	renin-angiotensin system drug pathway		The pharmacokinetics and pharmacodynamics of drugs that target the angiotensin converting enzyme ACE. In the renin-angiotensin cascade, several bioactive peptides are derived from the precursor angiotensinogen. ACE converts angiotensin I to the potent angiotensin II. The various ACE inhibitors are grouped based on their molecular structure, the dicarboxylate-containing agents represent the largest group. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001229	xenobiotic metabolic pathway	http://purl.obolibrary.org/obo/PW_0000002	classic metabolic pathway		Those metabolic reactions involved in the uptake, modification and elimination of chemical compounds that are foreign to the biological system. This includes the biotransformation pathways organisms use to detoxify the system and the degradation of toxic pollutants by microorganisms. Many of the compounds that enter the cell are inactive and the transformation pathways aim to increase their hydrophilicity and ease elimination. In the process, some of the intermediates may give rise to toxic metabolites and effects. The transformation pathways are also important for the pharmacokinetics aspect of drug metabolism. The distinction is that a drug is a foreign compound intentionally administered. In the case of the degradation pathway, microoganismal enzymes have the ability to degrade otherwise resistant compounds.
http://purl.obolibrary.org/obo/PW_0001230	ACE inhibitor pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001228	ACE inhibitor drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of ACE inhibitors. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001231	ACE inhibitor pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001228	ACE inhibitor drug pathway		The pathway of ACE inhibitor-target interaction and of the biochemical or physiological responses to drug. The drugs are used for the treatment of hypertension and also for other cardiovascular and kidney diseases. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001233	benzo(a)pyrene metabolic pathway	http://purl.obolibrary.org/obo/PW_0001438	polycyclic aromatic hydrocarbon metabolic pathway		Those metabolic reaction involved in handling this polycyclic aromatic hydrocarbon whose metabolites are mutagenic and carcinogenic.
http://purl.obolibrary.org/obo/PW_0001234	biogenic amine biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000211	biogenic amines and polyamines metabolic pathway		Those metabolic reactions involved in the synthesis of biogenic amines.
http://purl.obolibrary.org/obo/PW_0001235	catecholamine biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001234	biogenic amine biosynthetic pathway		Those metabolic reactions involved in the synthesis of catecholamines. Epinephrine, norepinephrine and dopamine are among the most abundant and are produced primarily from the adrenal medulla and the postganglionic fibers of the sympathetic nervous system.
http://purl.obolibrary.org/obo/PW_0001236	histamine biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001238	indoleamine and related compounds biosynthetic pathway		Histamine is derived from the amino acid histidine via a decarboxylation reaction carried out by the enzyme L-histidine decarboxylase.
http://purl.obolibrary.org/obo/PW_0001237	serotonin biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001238	indoleamine and related compounds biosynthetic pathway		Those metabolic reactions involved in the synthesis of serotonin, a monoamine neurotransmitter involved in modulating mood, memory and other biological processes.
http://purl.obolibrary.org/obo/PW_0001239	eicosanoid biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000485	eicosanoid metabolic pathway		Those metabolic reactions involved in the synthesis of eicosanoids, molecules that play important roles in the immune and vascular systems. They are derived from either omega-3 or omega-6 fatty acids, with the route via the conversion of arachidonic acid being better known.
http://purl.obolibrary.org/obo/PW_0001240	prostanoid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000485	eicosanoid metabolic pathway		Those enzymatic reactions involved in the synthesis, utilization or degradation of prostanoids, a class of eicosanoids that contains the prostaglandins, the thromboxanes and prostacycline.
http://purl.obolibrary.org/obo/PW_0001241	prostacyclin metabolic pathway	http://purl.obolibrary.org/obo/PW_0001240	prostanoid metabolic pathway		Those metabolic reactions involving prostacycline - a family of prostanoid eicosanoids with important functions in the cardiovascular system.
http://purl.obolibrary.org/obo/PW_0001242	leukotriene biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001239	eicosanoid biosynthetic pathway		Those metabolic reactions involved in the synthesis of leukotrienes, a class of eicosanoids, molecules exerting important roles in the immune and vascular systems.
http://purl.obolibrary.org/obo/PW_0001243	prostanoid biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001240	prostanoid metabolic pathway		Those metabolic reactions involved in the synthesis of prostanoids, a class of eicosanoids that includes several families and which has important roles in the immune and vascular systems.
http://purl.obolibrary.org/obo/PW_0001244	codeine and morphine drug pathway	http://purl.obolibrary.org/obo/PW_0002443	opioid drug pathway		The pharmacokinetics and pharmacodynamics pathway of codeine and morphine, a class of drugs in the opiate family used as pain relievers. Both are naturally found in the poppy plant with codeine derived from the more abundant morphine, as methylated morphine. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001245	codeine and morphine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001244	codeine and morphine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of codeine and morphine, a class of drug opiates used as pain relievers. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001246	codeine and morphine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001244	codeine and morphine drug pathway		The pathway of codeine/morphine-target interaction and of the biochemical or physiological responses to drug. The drugs are potential ligands for the mu-opioid receptor, a class of opioid receptor. Opioid receptors are G-protein coupled receptors (GPCR) activated by endogenous and also exogenous opioids. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001247	nifedipine drug pathway	http://purl.obolibrary.org/obo/PW_0001894	dihydropyridine calcium channel blocker drug pathway		The pharmacokinetics and pharmacodynamics pathway of nifedipine, a calcium channel blocker used primarily in the treatment of hypertension and angina. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001248	nifedipine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001247	nifedipine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of nifedipine. The drug is a calcium channel blocker used in the treatment of hypertension and angina.  Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001249	nifedipine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001247	nifedipine drug pathway		The pathway of nifedipine-target interaction and of the biochemical or physiological responses to drug. The drug is a calcium channel blocker, particularly the L-type channel.  Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001250	monoamine transport pathway	http://purl.obolibrary.org/obo/PW_0001251	regulatory pathway pertinent to the brain		The pathway responsible for the transport of monoamines, biogenic amines representing various neurotransmitters. The reuptake of neurotransmitters following their release is a key element determining the duration and intensity of their signaling and is thus essential for the proper functioning of the nervous system.
http://purl.obolibrary.org/obo/PW_0001252	prolactin signaling pathway	http://purl.obolibrary.org/obo/PW_0000467	peptide and protein hormone signaling pathway		The prolactin signaling pathway is important for normal reproduction. Prolactin is a peptide hormone whose signaling activates several intracellular cascades.
http://purl.obolibrary.org/obo/PW_0001253	fatty acid omega degradation pathway	http://purl.obolibrary.org/obo/PW_0000642	fatty acid degradation pathway		The omega degradation pathway is an alternative route to the common beta degradation pathway.
http://purl.obolibrary.org/obo/PW_0001254	amino acid biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000011	amino acid metabolic pathway		Those metabolic reactions involved in the synthesis of amino acids, the building blocks for proteins.
http://purl.obolibrary.org/obo/PW_0001257	amino acid degradation pathway	http://purl.obolibrary.org/obo/PW_0000011	amino acid metabolic pathway		Those metabolic reactions involved in the degradation of amino acids.
http://purl.obolibrary.org/obo/PW_0001260	arginine biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001255	hydrophilic amino acid biosynthetic pathway		Those metabolic reactions involved in the synthesis of arginine. Although primarily a non-essential amino acid, its synthesis from citrulline may be insufficient and it is also energetically costly. Diet-derived arginine can circumvent these aspects.
http://purl.obolibrary.org/obo/PW_0001261	arginine degradation pathway	http://purl.obolibrary.org/obo/PW_0001259	hydrophilic amino acid degradation pathway		Those metabolic reactions involved in the degradation of arginine. Higher organisms do not possess the enzymes involved in this catabolic pathway.
http://purl.obolibrary.org/obo/PW_0001262	glutamic acid/glutamate biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001255	hydrophilic amino acid biosynthetic pathway		Those metabolic reaction involved in the biosynthesis of glutamic acid/glutamate. Glutamate is the main excitatory neurotransmitter.
http://purl.obolibrary.org/obo/PW_0001263	glutamic acid/glutamate degradation pathway	http://purl.obolibrary.org/obo/PW_0001259	hydrophilic amino acid degradation pathway		Those metabolic reactions involved in the degradation of glutamic acid/glutamate. There are several routes of glutamic acid/glutamate degradation. Some are found only in microorganisms and plants; others can be found in mammalian cells.
http://purl.obolibrary.org/obo/PW_0001264	glycine biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001256	hydrophobic amino acid biosynthetic pathway		Those metabolic reactions involved in the synthesis of glycine, a major inhibitory neurotransmitter.
http://purl.obolibrary.org/obo/PW_0001265	glycine degradation pathway	http://purl.obolibrary.org/obo/PW_0001258	hydrophobic amino acid degradation pathway		Those metabolic reactions involved in the degradation of glycine. Several routes are available, of which the glycine cleavage system is the predominant one. It occurs in the mitochondria and produces 5,10-methylene tetrahydrofolate and as such, is an important component of the folate cycle pathway.
http://purl.obolibrary.org/obo/PW_0001266	histidine biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000051	histidine metabolic pathway		Those metabolic reactions involved in the synthesis of histidine, an essential amino acid for humans. The biosynthesis of histidine has been extensively studied in E. coli and S. typhimurium.
http://purl.obolibrary.org/obo/PW_0001267	histidine degradation pathway	http://purl.obolibrary.org/obo/PW_0001259	hydrophilic amino acid degradation pathway		Those metabolic reactions involved in the degradation of histidine. Histidine degradation provides a source of nitrogen and is carried out in microorganisms.
http://purl.obolibrary.org/obo/PW_0001268	isoleucine biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001256	hydrophobic amino acid biosynthetic pathway		Those metabolic reactions involved in the synthesis of isoleucine, an essential amino acid for humans. Its synthesis in plants and microorganisms proceeds via several steps.
http://purl.obolibrary.org/obo/PW_0001269	isoleucine degradation pathway	http://purl.obolibrary.org/obo/PW_0001258	hydrophobic amino acid degradation pathway		Those metabolic reactions involved in the degradation of isoleucine.
http://purl.obolibrary.org/obo/PW_0001270	leucine biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001256	hydrophobic amino acid biosynthetic pathway		Those metabolic reactions involved in the biosynthesis of leucine, an essential amino acid for humans. In plants and microorganisms its synthesis proceeds via a number of steps.
http://purl.obolibrary.org/obo/PW_0001271	leucine degradation pathway	http://purl.obolibrary.org/obo/PW_0001258	hydrophobic amino acid degradation pathway		Those metabolic reactions involved in the degradation of leucine.
http://purl.obolibrary.org/obo/PW_0001272	RNA polymerase transcription pathway	http://purl.obolibrary.org/obo/PW_0000100	transcription pathway		The pathway of DNA transcription carried out by the prokaryotic and the several eukaryotic polymerases.
http://purl.obolibrary.org/obo/PW_0001273	prokaryotic RNA polymerase transcription pathway	http://purl.obolibrary.org/obo/PW_0001272	RNA polymerase transcription pathway		The pathway of DNA transcription in prokaryotic organisms is carried out by a single polymerase. Five subunits constitute the core enzyme.
http://purl.obolibrary.org/obo/PW_0001275	eukaryotic RNA polymerase transcription pathway	http://purl.obolibrary.org/obo/PW_0001272	RNA polymerase transcription pathway		The pathway of DNA transcription carried out by the eukaryotic polymerases.
http://purl.obolibrary.org/obo/PW_0001276	de novo nicotinamide adenine dinucleotide biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000219	nicotinamide adenine dinucleotide biosynthetic pathway		Those metabolic reactions involved in the de novo synthesis of nicotinamide adenine dinucleotide (NAD), downstream of kynurenine metabolism of tryptophan degradation.
http://purl.obolibrary.org/obo/PW_0001277	glutathione biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000134	glutathione metabolic pathway		Those metabolic reactions involved in the synthesis of glutathione. Glutathione is a tripeptide that exerts important functions as an antioxidant and in the conjugation of xenobiotics and drugs by phase II biotransformation enzymes.
http://purl.obolibrary.org/obo/PW_0001278	threonine biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001085	threonine metabolic pathway		Those metabolic reaction involved in the synthesis of threonine. Threonine is an essential amino acid that humans cannot synthesize. Its synthesis takes place in plants and microorganisms.
http://purl.obolibrary.org/obo/PW_0001279	threonine degradation pathway	http://purl.obolibrary.org/obo/PW_0001085	threonine metabolic pathway		Those metabolic reactions involved in the degradation of threonine, an essential amino acid for humans. There are several routes for the degradation of threonine.
http://purl.obolibrary.org/obo/PW_0001280	tryptophan biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001256	hydrophobic amino acid biosynthetic pathway		Those metabolic reactions involved in the synthesis of tryptophan, an essential amino acid that humans cannot synthesize. Its synthesis takes place in plants and microorganisms. In plants, the synthesis of aromatic amino acids is part of the chorismate pathway, the end branch point of the shikimate pathway.
http://purl.obolibrary.org/obo/PW_0001281	tryptophan degradation pathway	http://purl.obolibrary.org/obo/PW_0001258	hydrophobic amino acid degradation pathway		Those metabolic reactions involved in the degradation of tryptophan, an essential amino acid. Tryptophan undergoes oxidative catabolism carried out by several hemeprotein enzymes. In plants, tyrosine is the precursor for several secondary metabolites.
http://purl.obolibrary.org/obo/PW_0001282	kynurenine metabolic pathway	http://purl.obolibrary.org/obo/PW_0001281	tryptophan degradation pathway		Those enzymatic reactions involved in the synthesis, utilization or degradation of kynurenine, a product of tryptophan degradation pathway. Kynurenine and its metabolites play important roles in the nervous system and also in immunity.
http://purl.obolibrary.org/obo/PW_0001283	tyrosine biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001256	hydrophobic amino acid biosynthetic pathway		Those metabolic reactions involved in the synthesis of tyrosine. In mammals, it is derived from phenylalanine or from diet. In plants, it is produced as part of the chorismate pathway, the end branch point of the shikimate pathway.
http://purl.obolibrary.org/obo/PW_0001284	tyrosine degradation pathway	http://purl.obolibrary.org/obo/PW_0001258	hydrophobic amino acid degradation pathway		Those metabolic reactions involved in the degradation and/or conversion of tyrosine, a non-essential amino acid. Tyrosine is the precursor of several neurotransmitters and hormones. Tyrosine can also be degraded to acetoacetate and fumarate. In plants, tyrosine is the precursor of several families of secondary metabolites.
http://purl.obolibrary.org/obo/PW_0001285	valine biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001256	hydrophobic amino acid biosynthetic pathway		Those metabolic reactions involved in the synthesis of valine, an essential amino acid for humans. Plants synthesize valine from pyruvic acid via a number of steps.
http://purl.obolibrary.org/obo/PW_0001286	valine degradation pathway	http://purl.obolibrary.org/obo/PW_0001258	hydrophobic amino acid degradation pathway		Those metabolic reactions involved in the degradation of valine, a branched-chain essential amino acid.
http://purl.obolibrary.org/obo/PW_0001287	phenylalanine biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001256	hydrophobic amino acid biosynthetic pathway		Those metabolic reactions involved in the synthesis of phenylalanine, an essential amino acid for humans. In plants, the synthesis of aromatic amino acids is part of the chorismate pathway, the end branch point of the shikimate pathway.
http://purl.obolibrary.org/obo/PW_0001288	phenylalanine degradation pathway	http://purl.obolibrary.org/obo/PW_0001258	hydrophobic amino acid degradation pathway		Those metabolic reactions involved in the degradation and/or conversion of phenylalanine. Phenylalanine is the precursor of tyrosine, which is in turn a precursor for a number of neurotransmitters and hormones. In plants, phenylalanine serves as a precursor for a large number of functional secondary metabolites.
http://purl.obolibrary.org/obo/PW_0001289	carotene metabolic pathway	http://purl.obolibrary.org/obo/PW_0000005	carbohydrate metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of carotenes, collectively referring to several related unsaturated hydrocarbon compounds that are synthesized by plants. Some are vitamin precursors, such as the beta-carotene precursor of vitamin A.
http://purl.obolibrary.org/obo/PW_0001290	lycopene metabolic pathway	http://purl.obolibrary.org/obo/PW_0001289	carotene metabolic pathway		Those metabolic reactions involved ion the synthesis, utilization and/or degradation of lycopene - a carotene and phytochemical found in red fruits and vegetables.
http://purl.obolibrary.org/obo/PW_0001291	lycopene biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001292	carotene biosynthetic pathway		Those metabolic reactions involved in the synthesis of lycopene, a carotene and phytochemical found in red fruits and vegetables. Plants and bacteria have the ability to synthesize lycopene.
http://purl.obolibrary.org/obo/PW_0001292	carotene biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001289	carotene metabolic pathway		Those metabolic reactions involved in the synthesis of carotenes, several related unsaturated hydrocarbon compounds that are synthesized by plants. Some are vitamin precursors, such as the beta-carotene precursor of vitamin A.
http://purl.obolibrary.org/obo/PW_0001293	carotene degradation pathway	http://purl.obolibrary.org/obo/PW_0001289	carotene metabolic pathway		Those metabolic reactions involved in the degradation of carotenes.
http://purl.obolibrary.org/obo/PW_0001295	leukotriene signaling pathway	http://purl.obolibrary.org/obo/PW_0000565	eicosanoid signaling pathway		Leukotriene are eicosanoids derived from omega-3 or omega-6 fatty acids. One such source is arachidonic acid metabolism via the 5-lipoxygenase-mediated route. Leukotriene signaling plays a major role in inflammation.
http://purl.obolibrary.org/obo/PW_0001296	prostanoid signaling pathway	http://purl.obolibrary.org/obo/PW_0000565	eicosanoid signaling pathway		Prostanoids are eicosanoids derived from omega-3 or omega-6 fatty acids and represented by several families. One such source is the arachidonic acid metabolism via the cyclooxygenase mediated route. Several categories of prostanoids can be generated and signaling via several receptor types elicits a range of physiological responses. Historically, they are viewed as mediators of inflammation.
http://purl.obolibrary.org/obo/PW_0001297	prostaglandin signaling pathway	http://purl.obolibrary.org/obo/PW_0001296	prostanoid signaling pathway		Prostaglandins are one of several families of prostanoids, eicosanoids derived from omega-3 or omega-6 fatty acids. Of the several prostaglandins, prostaglandin E2 signaling via four distinct receptors mediates a broad range of  physiological effects. Others include prostaglandin D2 with various central nervous system (CNS) activities and prostaglandin I2 or prostacyclin with important vascular functions.
http://purl.obolibrary.org/obo/PW_0001298	trehalose metabolic pathway	http://purl.obolibrary.org/obo/PW_0000005	carbohydrate metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of trehalose - a disaccharide synthesized by bacteria, fungi, plants and invertebrates. It has important roles in plant development and it represents the energy storage that insects use for flight. It is believed to be involved in the ability of plants and animals to withstand long periods of desiccation or anhydrobiosis.
http://purl.obolibrary.org/obo/PW_0001299	trehalose biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001298	trehalose metabolic pathway		Those metabolic reactions involved on the synthesis of trehalose, a disaccharide found in bacteria, fungi, plants and invertebrates.
http://purl.obolibrary.org/obo/PW_0001300	trehalose degradation pathway	http://purl.obolibrary.org/obo/PW_0001298	trehalose metabolic pathway		Those metabolic reactions involved in the degradation of trehalose. While the synthesis of trehalose does not take place in vertebrates, the catabolic route of its metabolism does occur.
http://purl.obolibrary.org/obo/PW_0001301	methionine biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000048	methionine cycle/metabolic pathway		Those metabolic reactions involved in the synthesis of methionine. As an essential amino acid, methionine can not be synthesized by humans. Its synthesis takes place in plants and microorganisms.
http://purl.obolibrary.org/obo/PW_0001302	methionine degradation pathway	http://purl.obolibrary.org/obo/PW_0000048	methionine cycle/metabolic pathway		Those metabolic reactions involved in the degradation of methionine. In higher organisms methionine is either recycled via the remethylation pathways or is converted to cysteine via the transsulfuration pathway of homocysteine metabolism. In fungi, plants and bacteria, methionine can be processed to compounds such as methionol and/or 2-oxobutanoate.
http://purl.obolibrary.org/obo/PW_0001303	steroid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000248	isoprenoid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of steroids.
http://purl.obolibrary.org/obo/PW_0001304	cholesterol metabolic pathway	http://purl.obolibrary.org/obo/PW_0001303	steroid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of cholesterol, an essential component of cell membranes and lipid rafts and the precursor for the synthesis of steroid hormones and bile acids.
http://purl.obolibrary.org/obo/PW_0001305	steroid hormone metabolic pathway	http://purl.obolibrary.org/obo/PW_0001303	steroid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of steroid hormones.
http://purl.obolibrary.org/obo/PW_0001307	phosphatidylcholine metabolic pathway	http://purl.obolibrary.org/obo/PW_0000354	glycerophospholipid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of phosphatidylcholine, an essential component of membranes.
http://purl.obolibrary.org/obo/PW_0001309	abscisic acid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000248	isoprenoid metabolic pathway		Abscisic acid is a plant isoprenoid hormone important for development and stress responses.
http://purl.obolibrary.org/obo/PW_0001310	abscisic acid biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001309	abscisic acid metabolic pathway		Those metabolic reactions involved in the synthesis of abscisic acid, an important plant isoprenoid hormone.
http://purl.obolibrary.org/obo/PW_0001311	sulfate assimilation pathway	http://purl.obolibrary.org/obo/PW_0000037	sulfur metabolic pathway		Sulfur, mostly found as inorganic sulfate, can be taken up by plants, microorganisms and algae. Upon reduction to sulfide, it is then incorporated into bioinorganic compounds. The underlying reactions and interactions constitute the sulfate assimilation pathway, best characterized in plants.
http://purl.obolibrary.org/obo/PW_0001312	Nodal signaling pathway	http://purl.obolibrary.org/obo/PW_0000650	signaling pathway pertinent to development		Nodal of the Nodal signaling pathway belongs to the transforming growth factor-beta superfamily and plays important roles during vertebrate embryogenesis, where it is involved in pattern formation and differentiation.
http://purl.obolibrary.org/obo/PW_0001315	ascaroside metabolic pathway	http://purl.obolibrary.org/obo/PW_0000733	glycosphingolipid metabolic pathway		Those metabolic reactions involving ascaroside, a glycolipid containing the sugar ascarylose, found in nematodes.
http://purl.obolibrary.org/obo/PW_0001316	ascaroside biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001315	ascaroside metabolic pathway		Those metabolic reactions involved in the synthesis of ascaroside - a glycolipid containing the sugar ascarylose, found in nematodes.
http://purl.obolibrary.org/obo/PW_0001317	cell cycle pathway	http://purl.obolibrary.org/obo/PW_0000085	pathway pertinent to DNA replication and repair, cell cycle, maintenance of genomic integrity, RNA and protein biosynthesis		The series of events, collectively known as the cell cycle, that underlie the replication of the genome and the segregation of chromosomes into daughter cells. The mitotic cell cycle pathway underlies the generation of new cells. The meiotic cell cycle pathway is a special type of cell division that takes place in germ cells.
http://purl.obolibrary.org/obo/PW_0001318	cell cycle pathway, meiotic	http://purl.obolibrary.org/obo/PW_0001317	cell cycle pathway		The series of events that take place in the germ cells resulting in the production of four non-identical haploid cells from each diploid cell that enters the cycle. Meiosis involves chromosomal pairing and exchange of DNA segments or recombination.
http://purl.obolibrary.org/obo/PW_0001319	toxic secondary metabolite biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001365	toxic secondary metabolite metabolic pathway		Those metabolic reactions involved in the synthesis of toxic secondary metabolites, known as mycotoxins, produced by some fungi, such as Fusarium. The mycotoxins they produce in cereal crops, such as species of fumonisins and trichothecenes, can affect humans and animals if present in food.
http://purl.obolibrary.org/obo/PW_0001320	fumonisin biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001367	fumonisin metabolic pathway		Those metabolic reactions involved in the synthesis of fumonisins, mycotoxins produced by members of the fungal genus Fusarium.
http://purl.obolibrary.org/obo/PW_0001321	trichothecene biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001368	trichothecene metabolic pathway		Those metabolic reactions involved in the synthesis of trichothecene mycotoxins by members of Fusarium fungi.
http://purl.obolibrary.org/obo/PW_0001322	deoxynivalenol biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001321	trichothecene biosynthetic pathway		Those metabolic reactions involved in the synthesis of deoxynivalenol, a type B trichothecene produced by members of the fungal genus Fusarium.
http://purl.obolibrary.org/obo/PW_0001323	mitochondrial translation pathway	http://purl.obolibrary.org/obo/PW_0000101	translation pathway		The translation pathway that takes place in the mitochondrion. The mitochondrial translation pathway utilizes 22 tRNAs which are encoded in the mitochondrial genome. The mitochondrial genome also encodes 2 ribosomal genes. A small set of mitochondrially-encoded proteins is translated in the mitochondrion. Most others are nuclear genes, synthesized on cytosolic ribosomes and then targeted to the organelle.
http://purl.obolibrary.org/obo/PW_0001327	altered mitochondrial aminoacyl-tRNA biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001326	altered mitochondrial translation pathway		Mutations in the mitochondrial tRNA genes are associated with a number of disorders. These mutations may affect steps in the biosynthesis of tRNA.
http://purl.obolibrary.org/obo/PW_0001328	uridine diphosphate glucose metabolic pathway	http://purl.obolibrary.org/obo/PW_0000055	nucleotide sugar metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of uridine diphosphate glucose, a nucleotide sugar.
http://purl.obolibrary.org/obo/PW_0001329	guanosine diphosphate mannose metabolic pathway	http://purl.obolibrary.org/obo/PW_0000055	nucleotide sugar metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of guanosine diphosphate mannose, a nucleotide sugar.
http://purl.obolibrary.org/obo/PW_0001330	receptor for advanced glycation end-products signaling pathway	http://purl.obolibrary.org/obo/PW_0000819	signaling pathway in the innate immune response		The receptor for advanced glycation end-products is a multi-ligand receptor whose signaling engages several downstream cascades. In addition to its pro-inflammatory role in innate immunity, it is also involved in tissue homeostasis and repair. It has been associated with a range of pathological states.
http://purl.obolibrary.org/obo/PW_0001333	mitochondrial transcription pathway	http://purl.obolibrary.org/obo/PW_0000100	transcription pathway		The transcription of mitochondrial DNA which encodes several genes involved in the oxidative phosphorylation pathway as well as the ribosomal and transfer RNA genes involved in their translation.
http://purl.obolibrary.org/obo/PW_0001334	non-coding RNA pathway	http://purl.obolibrary.org/obo/PW_0000085	pathway pertinent to DNA replication and repair, cell cycle, maintenance of genomic integrity, RNA and protein biosynthesis		Non-coding RNA are functional RNA molecules that are not translated into proteins. In addition to ribosomal and transfer RNA involved in protein translation many other small and long RNA are transcribed with important roles in the regulation of gene expression.
http://purl.obolibrary.org/obo/PW_0001335	long non-coding RNA pathway	http://purl.obolibrary.org/obo/PW_0001334	non-coding RNA pathway		Long non-coding RNA, of which there are several types, perform important regulatory roles whose function and mechanism are under investigation.
http://purl.obolibrary.org/obo/PW_0001336	CDP-choline pathway of phosphatidylcholine biosynthesis	http://purl.obolibrary.org/obo/PW_0000878	phosphatidylcholine biosynthetic pathway		CDP-choline is one of the three distinct pathways of phosphatidylcholine biosynthesis. A second has been better studied in yeast while the third has only been identified in certain bacteria.
http://purl.obolibrary.org/obo/PW_0001337	chromatin modification/remodeling pathway	http://purl.obolibrary.org/obo/PW_0000085	pathway pertinent to DNA replication and repair, cell cycle, maintenance of genomic integrity, RNA and protein biosynthesis		Chromatin modification/remodeling plays a major role in the epigenetic control of gene expression. The dynamics of chromatin structure impacts on DNA replication, transcription and repair pathways. It includes the covalent modification of histones and DNA and the actions carried out by the ATP-dependent remodelers.
http://purl.obolibrary.org/obo/PW_0001338	histone modification pathway	http://purl.obolibrary.org/obo/PW_0001403	chromatin modification pathway		The tails of histone proteins are subject to a wide array of modifications of which methylation and acetylation have been more thoroughly documented. The modified residues are recognized by particular proteins or readers, in turn acting upon their targets. The modifications are rendered reversible by the enzymes that carry out the reaction in the opposite direction, also referred to as erasers.
http://purl.obolibrary.org/obo/PW_0001339	chromatin remodeling pathway	http://purl.obolibrary.org/obo/PW_0001337	chromatin modification/remodeling pathway		Chromatin remodelers are large complexes that use the energy derived from ATP hydrolysis to promote nucleosome sliding, ejection or repositioning, and histone exchange. Currently, there are four different families of chromatin remodeling complexes.
http://purl.obolibrary.org/obo/PW_0001340	DNA modification pathway	http://purl.obolibrary.org/obo/PW_0001403	chromatin modification pathway		DNA modification is a component of the chromatin modification pathway. At least four DNA modification types are known. The modifications are recognized by specific readers and removed by eraser enzymes.
http://purl.obolibrary.org/obo/PW_0001341	altered chromatin remodeling/modification pathway	http://purl.obolibrary.org/obo/PW_0001337	chromatin modification/remodeling pathway		A chromatin remodeling/modification pathway that deviate from what its normal course should be. Aberrant chromatin remodeling and modification has been associated with various conditions, particularly cancer.
http://purl.obolibrary.org/obo/PW_0001342	sucrose biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000151	starch and sucrose metabolic pathway		Those metabolic reactions involved in the synthesis of sucrose. The disaccharide is synthesized by plants and cyanobacteria.
http://purl.obolibrary.org/obo/PW_0001343	phosphatidylglycerol metabolic pathway	http://purl.obolibrary.org/obo/PW_0000354	glycerophospholipid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of phosphatidylglycerol. The molecule is a glycerophospholipid found in pulmonary surfactant.
http://purl.obolibrary.org/obo/PW_0001344	cardiolipin metabolic pathway	http://purl.obolibrary.org/obo/PW_0001343	phosphatidylglycerol metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of cardiolipin. The molecule is derived from phosphatidylglycerol as an immature cardiolipin, and further remodeled by phospholipases. Cardiolipin is important for a range of mitochondrial functions.
http://purl.obolibrary.org/obo/PW_0001345	cardiolipin biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001344	cardiolipin metabolic pathway		Those metabolic reactions involved in the synthesis of cardiolipin, a molecule important for mitochondrial function.
http://purl.obolibrary.org/obo/PW_0001346	cholesterol transport pathway	http://purl.obolibrary.org/obo/PW_0000103	transport pathway		The pathways involved in the absorption and efflux of cholesterol.
http://purl.obolibrary.org/obo/PW_0001348	ion transport pathway	http://purl.obolibrary.org/obo/PW_0000103	transport pathway		Those pathways that mediate the uptake and transport of ions. Ion transport can be passive (facilitated) or active.
http://purl.obolibrary.org/obo/PW_0001349	non-metal ion transport pathway	http://purl.obolibrary.org/obo/PW_0001348	ion transport pathway		The transport pathways of elements in group 1, 14, 15, 16 and 17 of the periodic table.
http://purl.obolibrary.org/obo/PW_0001350	chloride ion transport pathway	http://purl.obolibrary.org/obo/PW_0001349	non-metal ion transport pathway		The transport pathway of chloride ion as carried out by chloride channels and transporters in cell and organelles.
http://purl.obolibrary.org/obo/PW_0001354	altered chloride ion transport pathway	http://purl.obolibrary.org/obo/PW_0001351	altered non-metal ion transport pathway		A chloride ion transport pathway that deviates from what its normal course should be. Aberrant chloride ion transport have been implicated in diseases. For instance, mutations in the ABC type transporter that functions as both a chloride channel and as a regulator of other transport pathways, have been implicated in two genetic disorders of which one is cystic fibrosis.
http://purl.obolibrary.org/obo/PW_0001355	peroxisome proliferator-activated receptor signaling pathway	http://purl.obolibrary.org/obo/PW_0001313	transcription pathway via transcription factor mediated signaling		Peroxisome proliferator-activated receptor signaling is initiated in response to binding several compounds within classes of lipids such as the eicosanoids, leukotrienes and prostagladins, among others. The receptors form heterodimers with the retinoid X receptor, bind to specific DNA elements and regulate the expression of target genes. Deregulation of the pathway has been implicated in several conditions.
http://purl.obolibrary.org/obo/PW_0001356	altered peroxisome proliferator-activated receptor signaling pathway	http://purl.obolibrary.org/obo/PW_0001355	peroxisome proliferator-activated receptor signaling pathway		Deregulation of peroxisome proliferator-activated receptor signaling can affect innate immunity and play a role in metabolic diseases.
http://purl.obolibrary.org/obo/PW_0001357	coenzyme A metabolic pathway	http://purl.obolibrary.org/obo/PW_0000167	pantothenic acid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of coenzyme A, important for fatty acid, pyruvate and citric acid metabolic pathways.
http://purl.obolibrary.org/obo/PW_0001358	coenzyme A biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001357	coenzyme A metabolic pathway		Those metabolic reactions involved in the synthesis of coenzyme A. The five-step reaction pathway requires pantothenate (vitamin B5) and cysteine as precursors.
http://purl.obolibrary.org/obo/PW_0001359	altered nucleotide excision repair pathway	http://purl.obolibrary.org/obo/PW_0000666	altered single-strand DNA repair pathway		A nucleotide excision repair pathway that deviates from what its normal course should be. Defects in this repair pathway have been associated with cancer and premature aging.
http://purl.obolibrary.org/obo/PW_0001360	DNA damage response pathway	http://purl.obolibrary.org/obo/PW_0000085	pathway pertinent to DNA replication and repair, cell cycle, maintenance of genomic integrity, RNA and protein biosynthesis		The response mechanism/pathways that assure the maintenance of genomic integrity. This involves detection of DNA damage, signaling and amplification of the signal leading to activation of effectors and resulting in repair of damage, cell cycle arrest or, if necessary, cell death. Such  response mechanism/pathways may operate collectively with some of their components being shared.
http://purl.obolibrary.org/obo/PW_0001361	ataxia telangiectasia-mutated (ATM) signaling pathway	http://purl.obolibrary.org/obo/PW_0001194	serine/threonine-specific kinase mediated signaling pathway		The ataxia telangiectasia-mutated (ATM) serine/threonine kinase mediated signaling plays a major role in the response to DNA double strand breaks (DSB). Following lesion sensing by the MRN complex, ATM gets activated. Active ATM phosphorylates itself and targets resulting in triggering of  DNA repair, cell cycle checkpoint and signaling pathways. While ATM signaling is best documented for its role in DSB responses, evidence accumulates that it functions in a range of other, DNA damage unrelated, responses.
http://purl.obolibrary.org/obo/PW_0001362	ATM and Rad3-related (ATR) signaling pathway	http://purl.obolibrary.org/obo/PW_0001194	serine/threonine-specific kinase mediated signaling pathway		The ATM and Rad3-related (ATR) serine/threonine kinase mediated signaling responds to several kinds of DNA damage, of which single-stranded DNA (ssDNA) exerts a key role. ssDNAs are induced by stressed replication forks. ATR acting on its substrates prevents the cell from erroneous mitotic entry, plays a key role in interstrand cross link (ICL) repair pathway and also exerts important regulatory roles in  homologous recombination pathway of double-strand break repair.
http://purl.obolibrary.org/obo/PW_0001363	lactose metabolic pathway	http://purl.obolibrary.org/obo/PW_0000005	carbohydrate metabolic pathway		Those metabolic reactions involving lactose, a disaccharide found in milk.
http://purl.obolibrary.org/obo/PW_0001364	lactose degradation pathway	http://purl.obolibrary.org/obo/PW_0001363	lactose metabolic pathway		The breaking down of lactose to its constituent sugars.
http://purl.obolibrary.org/obo/PW_0001365	toxic secondary metabolite metabolic pathway	http://purl.obolibrary.org/obo/PW_0000147	metabolic pathway of secondary metabolites		Toxic secondary metabolites, also known as mycotoxins, are natural toxins produced by organisms that belong to the fungi kingdom. They can contaminate crops and if ingested, they can cause sickness or death.
http://purl.obolibrary.org/obo/PW_0001366	aflatoxin metabolic pathway	http://purl.obolibrary.org/obo/PW_0001365	toxic secondary metabolite metabolic pathway		Those metabolic reactions involved in the synthesis, transport and/or degradation of aflatoxins. Aflatoxins are potent toxic secondary metabolites that contaminate grain and nut crops. Of the four types, aflatoxin B1 is the most toxic one.
http://purl.obolibrary.org/obo/PW_0001367	fumonisin metabolic pathway	http://purl.obolibrary.org/obo/PW_0001365	toxic secondary metabolite metabolic pathway		Those metabolic reactions involved in the synthesis, transport and/or degradation of fumonisins. These are mycotoxins produced by the fungal genus Fusarium that contaminate crops worldwide, mainly corn.
http://purl.obolibrary.org/obo/PW_0001369	shikimate metabolic pathway	http://purl.obolibrary.org/obo/PW_0001074	hydrophobic amino acid metabolic pathway		The shikimate pathway is the metabolic route for the production of aromatic amino acids in plants. Seven reactions catalyzed by six enzymes result in the production of chorismate, the major branch point metabolite. Chorismate is the precursor for the biosynthesis of phenylalanine, tryptophan and tyrosine.
http://purl.obolibrary.org/obo/PW_0001370	chorismate metabolic pathway	http://purl.obolibrary.org/obo/PW_0001369	shikimate metabolic pathway		Chorismate, the major branch point metabolite of the shikimate pathway, is the precursor for the biosynthesis of aromatic amino acids phenylalanine, tryptophan and tyrosine in plants.
http://purl.obolibrary.org/obo/PW_0001371	basic helix-loop-helix signaling pathway	http://purl.obolibrary.org/obo/PW_0001313	transcription pathway via transcription factor mediated signaling		Basic helix-loop-helix proteins represent a large superfamily of transcription factors that regulate the expression of genes involved in growth and development as well as environmental responses. Phylogenetically, they are classified into six clades of which the sixth, also referred to as clade F only contains plant genes.
http://purl.obolibrary.org/obo/PW_0001372	Inhibitor of DNA binding signaling pathway	http://purl.obolibrary.org/obo/PW_0001371	basic helix-loop-helix signaling pathway		The inhibitor of DNA binding (ID) family belongs to the basic helix-loop-helix superfamily of transcription factor that regulate cell growth and differentiation. They lack the DNA binding domain and exert their gene expression regulatory function through the interaction with other transcription factors. They also appear to play a role in malignant biology; in neural cancers, deregulated activity has been associated with tumor progression.
http://purl.obolibrary.org/obo/PW_0001373	altered inhibitor of DNA binding signaling pathway	http://purl.obolibrary.org/obo/PW_0001374	altered basic helix-loop-helix signaling pathway		An inhibitor of DNA signaling pathway that deviates from what its normal course should be. In neural cancers, deregulated activity of the pathway has been associated with tumor progression.
http://purl.obolibrary.org/obo/PW_0001374	altered basic helix-loop-helix signaling pathway	http://purl.obolibrary.org/obo/PW_0001371	basic helix-loop-helix signaling pathway		A  basic helix-loop-helix signaling pathway that deviates from its normal course should be.
http://purl.obolibrary.org/obo/PW_0001375	nicotinamide adenine dinucleotide biosynthesis, the salvage pathway	http://purl.obolibrary.org/obo/PW_0000219	nicotinamide adenine dinucleotide biosynthetic pathway		Those metabolic reactions involved in the synthesis of nicotinamide adenine dinucleotide (NAD) from precursors such as nicotinamide, nicotinic acid or nicotinamide riboside, collectively known as vitamin B3 or niacin.
http://purl.obolibrary.org/obo/PW_0001376	formaldehyde assimilation pathway	http://purl.obolibrary.org/obo/PW_0000068	methane metabolic pathway		Methane oxidation by methanotrophs produces formaldehyde which is assimilated to form metabolites subsequently used for the biosynthesis of multi-carbon compounds. Two pathways of formaldehyde assimilation are known. Both pathways are cyclic.
http://purl.obolibrary.org/obo/PW_0001377	serine pathway of formaldehyde assimilation	http://purl.obolibrary.org/obo/PW_0001376	formaldehyde assimilation pathway		The serine pathway is one of two pathways of formaldehyde assimilation resulting in a three-carbon intermediate.
http://purl.obolibrary.org/obo/PW_0001378	RuMP pathway of formaldehyde assimilation	http://purl.obolibrary.org/obo/PW_0001376	formaldehyde assimilation pathway		The RuMP pathway, or RuMP cycle, is one of two pathways of formaldehyde assimilation resulting in a three-carbon intermediate.
http://purl.obolibrary.org/obo/PW_0001379	octane oxidation pathway	http://purl.obolibrary.org/obo/PW_0000033	energy metabolic pathway		Those metabolic reactions involved in the oxidation of octane and found in some bacteria. The final product can be utilized as a source of carbon and energy.
http://purl.obolibrary.org/obo/PW_0001380	glutamate degradation pathway I	http://purl.obolibrary.org/obo/PW_0001263	glutamic acid/glutamate degradation pathway		Those metabolic reactions involved in the deamination pathway of glutamate degradation that is found in microorganisms and plants. It results in ammonia and the 2-oxoglutarate compound which is fed into the citric acid cycle.
http://purl.obolibrary.org/obo/PW_0001381	glutamate degradation pathway II	http://purl.obolibrary.org/obo/PW_0001263	glutamic acid/glutamate degradation pathway		Those metabolic reactions involved in the glutamate degradation pathway II found in certain bacteria.
http://purl.obolibrary.org/obo/PW_0001382	glutamate degradation pathway III	http://purl.obolibrary.org/obo/PW_0001263	glutamic acid/glutamate degradation pathway		Those metabolic reactions involved in glutamate degradation pathway III which proceeds via 4-aminobutanoate (GABA) and is found in humans and other mammals.
http://purl.obolibrary.org/obo/PW_0001383	glutamate degradation pathway IV	http://purl.obolibrary.org/obo/PW_0001263	glutamic acid/glutamate degradation pathway		Those metabolic reaction involved in glutamate degradation pathway IV. It proceeds via 4-aminobutanoate (GABA), like degradation pathway III, but is found in plants.
http://purl.obolibrary.org/obo/PW_0001384	glutamate degradation pathway V	http://purl.obolibrary.org/obo/PW_0001385	glutamate fermentation pathway		Those metabolic reactions involved in glutamate degradation pathway V, a fermentation pathway of glutamate degradation. Glutamate degradation pathway V proceeds via hydroxyglutarate and is one of the major pathways of glutamate fermentation.
http://purl.obolibrary.org/obo/PW_0001385	glutamate fermentation pathway	http://purl.obolibrary.org/obo/PW_0001263	glutamic acid/glutamate degradation pathway		Certain anaerobic bacteria are capable of fermenting amino acids. While at least one fermentation pathway is known for every amino acid, several have been reported for glutamate.
http://purl.obolibrary.org/obo/PW_0001386	glutamate degradation pathway VII	http://purl.obolibrary.org/obo/PW_0001385	glutamate fermentation pathway		Those metabolic reactions involved in glutamate degradation pathway VII, a fermentation pathway of glutamate degradation. It is a methylaspartate pathway and a major route of glutamate fermentation, together with degradation pathway VI and VIII.
http://purl.obolibrary.org/obo/PW_0001387	glutamate degradation pathway VI	http://purl.obolibrary.org/obo/PW_0001385	glutamate fermentation pathway		Those metabolic reactions involved in glutamate degradation pathway VI, a fermentation pathway of glutamate degradation. It is a methylaspartate pathway and a major route of glutamate fermentation, together with degradation pathway VII and VIII.
http://purl.obolibrary.org/obo/PW_0001388	glutamate degradation pathway VIII	http://purl.obolibrary.org/obo/PW_0001385	glutamate fermentation pathway		Those metabolic reactions involved in glutamate degradation pathway VIII, a fermentation pathway of glutamate degradation. It is a methylaspartate pathway and a major route of glutamate fermentation, together with degradation pathway VI and VII.
http://purl.obolibrary.org/obo/PW_0001390	starch biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001391	starch and cellulose metabolic pathway		Those metabolic reactions involved in the synthesis of starch, a carbohydrate produced by all green plants as an energy store.
http://purl.obolibrary.org/obo/PW_0001391	starch and cellulose metabolic pathway	http://purl.obolibrary.org/obo/PW_0000005	carbohydrate metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of starch and cellulose, two similar polymers produced and used by green plants. Both are made from glucose repeat units that differ in their orientation.
http://purl.obolibrary.org/obo/PW_0001392	cellulose biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001391	starch and cellulose metabolic pathway		Those metabolic reactions involved in the synthesis of cellulose, an important structural component of cell walls of green plants, many forms of algae and some fungus-like microorganisms.
http://purl.obolibrary.org/obo/PW_0001393	starch and cellulose biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001391	starch and cellulose metabolic pathway		Those metabolic reactions involved in the synthesis of starch and cellulose, two related polymers.
http://purl.obolibrary.org/obo/PW_0001394	terpene and terpenoid biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001397	terpene and terpenoid metabolic pathway		Those metabolic reactions involved in the biosynthesis of terpene and terpenoid, large classes of related organic compounds. Modified terpenes, via oxidation or re-arrangement of the carbon skeleton, the resulting compounds are generally referred to as terpenoids.
http://purl.obolibrary.org/obo/PW_0001395	terpene biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001394	terpene and terpenoid biosynthetic pathway		Those metabolic reactions involved in the synthesis of terpenes, a large class or organic compounds produced by a variety of plants and some insects.
http://purl.obolibrary.org/obo/PW_0001396	monoterpene biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001395	terpene biosynthetic pathway		Those metabolic reactions involved in the synthesis of monoterpenes, a class of terpenes composed of two isoprene units.
http://purl.obolibrary.org/obo/PW_0001397	terpene and terpenoid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000147	metabolic pathway of secondary metabolites		Those metabolic reactions involved in the synthesis, utilization and/or degradation of terpene and terpenoid, large classes of related organic compounds.
http://purl.obolibrary.org/obo/PW_0001399	terpene degradation pathway	http://purl.obolibrary.org/obo/PW_0001398	terpene and terpenoid degradation pathway		Those metabolic reactions involved in the degradation of terpenes, a large class or organic compounds produced by a variety of plants and some insects.
http://purl.obolibrary.org/obo/PW_0001400	terpenoid degradation pathway	http://purl.obolibrary.org/obo/PW_0001398	terpene and terpenoid degradation pathway		Those metabolic reactions involved in the degradation of terpenoids, a large class or organic compounds produced by a variety of plants and some insects.
http://purl.obolibrary.org/obo/PW_0001401	diterpene biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001395	terpene biosynthetic pathway		Those metabolic reactions involved in the synthesis of diterpenes, a class of terpenes composed of four isoprene units.
http://purl.obolibrary.org/obo/PW_0001402	momilactone biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001401	diterpene biosynthetic pathway		Those metabolic reactions involved in the synthesis of momilactone - a diterpene produced by rice. Momilactone A and B can act as potent phytoalexins and allelochemicals
http://purl.obolibrary.org/obo/PW_0001403	chromatin modification pathway	http://purl.obolibrary.org/obo/PW_0001337	chromatin modification/remodeling pathway		The pathway of chromatin - DNA  and constituent histones, modification mediated by writers and recognized by readers which in turn, act upon their effectors. The modifications are removed by erasers. Mutations in the writer, reader or eraser categories are known to be implicated in cancer.
http://purl.obolibrary.org/obo/PW_0001404	altered chromatin modification pathway	http://purl.obolibrary.org/obo/PW_0001403	chromatin modification pathway		A chromatin modification pathway that deviate from what its normal course should be. Mutations in the writer, reader or eraser categories of chromatin modification have been implicated in cancer.
http://purl.obolibrary.org/obo/PW_0001405	altered chromatin remodeling pathway	http://purl.obolibrary.org/obo/PW_0001341	altered chromatin remodeling/modification pathway		A chromatin remodeling pathway that deviates from what its normal course should be. Mutations in members of the various chromatin remodeling families have been implicated in cancer.
http://purl.obolibrary.org/obo/PW_0001406	SWI/SNF family mediated chromatin remodeling pathway	http://purl.obolibrary.org/obo/PW_0001339	chromatin remodeling pathway		The SWI/SNF (switching defective/sucrose nonfermenting) family of remodelers has initially been purified from Saccharomyces cerevisiae. In  mammals, two complexes are comprised of one of two mutually exclusive catalytic ATPase subunits along with a set of conserved core subunits and variant subunits. The SWI/SNF is involved in nucleosome sliding and ejection. Deregulation of pathway is associated with several human cancers.
http://purl.obolibrary.org/obo/PW_0001407	ISWI family mediated chromatin remodeling pathway	http://purl.obolibrary.org/obo/PW_0001339	chromatin remodeling pathway		The ISWI (imitation switch) family of remodelers has initially been purified from Drosophila melanogaster. Eukaryotes assemble several ISWI complexes using one or two different catalytic subunits. Many complexes function to promote chromatin assembly and repression of transcription. Overall, the pathway is important for DNA replication and repair along with the regulation of transcription.
http://purl.obolibrary.org/obo/PW_0001408	INO80 family mediated chromatin remodeling pathway	http://purl.obolibrary.org/obo/PW_0001339	chromatin remodeling pathway		The INO80 (inositol requiring 80) family of remodelers has been initially purified from Saccharomyces cerevisiae. It promotes transcriptional activation and DNA repair.
http://purl.obolibrary.org/obo/PW_0001409	CHD family mediated chromatin remodeling pathway	http://purl.obolibrary.org/obo/PW_0001339	chromatin remodeling pathway		The CHD (chromodomain, helicase, DNA binding) family of remodelers has initially been purified from Xenopus laevis. Some CHD remodelers are involved in sliding and ejection of nucleosome to promote transcription while others may have repressive roles.
http://purl.obolibrary.org/obo/PW_0001410	altered DNA modification pathway	http://purl.obolibrary.org/obo/PW_0001404	altered chromatin modification pathway		A DNA modification pathway that deviates from what its normal course should be. Mutations in the writer, reader or eraser categories of DNA modification have been implicated in several developmental abnormalities and human malignancies.
http://purl.obolibrary.org/obo/PW_0001411	altered histone modification pathway	http://purl.obolibrary.org/obo/PW_0001404	altered chromatin modification pathway		A histone modification pathway that deviates from what its normal course should be. Mutations in the writer, reader or eraser categories of several types of histone modification have been implicated in various forms of cancer.
http://purl.obolibrary.org/obo/PW_0001412	nervous system disease pathway	http://purl.obolibrary.org/obo/PW_0000013	disease pathway		Any disease that affects the central or peripheral nervous system. It includes disorders of the brain, neurological, neurodegenerative, cerebrovascular disorders, syndromes, dystrophies, diseases of the central and peripheral nervous system, and others. However, mental or neuropsychiatric disorders are not included.
http://purl.obolibrary.org/obo/PW_0001413	liver disease pathway	http://purl.obolibrary.org/obo/PW_0001697	digestive system disease pathway		The congenital and acquired diseases affecting the liver.
http://purl.obolibrary.org/obo/PW_0001414	brain disease pathway	http://purl.obolibrary.org/obo/PW_0001412	nervous system disease pathway		The congenital and acquired diseases affecting the brain, including but not limited to the cerebral cortex, basal ganglia, thalamus and hypothalamus, brain stem, cerebellum.
http://purl.obolibrary.org/obo/PW_0001415	Zellweger syndrome pathway	http://purl.obolibrary.org/obo/PW_0001414	brain disease pathway		A cerebro-hepato-renal phenotype caused by mutations in genes involved in the peroxisome biogenesis pathway.
http://purl.obolibrary.org/obo/PW_0001416	Leigh disease pathway	http://purl.obolibrary.org/obo/PW_0001751	inborn error of pyruvate metabolism pathway		A neurometabolic disorder affecting the central nervous system, caused by defects in mitochondrial and/or nuclear genes involved in energy metabolic pathways.
http://purl.obolibrary.org/obo/PW_0001417	Canavan disease pathway	http://purl.obolibrary.org/obo/PW_0001646	inborn error of brain metabolic pathway		A rare autosomal recessive condition characterized by degeneration of the nervous system due to white matter vacuolization and demeylination. It results from defects in ASPA, aspartoacylase gene involved in several amino acid metabolic pathways.
http://purl.obolibrary.org/obo/PW_0001418	abciximab drug pathway	http://purl.obolibrary.org/obo/PW_0002150	antiplatelet drug pathway		The pharmacokinetics and pharmacodynamics of abciximab, an integrin receptor antagonist used as a platelet aggregation inhibitor. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001419	abciximab pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001418	abciximab drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of abciximab, a platelet aggregation inhibitor. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001420	abciximab pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001418	abciximab drug pathway		The pathway of abciximab-target interaction and of the biochemical or physiological responses to drug. Abciximab is an antagonist of the integrin alpha2b/beta3 complex found on platelets. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001421	kanamycin drug pathway	http://purl.obolibrary.org/obo/PW_0000996	anti-infective drug pathway		The pharmacokinetics and pharmacodynamics of kanamycin, an aminoglycoside antibiotic that inhibits bacterial protein synthesis. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001422	kanamycin pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001421	kanamycin drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination of kanamycin - an antibiotic that interferes with bacterial protein synthesis. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001423	kanamycin pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001421	kanamycin drug pathway		The pathway of kanamycin-target interaction and of the biochemical or physiological responses to drug. Kanamycin interferes with bacterial protein synthesis and is used in the treatment of several infections caused by both Gram-negative and Gram-positive bacteria. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001424	neviparine drug pathway	http://purl.obolibrary.org/obo/PW_0000996	anti-infective drug pathway		The pharmacokinetics and pharmacodynamics of neviparine, a non-nucleoside reverse transcriptase inhibitor used in the treatment of HIV type 1. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001425	neviparine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001424	neviparine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination of neviparine, a reverse transcriptase inhibitor. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001426	neviparine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001424	neviparine drug pathway		The pathway of neviaparine-target interaction and of the biochemical or physiological responses to drug. Neviparine is a non-nucleoside reverse transcriptase inhibitor used in combination with other antiretroviral drugs  for the treatment of HIV type. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001427	amikacin drug pathway	http://purl.obolibrary.org/obo/PW_0000996	anti-infective drug pathway		The pharmacokinetics and pharmacodynamics of amikacin, an aminoglycoside antibiotic that inhibits bacterial protein synthesis. It is used for the treatment of infections induced by Gram-negative bacteria. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001428	amikacin pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001427	amikacin drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination of amikacin, an antibiotic used for the treatment of infections induced by Gram-negative bacteria. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001429	amikacin pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001427	amikacin drug pathway		The pathway of amikacin-target interaction and of the biochemical or physiological responses to drug. Amikacin inhibits bacterial protein synthesis and is used for the treatment of infections induced by Gram-negative bacteria. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001430	lamivudine drug pathway	http://purl.obolibrary.org/obo/PW_0000996	anti-infective drug pathway		The pharmacokinetics and pharmacodynamics of lamivudine, a reverse transcriptase enzyme inhibitor used for the treatment of HIV type 1 and 2 and Hepatitis B virus. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001431	lamivudine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001430	lamivudine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination of lamivudine, a reverse transcriptase inhibitor used for the treatment of several virally induced diseases. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001432	lamivudine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001430	lamivudine drug pathway		The pathway of lamivudine-target interaction and of the biochemical or physiological responses to drug. Lamivudine is a a reverse transcriptase enzyme inhibitor used for the treatment of HIV typ1 and 2 and Hepatitis B. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001433	gentamicin drug pathway	http://purl.obolibrary.org/obo/PW_0000996	anti-infective drug pathway		The pharmacokinetics and pharmacodynamics of gentamicin, an antibiotic that inhibits bacterial protein synthesis. The drug can cause inner ear and kidney problems. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001434	toxin and toxicant response pathway	http://purl.obolibrary.org/obo/PW_0000124	cellular detoxification pathway		The responses triggered by exposure to a toxin or a toxicant, a poisonous substance naturally produced by an organism or made by humans, respectively. A toxicant can be a poison, such as a pesticide. It can also be a compound for use in certain applications or a drug, the exposure to which may be toxic. Inflammatory responses, various types of cell death, changes in gene and protein expression can be induced upon exposure.
http://purl.obolibrary.org/obo/PW_0001435	nanomaterial response pathway	http://purl.obolibrary.org/obo/PW_0001434	toxin and toxicant response pathway		A pathway triggered by exposure to a nanomaterial. Nanomaterials, such as fullerenes and inorganic nanoparticles are increasingly being used in a broad range of applications. However, in a dose-dependent manner, they may exert toxic effects that affect cellular pathways and processes and elicit defense mechanisms.
http://purl.obolibrary.org/obo/PW_0001436	carbon nanotube response pathway	http://purl.obolibrary.org/obo/PW_0001435	nanomaterial response pathway		A pathway triggered by exposure to carbon nanotube (CNT), an allotrope of carbon of the fullerene structural family. CNTs have a very broad range of applications but can also exert toxic effects. Pulmonary toxicity possibly via reactive oxygen species, inhibition of potassium channels and DNA repair are some of the potential mechanisms of CNT genotoxicity. Various forms of cell death and inflammatory responses are triggered in response to CNT.
http://purl.obolibrary.org/obo/PW_0001437	titanium dioxide nanoparticle response pathway	http://purl.obolibrary.org/obo/PW_0001435	nanomaterial response pathway		A pathway triggered by exposure to titanium dioxide nanoparticle (nano-TiO2). Nano-TiO2 has a broad range of applications but studies indicate that under conditions of long and high dose exposure, it can exert cytotoxic and genotoxic effects. Nano-TiO2 has been shown to induce inflammation, oxidative stress and MAP kinase activity.
http://purl.obolibrary.org/obo/PW_0001438	polycyclic aromatic hydrocarbon metabolic pathway	http://purl.obolibrary.org/obo/PW_0001229	xenobiotic metabolic pathway		Those metabolic reactions involved in the uptake, modification and elimination of polycyclic aromatic hydrocarbons (PAHs), a class of compounds, members of which are potent mutagens and carcinogens. Metabolites of PAHs can form DNA adducts, considered a necessary step of their carcinogenic property.
http://purl.obolibrary.org/obo/PW_0001439	ceric oxide nanoparticle response pathway	http://purl.obolibrary.org/obo/PW_0001435	nanomaterial response pathway		A pathway triggered by exposure to cerium oxide nanoparticles, also known as nanoceria. Like other nanoparticles, nanoceria has a broad range of applications. A peculiar feature is the anti-oxidant property; by catalytically reacting with superoxide and hydrogen peroxide, it mimics the activities of superoxide dismutase and catalase enzymes. In addition, beneficial effects on cell differentiation and dopamine production have been shown. However, toxic effects have also been demonstrated.
http://purl.obolibrary.org/obo/PW_0001440	arthritis pathway	http://purl.obolibrary.org/obo/PW_0001593	musculoskeletal disease pathway		Arthritis collectively describes several conditions whose primary feature is represented by joint pain resulting from inflammation.
http://purl.obolibrary.org/obo/PW_0001441	gout pathway	http://purl.obolibrary.org/obo/PW_0001440	arthritis pathway		A metabolic disorder characterized by recurrent acute arthritis, hyperuricemia and deposition of sodium urate in and around the joints, sometimes with formation of uric acid calculi. Elements of the gout pathway potentially contributory to the disease are urate excretion by renal transporters where mutations in these genes can increase the risk of gout, hepatic production of urate, urate crystal formation in joints and initiation of the inflammatory response.
http://purl.obolibrary.org/obo/PW_0001442	inflammatory bowel disease pathway	http://purl.obolibrary.org/obo/PW_0001018	immune system disease pathway		The inflammatory bowel disease (IBD) results from the deregulation of the immune system to which both genetic and environmental factors contribute. Alterations in pattern recognition receptor signaling, such as Toll-like or Nod and signaling downstream of them, among others, may contribute to and/or lead to the chronic inflammation characteristic of the condition. The main forms of IBD are Crohn's and ulcerative colitis.
http://purl.obolibrary.org/obo/PW_0001443	ezetimibe drug pathway	http://purl.obolibrary.org/obo/PW_0000920	cardiovascular system drug pathway		The pharmacokinetics and pharmacodynamics pathway of ezetimibe - a drug used to lower the plasma cholesterol level. Ezetimibe is a selective cholesterol absorption inhibitor used both as monotherapy and in combination with statins. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001444	ezetimibe pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001443	ezetimibe drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of ezetimibe, a selective inhibitor of cholesterol absorption. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001445	ezetimibe pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001443	ezetimibe drug pathway		The pathway of ezetimibe-target interaction and of the biochemical or physiological responses to drug. Ezetimibe is a selective inhibitor of cholesterol absorption used both as monotherapy and in combination with statins. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001446	lomitapide drug pathway	http://purl.obolibrary.org/obo/PW_0000920	cardiovascular system drug pathway		The pharmacokinetics and pharmacodynamics pathway of lomitapide, a drug used to lower cholesterol levels. Lomitapide is an inhibitor of microsomal triglyceride transfer protein used both as monotherapy and in combination with statins. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001447	lomitapide pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001446	lomitapide drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of lomitapide, an inhibitor of microsomal triglyceride transfer protein. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001448	lomitapide pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001446	lomitapide drug pathway		The pathway of lomitapide-target interaction and of the biochemical or physiological responses to drug. The drug is an inhibitor of microsomal triglyceride transport protein and used to lower cholesterol levels. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001449	nicotine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0000721	nicotine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of nicotine, an agonist of nicotinic acetylcholine receptors. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001450	nicotine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0000721	nicotine drug pathway		The pathway of nicotine-target interaction and of the biochemical or physiological responses to drug. Nicotine is an agonist of the nicotinic acetylcholine receptors and exerts stimulatory roles. It is also responsible for tobacco dependence.  Prolonged exposure and high levels of nicotine can have toxic effects. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001451	valproic acid drug pathway	http://purl.obolibrary.org/obo/PW_0002295	antiepileptic drug pathway		The pharmacokinetics and pharmacodynamics pathway of valproic acid, a branched short-chain fatty acid derived from valeric acid used as a mood-stabilizing drug and in the treatment of epilepsy. More recently it has also been found to inhibit the proliferation of cancers. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001452	valproic acid pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001451	valproic acid drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of valproic acid, a drug used as a mood-stabilizing and for the treatment of epilepsy. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001453	valproic acid pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001451	valproic acid drug pathway		The pathway of valproic acid-target interaction and of the biochemical or physiological responses to drug. Valproic acid is used as a mood-stabilizing drug and in the treatment of epilepsy. More recently it has also been found to inhibit the proliferation of cancers. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001454	Gaucher's disease pathway	http://purl.obolibrary.org/obo/PW_0002301	sphingolipidosis pathway		Gaucher's disease is caused by defective sphingolipid metabolism and accumulation of glucosylceramide in the brain and other tissues.
http://purl.obolibrary.org/obo/PW_0001455	doxorubicin drug pathway	http://purl.obolibrary.org/obo/PW_0002367	antineoplastic drug pathway		The pharmacokinetics and pharmacodynamics pathway of doxorubicin, a streptomyces metabolite used as a chemotherapeutic agent used in the treatment of cancers. However, its use is limited by the serious cardiotoxic side effects. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001456	nystatin drug pathway	http://purl.obolibrary.org/obo/PW_0001202	genito-urinary system and sex hormones drug pathway		The pharmacokinetics and pharmacodynamics pathway of nystatin - a polyene antifungal drug used to treat yeast infections. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001457	nystatin pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001456	nystatin drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination -of nystatin. Nystatin is an antifungal that binds to ergosterol - a component of the fungal cell membrane, and also with cholesterol. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001458	nystatin pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001456	nystatin drug pathway		The pathway of nystatin-target interactions and of the biochemical or physiological responses to drug. Nystatin interacts with both the fungal ergosterol and the host cholesterol but its afinity for ergosterol is higher. The interaction with cholesterol impacts on the uptake and activity of the anti-angiogenic endostatin.
http://purl.obolibrary.org/obo/PW_0001462	losartan drug pathway	http://purl.obolibrary.org/obo/PW_0001789	renin-angiotensin system drug pathway		The pharmacokinetics and pharmacodynamics pathway of losartan, an angiotensin II receptor type 1 antagonist used in the treatment of hypertension and heart failure. Losartan is one of several angiotensin II receptor type 1 antagonists and the first used on the market. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001463	losartan pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001462	losartan drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of losartan. The drug is an angiotensin II receptor type 1 antagonist used in the treatment of hypertension and heart failure. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001464	losartan pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001462	losartan drug pathway		The pathway of losartan-target interaction and of the biochemical or physiological responses to drug. Losartan is an angiotensin II receptor type 1 antagonist used in the treatment of hypertension and heart failure. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001465	clopidogrel drug pathway	http://purl.obolibrary.org/obo/PW_0002150	antiplatelet drug pathway		The pharmacokinetics and pharmacodynamics pathway of clopidogrel, a platelet aggregation inhibitor. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001466	clopidogrel pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001465	clopidogrel drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of clopidogrel. The drug is an inhibitor of ADP-dependent platelet activation and aggregation. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001467	clopidogrel pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001465	clopidogrel drug pathway		The pathway of clopidogrel-target interaction and of the biochemical or physiological responses to drug. The drug is an inhibitor of purinergic receptor P2RY12 a G-protein coupled receptor and chemoreceptor for adenosine diphosphate (ADP) receptor. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001468	ibuprofen drug pathway	http://purl.obolibrary.org/obo/PW_0001546	analgesic and/or antipyretic drug pathway		The pharmacokinetics and pharmacodynamics pathway of ibuprofen, a non-steroidal anti-inflammatory drug that inhibits cyclooxygenase enzymes and is used in the treatment of inflammation and pain. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001469	ibuprofen pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001468	ibuprofen drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of ibuprofen. The drug is used in the treatment of pain and inflammation. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001470	ibuprofen pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001468	ibuprofen drug pathway		The pathway of ibuprofen-target interaction and of the biochemical or physiological responses to drug. Ibuprofen is an inhibitor of cyclooxygenase enzymes used in the treatment of pain and inflammation. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001471	Fabry disease pathway, cerebrovascular	http://purl.obolibrary.org/obo/PW_0002103	Fabry disease pathway		An X-linked inherited metabolic disorder affecting the cerebrovascular system. It is caused by alterations in sphingolipid metabolic pathway.
http://purl.obolibrary.org/obo/PW_0001472	metabolic disease pathway	http://purl.obolibrary.org/obo/PW_0001583	nutritional and metabolic disease pathway		Those diseases and disorders that are caused by deregulation of a metabolic pathway. It can be due to an inherited defect in an enzyme function and thus congenital, or acquired, when resulting from the failure or malfunctioning of an important metabolic organ.
http://purl.obolibrary.org/obo/PW_0001473	lipid metabolism disease pathway	http://purl.obolibrary.org/obo/PW_0001472	metabolic disease pathway		Those diseases and disorders that are caused by deregulation of lipid metabolic pathways. The condition(s) can be inherited or acquired.
http://purl.obolibrary.org/obo/PW_0001474	xanthomatosis pathway	http://purl.obolibrary.org/obo/PW_0001473	lipid metabolism disease pathway		Xanthomatosis results from deregulation of cholesterol metabolic pathways and is manifested by the formation of yellow,  cholesterol-rich deposits. It is a rare, inherited condition and can affect several tissues.
http://purl.obolibrary.org/obo/PW_0001475	cerebrotendinous xanthomatosis pathway	http://purl.obolibrary.org/obo/PW_0001643	inborn error of lipid metabolism pathway		The cerebrotendinous type of xanthomatosis is caused by mutation in the CYP27A1 gene - a sterol hydrolase involved in the oxidation of side chain sterol intermediates. It affects many tissues, predominantly the brain and lungs.
http://purl.obolibrary.org/obo/PW_0001476	congenital disease pathway	http://purl.obolibrary.org/obo/PW_0000013	disease pathway		Those diseases present at birth and also before birth, or those that develop during the first month of life. Alteration(s) in one or several pathways can contribute to the development of the condition usually manifested in structural deformities.
http://purl.obolibrary.org/obo/PW_0001477	inborn genetic disease pathway	http://purl.obolibrary.org/obo/PW_0001476	congenital disease pathway		Those diseases that are caused by genetic mutations present during fetal development and that may be inherited from a parent or acquired in utero. The mutations can disrupt one or several pathways that give rise to a broad spectrum of conditions affecting many types of organs and/or tissues.
http://purl.obolibrary.org/obo/PW_0001478	congenital adrenal hyperplasia pathway	http://purl.obolibrary.org/obo/PW_0001477	inborn genetic disease pathway		Congenital adrenal hyperplasia pathway represents a group of inherited disorders of the adrenal glands that results from defects in several enzymes involved in steroid hormone metabolic pathways.
http://purl.obolibrary.org/obo/PW_0001479	lipoid congenital adrenal hyperplasia pathway	http://purl.obolibrary.org/obo/PW_0001478	congenital adrenal hyperplasia pathway		Lipoid congenital adrenal hyperplasia, the most severe disorder of steroid hormone biosynthesis, is caused by a defect in the conversion of cholesterol to pregnenolone, the first step in adrenal and gonadal steroidogenesis. All affected individuals are phenotypic females with a severe salt-losing syndrome that is fatal if not treated in early infancy.
http://purl.obolibrary.org/obo/PW_0001481	peripheral dopamine signaling pathway	http://purl.obolibrary.org/obo/PW_0000798	catecholamine signaling pathway		The peripheral dopaminergic system is distinct from the neuronal one. In the kidney, dopamine signaling plays an important role in the regulation of blood pressure and accounts for ~50% of total water and sodium excretion. Both type1-like and 2-like receptors are expressed in the mammalian kidney. They couple to distinct G protein alpha subunits to elicit renal dopamine responses. Type 1-like may be responsible for many of dopamine effects.
http://purl.obolibrary.org/obo/PW_0001482	altered peripheral dopamine signaling pathway	http://purl.obolibrary.org/obo/PW_0001483	altered catecholamine signaling pathway		A peripheral dopamine signaling pathway that deviates from what its normal course should be. Altered peripheral dopamine signaling has been associated with elevated blood pressure in rodent models and with essential hypertension in certain populations.
http://purl.obolibrary.org/obo/PW_0001483	altered catecholamine signaling pathway	http://purl.obolibrary.org/obo/PW_0001484	altered amine and amino acid-derived hormone signaling pathway		A catecholamine signaling pathway that deviates from what its normal course should be.
http://purl.obolibrary.org/obo/PW_0001484	altered amine and amino acid-derived hormone signaling pathway	http://purl.obolibrary.org/obo/PW_0000509	altered hormone signaling pathway		An amino and amino acid-derived hormone signaling pathway that deviates from what its normal course should be.
http://purl.obolibrary.org/obo/PW_0001485	losartan-gene, gene-chemical, gene-gene interaction pathway	http://purl.obolibrary.org/obo/PW_0001462	losartan drug pathway		The expanded network of losartan-interacting genes.
http://purl.obolibrary.org/obo/PW_0001486	carbon tetrachloride response pathway	http://purl.obolibrary.org/obo/PW_0001434	toxin and toxicant response pathway		A pathway triggered by exposure to carbon tetrachloride, an organic compound used in several application. It is one oft he most potent hepatotoxins and has been banned in consumer products. In vivo studies using animal models show that exposure to carbon tetrachloride triggers the activity of several enzymes and the production of antioxidant molecules in a dose-dependent manner.
http://purl.obolibrary.org/obo/PW_0001487	ozone response pathway	http://purl.obolibrary.org/obo/PW_0001434	toxin and toxicant response pathway		A pathway triggered by exposure to ozone, a powerful oxidant with numerous industrial and consumer applications. However, it can induce tissue damage in animal and plants. Exposure to ozone induces the generation of free radicals, depletion of antioxidants and secretion of proinflammatory factors.
http://purl.obolibrary.org/obo/PW_0001488	metformin drug pathway	http://purl.obolibrary.org/obo/PW_0000723	anti-diabetic drug pathway		The pharmacokinetics and pharmacodynamics pathway of metformin, an antihyperglycemic drug used in the treatment of type 2 diabetes mellitus. Metformin has also been shown to have a  tumor suppressor function. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001489	metformin pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001488	metformin drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of metformin, an anti-diabetic drug used in the treatment of type 2 diabetes mellitus. Metformin is widely distributed in various tissues. Meformin is excreted unchanged and several transporters are involved in its tissue uptake and elimination. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001490	metformin pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001488	metformin drug pathway		The pathway of metformin-target interaction and of the biochemical or physiological responses to drug. Metformin lowers blood glucose levels by promoting the activation of AMPK signaling via molecular mechanisms that are not well understood. Mitochondria is the primary target of metformin which specifically inhibits complex I of the respiratory chain. The resulting change in AMP:ATP ratio can contribute to AMPK activation. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001491	metformin-gene, gene-chemical, gene-gene interaction pathway	http://purl.obolibrary.org/obo/PW_0001488	metformin drug pathway		The expanded network of metformin-interacting genes.
http://purl.obolibrary.org/obo/PW_0001495	altered visual phototransduction pathway	http://purl.obolibrary.org/obo/PW_0001494	altered vitamin A and metabolites signaling pathway		Alterations in the visual phototransduction signaling have been linked to a number conditions such as retinits pigmentosa (RP), Bardet-Biedl syndrome (BBS), macular degeneration and others. More than 200 point mutations in rhodopsin account for ~25% of the autosomal dominant type of RP.
http://purl.obolibrary.org/obo/PW_0001497	retinitis pigmentosa pathway	http://purl.obolibrary.org/obo/PW_0001496	sensory system disease pathway		Retinitis pigmentosa (RP) is a common form of photoreceptor degeneration with a varied pattern of inheritance that includes autosomal dominant and recessive and X-linked forms. Mutations in components of the visual phototransduction and visual cycle (retinoid) metabolic pathways have been associated with RP manifestations. Other genes and potential miRNAs also play a role. A fraction of RP patients also have Usher syndrome which in addition to vision loss, also involves hearing loss.
http://purl.obolibrary.org/obo/PW_0001498	altered retinoid cycle metabolic pathway	http://purl.obolibrary.org/obo/PW_0001499	altered retinoid metabolic pathway		Alteration in the retinoid cycle, or the visual cycle, have been associated with retinitis pigmentosa and a few other forms of photoreceptor degeneration.
http://purl.obolibrary.org/obo/PW_0001499	altered retinoid metabolic pathway	http://purl.obolibrary.org/obo/PW_0001501	altered vitamin A homeostasis		A retinoid metabolic pathway that deviates from what its normal course should be.
http://purl.obolibrary.org/obo/PW_0001502	mechanotransduction pathway	http://purl.obolibrary.org/obo/PW_0000003	signaling pathway		The mechanostransduction pathway involves the conversion of a mechanical stimulus into an electrical signal whose processing underlies proprioception, hearing, balance and touch. Auditory and cytoskeleton mechanotransduction are examples.
http://purl.obolibrary.org/obo/PW_0001503	auditory mechanotransduction pathway	http://purl.obolibrary.org/obo/PW_0001536	sensory system signaling pathway		The auditory mechanotransduction pathway converts mechanical stimuli into electrical signaling that are processed by the brain and account for the perception of sound, gravity and movement. The inner ear contains the cochlea and the vestibule responsible for sound and movement mechanotransduction, respectively. The auditory mechanotransduction primarily depicts the sound generated responses by the hair cells in the organ of Corti.
http://purl.obolibrary.org/obo/PW_0001504	altered auditory mechanotransduction pathway	http://purl.obolibrary.org/obo/PW_0001505	altered mechanotransduction pathway		Alterations in the auditory mechanotransduction pathway is associated with hearing impairment and deafness.
http://purl.obolibrary.org/obo/PW_0001506	Usher syndrome pathway	http://purl.obolibrary.org/obo/PW_0001496	sensory system disease pathway		The Usher syndrome is characterized by both vision and hearing loss. One sixth of patients with retinitis pigmentosa also have Usher syndrome. Clinically, there are three types of Usher syndromes that vary in terms of severity and onset. The genes involved are located in inner ear hair cells and the connecting cilium of photoreceptor cells. Their associations with auditory mechanotransduction are better known but their roles in visual phototransduction and altered pathways are still to be delineated.
http://purl.obolibrary.org/obo/PW_0001507	platinum (Pt) containing drug pathway	http://purl.obolibrary.org/obo/PW_0002367	antineoplastic drug pathway		The pharmacokinetics/pharmacodynamics of platinum (Pt) containing drugs, widely used in the treatment of cancer. These drugs introduce intra- and inter-strand DNA breaks. The DNA lesion and responses it triggers is toxic to tumor cells. However, it can also exert toxic side effects. Three Pt-containing drugs are being used and they vary in their efficacy and toxicity. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001508	cisplatin drug pathway	http://purl.obolibrary.org/obo/PW_0001507	platinum (Pt) containing drug pathway		The pharmacokinetics/pharmacodynamics of cisplatin, a platinum (Pt) containing drug widely used in the treatment of solid tumors. Cisplatin is the most potent of such drugs, it si also the one with the strongest toxic side effects. Nephorotoxicity and ototoxicity are among the primary toxic side effects. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001509	platinum (Pt) containing drug response pathway	http://purl.obolibrary.org/obo/PW_0001434	toxin and toxicant response pathway		A pathway triggered by exposure to platinum (Pt) containing drugs used in the treatment of solid tumors. The DNA lesion they introduce is toxic to the tumor cells. However, they also exert powerful toxic side effects. Cisplatin, the most potent drug is also the most toxic followed by the less potent carboplatin.
http://purl.obolibrary.org/obo/PW_0001510	cisplatin response pathway	http://purl.obolibrary.org/obo/PW_0001509	platinum (Pt) containing drug response pathway		A pathway triggered by exposure to cisplatin, a widely used and very potent anti-cancer platinum containing drug. It is also the one with the most toxic side effects. Nephorotoxicity and ototoxicity are among the primary toxic side effects.
http://purl.obolibrary.org/obo/PW_0001511	bisphenol A response pathway	http://purl.obolibrary.org/obo/PW_0001434	toxin and toxicant response pathway		A pathway triggered by exposure to bisphenol A - a synthetic compound used in the production of plastics and certain resins. It mimics estrogen and has negative health effects with the early developmental stages being the more sensitive to its effects. It may be implicated in the etiology of several chronic diseases.
http://purl.obolibrary.org/obo/PW_0001512	oxaliplatin drug pathway	http://purl.obolibrary.org/obo/PW_0001507	platinum (Pt) containing drug pathway		The pharmacokinetics/pharmacodynamics of oxaliplatin, a platinum (Pt) containing drug widely used in the treatment of solid tumors. While less potent than cisplatin - the most potent of the platinum containing drugs, oxaliplatin is also less toxic. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001513	carboplatin drug pathway	http://purl.obolibrary.org/obo/PW_0001507	platinum (Pt) containing drug pathway		The pharmacokinetics/pharmacodynamics of carboplatin, a platinum (Pt) containing drug used in the treatment of solid tumors. It is not as effective as cisplatin and while exerting less severe side affects, it can lead to myelosuppression and thrombocytopenia. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001514	carboplatin response pathway	http://purl.obolibrary.org/obo/PW_0001509	platinum (Pt) containing drug response pathway		A pathway triggered by exposure to carboplatin, a platinum containing drug used in the treatment of solid tumor. It is less potent than cisplatin but it can have serious toxic side effects such as myelosuppression and thrombocytopenia.
http://purl.obolibrary.org/obo/PW_0001515	Hippo signaling pathway	http://purl.obolibrary.org/obo/PW_0001194	serine/threonine-specific kinase mediated signaling pathway		The Hippo signaling pathway plays important roles in organ development and growth and tumor suppression. The pathway consists of a core of four kinases which once activated by upstream regulators promote the cytoplasmic sequestration of YAP/TAZ transcriptional regulators. Dysregulation of the pathway has been implicated in tumor metastasis.
http://purl.obolibrary.org/obo/PW_0001516	organophosphate response pathway	http://purl.obolibrary.org/obo/PW_0001434	toxin and toxicant response pathway		Organophosphates (OPs) represent one of the main classes of pesticides. However, they exert serious adverse effects, primarily affecting the cholinergic nervous system. OPs inhibit acetylcholinesterase, the enzyme that hydrolyzes acetylcholine, a major neurotransmitter in the nervous system and periphery.
http://purl.obolibrary.org/obo/PW_0001517	altered Hippo signaling pathway	http://purl.obolibrary.org/obo/PW_0001515	Hippo signaling pathway		A Hippo signaling pathway that deviates from what its normal course should be. Deregulated Hippo signaling has been implicated in tumor metastasis.
http://purl.obolibrary.org/obo/PW_0001520	polyol pathway	http://purl.obolibrary.org/obo/PW_0001519	glucose reduction pathway		The polyol pathway is triggered by excess glucose which is reduced to sorbitol in the first step which requires NADPH as a cofactor. Sorbitol is eventually converted to fructose. Sorbitol, which is membrane impermeable and metabolites of fructose which can lead to the production of AGEs (advance glycation endproduct), along with other pathways affected by a hyperglycemic state are thought to be associated with the pathophysiology of diabetic retinopathy. The intermediate sorbitol in the pathway is a sugar alcohol; sugar alcohols are a class of polyols - alcohol molecules with multiple hydroxyl groups.
http://purl.obolibrary.org/obo/PW_0001521	sugar alcohol metabolic pathway	http://purl.obolibrary.org/obo/PW_0000005	carbohydrate metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of sugar alcohols. Sugar alcohols represent a class of polyols - alcohol molecules with multiple hydroxyl groups. They are used in place of table sugar and in combination with artificial sweeteners and while they can occur naturally, many are commercially produced.
http://purl.obolibrary.org/obo/PW_0001522	dermatan sulfate biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0002698	dermatan sulfate metabolic pathway		Those metabolic reactions involved in the biosynthesis of dermatan sulfate - a mucopolysaccharide found primarily in skin but also in tendons, lungs, heart valves and blood vessels.
http://purl.obolibrary.org/obo/PW_0001523	nicotine response pathway	http://purl.obolibrary.org/obo/PW_0001434	toxin and toxicant response pathway		A pathway triggered by exposure to nicotine, the alkaloid found in tobacco and other plants. Nicotine can act as a stimulant and is an agonist of the ionotropic acetylcholine receptors, also known as nicotinic. Sustained exposure however has an inhibitory effect resulting in muscular paralysis, seizures, hypotension and respiratory failure. Some of the symptoms are reminiscent of organophosphate poisoning; organophosphates inhibit the enzyme acetylcholinesterase leading to uncensored stimulation of both the  nicotinic and the metabotropic muscarinic acetylcholine receptors.
http://purl.obolibrary.org/obo/PW_0001524	paracetamol drug pathway	http://purl.obolibrary.org/obo/PW_0001546	analgesic and/or antipyretic drug pathway		The pharmacokinetics/pharmacodynamics of paracetamol, a widely used analgesic, known as acetaminophen (APAP). The analgesic effect is believed to be due to the inhibition of prostaglandins biosynthesis. Paracetamol overdose is associated with hepatic toxicity and a leading cause of liver failure. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001525	paracetamol pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001524	paracetamol drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of paracetamol, a widely used analgesic known as acetaminophen. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001526	paracetamol response pathway	http://purl.obolibrary.org/obo/PW_0001434	toxin and toxicant response pathway		A pathway triggered by exposure to paracetamol, a widely used analgesic also known as acetaminophen. Paracetamol overdose is associated with hepatic toxicity and a leading cause of liver failure.
http://purl.obolibrary.org/obo/PW_0001527	thromboxane A2 signaling pathway	http://purl.obolibrary.org/obo/PW_0001296	prostanoid signaling pathway		Thromboxane is one of several families of prostanoids, eicosanoids derived from omega-3 or omega-6 fatty acids. Of the two thromboxane molecules, only A2 has activity. Thromboxane A2 signaling exerts vasoconstrictor and platelet aggregation roles. Its actions oppose those of prostaglandin I2, the other important prostanoid for cardiovascular system homeostasis.
http://purl.obolibrary.org/obo/PW_0001529	prostaglandin E2 signaling pathway	http://purl.obolibrary.org/obo/PW_0001297	prostaglandin signaling pathway		Prostagladin E2 is the most abundant product of prostaglandin biosynthesis via the cyclooxygenase mediated metabolism of arachidonic acid. It exerts a plethora of functions by activating four receptors of the G-protein coupled (GPCRs) family.
http://purl.obolibrary.org/obo/PW_0001530	prostaglandin D2 signaling pathway	http://purl.obolibrary.org/obo/PW_0001297	prostaglandin signaling pathway		Prostaglandin D2 signaling exerts important functions in the central nervous system (CNS) that among others, include the regulation of sleep and the perception of pain. The two D2 receptors are G-protein coupled receptors (GPCR).
http://purl.obolibrary.org/obo/PW_0001531	prostaglandin I2 signaling pathway	http://purl.obolibrary.org/obo/PW_0001297	prostaglandin signaling pathway		Prostaglandin I2 signaling exerts potent vasodilator and anti-thrombic effects. Its actions oppose those of thromboxane A2, the other prostanoid important for the cardiovascular system homeostasis.
http://purl.obolibrary.org/obo/PW_0001532	prostaglandin biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001243	prostanoid biosynthetic pathway		Those metabolic reactions involved in the synthesis of prostaglandins - a class of eicosanoid prostanoids with several members, exerting a range of important functions in the immune and cardiovascular systems.
http://purl.obolibrary.org/obo/PW_0001533	thromboxane biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001243	prostanoid biosynthetic pathway		Those metabolic reactions involved in the synthesis of thromboxane - eicosanoid prostanoids essential for the homeostasis of the cardiovascular system.
http://purl.obolibrary.org/obo/PW_0001534	prostacyclin biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001243	prostanoid biosynthetic pathway		Those metabolic reactions involved in the biosynthesis of prostacyclin, also known as prostaglandin I2. Prostacyclin and thromboxane play essential roles in cardiovascular system homeostasis.
http://purl.obolibrary.org/obo/PW_0001535	prostaglandin F2alpha signaling pathway	http://purl.obolibrary.org/obo/PW_0001297	prostaglandin signaling pathway		Prostaglandin F2alpha signaling engages one receptor and plays important roles in mammalian reproduction.
http://purl.obolibrary.org/obo/PW_0001539	heterotrimeric G protein mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000125	G protein mediated signaling pathway		The heterotrimer G proteins are transducers of G proteins coupled receptors (GPCRs). Many types of signals are received by the members of the large GPCR superfamily which then activate distinct G-proteins that route the signal to many and distinct intracellular signaling pathways.
http://purl.obolibrary.org/obo/PW_0001542	organismal aging pathway	http://purl.obolibrary.org/obo/PW_0000651	aging pathway		Organismal aging represents the sum of impaired functions and pathways. It is associated with changes in homeostatic responses and circadian rhythm, mitochondrial  stress and dysfunction.
http://purl.obolibrary.org/obo/PW_0001545	altered stress response pathway	http://purl.obolibrary.org/obo/PW_0000263	altered regulatory pathway		Alterations in the pathways and processes elicited in  response to various cues/insults the organism perceives as threatening.
http://purl.obolibrary.org/obo/PW_0001546	analgesic and/or antipyretic drug pathway	http://purl.obolibrary.org/obo/PW_0000923	nervous system drug pathway		The pharmacokinetics and pharmacodynamics of compounds used to alleviate pain and/or reduce fever. Examples include the nonsteroidal anti-inflammatory drugs such as aspirin or ibuprofen and the widely used paracetamol, known as acetaminophen, among others.
http://purl.obolibrary.org/obo/PW_0001550	nervous system and nerve tissue cancer pathway	http://purl.obolibrary.org/obo/PW_0000605	cancer pathway		A general term grouping neoplastic pathways of the brain, spinal cord or central nervous system and of nerve tissue such as neuroepithelial or neurectodermal.
http://purl.obolibrary.org/obo/PW_0001553	altered G1/S transition pathway	http://purl.obolibrary.org/obo/PW_0001552	altered cell cycle pathway, mitotic		The G1/S transition pathway defines the point when the decision to complete the cell cycle is made. Deregulation of G1/S transition is observed in many human cancers and involves important players/regulators of the pathway.
http://purl.obolibrary.org/obo/PW_0001554	altered SWI/SNF family mediated chromatin remodeling pathway	http://purl.obolibrary.org/obo/PW_0001406	SWI/SNF family mediated chromatin remodeling pathway		Alterations in the SWI/SNF family mediated pathway of chromatin remodeling are implicated in a number of human cancers that include ovarian, pancreatic and renal, among others. Many mutations are found in Smarca4, one of the two mutually exclusive, ATP-dependent, enzymatic subunits or Arid1a subunit.
http://purl.obolibrary.org/obo/PW_0001555	altered homologous recombination pathway of double-strand break repair	http://purl.obolibrary.org/obo/PW_0000667	altered double-strand DNA repair pathway		Defective repair pathway(s) of double-strand breaks can lead to chromosomal rearrangements, genomic instability and oncogenic activation. Mutations in several components of the homologous recombination (HR) pathway have been implicated in several conditions in both an autosomal dominant and recessive fashion.
http://purl.obolibrary.org/obo/PW_0001556	altered non-homologous end joining pathway of double-strand break repair	http://purl.obolibrary.org/obo/PW_0000667	altered double-strand DNA repair pathway		Defective repair pathway(s) of double-strand breaks can lead to chromosomal rearrangements, genomic instability and oncogenic activation. Mutations in several components of the non-homologous end joining (NHEJ) pathway have been implicated in several conditions.
http://purl.obolibrary.org/obo/PW_0001557	programmed cell death pathway	http://purl.obolibrary.org/obo/PW_0000275	cell death pathway		Programmed cell death pathways group together several types that can be described as apoptotic or non-apoptotic, based on morphological characteristics. The common feature is their highly regulated nature, as opposed to accidental, non-programmed cell death.
http://purl.obolibrary.org/obo/PW_0001558	non-programmed cell death pathway	http://purl.obolibrary.org/obo/PW_0000275	cell death pathway		Cell death pathways that are not the result of a regulated process and may be the result of injury or trauma, such as necrosis.
http://purl.obolibrary.org/obo/PW_0001559	altered programmed cell death pathway	http://purl.obolibrary.org/obo/PW_0001557	programmed cell death pathway		A programmed cell death pathway that deviates from what its normal course should be.
http://purl.obolibrary.org/obo/PW_0001560	pyroptosis pathway	http://purl.obolibrary.org/obo/PW_0000276	non-apoptotic cell death pathway		The pyroptosis pathway is a form of programmed cell death triggered by microbial infection and release of cytokines. It can also occur independently of microbial virulence. Pyroptosis can have either apoptotic or necrotic morphological features.
http://purl.obolibrary.org/obo/PW_0001561	necroptosis pathway	http://purl.obolibrary.org/obo/PW_0000276	non-apoptotic cell death pathway		Necroptosis is a programmed or regulated form of necrosis generally triggered by DNA damage, leading to cell swelling and lysis.
http://purl.obolibrary.org/obo/PW_0001562	altered autophagy pathway	http://purl.obolibrary.org/obo/PW_0002403	altered cellular autophagy		An autophagy pathway that deviates from what its normal course should be. Altered autophagy has been implicated in a variety of conditions, including neurodegenerative diseases, cancer and atherosclerosis, among others.
http://purl.obolibrary.org/obo/PW_0001564	anoikis pathway	http://purl.obolibrary.org/obo/PW_0000009	apoptotic cell death pathway		Anoikis is a form of apoptotic programmed cell death triggered by the absence of cell-matrix interactions.
http://purl.obolibrary.org/obo/PW_0001565	doxorubicin pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001455	doxorubicin drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of doxorubicin. Doxorubicin is used as a chemotherapeutic agent for the treatment of various cancers. Its use is limited by the serious cardiotoxic side effects it exerts. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001566	doxorubicin pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001455	doxorubicin drug pathway		The pathway of doxorubicin-target interaction and of the biochemical or physiological responses to drug. Doxorubicin is used as a chemotherapeutic agent for the treatment of many cancers. Its use is restricted by the serious cardiotoxic effects it exerts. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001567	RNA processing pathway	http://purl.obolibrary.org/obo/PW_0000085	pathway pertinent to DNA replication and repair, cell cycle, maintenance of genomic integrity, RNA and protein biosynthesis		The various pathways whereby initial RNA transcripts are processed into their mature, functional forms and those involved in removing excess or erroneous RNA.
http://purl.obolibrary.org/obo/PW_0001568	RNA maturation pathway	http://purl.obolibrary.org/obo/PW_0001567	RNA processing pathway		Those reactions involved in producing the mature forms of RNAs: mRNA, tRNA and rRNA.
http://purl.obolibrary.org/obo/PW_0001569	mRNA maturation pathway	http://purl.obolibrary.org/obo/PW_0001568	RNA maturation pathway		mRNA maturation involves 5'-capping and 3' processing of pre-mRNA, splicing and alternative splicing to produce the mature mRNA molecule(s).
http://purl.obolibrary.org/obo/PW_0001573	tRNA maturation pathway	http://purl.obolibrary.org/obo/PW_0001568	RNA maturation pathway		Processing of the initial tRNA transcript, including splicing of intron-containing pre-tRNAs and multiple modifications to produce the mature tRNA molecule that is exported to the cytoplasm.
http://purl.obolibrary.org/obo/PW_0001574	rRNA maturation pathway	http://purl.obolibrary.org/obo/PW_0001568	RNA maturation pathway		The reactions involved in processing the primary Pol I-transcribed rRNA and the 5S pre-rRNA transcribed by Pol III. The large Pol I transcribed pre-rRNA contains the mature 18S, 5.8S and 25S/28S rRNAs separated by internal (ITS) and flanked by external transcribed spacers (ETS). The nascent pre-rRNA associates co-transcriptionally with various factors, folds and is modified, while endo- and exo-nucleolytic cleavages sequentially remove the spacers. Cleavage at site ITS1 separates the initial 90S pre-ribosome into pre-40S and pre-60S particles whose nucleocytoplasmic processing will follow independent routes.
http://purl.obolibrary.org/obo/PW_0001578	5'-end pre-mRNA capping pathway	http://purl.obolibrary.org/obo/PW_0001569	mRNA maturation pathway		5'-end capping occurs earlier in transcription and, along with phosphorylation of pol II, promotes productive elongation.
http://purl.obolibrary.org/obo/PW_0001579	3'-end pre-mRNA processing pathway	http://purl.obolibrary.org/obo/PW_0001569	mRNA maturation pathway		The 3'-end processing of pre-mRNA is intimately coupled to pol II transcription termination, splicing, mRNA transport and translation.
http://purl.obolibrary.org/obo/PW_0001580	lncRNA maturation pathway	http://purl.obolibrary.org/obo/PW_0001568	RNA maturation pathway		Long non-coding RNA transcripts are subject to processing in a manner analogous to mRNA thereby they are capped and polyadenylated, and also frequently spliced.
http://purl.obolibrary.org/obo/PW_0001581	lncRNA capping pathway	http://purl.obolibrary.org/obo/PW_0001580	lncRNA maturation pathway		Long non-coding RNA transcripts are subject to processing in a manner analogous to mRNA thereby they are capped and polyadenylated, and also frequently spliced.
http://purl.obolibrary.org/obo/PW_0001582	lncRNA polyadenylation pathway	http://purl.obolibrary.org/obo/PW_0001580	lncRNA maturation pathway		Long non-coding RNA transcripts are subject to processing in a manner analogous to mRNA thereby they are capped and polyadenylated, and also frequently spliced.
http://purl.obolibrary.org/obo/PW_0001583	nutritional and metabolic disease pathway	http://purl.obolibrary.org/obo/PW_0000013	disease pathway		Those disorders and diseases resulting from nutritional imbalances and by alterations in various aspects of metabolism.
http://purl.obolibrary.org/obo/PW_0001584	avitaminosis pathway	http://purl.obolibrary.org/obo/PW_0001601	nutritional disorder pathway		Those conditions caused by inadequate levels of one or more essential vitamins due to defects in their metabolism.
http://purl.obolibrary.org/obo/PW_0001586	Wolman disease pathway	http://purl.obolibrary.org/obo/PW_0002347	cholesterol ester storage disease pathway		A severe form of lipid storage disease in infants caused by deficiency of acid lipase.
http://purl.obolibrary.org/obo/PW_0001587	mRNA nuclear export pathway	http://purl.obolibrary.org/obo/PW_0001160	RNA transport pathway		The pathway thereby processed, mature mRNA is exported to the cytoplasm. Two distinct export pathways are mediated by specific transport receptors. The NXF1-NXT1 heterodimer exports the bulk of mRNA whereas a subset of mRNA is exported by the CRM1 system.
http://purl.obolibrary.org/obo/PW_0001588	tRNA nuclear export pathway	http://purl.obolibrary.org/obo/PW_0001160	RNA transport pathway		The pathway thereby processed, mature tRNA is exported to the cytoplasm. It is dependent upon export receptors and Ran GTPases of the small G protein of the Ras superfamily.
http://purl.obolibrary.org/obo/PW_0001589	inborn error of metabolism pathway	http://purl.obolibrary.org/obo/PW_0001477	inborn genetic disease pathway		Those diseases resulting from alterations in metabolic pathways that are caused by genetic mutations present during fetal development and that may be inherited from a parent or acquired in utero. The mutations can disrupt one or several pathways, giving rise to a broad spectrum of conditions affecting many types of organs and/or tissues.
http://purl.obolibrary.org/obo/PW_0001590	xanthinuria pathway	http://purl.obolibrary.org/obo/PW_0001776	inborn error of purine-pyrimidine metabolism pathway		Xanthinuria is a rare genetic disorder due to alterations in the purine metabolic pathway causing accumulation of xanthine and resulting in a range of symptoms. There are two types of disorders with similar clinical manifestations.
http://purl.obolibrary.org/obo/PW_0001591	xanthinuria  type I pathway	http://purl.obolibrary.org/obo/PW_0001590	xanthinuria pathway		Xanthinuria is a rare genetic disorder due to alterations in the purine metabolic pathway causing accumulation of xanthine and resulting in a range of symptoms. Of the two types of clinically related disorders, type I is caused by genetic defects in the xanthine dehydrogenase enzyme.
http://purl.obolibrary.org/obo/PW_0001592	xanthinuria type II pathway	http://purl.obolibrary.org/obo/PW_0001590	xanthinuria pathway		Xanthinuria is a rare genetic disorder due to alterations in the purine metabolic pathway causing accumulation of xanthine and resulting in a range of symptoms.  Of the two types of clinically related disorders, type II is caused by genetic defects in the xanthine dehydrogenase and aldehyde dehydrogenase enzymes.
http://purl.obolibrary.org/obo/PW_0001593	musculoskeletal disease pathway	http://purl.obolibrary.org/obo/PW_0000013	disease pathway		Those conditions affecting the muscular and skeletal systems and elements associated with them, arising from deregulation in a number of pathways.
http://purl.obolibrary.org/obo/PW_0001594	very long-chain acyl-CoA dehydrogenase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001643	inborn error of lipid metabolism pathway		VLCAD deficiency is due to alterations in fatty acid beta oxidation pathway. It is an inherited metabolic disease due to mutations in the ACADVL gene. It appears in infancy or early childhood and is manifested  as lack of energy and muscle weakness.
http://purl.obolibrary.org/obo/PW_0001595	abacavir drug pathway	http://purl.obolibrary.org/obo/PW_0000996	anti-infective drug pathway		The pharmacokinetics and pharmacodynamics pathway of abacavir, an anti-viral drug used for the treatment of HIV infection. It belongs to the family of nucleoside analog reverse transcriptase inhibitors. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001596	abacavir pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001595	abacavir drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of abacavir, a drug used for the treatment of HIV. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001597	abacavir pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001595	abacavir drug pathway		The pathway of abacavir-target interaction and of the biochemical or physiological responses to them. Abacavir is a drug used for the treatment of HIV infection. Abacavir inhibits HIV-1 reverse transcriptase activity by competing with the natural substrate dGTP and by its incorporation into viral DNA whose growth is then terminated. Genetic variations can cause differences in the response of the organism to the drug. A small percentage of individuals receiving the drug develop immune-mediated hypersensitivity reactions (HSR), those carrying a variant in the human leukocyte antigen B (HLA-B) gene.
http://purl.obolibrary.org/obo/PW_0001598	acenocoumarol drug pathway	http://purl.obolibrary.org/obo/PW_0002325	vitamin K antagonist drug pathway		The pharmacokinetics and pharmacodynamics pathway of acenocoumarol. Acenocoumarol  is used as anticoagulant that antagonizes the vitamin K dependent clotting pathway. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001599	acenocoumarol pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001598	acenocoumarol drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of acenocoumarol. Acenocoumarol is used as anticoagulant that antagonizes the vitamin K dependent clotting pathway. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001600	acenocoumarol pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001598	acenocoumarol drug pathway		The pathway of acenocoumarol-target interaction and of the biochemical or physiological responses to drug. Acenocoumarol is used as anticoagulant that antagonizes the vitamin K dependent clotting pathway. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001601	nutritional disorder pathway	http://purl.obolibrary.org/obo/PW_0001583	nutritional and metabolic disease pathway		Those disorders caused by nutritional imbalance.
http://purl.obolibrary.org/obo/PW_0001602	glucose metabolism disease pathway	http://purl.obolibrary.org/obo/PW_0001472	metabolic disease pathway		Those diseases and disorders that are caused by deregulation of glucose metabolic pathways. The condition(s) can be inherited or acquired.
http://purl.obolibrary.org/obo/PW_0001603	beta-ureidopropionase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001611	movement disorder pathway		A rare, autosomal recessive inborn metabolic disease caused by alterations in pyrimidine metabolic pathway.
http://purl.obolibrary.org/obo/PW_0001604	orotic aciduria pathway	http://purl.obolibrary.org/obo/PW_0001776	inborn error of purine-pyrimidine metabolism pathway		Alterations in the pyrimidine biosynthetic pathway resulting in excessive excretion of orotic acid. The inborn metabolic condition is primarily due to deficiency in the bifunctional uridine monophosphate (UMP) synthetase enzyme.  Orotic aciduria is also due to ornithine transcarbamylase (OTC) deficiency and its hyperammonemia.
http://purl.obolibrary.org/obo/PW_0001605	orotic aciduria 1 pathway	http://purl.obolibrary.org/obo/PW_0001604	orotic aciduria pathway		The most common form of the orotic acid inborn error metabolic disease pathway is due to deficiency in the uridine monophosphate (UMP) synthase enzyme.
http://purl.obolibrary.org/obo/PW_0001606	orotic aciduria 2 pathway	http://purl.obolibrary.org/obo/PW_0001604	orotic aciduria pathway		A secondary form of the orotic acid inborn error metabolic disease pathway due to deficiency in orotidine-5-monophosphate decarboxylase (C-terminal activity of uridine monophosphate synthetase).
http://purl.obolibrary.org/obo/PW_0001607	tyrosinemia pathway	http://purl.obolibrary.org/obo/PW_0001646	inborn error of brain metabolic pathway		A group of disorders due to inborn errors of the tyrosine metabolic pathway. The three types of tyrosinemia are caused by deficiencies in distinct enzymes of the tyrosine degradation pathway and exhibit specific phenotypes.
http://purl.obolibrary.org/obo/PW_0001608	tyrosinemia type I pathway	http://purl.obolibrary.org/obo/PW_0001607	tyrosinemia pathway		Type I tyrosinemia results from defects in the fumarylacetoacetate hydrolase (FAH) enzyme that catalyzes the last step in the tyrosine degradation pathway.
http://purl.obolibrary.org/obo/PW_0001609	tyrosinemia type II pathway	http://purl.obolibrary.org/obo/PW_0001607	tyrosinemia pathway		Type II tyrosinemia results from defects in the tyrosine aminotransferase (TAT) enzyme that catalyzes the conversion of tyrosine to 4-hydroxyphenylpyruvate in the tyrosine degradation pathway.
http://purl.obolibrary.org/obo/PW_0001610	tyrosinemia type III pathway	http://purl.obolibrary.org/obo/PW_0001607	tyrosinemia pathway		Type III tyrosinemia results from defects in the 4-hydroxyohenylpyruvate dioxygenase (HPD) enzyme that catalyzes the second step in the tyrosine degradation pathway.
http://purl.obolibrary.org/obo/PW_0001611	movement disorder pathway	http://purl.obolibrary.org/obo/PW_0001412	nervous system disease pathway		Abnormal and involuntary movement due degenerative, post-traumatic, inflammatory, hereditary or medication-induced conditions.
http://purl.obolibrary.org/obo/PW_0001612	Segawa syndrome pathway	http://purl.obolibrary.org/obo/PW_0001611	movement disorder pathway		A movement disorder caused by defects in the tyrosine hydroxylase enzyme that converts tyrosine to L-DOPA, the precursor of dopamine in the dopamine biosynthetic pathway of the other two catecholamines downstream of it, norepinephrine and epinephrine.
http://purl.obolibrary.org/obo/PW_0001613	acetylsalicylic acid drug pathway	http://purl.obolibrary.org/obo/PW_0002150	antiplatelet drug pathway		The pharmacokinetics and pharmacodynamics pathway of acetylasalicylic acid, known as aspirin. It is a non-steroidal anti-inflammatory drug (NSAID) used as analgesic, antipyretic and antitrombic agent. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001614	acetylsalicylic acid pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001613	acetylsalicylic acid drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of acetylsalicylic acid, known as aspirin. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001615	acetylsalicylic acid pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001613	acetylsalicylic acid drug pathway		The actual targets of acetylsalicylic acid known as aspirin were discovered after the drug was marketed. It was believed that it acts upon the central nervous system, but its true mode of action is to  irreversibly inhibit  cuclooxygenase enzyme COX-1 and to a lesser extent COX-2, thus suppressing the downstream production of prostaglandins and thromboxanes. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001616	adefovir drug pathway	http://purl.obolibrary.org/obo/PW_0000996	anti-infective drug pathway		The pharmacokinetics and pharmacodynamics pathway of adefovir, an anti-viral drug used for the treatment of hepatitis B. It is administered as adefovir dipivoxil prodrug. Once metabolized, it acts as a nucleotide analog reverse transcriptase inhibitor.
http://purl.obolibrary.org/obo/PW_0001617	adefovir pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001616	adefovir drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of adefovir. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001618	adefovir pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001616	adefovir drug pathway		Adefovir is an anti-viral drug used for the treatment of chronic hepatitis B.
http://purl.obolibrary.org/obo/PW_0001619	rRNA nuclear export pathway	http://purl.obolibrary.org/obo/PW_0001160	RNA transport pathway		The pathway whereby the pre- ribosomal particles, pre-40S and pre-60S containing three of the four rRNA genes, are exported to the cytoplasm. The two particles follow independent transport routes, embedded within ribosome biogenesis. The 5S rRNA transcribed by RNA polymerase III is independently transported to be delivered to the ribosome immediately or from a cytoplasmic pool.
http://purl.obolibrary.org/obo/PW_0001620	bisphosphonate drug pathway	http://purl.obolibrary.org/obo/PW_0001170	musculo-skeletal system drug pathway		The pharmacokinetics and pharmacodynamics pathway of bisphoshonate drugs that help prevent the loss of bone mass and are used in the treatment of osteoporosis. The two classes - non-nitrogenous and nitrogen-containing drugs, employ different mechanisms to affect osteoclast activity. Bisphosphonates are preferentially taken up by osteoclast cells. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001621	nitrogenous bisphosphonate drug pathway	http://purl.obolibrary.org/obo/PW_0001620	bisphosphonate drug pathway		The pharmacokinetics and pharmacodynamics pathway of nitrogenous bisphosphate drugs, inhibitors of farnesyl diphosphate synthase. The disruption of geranyl and farnesyl pyrophosphate production affects the cell membrane localization of proteins that depend on this lipid modification for proper placement. They include the members of the small G proteins and the impact on Ras, Rho and Rac G proteins is thought to underlie the effect of drugs.
http://purl.obolibrary.org/obo/PW_0001622	non-nitrogenous bisphosphonate drug pathway	http://purl.obolibrary.org/obo/PW_0001620	bisphosphonate drug pathway		Non-nitrogenous bisphosphonate drugs are metabolized to compounds that render the ATP molecule non-functional, thus promoting cell death.
http://purl.obolibrary.org/obo/PW_0001623	nitrogenous bisphosphanate pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001621	nitrogenous bisphosphonate drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of nitrogenous bisphosphonates such as alendronate, ibandronate, pamidronate or risedronate. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001624	nitrogenous bisphosphonate pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001621	nitrogenous bisphosphonate drug pathway		The pathway of nitrogenous bisphosphonate-target interaction and of the biochemical or physiological responses to them. They include alendronate, ibandronate, pamidronate or risedronate. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001625	NXF1-NXT1 export pathway	http://purl.obolibrary.org/obo/PW_0001587	mRNA nuclear export pathway		The NXF1-NXT export pathway is involved in the trafficking of bulk mRNA. It is dependent upon the TREX/THO complex for receptor recruitment to the cargo.
http://purl.obolibrary.org/obo/PW_0001626	CRM1 export pathway	http://purl.obolibrary.org/obo/PW_0001587	mRNA nuclear export pathway		CRM1 export pathway is involved in trafficking a subset of mRNA as well as other RNA particles. Depending on the adaptor proteins that recruit CRM1 to cargo, there are several routes of export.
http://purl.obolibrary.org/obo/PW_0001627	trifunctional protein deficiency pathway	http://purl.obolibrary.org/obo/PW_0001643	inborn error of lipid metabolism pathway		Trifunctional protein deficiency is caused by alteration in the fatty acid beta degradation pathway. Specifically, mutations in the alpha and beta subunits of the mitochondrial enzyme that catalyzes the last three steps, have been linked to this inherited metabolic condition.
http://purl.obolibrary.org/obo/PW_0001628	triosephosphate isomerase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001644	inborn error of carbohydrate metabolism pathway		The rare autosomal recessive condition is caused by mutations in the triosephosphate isomerase enzyme involved in glycolysis/gluconeogenesis metabolic pathways.
http://purl.obolibrary.org/obo/PW_0001629	transaldolase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001644	inborn error of carbohydrate metabolism pathway		Transaldolase deficiency results from alteration in the pentose phosphate metabolic pathway, an alternative route of glucose oxidation that produces reducing equivalents. The condition affects many systems.
http://purl.obolibrary.org/obo/PW_0001630	lysosomal storage disease pathway	http://purl.obolibrary.org/obo/PW_0001589	inborn error of metabolism pathway		Lysosomal storage disease represents a group of rare genetic conditions resulting from deficiencies in particular lysosomal enzymes.
http://purl.obolibrary.org/obo/PW_0001631	Tay-Sachs disease pathway	http://purl.obolibrary.org/obo/PW_0002300	nervous system lysosomal storage disease pathway		There are several forms of Tay-Sachs disease resulting from mutations in the lysosomal hexosaminidase A enzyme. The accumulation of gangliosides in nerve cells leads to loss of mental and physical abilities, neurodegeneration and eventually death.
http://purl.obolibrary.org/obo/PW_0001632	alfentanil drug pathway	http://purl.obolibrary.org/obo/PW_0002443	opioid drug pathway		The pharmacokinetics and pharmacodynamics pathway of alfentanil - a synthetic opioid used for anesthesia in surgery. The drug is short-acting but potent and classified as restricted. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001633	alfentanil pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001632	alfentanil drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of alfentanil. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001634	alfentanil pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001632	alfentanil drug pathway		The pathway of alfentanil-target interaction and of the biochemical or physiological responses to drug. The drug is an agonist for mu opioid receptors, is classified as a restrictive drug and is almost exclusively used for anesthesia in surgery. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001635	alteplase drug pathway	http://purl.obolibrary.org/obo/PW_0002152	thrombolytic drug pathway		The pharmacokinetics and pharmacodynamics pathway of alteplase - one of several recombinant tissue plasminogen activators. Plasminogen is a key player in the fibrinolytic cascade pathway of blood clots breakdown. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001636	alteplase pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001635	alteplase drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of alteplase, one of several recombinant tissue plasminogen activators. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001637	alteplase pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001635	alteplase drug pathway		The pathway of alteplase-target interaction and of the biochemical or physiological responses to drug. Alteplase is one of several recombinant tissue plasminogen activators. Alteplase is used for treatment of myocardial infarction and ischemic stroke, among others. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001638	amiloride drug pathway	http://purl.obolibrary.org/obo/PW_0002121	diuretic drug pathway		The pharmacokinetics and pharmacodynamics pathway of amiloride - a blocker of epithelial sodium channels used for the treatment of hypertension and congestive heart failure. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001639	amiloride pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001638	amiloride drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of amiloride. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001640	amiloride pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001638	amiloride drug pathway		The pathway of amiloride-target interaction and of the biochemical or physiological responses to drug. The drug blocks the epithelial sodium channels and is used in the treatment of hypertension and congestive heart failure. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001641	rRNA decay pathway	http://purl.obolibrary.org/obo/PW_0001161	RNA degradation pathway		The pathways of rRNA quality control whereby non-functional rRNAs, both at the level of transcript and of mature ribosome components, are subject to degradation. Bulk ribosomes can also be degraded via autophagy.
http://purl.obolibrary.org/obo/PW_0001642	tRNA decay pathway	http://purl.obolibrary.org/obo/PW_0001161	RNA degradation pathway		The pathways of tRNA quality control thereby erroneous tRNA is degraded or normal tRNA is cleaved under stress conditions.
http://purl.obolibrary.org/obo/PW_0001643	inborn error of lipid metabolism pathway	http://purl.obolibrary.org/obo/PW_0001589	inborn error of metabolism pathway		Those diseases that are caused by inborn errors of lipid metabolism. The mutations can disrupt one or several pathways.
http://purl.obolibrary.org/obo/PW_0001644	inborn error of carbohydrate metabolism pathway	http://purl.obolibrary.org/obo/PW_0001589	inborn error of metabolism pathway		Those diseases that are caused by inborn errors of carbohydrate metabolism. The mutations can disrupt one or several pathways.
http://purl.obolibrary.org/obo/PW_0001645	inborn error of amino acid metabolism pathway	http://purl.obolibrary.org/obo/PW_0001589	inborn error of metabolism pathway		Those diseases that are caused by inborn errors of amino acid metabolism. The mutations can disrupt one or several pathways.
http://purl.obolibrary.org/obo/PW_0001646	inborn error of brain metabolic pathway	http://purl.obolibrary.org/obo/PW_0001589	inborn error of metabolism pathway		Those brain diseases that are caused by inborn metabolic errors. The mutations can disrupt one or several pathways.
http://purl.obolibrary.org/obo/PW_0001647	sulfite oxidase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001645	inborn error of amino acid metabolism pathway		An autosomal recessive inherited condition resulting from alteration in sulfur metabolism. It exhibits severe neurological symptoms in the neonatal period and is possibly fatal.
http://purl.obolibrary.org/obo/PW_0001648	congenital sucrase-isomaltase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001644	inborn error of carbohydrate metabolism pathway		A congenital disorder of sucrose metabolism resulting from mutations in the enzyme involved in the hydrolysis of dietary sugars.
http://purl.obolibrary.org/obo/PW_0001649	succinic semialdehyde dehydrogenase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001645	inborn error of amino acid metabolism pathway		A rare autosomal recessive condition resulting from mutations in the enzyme involved in the metabolism of the neurotransmitter 4-aminobutyric acid (GABA).
http://purl.obolibrary.org/obo/PW_0001650	Smith-Lemli-Opitz Syndrome pathway	http://purl.obolibrary.org/obo/PW_0002102	inborn error of steroid metabolism pathway		An autosomal recessive disorder due to altered cholesterol metabolism.
http://purl.obolibrary.org/obo/PW_0001651	antithrombotic drug pathway	http://purl.obolibrary.org/obo/PW_0000922	blood and blood forming organs drug pathway		The pharmacokinetics and pharmacodynamics pathway of drugs that reduce or prevent the formation of blood clots.  They are further classified depending on the blood clotting processes they affect. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001652	antihemorrhagic drug pathway	http://purl.obolibrary.org/obo/PW_0000922	blood and blood forming organs drug pathway		The pharmacokinetics and pharmacodynamics pathway of drugs that reduce or prevent bleeding. It is to be noted here that genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001653	aminocaproic acid drug pathway	http://purl.obolibrary.org/obo/PW_0001652	antihemorrhagic drug pathway		The pharmacokinetics and pharmacodynamics pathway of aminocaproic acid, an inhibitor of enzymes involved in fibrinolysis and as such, effective in the treatment of certain bleeding disorders. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001654	aminocaproic acid pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001653	aminocaproic acid drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of aminocaproic acid. The drug is used in the treatment of certain bleeding disorders. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001655	aminocaproic acid pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001653	aminocaproic acid drug pathway		The pathway of aminocaproic acid-target interaction and of the biochemical or physiological responses to drug. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001656	amiodarone drug pathway	http://purl.obolibrary.org/obo/PW_0002336	antiarrhythmic drug pathway		The pharmacokinetics and pharmacodynamics pathway of amiodarone, a drug used in the treatment of arrhythmia. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001657	amiodarone pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001656	amiodarone drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of amiodarone. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001658	amiodarone pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001656	amiodarone drug pathway		The pathway of amiodarone-target interaction and of the biochemical or physiological responses to drug. Amiodarone has beta blocker-like and calcium channel blocker-like actions. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001659	amlodipine drug pathway	http://purl.obolibrary.org/obo/PW_0001894	dihydropyridine calcium channel blocker drug pathway		The pharmacokinetics and pharmacodynamics pathway of amlodipine, a calcium channel blocker used to lower blood pressure. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001660	amlodipine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001659	amlodipine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of amlodipine, a calcium channel blocker. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001661	amlodipine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001659	amlodipine drug pathway		The pathway of amlodipine-target interaction and of the biochemical or  physiological responses to drug. Amlodipine, a calcium channel blocker is used to lower blood pressure. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001662	anistreplase drug pathway	http://purl.obolibrary.org/obo/PW_0002152	thrombolytic drug pathway		The pharmacokinetics and pharmacodynamics pathway of anistreplase, an antithrombic drug that converts plasminogen to the active plasmin which degrades fibrin (blood clots). Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001663	anistreplase pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001662	anistreplase drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of anistreplase. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001664	anistreplase pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001662	anistreplase drug pathway		The pathway of anistreplase-target interaction and of the biochemical or physiological responses to drug. An anithrombic drug, anistreplase cleaves a bond in plasminogen to form plasmin. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001665	antipyrine drug pathway	http://purl.obolibrary.org/obo/PW_0001546	analgesic and/or antipyretic drug pathway		The pharmacokinetics/pharmacodynamics of anitpyrine, an analgesic and antipyretic drug used to relieve pain and fever.  It is thought to inhibit prostaglandin biosynthesis. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001666	antipyrine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001665	antipyrine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of antipyrine, a drug used to relieve pain and fever. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001667	short-chain acyl-CoA dehydrogenase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001643	inborn error of lipid metabolism pathway		An autosomal recessive metabolic disease due to alteration in the fatty acid beta oxidation pathway.
http://purl.obolibrary.org/obo/PW_0001669	mitochondrial disease pathway	http://purl.obolibrary.org/obo/PW_0001472	metabolic disease pathway		Those conditions resulting from impaired mitochondrial function and alterations in mitochondrial pathways and due to acquired or inherited mutations.
http://purl.obolibrary.org/obo/PW_0001670	sarcosinemia pathway	http://purl.obolibrary.org/obo/PW_0001669	mitochondrial disease pathway		A rare autosomal recessive metabolic disorder due to mutations in sarcosine dehydrogenase resulting in alterations of sarcosine metabolism.
http://purl.obolibrary.org/obo/PW_0001671	no-go mRNA decay pathway	http://purl.obolibrary.org/obo/PW_0000546	mRNA decay pathway		The no-go mRNA decay pathway degrades mRNA that causes ribosomes to stall during the elongation phase of translation. It can be due to the presence of pseudoknots, stem loop structures, rare codons, other features.
http://purl.obolibrary.org/obo/PW_0001672	vinca alkaloid drug pathway	http://purl.obolibrary.org/obo/PW_0002367	antineoplastic drug pathway		Vinca alkaloids are anti-mitotic and anti-microtubule agents originally derived from plants and also produced as semisynthetic compounds. They have a hypoglycemic and cytotoxic effects and are widely used as cancer drugs.
http://purl.obolibrary.org/obo/PW_0001673	vinblastine drug pathway	http://purl.obolibrary.org/obo/PW_0001672	vinca alkaloid drug pathway		The pharmacokinetics and pharmacodynamics of vinblastine - a vinca alkaloid used as anticancer agent. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001674	vinorelbine drug pathway	http://purl.obolibrary.org/obo/PW_0001672	vinca alkaloid drug pathway		The pharmacokinetics and pharmacodynamics of vinorelbine - a vinca alkaloid used as anticancer agent. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001675	vincristine drug pathway	http://purl.obolibrary.org/obo/PW_0001672	vinca alkaloid drug pathway		The pharmacokinetics and pharmacodynamics of vincristine - a vinca alkaloid used as anticancer agent. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001676	vindesine drug pathway	http://purl.obolibrary.org/obo/PW_0001672	vinca alkaloid drug pathway		The pharmacokinetics and pharmacodynamics of vindesine - a vinca alkaloid used as anticancer agent. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001677	vinblastine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001673	vinblastine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of vinblastine, an anti-mitotic, anticancer agent. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001678	vinblastine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001673	vinblastine drug pathway		The pathway of vinblastine-target interaction and of the biochemical or physiological responses to drug. The drug interacts with tubulin and disrupts microtubules function, particularly those at the mitotic spindle. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001679	vincristine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001675	vincristine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of vincristine, an anti-mitotic, anticancer agent. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001680	vincristine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001675	vincristine drug pathway		The pathway of vincristne-target interaction and of the biochemical or physiological responses to drug. The drug interacts with tubulin and disrupts microtubules function, particularly those at the mitotic spindle. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001681	vindesine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001676	vindesine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of vindesine, an anti-mitotic, anticancer agent. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001682	vindesine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001676	vindesine drug pathway		The pathway of vindesine-target interaction and of the biochemical or physiological responses to drug. The drug interacts with tubulin and disrupts microtubules function, particularly those at the mitotic spindle. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001683	vinorelbine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001674	vinorelbine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of vinorelbine, an anti-mitotic, anticancer agent. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001684	vinorelbine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001674	vinorelbine drug pathway		The pathway of vinorelbine-target interaction and of the biochemical or physiological responses to drug. The drug interacts with tubulin and disrupts microtubules function, particularly those at the mitotic spindle. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001685	verapamil drug pathway	http://purl.obolibrary.org/obo/PW_0001893	non-dihydropyridine calcium channel blocker drug pathway		The pharmacokinetics and pharmacodynamics pathway of verapamil - an L-type calcium channel blocker of the phenylalkylamine class. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001686	verapamil pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001685	verapamil drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of verapamil, an L-type calcium channel blocker used for the treatment of cardiovascular conditions. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001687	verapamil pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001685	verapamil drug pathway		The pathway of verapamil-target interaction and of the biochemical or physiological responses to drug. The drug is an L-type calcium channel blocker used in the treatment of hypertension and other cardiovascular conditions. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001688	valsartan drug pathway	http://purl.obolibrary.org/obo/PW_0001789	renin-angiotensin system drug pathway		The pharmacokinetics and pharmacodynamics pathway of valsartan, an angiotensin II receptor type 1 antagonist used in the treatment of high blood pressure and congestive heart failure. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001689	valsartan pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001688	valsartan drug pathway		The pathway of valsartan-target interaction and of the biochemical or physiological responses to drug. The drug is an antagonist of the angiotensin II receptor type 1. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001690	valsartan pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001688	valsartan drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of valsartan. The drug is an antagonist of angiotensin II receptor type 1. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001691	organic chemical homeostasis pathway	http://purl.obolibrary.org/obo/PW_0000355	homeostasis pathway		Those pathways involved in the proper balance of organic chemical levels, uptake and transport, utilization and storage, as demanded by the needs of cells tissues and organs. Disruption of organic chemical homeostasis can have harmful consequences. Collectively they represent a broad class of substances containing carbon.
http://purl.obolibrary.org/obo/PW_0001692	inorganic chemical homeostasis pathway	http://purl.obolibrary.org/obo/PW_0000355	homeostasis pathway		Those pathways involved in the proper balance of inorganic chemical levels, uptake and transport, utilization and storage, as demanded by the needs of cells tissues and organs. Disruption of inorganic chemical homeostasis can have harmful consequences. Collectively they represent a broad class of substances that do not  contain carbon. Chemical elements are also included.
http://purl.obolibrary.org/obo/PW_0001693	S-adenosylmethionine homeostasis pathway	http://purl.obolibrary.org/obo/PW_0001691	organic chemical homeostasis pathway		Those pathways that involve the balanced generation and utilization of S-adenosylmethionine (AdoMet or SAM). SAM is a universal methyl donor and at the cross roads of metabolism, gene expression regulation and cellular signaling.
http://purl.obolibrary.org/obo/PW_0001694	valdecoxib drug pathway	http://purl.obolibrary.org/obo/PW_0001170	musculo-skeletal system drug pathway		The pharmacokinetics and pharmacodynamics pathway of valdecoxib, a non-steroidal anti-inflammatory drug used in the treatment of osteoarthritis, rheumatoid arthritis. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001695	valdecoxib pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001694	valdecoxib drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination of valdecoxib, an antirheumatic drug. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001696	valdecoxib pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001694	valdecoxib drug pathway		The pathway of valdecoxib-target interaction and of the biochemical or physiological responses to drug. The drug is a selective cyclooxygenase-2 inhibitor. Currently, the prodrug parecoxib is being used as valdecoxib has been removed from the market because its side effects risks.
http://purl.obolibrary.org/obo/PW_0001697	digestive system disease pathway	http://purl.obolibrary.org/obo/PW_0000013	disease pathway		The congenital and acquired diseases affecting the digestive system.
http://purl.obolibrary.org/obo/PW_0001702	french type sialuria pathway	http://purl.obolibrary.org/obo/PW_0002381	sialic acid storage disease pathway		Alterations in the biosynthetic pathway of sialic acid (N-acetylneuraminic acid) lead to its excessive accumulation in the urine, resulting in several phenotypes.
http://purl.obolibrary.org/obo/PW_0001703	saccharopinuria pathway	http://purl.obolibrary.org/obo/PW_0001936	hyperlysinemia pathway		Saccharopinuria, also known as hyperlysinemia type II, is an autosomal recessive condition due to alteration in metabolic pathways of lysine and its derivatives.
http://purl.obolibrary.org/obo/PW_0001704	ribose 5-phosphate isomerase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001644	inborn error of carbohydrate metabolism pathway		A disorder due to alteration in the pentose phosphate metabolic pathway.
http://purl.obolibrary.org/obo/PW_0001705	Refsum disease pathway	http://purl.obolibrary.org/obo/PW_0001646	inborn error of brain metabolic pathway		An autosomal recessive disorder due to alterations in peroxisomal metabolic pathways manifesting in hearing loss and impaired vision.
http://purl.obolibrary.org/obo/PW_0001706	pyruvate kinase deficiency of red cells pathway	http://purl.obolibrary.org/obo/PW_0001751	inborn error of pyruvate metabolism pathway		An inherited disorder affecting the red blood cells, resulting from alteration in the pyruvate metabolic pathway and manifesting in hemolytic anemia.
http://purl.obolibrary.org/obo/PW_0001707	enalapril drug pathway	http://purl.obolibrary.org/obo/PW_0001228	ACE inhibitor drug pathway		The pharmacokinetics and pharmacodynamics of enalapril - an angiotensin converting enzyme (ACE) inhibitor. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001708	enalapril pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001707	enalapril drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of enalapril, an ACE inhibitor. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001709	enalapril pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001707	enalapril drug pathway		The pathway of enalapril-target interaction and of the biochemical or physiological responses to drug. The drug is an ACE inhibitor used for the treatment of hypertension and also for other cardiovascular and kidney diseases. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001710	ramipril drug pathway	http://purl.obolibrary.org/obo/PW_0001228	ACE inhibitor drug pathway		The pharmacokinetics and pharmacodynamics of ramipril - an angiotensin converting enzyme (ACE) inhibitor. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001711	ramipril pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001710	ramipril drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of ramipril, an ACE inhibitor. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001712	ramipril pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001710	ramipril drug pathway		The pathway of ramipril-target interaction and of the biochemical or physiological responses to drug. The drug is an ACE inhibitor used for the treatment of hypertension and also for other cardiovascular and kidney diseases. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001713	quinapril drug pathway	http://purl.obolibrary.org/obo/PW_0001228	ACE inhibitor drug pathway		The pharmacokinetics and pharmacodynamics of quinapril - an angiotensin converting enzyme (ACE) inhibitor. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001714	quinapril pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001713	quinapril drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of quinapril, an ACE inhibitor. Quinapril is a prodrug that is converted to its active  metabolite, quinaprilat, in the liver. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001715	quinapril pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001713	quinapril drug pathway		The pathway of quinapril-target interaction and of the biochemical or physiological responses to drug. The drug is an ACE inhibitor used for the treatment of hypertension and also for other cardiovascular and kidney diseases. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001716	perindopril drug pathway	http://purl.obolibrary.org/obo/PW_0001228	ACE inhibitor drug pathway		The pharmacokinetics and pharmacodynamics of perindopril - an angiotensin converting enzyme (ACE) inhibitor. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001717	perindopril pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001716	perindopril drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of perindopril, an ACE inhibitor. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001718	perindopril pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001716	perindopril drug pathway		The pathway of perindopril-target interaction and of the biochemical or physiological responses to drug. The drug is an ACE inhibitor used for the treatment of hypertension and also for other cardiovascular and kidney diseases. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001719	lisinopril drug pathway	http://purl.obolibrary.org/obo/PW_0001228	ACE inhibitor drug pathway		The pharmacokinetics and pharmacodynamics of lisinopril - an angiotensin converting enzyme (ACE) inhibitor. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001720	lisinopril pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001719	lisinopril drug pathway		The pathway of lisinopril-target interaction and of the biochemical or physiological responses to drug. The drug is an ACE inhibitor used for the treatment of hypertension and also for other cardiovascular and kidney diseases. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001721	lisinopril pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001719	lisinopril drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of lisinopril, an ACE inhibitor. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001722	benazepril drug pathway	http://purl.obolibrary.org/obo/PW_0001228	ACE inhibitor drug pathway		The pharmacokinetics and pharmacodynamics of benazepril - an angiotensin converting enzyme (ACE) inhibitor. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001723	benazepril pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001722	benazepril drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of benazepril, an ACE inhibitor. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001724	benazepril pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001722	benazepril drug pathway		The pathway of benazepril-target interaction and of the biochemical or physiological responses to drug. The drug is an ACE inhibitor used for the treatment of hypertension and also for other cardiovascular and kidney diseases. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001725	trandolapril drug pathway	http://purl.obolibrary.org/obo/PW_0001228	ACE inhibitor drug pathway		The pharmacokinetics and pharmacodynamics of trandolapril - an angiotensin converting enzyme (ACE) inhibitor. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001726	trandolapril pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001725	trandolapril drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of trandolapril, an ACE inhibitor. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001727	trandolapril pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001725	trandolapril drug pathway		The pathway of trandolapril-target interaction and of the biochemical or physiological responses to drug. The drug is an ACE inhibitor used for the treatment of hypertension and also for other cardiovascular and kidney diseases. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001728	cilazapril drug pathway	http://purl.obolibrary.org/obo/PW_0001228	ACE inhibitor drug pathway		The pharmacokinetics and pharmacodynamics of cilazapril - an angiotensin converting enzyme (ACE) inhibitor. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001729	cilazapril pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001728	cilazapril drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of cilazapril, an ACE inhibitor. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001730	cilazapril pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001728	cilazapril drug pathway		The pathway of cilazapril-target interaction and of the biochemical or physiological responses to drug. The drug is an ACE inhibitor used for the treatment of hypertension and also for other cardiovascular and kidney diseases. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001731	ticlopidine drug pathway	http://purl.obolibrary.org/obo/PW_0002150	antiplatelet drug pathway		The pharmacokinetics and pharmacodynamics pathway of ticlopidine, a platelet aggregation inhibitor. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001732	ticlopidine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001731	ticlopidine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of ticlopidine, a platelet aggregation inhibitor. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001733	ticlopidine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001731	ticlopidine drug pathway		The pathway of ticlopidine-interaction and of the biochemical or physiological responses to drug. The drug can irreversibly block the adenosine diphosphate (ADP) receptor. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001735	adrenergic beta receptor antagonist drug pathway	http://purl.obolibrary.org/obo/PW_0000920	cardiovascular system drug pathway		The pharmacokinetics and pharmacodynamics pathway of adrenergic beta receptors blockers. Adrenergic beta receptors, in response to epinephrine or norepinephrine couple to the Gs alpha subunit of heterotrimeric G protein to elicit several responses. Beta receptor antagonists are used to inhibit these responses and they are either selective or non-selective. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001737	adrenergic beta receptor selective antagonist drug pathway	http://purl.obolibrary.org/obo/PW_0001735	adrenergic beta receptor antagonist drug pathway		The pharmacokinetics and pharmacodynamics pathway of selective adrenergic beta receptors blockers. Adrenergic beta receptors, in response to epinephrine or norepinephrine couple to the Gs alpha subunit of heterotrimeric G protein to elicit several responses. Beta-1 receptor antagonists are used to inhibit these responses. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001738	adrenergic beta receptor non-selective antagonist drug pathway	http://purl.obolibrary.org/obo/PW_0001735	adrenergic beta receptor antagonist drug pathway		The pharmacokinetics and pharmacodynamics pathway of non-selective adrenergic beta receptors blockers. Adrenergic beta receptors, in response to epinephrine or norepinephrine couple to the Gs alpha subunit of heterotrimeric G protein to elicit several responses. Beta receptor antagonists are used to inhibit these responses. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001739	timolol drug pathway	http://purl.obolibrary.org/obo/PW_0001738	adrenergic beta receptor non-selective antagonist drug pathway		The pharmacokinetics and pharmacodynamics pathway of timolol - a non-selective adrenergic beta receptor blocker. It binds and inhibits the beta 1 receptor and is used in for the treatment of hypertension and other cardiovascular conditions. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001740	timolol pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001739	timolol drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of timolol. The drug is a non-selective adrenergic beta receptor blocker. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001741	timolol pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001739	timolol drug pathway		The pathway of timolol-target interaction and of the biochemical or physiological responses to drug. The drug is non-selective blocker of adrenergic receptor beta 1. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001742	tirofiban drug pathway	http://purl.obolibrary.org/obo/PW_0002150	antiplatelet drug pathway		The pharmacokinetics and pharmacodynamics pathway of tirofiban, a platelet aggregation inhibitor. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001743	tirofiban pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001742	tirofiban drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of tirofiban, a platelet aggregation inhibitor.  Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001744	tirofiban pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001742	tirofiban drug pathway		The pathway of tirofiban-interaction and of the biochemical or physiological responses to drug. Tirofiban is a reversible inhibitor of glycoprotein IIb/IIIa. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001745	tobramycin drug pathway	http://purl.obolibrary.org/obo/PW_0000996	anti-infective drug pathway		The pharmacokinetics and pharmacodynamics pathway of tobramycine - an anti-bacterial antibiotic, used primarily for the treatment of Gram-negative infections. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001746	tobramycin pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001745	tobramycin drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination of tobramycin - an antibiotic that interferes with bacterial protein synthesis. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001747	tobramycin pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001745	tobramycin drug pathway		The pathway of tobramycin-target interaction and of the biochemical or physiological responses to drug. Kanamycin interferes with bacterial protein synthesis and is used in the treatment of Gram-negative infections. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001748	tolmetin drug pathway	http://purl.obolibrary.org/obo/PW_0001170	musculo-skeletal system drug pathway		The pharmacokinetics and pharmacodynamics pathway of tolmetin, a non-steroidal anti-inflammatory drug used in the treatment of osteoarthritis, rheumatoid arthritis. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001749	tolmetin pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001748	tolmetin drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination of tolmetin, an antirheumatic drug. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001750	tolmetin pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001748	tolmetin drug pathway		The pathway of tolmetin-target interaction and of the biochemical or physiological responses to drug. Tolmetin is thought to inhibit cyclooxygenases and thus block prostaglandin synthesis. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001751	inborn error of pyruvate metabolism pathway	http://purl.obolibrary.org/obo/PW_0001644	inborn error of carbohydrate metabolism pathway		Those diseases that are caused by inborn errors of pyruvate metabolism. The pyruvate metabolic pathway is at the intersection of pathways important for glucose and energy homeostasis. Alterations involve several and important components.
http://purl.obolibrary.org/obo/PW_0001756	peptide and protein metabolic pathway	http://purl.obolibrary.org/obo/PW_0000002	classic metabolic pathway		Those metabolic reactions involved in the synthesis, folding and/or degradation of peptides and proteins, including the synthesis of protein/peptide/amino-acid based hormones.
http://purl.obolibrary.org/obo/PW_0001757	peptide and protein hormone metabolic pathway	http://purl.obolibrary.org/obo/PW_0001756	peptide and protein metabolic pathway		Those metabolic reactions involved in the synthesis, folding and/or degradation of peptide and protein hormones, and those derived from them.
http://purl.obolibrary.org/obo/PW_0001758	insulin biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001757	peptide and protein hormone metabolic pathway		The insulin precursor, preproinsulin is subject to several processing steps in the endoplasmic reticulum and the Golgi apparatus before ending as the mature zinc-insulin hexamer stored in secretory granules. The expression of insulin is confined to the beta cells of the pancreatic islets of Langerhans.
http://purl.obolibrary.org/obo/PW_0001759	preproglucagon processing pathway	http://purl.obolibrary.org/obo/PW_0001757	peptide and protein hormone metabolic pathway		The preproglucagon processing pathway gives rise to several peptide hormones in a tissue and cell specific manner. A subset, including glucagon, glucagon-like peptide-1 and peptide-2, and oxyntomodulin, are better characterized. The function of other preproglucagon derived peptides, remains to be established.
http://purl.obolibrary.org/obo/PW_0001760	glucagon biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001759	preproglucagon processing pathway		The processing of preproglucagon precursor that gives to the glucagon hormone in the alpha cells of the pancreatic islets of Langerhans.
http://purl.obolibrary.org/obo/PW_0001761	glucagon-like peptide-1 biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001759	preproglucagon processing pathway		The processing of the preproglucagon precursor that gives rise to glucagon-like peptide-1 (GLP-1) in the intestinal L cells and discrete sets of neurons.
http://purl.obolibrary.org/obo/PW_0001762	glucagon-like peptide-2 biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001759	preproglucagon processing pathway		The processing of the preproglucagon precursor that gives rise to glucagon-like peptide-2 (GLP-2) in the intestinal L cell and discrete sets of neurons.
http://purl.obolibrary.org/obo/PW_0001763	oxyntomodulin biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001759	preproglucagon processing pathway		The processing of the preproglucagon precursor that gives rise to oxyntomodulin in the intestinal L cells and discrete sets of neurons.
http://purl.obolibrary.org/obo/PW_0001764	radical mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0001162	chemical compound signaling pathway		The signaling pathway initiated by a radical. The reactivity of free radicals renders them potentially hazardous but it can also positively contribute to many biological processes. The generation, utilization and neutralization of radicals is tightly regulated. Disturbance in the levels and regulation of radicals leads to pathological states including cardiovascular diseases, diabetes, cancer and aging.
http://purl.obolibrary.org/obo/PW_0001765	superoxide mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0001764	radical mediated signaling pathway		Superoxide and the radicals for which it is a precursor participate in several reactions and processes important in immunity and epigenetics.
http://purl.obolibrary.org/obo/PW_0001766	radical SAM enzyme mediated RNA processing pathway	http://purl.obolibrary.org/obo/PW_0001767	radical SAM enzyme mediated metabolic pathway		RNA molecules such as ribosomal and transfer RNA, rRNA and tRNA respectively, undergo many modifications to achieve functionality. Among the many modifications, there are those introduced by iron-sulfur (Fe/S) cluster-containing enzymes. Most have radical S-adenosylmethionine (SAM) domains that use SAM to produce 5-adenosyl radical; the intermediate allows them to mediate a vast range of chemical transformations.
http://purl.obolibrary.org/obo/PW_0001767	radical SAM enzyme mediated metabolic pathway	http://purl.obolibrary.org/obo/PW_0000135	metabolic pathway of cofactors, vitamins, nutrients		The radical SAM enzymes use their iron-sulfur (Fe/S) cluster(s) generate a radical using the S-adenosylmethionine (SAM) as the substrate. The intermediate radical allows these enzymes to mediate a vast range of chemical transformations important for co-factor and lipid metabolism, peptide and RNA modification.
http://purl.obolibrary.org/obo/PW_0001768	docetaxel drug pathway	http://purl.obolibrary.org/obo/PW_0002367	antineoplastic drug pathway		The pharmacokinetics and pharmacodynamics pathway of docetaxel - an antineoplastiic agent. It is an anti-mitotic drug whose cytotoxicity affects tumor cells but can also extend to other dividing cells. In some cases, the drug could cause severe side effects and deaths due to its toxicity have been reported. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001769	docetaxel pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001768	docetaxel drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of docetaxel. Docetaxel is used as a chemotherapeutic agent for the treatment of various cancers. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001770	docetaxel pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001768	docetaxel drug pathway		The pathway of docetaxel-target interaction and of the biochemical or physiological responses to drug. Docetaxel  is used as a chemotherapeutic agent for the treatment of various cancers. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001771	tenofovir drug pathway	http://purl.obolibrary.org/obo/PW_0000996	anti-infective drug pathway		The pharmacokinetics and pharmacodynamics pathway of tenofovir, an antirfetroviral drug used for the treatment of HIV infection and hepatitis B. It is a nucleoside analog reverse transcriptase inhibitor. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001772	tenofovir pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001771	tenofovir drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination of tenofovir - a nucleotide analogue reverse transcriptase inhibitor. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001773	tenofovir pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001771	tenofovir drug pathway		The pathway of tenofovir-target interaction and of the biochemical or physiological responses to drug. Tenofovir is a nucleotide analogue reverse transcriptase inhibitor. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001774	docetaxel response pathway	http://purl.obolibrary.org/obo/PW_0001434	toxin and toxicant response pathway		A pathway triggered by administration of docetaxel, a chemotherapeutic drug. Docetaxel inhibits mitotic cell division and its cytotoxicity extends to all dividing cells, not just tumor cells. Severe side effects and even death cases have been reported.
http://purl.obolibrary.org/obo/PW_0001775	pyruvate carboxylase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001751	inborn error of pyruvate metabolism pathway		An autosomal recessive metabolic disorder resulting from impaired pyruvate metabolism. An absent or decreased activity of pyruvate carboxylase results in an altered pyruvate pathway.
http://purl.obolibrary.org/obo/PW_0001776	inborn error of purine-pyrimidine metabolism pathway	http://purl.obolibrary.org/obo/PW_0001589	inborn error of metabolism pathway		Those diseases that are caused by inborn errors of purine and/or pyrimidine metabolism. The mutations can disrupt one or several pathways.
http://purl.obolibrary.org/obo/PW_0001777	purine nucleoside phosphorylase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001776	inborn error of purine-pyrimidine metabolism pathway		A rather rare autosomal recessive immunodeficiency resulting from decreased T-cell function. Disruption of purine nucleoside phosphorylase results in an altered purine salvage pathway.
http://purl.obolibrary.org/obo/PW_0001778	propionic acidemia pathway	http://purl.obolibrary.org/obo/PW_0001645	inborn error of amino acid metabolism pathway		An autosomal recessive metabolic disorder due to mutations in propionyl CoA carboxylase genes resulting in alteration of amino acid metabolic pathways.
http://purl.obolibrary.org/obo/PW_0001779	adenosine monophosphate deaminase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001776	inborn error of purine-pyrimidine metabolism pathway		A rare recessive metabolic disorder arising from alteration in the purine metabolic pathway.
http://purl.obolibrary.org/obo/PW_0001781	primary hyperoxaluria pathway	http://purl.obolibrary.org/obo/PW_0001780	hyperoxaluria pathway		A genetic disorder characterized by the excretion of large amounts of oxalate and present in several forms depending on the alteration of the glyoxalate metabolic pathway.
http://purl.obolibrary.org/obo/PW_0001782	primary hyperoxaluria type 1 pathway	http://purl.obolibrary.org/obo/PW_0001781	primary hyperoxaluria pathway		Hyperoxaluria results from alteration in the glyoxylate metabolic pathway. Type 1 is due to mutations in the alanine-glyoxylate aminotransferase (AGXT) enzyme.
http://purl.obolibrary.org/obo/PW_0001783	primary hyperoxaluria type 2 pathway	http://purl.obolibrary.org/obo/PW_0001781	primary hyperoxaluria pathway		Hyperoxaluria results from alteration in the glyoxylate metabolic pathway. Type 2 is due to mutations in the glyoxylate reductase/hydroxypyruvate reductase (GRHPR) enzyme.
http://purl.obolibrary.org/obo/PW_0001784	porphyria pathway	http://purl.obolibrary.org/obo/PW_0001589	inborn error of metabolism pathway		A group of metabolic conditions due to alterations in the heme biosynthetic pathway in bone marrow, the liver or both. They are further classified depending on the enzymes that are deficient or the site.
http://purl.obolibrary.org/obo/PW_0001785	variegate porphyria pathway	http://purl.obolibrary.org/obo/PW_0001980	hepatic porphyria pathway		One of several liver porphyrias, all resulting from alterations in the heme biosynthetic pathway. Here, the deficient enzyme is protoporphyrinogen oxidase.
http://purl.obolibrary.org/obo/PW_0001786	tranexamic acid drug pathway	http://purl.obolibrary.org/obo/PW_0001652	antihemorrhagic drug pathway		The pharmacokinetics and pharmacodynamics pathway of tranexamic acid, an inhibitor of enzymes involved in fibrinolysis and as such, effective in the treatment of certain bleeding disorders It is also used in surgery to prevent excessive bleeding. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001787	tranexamic acid pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001786	tranexamic acid drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of tranexamic acid. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001788	tranexamic acid pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001786	tranexamic acid drug pathway		The pathway of tranexamic acid-target interaction and of the biochemical or physiological responses to drug. It is an inhibitor of plasminogen and used to treat bleeding conditions and in surgery to prevent excessive bleeding  Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001789	renin-angiotensin system drug pathway	http://purl.obolibrary.org/obo/PW_0000920	cardiovascular system drug pathway		The pharmacokinetics and pharmacodynamics of drugs that target the renin-angiotensin system, such as ACE inhibitors and angiotensin II antagonists.
http://purl.obolibrary.org/obo/PW_0001790	triamterene drug pathway	http://purl.obolibrary.org/obo/PW_0000920	cardiovascular system drug pathway		The pharmacokinetics and pharmacodynamics pathway of triamterene, a sodium channel blocker used to lower blood pressure. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001791	triamterene pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001790	triamterene drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of triamterene. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001792	triamterene pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001790	triamterene drug pathway		The pathway of triamterene-target interaction and of the biochemical or physiological responses to drug. The drug blocks the epithelial sodium channels and is used in the treatment of hypertension. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001793	tenoxicam drug pathway	http://purl.obolibrary.org/obo/PW_0001170	musculo-skeletal system drug pathway		The pharmacokinetics and pharmacodynamics pathway of tenoxicam, a non-steroidal anti-inflammatory drug used in the treatment of osteoarthritis, rheumatoid arthritis. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001794	tenoxicam pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001793	tenoxicam drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination of tenoxicam, an antirheumatic drug. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001795	tenoxicam pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001793	tenoxicam drug pathway		The pathway of tenoxicam-target interaction and of the biochemical or physiological responses to drug. Tenoxicam is thought to inhibit cyclooxygenases and thus block prostaglandin synthesis. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001796	telmisartan drug pathway	http://purl.obolibrary.org/obo/PW_0001789	renin-angiotensin system drug pathway		The pharmacokinetics and pharmacodynamics pathway of telmisartan, an angiotensin II receptor type 1 antagonist used in the treatment of essential hypertension. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001797	telmisartan pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001796	telmisartan drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of telmisartan. The drug is an antagonist of angiotensin II receptor type 1. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001798	telmisartan pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001796	telmisartan drug pathway		The pathway of telmisartan-target interaction and of the biochemical or physiological responses to drug. The drug is an antagonist of the angiotensin II receptor type 1. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001799	sulindac drug pathway	http://purl.obolibrary.org/obo/PW_0001170	musculo-skeletal system drug pathway		The pharmacokinetics and pharmacodynamics pathway of sulindac, a non-steroidal anti-inflammatory drug used in the treatment of acute or chronic inflammatory conditions. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001800	sulindac pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001799	sulindac drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination of sulindac, an anti-inflammatory drug. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001801	sulindac pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001799	sulindac drug pathway		The pathway of sulindac-target interaction and of the biochemical or physiological responses to drug. Sulindac is thought to interfere with prostaglandin synthesis.
http://purl.obolibrary.org/obo/PW_0001802	doxorubicin response pathway	http://purl.obolibrary.org/obo/PW_0001434	toxin and toxicant response pathway		A pathway triggered by administration of doxorubicin, a widely used chemotherapeutic agent. The cytotoxicity of doxorubicin is primarily manifested in its cardiotoxic effect that can lead to heart failure, Possible causes are reactive oxygen species (ROS), impaired iron homeostasis and mitochondrial dysfunction.
http://purl.obolibrary.org/obo/PW_0001804	streptomycin pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001803	streptomycin drug pathway		Streptomycin inhibits bacterial protein synthesis in both Gram-positive and Gram-negative bacteria and as such is a broad-spectrum antibiotic.
http://purl.obolibrary.org/obo/PW_0001805	phenylketonuria pathway	http://purl.obolibrary.org/obo/PW_0001646	inborn error of brain metabolic pathway		A group of autosomal recessive disorders resulting from alterations in amino acid metabolism, mostly due to deficiency of hepatic phenylalanine hydroxylase. The enzyme catalyzes the hydroxylation of phenylalanine to tyrosine.
http://purl.obolibrary.org/obo/PW_0001806	ornithine carbamoyltransferase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001645	inborn error of amino acid metabolism pathway		An inherited disorder resulting from alteration in the urea cycle metabolic pathway.
http://purl.obolibrary.org/obo/PW_0001807	gyrate atrophy pathway	http://purl.obolibrary.org/obo/PW_0001496	sensory system disease pathway		A progressive atrophy of the choroid and retina resulting from alterations in amino acid metabolic pathways involving ornithine aminotransferase enzyme.
http://purl.obolibrary.org/obo/PW_0001808	nonketotic hyperglycinemia pathway	http://purl.obolibrary.org/obo/PW_0001646	inborn error of brain metabolic pathway		An autosomal recessive disorder resulting from alterations in the glycine metabolic pathway.
http://purl.obolibrary.org/obo/PW_0001809	methylmalonate semialdehyde dehydrogenase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001776	inborn error of purine-pyrimidine metabolism pathway		A rare autosomal recessive disorder resulting from alterations purine-pyrimidine and/or amino acid metabolic pathways.
http://purl.obolibrary.org/obo/PW_0001810	methylmalonic acidemia pathway	http://purl.obolibrary.org/obo/PW_0001645	inborn error of amino acid metabolism pathway		An inherited condition resulting from alterations in the metabolic pathway whereby methylmalonyl-coenzyme A (CoA) is converted into succinyl-CoA.
http://purl.obolibrary.org/obo/PW_0001811	methylmalonic aciduria, cobalamin-related pathway	http://purl.obolibrary.org/obo/PW_0001810	methylmalonic acidemia pathway		A form of methylmalonic aciduria disease pathway involving cobalamin (vitamin B12) in the methionine and homocysteine metabolic pathways.
http://purl.obolibrary.org/obo/PW_0001812	mevalonic aciduria pathway	http://purl.obolibrary.org/obo/PW_0001646	inborn error of brain metabolic pathway		An autosomal recessive disorder resulting from defects in mevalonate kinase, one of the two kinases sequentially phosphorylating mevalonate to isopentenyl pyrophosphate in the isoprenoid and cholesterol biosynthetic pathways.
http://purl.obolibrary.org/obo/PW_0001813	mitochondrial complex I deficiency pathway	http://purl.obolibrary.org/obo/PW_0001669	mitochondrial disease pathway		A condition resulting from alterations in the electron transport chain metabolic pathway involving the NADH ubiquinone oxidoreductase complex I.
http://purl.obolibrary.org/obo/PW_0001814	mitochondrial complex II deficiency pathway	http://purl.obolibrary.org/obo/PW_0001669	mitochondrial disease pathway		A condition resulting from alterations in the electron transport chain metabolic pathway involving the succinate dehydrogenase complex II.
http://purl.obolibrary.org/obo/PW_0001815	mitochondrial complex III deficiency pathway	http://purl.obolibrary.org/obo/PW_0001669	mitochondrial disease pathway		A condition resulting from alterations in the electron transport chain metabolic pathway involving complex III.
http://purl.obolibrary.org/obo/PW_0001816	inborn error of metal metabolism pathway	http://purl.obolibrary.org/obo/PW_0001589	inborn error of metabolism pathway		Those diseases that are caused by inborn errors of metal metabolism. The mutations can disrupt one or several pathways.
http://purl.obolibrary.org/obo/PW_0001817	molybdenum cofactor deficiency pathway	http://purl.obolibrary.org/obo/PW_0001816	inborn error of metal metabolism pathway		A disorder resulting from alterations in the molybdenum biosynthetic pathway.
http://purl.obolibrary.org/obo/PW_0001818	mucopolysaccharidoses pathway	http://purl.obolibrary.org/obo/PW_0001644	inborn error of carbohydrate metabolism pathway		A group of lysosomal storage diseases resulting from alterations in the glycosaminoglycans degradation pathway.
http://purl.obolibrary.org/obo/PW_0001819	stavudine drug pathway	http://purl.obolibrary.org/obo/PW_0000996	anti-infective drug pathway		The pharmacokinetics and pharmacodynamics pathway of stavudine, an anti-viral drug used for the treatment of HIV infection. It belongs to the family of nucleoside analog reverse transcriptase inhibitors. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001820	stavudine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001819	stavudine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of stavudine, a drug used for the treatment of HIV. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001821	stavudine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001819	stavudine drug pathway		The pathway of stavudine-target interaction and of the biochemical or physiological responses to drug. Stavudine is a drug used for the treatment of HIV infection. Stavudine, in its active triphosphate form, inhibits HIV-1 reverse transcriptase activity. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001822	spironolactone drug pathway	http://purl.obolibrary.org/obo/PW_0002121	diuretic drug pathway		The pharmacokinetics and pharmacodynamics pathway of spironolactone - a drug used in the treatment of hypertension and heart failure. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001823	spironolactone pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001822	spironolactone drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of spironolactone. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001824	spironolactone pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001822	spironolactone drug pathway		The pathway of spironolactone-target interaction and of the biochemical or physiological responses to drug. The drug inhibits the effects of aldosterone by competing with its receptor. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001825	spirapril drug pathway	http://purl.obolibrary.org/obo/PW_0001228	ACE inhibitor drug pathway		The pharmacokinetics and pharmacodynamics of spirapril - an angiotensin converting enzyme (ACE) inhibitor. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001826	spirapril pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001825	spirapril drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of spirapril, an ACE inhibitor. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001827	spirapril pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001825	spirapril drug pathway		The pathway of spirapril-target interaction and of the biochemical or physiological responses to drug. The drug is an ACE inhibitor used for the treatment of hypertension and also for other cardiovascular and kidney diseases. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001828	sotalol drug pathway	http://purl.obolibrary.org/obo/PW_0001738	adrenergic beta receptor non-selective antagonist drug pathway		The pharmacokinetics and pharmacodynamics pathway of sotalol - a non-selective adrenergic beta receptor blocker. It binds and inhibits the beta 1 and beta 2 receptors and is used for the treatment of hypertension and other cardiovascular conditions. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001829	sotalol pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001828	sotalol drug pathway		The pathway of sotalol-target interaction and of the biochemical or physiological responses to drug. The drug is non-selective blocker of adrenergic receptor beta 1 and beta 2. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001830	sotalol pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001828	sotalol drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of sotalol. The drug is a non-selective adrenergic beta receptor blocker. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001831	altered iron homeostasis pathway	http://purl.obolibrary.org/obo/PW_0001832	altered metal homeostasis pathway		An iron homeostasis pathway that deviates from what its normal course should be. Either iron deficiency or iron overload contributes to the development of numerous conditions, from anemia to inflammation, cancer, cardiovascular, infection and neurodegenerative diseases.
http://purl.obolibrary.org/obo/PW_0001833	altered inorganic chemical homeostasis pathway	http://purl.obolibrary.org/obo/PW_0001692	inorganic chemical homeostasis pathway		An inorganic chemical homeostasis pathway that deviates from what its normal course should be.
http://purl.obolibrary.org/obo/PW_0001834	roxatidine acetate drug pathway	http://purl.obolibrary.org/obo/PW_0000921	alimentary tract and metabolism drug pathway		The pharmacokinetics and pharmacodynamics pathway of roxatidine acetate - a histamine H2 specific receptor antagonist used in the treatment of acid disorders. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001835	roxatidine acetate pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001834	roxatidine acetate drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of roxatidine. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001836	roxatidine acetate pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001834	roxatidine acetate drug pathway		The pathway of roxatidine-target interaction and of the biochemical or physiological responses to drug. The drug is a specific antagonist H2 receptor and it is used for the treatment of various acid disorders. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001837	risedronate drug pathway	http://purl.obolibrary.org/obo/PW_0001621	nitrogenous bisphosphonate drug pathway		The pharmacokinetics and pharmacodynamics pathway of risedronate - a nitrogenous bisphosphonate drug used to treat bone diseases. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001838	risedronate pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001837	risedronate drug pathway		The pathway of risedronate-target interaction and of the biochemical or physiological responses to drug. Risedronate is a nitrogenous bisphosphonate drug used to treat bone diseases. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001839	risedronate pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001837	risedronate drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of risedronate, a nitrogenous bisphosphonate drug. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001840	hyperhomocysteinemia pathway	http://purl.obolibrary.org/obo/PW_0001645	inborn error of amino acid metabolism pathway		A condition of elevated levels of homocysteine usually due to alteration in folate metabolic pathways. Homocysteine is an intermediate in the methionine metabolic cycle. It can be remethylated to methionine or it can follow the transsulfuration pathway.
http://purl.obolibrary.org/obo/PW_0001841	homocystinuria pathway	http://purl.obolibrary.org/obo/PW_0001840	hyperhomocysteinemia pathway		An autosomal recessive condition downstream of homocysteine and involving alterations in the transsulfuration pathway. Usually, it is due to defects in the first enzyme of the transsulfuration pathway, cystathione beta synthase.
http://purl.obolibrary.org/obo/PW_0001842	mitochondrial autophagy pathway	http://purl.obolibrary.org/obo/PW_0002402	cellular autophagy pathway		Damage to mitochondria will promote mitophagy, the mitochondrial autophagy pathway. It exhibits features common to macroautophagy or the regular autophagy, and also features that are distinct. Under more sustained stress, the cell will promote apoptosis. Translocation of cardiolipin, the signature phospholipid of the mitochondrial inner membrane, to the outer membrane, provides a signal of mitochondrial dysfunction.
http://purl.obolibrary.org/obo/PW_0001843	ranitidine drug pathway	http://purl.obolibrary.org/obo/PW_0000921	alimentary tract and metabolism drug pathway		The pharmacokinetics and pharmacodynamics pathway of ranitidine acetate - a histamine H2 specific receptor antagonist used in the treatment of acid disorders. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001844	ranitidine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001843	ranitidine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of ranitidine. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001845	ranitidine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001843	ranitidine drug pathway		The pathway of ranitidine-target interaction and of the biochemical or physiological responses to drug. The drug is a specific antagonist H2 receptor and it is used for the treatment of various acid disorders. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001846	rabeprazole drug pathway	http://purl.obolibrary.org/obo/PW_0000918	proton pump inhibitor drug pathway		The pharmacokinetics and pharmacodynamics pathway of rabeprazole, a proton pump inhibitor. It is administered for the treatment of acid-related disorders. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001847	rabeprazole pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001846	rabeprazole drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of rabeprazole, a compound in the class of proton pump inhibitors. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001848	rabeprazole pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001846	rabeprazole drug pathway		The pathway of rabeprazole-target interaction and of the biochemical or physiological responses to drug. Rabeprazole is a compound in the class of proton pump inhibitors used in the treatment of acid-related disorders. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001849	quinidine drug pathway	http://purl.obolibrary.org/obo/PW_0002336	antiarrhythmic drug pathway		The pharmacokinetics and pharmacodynamics pathway of quinidine, a class I antiarrhythmic agent that can increase cardiac action potential. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001850	quinidine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001849	quinidine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of quinidine, a class I antiarrhythmic agent. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001851	quinidine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001849	quinidine drug pathway		The pathway of quinidine-target interaction and of the biochemical or physiological responses to drug. Its primary action is blocking the fast inward sodium current. However, it can impact on other currents and channels, such as the slow inward calcium, the rapid and slow components of the delayed potassium, and the inward potassium rectifier currents, and the ATP-sensitive potassium channel. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001852	propranolol drug pathway	http://purl.obolibrary.org/obo/PW_0001738	adrenergic beta receptor non-selective antagonist drug pathway		The pharmacokinetics and pharmacodynamics pathway of propanolol - a non-selective adrenergic beta receptor blocker, used for the treatment of hypertension and other cardiovascular conditions. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001853	propranolol pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001852	propranolol drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of propanolol. The drug is a non-selective adrenergic beta receptor blocker. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001854	propranolol pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001852	propranolol drug pathway		The pathway of propanolol-target interaction and of the biochemical or physiological responses to drug. The drug is non-selective blocker of adrenergic receptor beta. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001855	procaine drug pathway	http://purl.obolibrary.org/obo/PW_0002243	anesthetic drug pathway		The pharmacokinetics and pharmacodynamics pathway of procaine, a drug used as a local anesthetic. It also has anti--inflammatory and mood enhancing effects. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001856	procaine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001855	procaine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of procaine. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001857	procaine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001855	procaine drug pathway		The pathway of procaine-target interaction and of the biochemical or physiological responses to drug. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001858	procainamide drug pathway	http://purl.obolibrary.org/obo/PW_0002336	antiarrhythmic drug pathway		The pharmacokinetics and pharmacodynamics pathway of procainamide, a class Ia antiarrhythmic drug. There are many adverse side effects and the cytotoxicity of the drug is documented. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001859	procainamide pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001858	procainamide drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of procainamide. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001860	procainamide pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001858	procainamide drug pathway		The pathway of procainamide-target interaction and of the biochemical or physiological responses to drug. The drug is a class Ia antiarrhythmic drug that can also elicit serious cytotoxic effects.  Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001861	procainamide response pathway	http://purl.obolibrary.org/obo/PW_0001434	toxin and toxicant response pathway		A pathway triggered by administration of procainamide, a class Ia antiarrhythmic drug. The cytotoxic effects impact on lymphocytes and interfere with pacemaker, among others. Many of the toxic effects may result from acetylation of the drug.
http://purl.obolibrary.org/obo/PW_0001862	prednisone drug pathway	http://purl.obolibrary.org/obo/PW_0002369	immunosuppressant drug pathway		The pharmacokinetics and pharmacodynamics of prednisone - a synthetic glucocorticoid that is particularly effective as a immunosuppressant drug. Both short- and long-term effects can occur. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001863	prednisone pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001862	prednisone drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of prednisone, a synthetic glucocorticoid. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001864	prednisone pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001862	prednisone drug pathway		The pathway of prednisone-target interaction and of the biochemical or physiological responses to drug. The drug is particularly effective as an immunosuppressant. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001865	piroxicam drug pathway	http://purl.obolibrary.org/obo/PW_0001170	musculo-skeletal system drug pathway		The pharmacokinetics and pharmacodynamics pathway of piroxicam, a non-steroidal anti-inflammatory drug used in the treatment of inflammatory conditions and to relieve pain. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001866	piroxicam pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001865	piroxicam drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of piroxicam, an anti-inflammatory drug. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001867	piroxicam pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001865	piroxicam drug pathway		The pathway of piroxicam-target interaction and of the biochemical or physiological responses to drug. The drug is a non-selective cyclooxygenase (COX) inhibitor. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001868	hypermethioninemia pathway	http://purl.obolibrary.org/obo/PW_0001645	inborn error of amino acid metabolism pathway		An inborn metabolic disorder resulting from alterations in the methionine cycle/metabolic pathway.
http://purl.obolibrary.org/obo/PW_0001869	medium chain acyl-CoA dehydrogenase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001643	inborn error of lipid metabolism pathway		An inherited condition resulting from impaired lipid metabolic pathways.
http://purl.obolibrary.org/obo/PW_0001870	maple syrup urine disease pathway	http://purl.obolibrary.org/obo/PW_0001646	inborn error of brain metabolic pathway		An autosomal recessive condition resulting from alterations in branched-chain amino acid metabolic pathways. It has several forms and a range of phenotypes.
http://purl.obolibrary.org/obo/PW_0001871	lysinuric protein intolerance pathway	http://purl.obolibrary.org/obo/PW_0001645	inborn error of amino acid metabolism pathway		A disorder resulting from an impaired transport pathway of positively charged amino acids.
http://purl.obolibrary.org/obo/PW_0001872	X-linked genetic disease pathway	http://purl.obolibrary.org/obo/PW_0001477	inborn genetic disease pathway		Those conditions resulting from alterations in pathways involving genes on the X-chromosome in humans or in other species.
http://purl.obolibrary.org/obo/PW_0001873	Y-linked genetic disease pathway	http://purl.obolibrary.org/obo/PW_0001477	inborn genetic disease pathway		Those conditions resulting from alterations in pathways involving genes on the Y-chromosome in humans or in other species.
http://purl.obolibrary.org/obo/PW_0001874	isovaleric acidemia pathway	http://purl.obolibrary.org/obo/PW_0001645	inborn error of amino acid metabolism pathway		A rare autosomal condition resulting from an impaired amino acid metabolism.
http://purl.obolibrary.org/obo/PW_0001875	isobutyryl-CoA dehydrogenase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001645	inborn error of amino acid metabolism pathway		A condition resulting from impaired amino acid metabolism.
http://purl.obolibrary.org/obo/PW_0001876	plasmalogen metabolic pathway	http://purl.obolibrary.org/obo/PW_0000354	glycerophospholipid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of plasmalogen, a type of ether phospholipid found in many tissues, particularly in the cardiovascular, immune and nervous system.
http://purl.obolibrary.org/obo/PW_0001877	plasmalogen biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001876	plasmalogen metabolic pathway		Those metabolic reactions involved in the synthesis of plasmalogen.
http://purl.obolibrary.org/obo/PW_0001878	X-linked intellectual disability pathway	http://purl.obolibrary.org/obo/PW_0001872	X-linked genetic disease pathway		Genetic disorders involving intellectual disabilty resulting from alterations in pathways whose component genes are located on the X chromosome.
http://purl.obolibrary.org/obo/PW_0001879	Lesch-Nyhan syndrome pathway	http://purl.obolibrary.org/obo/PW_0001878	X-linked intellectual disability pathway		An inherited disorder with several psychomotor phenotypes resulting from altered purine metabolism, particularly the salvage pathway, due to defects in the hypoxanthine phosphoribosyltransferase 1 (HPRT1) gene, located on the X chromosome.
http://purl.obolibrary.org/obo/PW_0001880	iminoglycinuria pathway	http://purl.obolibrary.org/obo/PW_0000300	kidney disease pathway		A condition associated with impaired renal tubular transport.
http://purl.obolibrary.org/obo/PW_0001881	hypophosphatasia pathway	http://purl.obolibrary.org/obo/PW_0001816	inborn error of metal metabolism pathway		A genetic metabolic disorder due to impaired bone alkaline phosphatase activity and manifesting in a range of phenotypes.
http://purl.obolibrary.org/obo/PW_0001882	pirenzepine drug pathway	http://purl.obolibrary.org/obo/PW_0000921	alimentary tract and metabolism drug pathway		The pharmacokinetics and pharmacodynamics of pirenzepine, a muscarinic receptor antagonist used in the treatment of peptic ulcers. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001883	pirenzepine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001882	pirenzepine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of pirenzepine. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001884	pirenzepine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001882	pirenzepine drug pathway		The pathway of pirenzepine-target interaction and of the biochemical or physiological responses to drug.  Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001885	pentazocine drug pathway	http://purl.obolibrary.org/obo/PW_0002443	opioid drug pathway		The pharmacokinetics and pharmacodynamics pathway of pentazocine, an opioid analgesic. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001886	pentazocine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001885	pentazocine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of pentazocine, an opioid analgesic. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001887	pentazocine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001885	pentazocine drug pathway		The pathway of pentazocine-target interaction and of the biochemical or physiological responses to drug. Pentazocine is an opioid analgesic used to treat moderate to more severe pain. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001888	pantoprazole drug pathway	http://purl.obolibrary.org/obo/PW_0000918	proton pump inhibitor drug pathway		The pharmacokinetics and pharmacodynamics pathway of pantoprazole, a proton pump inhibitor. It is administered for the treatment of acid-related disorders. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001889	pantoprazole pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001888	pantoprazole drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of pantoprazole, a compound in the class of proton pump inhibitors. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001890	pantoprazole pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001888	pantoprazole drug pathway		The pathway of pantoprazole-target interaction and of the biochemical or physiological responses to drug. Pantoprazole is a compound in the class of proton pump inhibitors used in the treatment of acid-related disorders. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001891	streptomycin pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001803	streptomycin drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination of streptomycin - an antibiotic that interferes with bacterial protein synthesis. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001892	calcium channel blocker drug pathway	http://purl.obolibrary.org/obo/PW_0000920	cardiovascular system drug pathway		The pharmacokinetics and pharmacodynamics pathway of calcium channel blockers - agents used as antihypertensive drugs. They are further classified as dihydropyridine and non-dihydropyridine drugs, and both classes are rather selective. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001893	non-dihydropyridine calcium channel blocker drug pathway	http://purl.obolibrary.org/obo/PW_0001892	calcium channel blocker drug pathway		The pharmacokinetics and pharmacodynamics pathway of non-dihydropyridine calcium channel blockers - agents often used to treat angina and relatively selective for myocardium. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001894	dihydropyridine calcium channel blocker drug pathway	http://purl.obolibrary.org/obo/PW_0001892	calcium channel blocker drug pathway		The pharmacokinetics and pharmacodynamics pathway of dihydropyridine calcium channel blockers - agents derived from dihydropyridine and used to reduce arterial pressure. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001895	nimodipine drug pathway	http://purl.obolibrary.org/obo/PW_0001894	dihydropyridine calcium channel blocker drug pathway		The pharmacokinetics and pharmacodynamics pathway of nimodipine, a calcium channel blocker developed for the treatment of hypertension but now used to prevent vasospasm. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001896	nisoldipine drug pathway	http://purl.obolibrary.org/obo/PW_0001894	dihydropyridine calcium channel blocker drug pathway		The pharmacokinetics and pharmacodynamics pathway of nifedipine, a calcium channel blocker used in the treatment of hypertension. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001897	nitrendipine drug pathway	http://purl.obolibrary.org/obo/PW_0001894	dihydropyridine calcium channel blocker drug pathway		The pharmacokinetics and pharmacodynamics pathway of nitrendipine, a calcium channel blocker used in the treatment of hypertension. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001898	nimodipine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001895	nimodipine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of nimodipine. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001899	nisoldipine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001896	nisoldipine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of nisoldipine. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001900	nitrendipine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001897	nitrendipine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of nitrendipine. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001901	nimodipine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001895	nimodipine drug pathway		The pathway of nimodipine-target interaction and of the biochemical or physiological responses to drug. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001902	nisoldipine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001896	nisoldipine drug pathway		The pathway of nisoldipine-target interaction and of the biochemical or physiological responses to drug. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001903	nitrendipine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001897	nitrendipine drug pathway		The pathway of nitrendipine-target interaction and of the biochemical or physiological responses to drug. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001904	nizatidine drug pathway	http://purl.obolibrary.org/obo/PW_0000921	alimentary tract and metabolism drug pathway		The pharmacokinetics and pharmacodynamics pathway of nizatidine - a histamine H2 specific receptor antagonist used in the treatment of acid disorders. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001905	nizatidine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001904	nizatidine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of nizatidine. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001906	nizatidine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001904	nizatidine drug pathway		The pathway of nizatidine-target interaction and of the biochemical or physiological responses to drug. The drug is a histamine H2 receptor specific antagonist used for the treatment of various acid disorders. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001907	olmesartan drug pathway	http://purl.obolibrary.org/obo/PW_0001789	renin-angiotensin system drug pathway		The pharmacokinetics and pharmacodynamics pathway of olmesartan, an angiotensin II receptor type 1 antagonist used in the treatment of hypertension. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001908	olmesartan pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001907	olmesartan drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of olmesartan. The drug is an antagonist of angiotensin II receptor type 1. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001909	olmesartan pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001907	olmesartan drug pathway		The pathway of olmesartan-target interaction and of the biochemical or physiological responses to drug. The drug is an antagonist of the angiotensin II receptor type 1. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001910	nebivolol drug pathway	http://purl.obolibrary.org/obo/PW_0001737	adrenergic beta receptor selective antagonist drug pathway		The pharmacokinetics and pharmacodynamics pathway of nebivolol, a selective beta adrenergic type 1 receptor antagonist used in the treatment of hypertension. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001911	nebivolol pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001910	nebivolol drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of nebivolol. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001912	nebivolol pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001910	nebivolol drug pathway		The pathway of nebivolol-target interaction and of the biochemical or physiological responses to drug. The drug is a selective antagonist of beta adrenergic type 1 receptor. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001913	naproxen drug pathway	http://purl.obolibrary.org/obo/PW_0001546	analgesic and/or antipyretic drug pathway		The pharmacokinetics and pharmacodynamics pathway of naproxen, a non-steroidal anti-inflammatory drug that inhibits cyclooxygenase enzymes and is used in the treatment of inflammation and pain. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001914	naproxen pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001913	naproxen drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of naproxen. The drug is used in the treatment of pain and inflammation. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001915	naproxen pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001913	naproxen drug pathway		The pathway of naproxen-target interaction and of the biochemical or physiological responses to drug. Naproxen is an inhibitor of cyclooxygenase enzymes used in the treatment of pain and inflammation. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001916	naltrexone drug pathway	http://purl.obolibrary.org/obo/PW_0002443	opioid drug pathway		The pharmacokinetics and pharmacodynamics pathway of naltrexone, an antagonist of opioid receptors used in the treatment of substance dependence. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001917	naltrexone pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001916	naltrexone drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of naltrexone, an antagonist of opioid receptors. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001918	naltrexone pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001916	naltrexone drug pathway		The pathway of naltrexone-target interaction and of the biochemical or physiological responses to drug. The drug is an antagonist of mu opioid receptor and to a lesser and much lesser extent, the kappa and delta opioid receptors, respectively. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001919	nalbuphine drug pathway	http://purl.obolibrary.org/obo/PW_0002443	opioid drug pathway		The pharmacokinetics and pharmacodynamics pathway of nalbuphine, a semi-synthetic opioid used an analgesic for the relief of moderate to severe pain. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001920	nalbuphine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001919	nalbuphine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of nalbuphine. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001921	nalbuphine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001919	nalbuphine drug pathway		The pathway of nalbuphine-target interaction and of the biochemical or physiological responses to drug. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001922	nabumetone drug pathway	http://purl.obolibrary.org/obo/PW_0001170	musculo-skeletal system drug pathway		The pharmacokinetics and pharmacodynamics pathway of nabumetone, a non-steroidal anti-inflammatory drug that inhibits cyclooxygenase enzymes, preferentially COX-2 type. The drug is used in the treatment of inflammation and pain. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001923	nabumetone pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001922	nabumetone drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of nabumetone. The drug is rapidly metabolized in the liver to 6-methoxy-2-naphthyl, its major active metabolite. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001924	nabumetone pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001922	nabumetone drug pathway		The pathway of nabumetone-target interaction and of the biochemical or physiological responses to drug. Nabumetone is an inhibitor of COX-2 enzyme used in the treatment of pain and inflammation. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001925	metolazone drug pathway	http://purl.obolibrary.org/obo/PW_0002121	diuretic drug pathway		The pharmacokinetics and pharmacodynamics pathway of metolazone - a blocker of sodium -chloride symporter in the distal convoluted tubule of the nephron. The drug is used for the treatment of hypertension and congestive heart failure. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001926	metolazone pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001925	metolazone drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of metolazone. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001927	metolazone pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001925	metolazone drug pathway		The pathway of metolazone-target interaction and of the biochemical or physiological responses to drug. The drug blocks the sodium-chloride symporter and is used in the treatment of hypertension and congestive heart failure. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001928	metoprolol drug pathway	http://purl.obolibrary.org/obo/PW_0001737	adrenergic beta receptor selective antagonist drug pathway		The pharmacokinetics and pharmacodynamics pathway of metoprolol, a selective beta adrenergic type 1 receptor antagonist used in the treatment of hypertension and several other conditions involving a faster than normal heart rate. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001929	metoprolol pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001928	metoprolol drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of metoprolol. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001930	metoprolol pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001928	metoprolol drug pathway		The pathway of metoprolol-target interaction and of the biochemical or physiological responses to drug. The drug is a selective antagonist of beta adrenergic type 1 receptor. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001931	hyperprolinemia type I pathway	http://purl.obolibrary.org/obo/PW_0001645	inborn error of amino acid metabolism pathway		A condition resulting from alterations in the proline amino acid metabolic pathway and involving the enzyme proline oxidase.
http://purl.obolibrary.org/obo/PW_0001932	hyperprolinemia type II pathway	http://purl.obolibrary.org/obo/PW_0001645	inborn error of amino acid metabolism pathway		A rare condition resulting from alterations in the proline amino acid metabolic pathway leading to high levels of proline and the related compound pyrroline-5-carboxylase in the circulation.
http://purl.obolibrary.org/obo/PW_0001933	hypercholesterolemia pathway	http://purl.obolibrary.org/obo/PW_0001473	lipid metabolism disease pathway		A condition resulting from alterations in the various aspects of cholesterol metabolism or transport along with environmental or other diseases related aspects and manifesting in high levels of circulating cholesterol.
http://purl.obolibrary.org/obo/PW_0001935	hyperinsulinism pathway	http://purl.obolibrary.org/obo/PW_0001602	glucose metabolism disease pathway		A condition spanning a spectrum of manifestations that may also cause hypoglycemia resulting from alterations in glucose homeostasis and insulin related pathways.
http://purl.obolibrary.org/obo/PW_0001936	hyperlysinemia pathway	http://purl.obolibrary.org/obo/PW_0001646	inborn error of brain metabolic pathway		A group of inherited disorders resulting from alterations in the lysine metabolic pathway.
http://purl.obolibrary.org/obo/PW_0001939	methadone drug pathway	http://purl.obolibrary.org/obo/PW_0002443	opioid drug pathway		The pharmacokinetics and pharmacodynamics pathway of methadone, an acyclic analog of morphine and heroin acting on the same opioid receptors and used in the management of severe, chronic pain. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001940	methadone pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001939	methadone drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of methadone. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001941	methadone pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001939	methadone drug pathway		The pathway of methadone-target interaction and of the biochemical or physiological responses to drug. Methadone binds the mu-opioid receptor of sensory neurons triggering downstream cascades that activate potassium channels while inactivating calcium channels. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001942	mercaptopurine drug pathway	http://purl.obolibrary.org/obo/PW_0002369	immunosuppressant drug pathway		The pharmacokinetics and pharmacodynamics pathway of mercaptopurine, an immunosuppressive drug used in the treatment of leukemia, Crohn's disease and colitis. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001943	mercaptopurine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001942	mercaptopurine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of mercaptopurine. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001944	mercaptopurine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001942	mercaptopurine drug pathway		The pathway of mercaptopurine-target interaction and of the biochemical or physiological responses to drug. The drug is used as an immunosuppressive and its cytotoxic effects result from its interference with nucleic acids synthesis and function. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001945	mepivacaine drug pathway	http://purl.obolibrary.org/obo/PW_0002243	anesthetic drug pathway		The pharmacokinetics and pharmacodynamics pathway of mepivacaine, a drug used as a local anesthetic. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001946	mepivacaine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001945	mepivacaine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of mepivacaine. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001947	mepivacaine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001945	mepivacaine drug pathway		The pathway of mepivacaine-target interaction and of the biochemical or physiological responses to drug. It acts mainly as a blocker of voltage-gated sodium channels. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001948	meloxicam drug pathway	http://purl.obolibrary.org/obo/PW_0001170	musculo-skeletal system drug pathway		The pharmacokinetics and pharmacodynamics pathway of meloxicam, a non-steroidal anti-inflammatory drug used to relieve pain. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001949	meloxicam pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001948	meloxicam drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of piroxicam. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001950	meloxicam pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001948	meloxicam drug pathway		The pathway of meloxicam-target interaction and of the biochemical or physiological responses to drug. The drug is a non-selective cyclooxygenase (COX) inhibitor. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001951	mefenamic acid drug pathway	http://purl.obolibrary.org/obo/PW_0001170	musculo-skeletal system drug pathway		The pharmacokinetics and pharmacodynamics pathway of mefenamic acid, a non-steroidal anti-inflammatory drug used to treat mild to moderate pain. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001952	mefenamic acid pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001951	mefenamic acid drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of mefenamic acid. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001953	mefenamic acid pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001951	mefenamic acid drug pathway		The pathway of mefenamic acid-target interaction and of the biochemical or physiological responses to drug. The drug is a non-selective cyclooxygenase (COX) inhibitor. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001954	eukaryotic DNA replication pathway	http://purl.obolibrary.org/obo/PW_0000098	DNA replication pathway		Nuclear eukaryotic DNA replication takes place in the context of the cell cycle during the S-phase. The fast and accurate replication of DNA requires the presence and the coordinated function of a complex of proteins known as the replisome. The exact composition of the replisome in higher organisms still has to be fully determined. Mitochondria contain their own DNA. Human mtDNA is a small, circular molecule that resides in the matrix and, depending on cell type, can exist as a few to several thousands copies. mtDNA has its own replicative machinery.
http://purl.obolibrary.org/obo/PW_0001956	nuclear DNA replication pathway	http://purl.obolibrary.org/obo/PW_0001954	eukaryotic DNA replication pathway		Nuclear eukaryotic DNA replication takes place in the context of the cell cycle during the S-phase. The fast and accurate replication of DNA requires the presence and the coordinated function of a complex of proteins known as the replisome. The exact composition of the replisome in higher organisms still has to be fully determined.
http://purl.obolibrary.org/obo/PW_0001957	mitochondrial DNA replication pathway	http://purl.obolibrary.org/obo/PW_0001954	eukaryotic DNA replication pathway		Mitochondria contain their own DNA. Human mtDNA is a small, circular molecule that resides in the matrix and, depending on cell type, can exist as a few to several thousands copies. mtDNA has its own replicative machinery.
http://purl.obolibrary.org/obo/PW_0001958	altered mitochondrial autophagy pathway	http://purl.obolibrary.org/obo/PW_0002403	altered cellular autophagy		A mitophagy pathway that deviates from what its normal course should be. Mitochondrial damage and altered mitophagy pathway have been implicated in neurodegenerative diseases associated with aging, such as Parkinson, Huntington and Alzheimer diseases.
http://purl.obolibrary.org/obo/PW_0001959	mitochondria homeostasis pathway	http://purl.obolibrary.org/obo/PW_0000355	homeostasis pathway		The various pathways and mechanisms that assure the proper function and abundance of mitochondria within cells. In addition to being the powerhouse of the cell as the place of oxidative phosphorylation, mitochondria are also the site of other important metabolic pathways and play essential roles in calcium storage and signaling and apoptosis, among others.
http://purl.obolibrary.org/obo/PW_0001960	altered mitochondria homeostasis pathway	http://purl.obolibrary.org/obo/PW_0001959	mitochondria homeostasis pathway		Disruption of mitochondrial homeostasis is associated with neurodegenerative diseases, cancer and aging.
http://purl.obolibrary.org/obo/PW_0001962	mitochondrial protein import pathway	http://purl.obolibrary.org/obo/PW_0000535	protein transport pathway		Mitochondria are essential organelles that provide most of the ATP fuel for the cell, are the site of several important metabolic pathways and play essential roles in calcium storage, signaling and apoptosis. Of the many proteins involved, only 13 are encoded in the mammalian mitochondrial DNA. The remaining ~99% of mitochondrial proteins are translocated from the cytosol via a complex, multicomponent pathway system. Mitochondria-encoded proteins are translocated from the mitochondrial matrix into the inner mitochondrial membrane by a single system.
http://purl.obolibrary.org/obo/PW_0001963	lansoprazole drug pathway	http://purl.obolibrary.org/obo/PW_0000918	proton pump inhibitor drug pathway		The pharmacokinetics and pharmacodynamics pathway of lansoprazole, a proton pump inhibitor. It is administered for the treatment of acid-related disorders. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001964	lansoprazole pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001963	lansoprazole drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of lansoprazole, a compound in the class of proton pump inhibitors pharmacologically related to omeprazole. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001965	lansoprazole pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001963	lansoprazole drug pathway		The pathway of lansoprazole-target interaction and of the biochemical or physiological responses to drug. Lansoprazole is a compound in the class of proton pump inhibitors pharmacologically related to omperazole, used in the treatment of acid-related disorders. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001966	ketorolac drug pathway	http://purl.obolibrary.org/obo/PW_0001170	musculo-skeletal system drug pathway		The pharmacokinetics and pharmacodynamics pathway of ketorolac, a non-steroidal anti-inflammatory drug used to treat moderate to severe pain. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001967	ketorolac pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001966	ketorolac drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of ketorolac. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001968	ketorolac pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001966	ketorolac drug pathway		The pathway of ketorolac-target interaction and of the biochemical or physiological responses to drug. The drug is a non-selective cyclooxygenase (COX) inhibitor used for short-term management of moderate to severe pain. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001969	ketoprofen drug pathway	http://purl.obolibrary.org/obo/PW_0001546	analgesic and/or antipyretic drug pathway		The pharmacokinetics and pharmacodynamics pathway of ketoprofen, a non-steroidal anti-inflammatory drug that also has analgesic and antipyretic effects. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001970	ketoprofen pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001969	ketoprofen drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of ketoprofen. The drug is used in the treatment of inflammation and pain. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001971	ketoprofen pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001969	ketoprofen drug pathway		The pathway of ketoprofen-target interaction and of the biochemical or physiological responses to drug. Ketoprofen is an inhibitor of cyclooxygenase enzymes used in the treatment of inflammation and pain. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001972	isradipine drug pathway	http://purl.obolibrary.org/obo/PW_0001894	dihydropyridine calcium channel blocker drug pathway		The pharmacokinetics and pharmacodynamics pathway of isradipine, a calcium channel blocker used for the treatment of high blood pressure. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001973	isradipine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001972	isradipine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of isradipine. The drug is a calcium channel blocker used in the treatment of high blood pressure.  Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001974	isradipine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001972	isradipine drug pathway		The pathway of isradipine-target interaction and of the biochemical or physiological responses to drug. The drug is a calcium channel blocker, particularly the L-type channel, used for the treatment of high blood pressure.  Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001975	mitochondrial unfolded protein response pathway	http://purl.obolibrary.org/obo/PW_0000237	stress response pathway		A stress response pathway to mitochondrial DNA depletion or accumulation of misfolded protein in the matrix or intermembrane space. Mitochondrial-to-nucleus signaling results in the increased expression of genes important for mitochondrial protein homeostasis. UPRmt can promote increased lifespan but the mechanisms are not well understood. Mitochondrial dysfunction contributes to normal aging, but mild distress can extend lifespan by almost 50% in organisms ranging from yeast to worms, flies and mice.
http://purl.obolibrary.org/obo/PW_0001976	inborn error amino acid transport disorder pathway	http://purl.obolibrary.org/obo/PW_0001589	inborn error of metabolism pathway		Disorders caused by alterations in the amino acid transport pathways across cell membranes.
http://purl.obolibrary.org/obo/PW_0001977	Hartnup disease pathway	http://purl.obolibrary.org/obo/PW_0001976	inborn error amino acid transport disorder pathway		An autosomal recessive disorder caused by alterations in the transport of neutral amino acids in the intestine and proximal renal tubules. The condition is associated with psychosis and mental retardation.
http://purl.obolibrary.org/obo/PW_0001978	histidinemia pathway	http://purl.obolibrary.org/obo/PW_0001645	inborn error of amino acid metabolism pathway		An autosomal recessive condition resulting from alterations in the histidine metabolic pathway and characterized by increased levels of histidine in blood, cerebrospinal fluid and urine.
http://purl.obolibrary.org/obo/PW_0001979	homocarnosinosis pathway	http://purl.obolibrary.org/obo/PW_0001646	inborn error of brain metabolic pathway		The pathway involved in a progressive neurologic disorder resulting from a deficiency of homocarnosinase.
http://purl.obolibrary.org/obo/PW_0001980	hepatic porphyria pathway	http://purl.obolibrary.org/obo/PW_0001784	porphyria pathway		A group of metabolic conditions due to alterations in the heme biosynthetic pathway in the liver. They are further classified depending on the enzymes that are deficient or the site.
http://purl.obolibrary.org/obo/PW_0001981	hereditary coproporphyria pathway	http://purl.obolibrary.org/obo/PW_0001980	hepatic porphyria pathway		An autosomal dominant liver porphyria due to deficiency in the coproporphyrinogen oxidase gene.
http://purl.obolibrary.org/obo/PW_0001982	irbesartan drug pathway	http://purl.obolibrary.org/obo/PW_0001789	renin-angiotensin system drug pathway		The pharmacokinetics and pharmacodynamics pathway of irbesartan, an angiotensin II receptor type 1 antagonist used in the treatment of hypertension. Irbesartan is one of several angiotensin II receptor antagonists.  Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001983	irbesartan pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001982	irbesartan drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of irbesartan. The drug is an antagonist of angiotensin II receptor type 1. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001984	irbesartan pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001982	irbesartan drug pathway		The pathway of irbesartan-target interaction and of the biochemical or physiological responses to drug. The drug is an antagonist of the angiotensin II receptor type 1. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001985	imipramine drug pathway	http://purl.obolibrary.org/obo/PW_0002113	non-selective monoamine reuptake inhibitor drug pathway		The pharmacokinetics and pharmacodynamics pathway of imipramine, an antidepressant used in the treatment of major depression. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001986	imipramine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001985	imipramine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of imipramine. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001987	imipramine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001985	imipramine drug pathway		The pathway of imipramine-target interaction and of the biochemical or physiological responses to drug. The drug is used in the treatment of major depression and its effect results from inhibition of serotonin and norepinephrine neurotransmitter reuptake. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001988	ibutilide drug pathway	http://purl.obolibrary.org/obo/PW_0002336	antiarrhythmic drug pathway		The pharmacokinetics and pharmacodynamics pathway of ibutilide, an antiarrhythmic agent. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001989	ibutilide pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001988	ibutilide drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of ibutilide. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0001990	ibutilide pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001988	ibutilide drug pathway		The pathway of ibutilide-target interaction and of the biochemical or physiological responses to drug. The drug is an antiarrhythmic agent. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001991	glycogen storage disease pathway	http://purl.obolibrary.org/obo/PW_0001644	inborn error of carbohydrate metabolism pathway		A group of inherited metabolic disorders resulting from alterations in the glycogen metabolic pathway.
http://purl.obolibrary.org/obo/PW_0001992	glycogen storage disease  type Ia pathway	http://purl.obolibrary.org/obo/PW_0001991	glycogen storage disease pathway		One of the two forms of the type I glycogen storage disease pathway involving glucose-6-phosphate, here due to mutations in glucose-6-phosphatase. It is characterized by the accumulation of glycogen in particular organs and tissues.
http://purl.obolibrary.org/obo/PW_0001993	glycogen storage disease type Ib pathway	http://purl.obolibrary.org/obo/PW_0001991	glycogen storage disease pathway		One of the two forms of the type I glycogen storage disease pathway involving glucose-6-phosphate, here due to mutations affecting the glucose-6-phosphate transporter. It is characterized by the accumulation of glycogen in particular organs and tissues.
http://purl.obolibrary.org/obo/PW_0001994	glycogen storage disease type III pathway	http://purl.obolibrary.org/obo/PW_0001991	glycogen storage disease pathway		A type of glycogen disease pathway that involves the glycogen debranching enzyme. There are further subdivisions, to delineate the clinical manifestations.
http://purl.obolibrary.org/obo/PW_0001995	glycogen storage disease type IV pathway	http://purl.obolibrary.org/obo/PW_0001991	glycogen storage disease pathway		A type of glycogen storage disease pathway involving glycogen branching enzyme 1.
http://purl.obolibrary.org/obo/PW_0001996	glycogen storage disease type VI pathway	http://purl.obolibrary.org/obo/PW_0001991	glycogen storage disease pathway		A type of glycogen storage disease pathway involving the liver phosphorylase.
http://purl.obolibrary.org/obo/PW_0001997	glycogen storage disease type VII pathway	http://purl.obolibrary.org/obo/PW_0001991	glycogen storage disease pathway		A type of glycogen storage disease pathway involving muscle phosphofructokinase.
http://purl.obolibrary.org/obo/PW_0002000	ibandronate drug pathway	http://purl.obolibrary.org/obo/PW_0001621	nitrogenous bisphosphonate drug pathway		The pharmacokinetics and pharmacodynamics pathway of ibandronate - a nitrogenous bisphosphonate drug used to treat bone diseases. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002001	ibandronate pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002000	ibandronate drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of ibandronate, a nitrogenous bisphosphonate drug. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002002	ibandronate pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002000	ibandronate drug pathway		The pathway of ibandronate-target interaction and of the biochemical or physiological responses to drug. Ibandronate is a nitrogenous bisphosphonate drug used to treat bone diseases. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002003	hydrochlorothiazide drug pathway	http://purl.obolibrary.org/obo/PW_0002121	diuretic drug pathway		The pharmacokinetics and pharmacodynamics pathway of hydrochlorothiazide, a drug used in the treatment of high blood pressure.  Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002004	hydrochlorothiazide pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002003	hydrochlorothiazide drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of hydrochlorothiazide. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002005	hydrochlorothiazide pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002003	hydrochlorothiazide drug pathway		The pathway of hydrochlorothiazide-target interaction and of the biochemical or physiological responses to drug. The drug reduces sodium reabsorption in the distal convoluted tubule of kidney nephron. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002006	gliclazide drug pathway	http://purl.obolibrary.org/obo/PW_0000723	anti-diabetic drug pathway		The pharmacokinetics and pharmacodynamics pathway of gliclazide, a second generation sulfonylurea anti-diabetic drug used in the treatment of type 2 diabetes mellitus. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002007	gliclazide pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002006	gliclazide drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of gliclazide, an anti-diabetic drug used in the treatment of type 2 diabetes mellitus. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002008	gliclazide pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002006	gliclazide drug pathway		The pathway of gliclazide-target interaction and of the biochemical or physiological responses to drug. The drug is used in the treatment of type 2 diabetes mellitus. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002009	glyburide drug pathway	http://purl.obolibrary.org/obo/PW_0000723	anti-diabetic drug pathway		The pharmacokinetics and pharmacodynamics pathway of glyburide, a second generation sulfonylurea anti-diabetic drug used in the treatment of type 2 diabetes mellitus. The drug is also known as glibenclamide. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002010	glyburide pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002009	glyburide drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of glyburide, an anti-diabetic drug used in the treatment of type 2 diabetes mellitus. The drug is also known is glibenclamide. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002011	glyburide pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002009	glyburide drug pathway		The pathway of glyburide-target interaction and of the biochemical or physiological responses to drug. The drug is used in the treatment of type 2 diabetes mellitus. Glyburide is also known as glibenclamide. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002012	gentamicin pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001433	gentamicin drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination of gentamicin - an antibiotic that interferes with bacterial protein synthesis. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002013	gentamicin pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001433	gentamicin drug pathway		The pathway of gentamicin-target interaction and of the biochemical or physiological responses to drug. Gentamicin interferes with bacterial protein synthesis and is used in the treatment of several infections caused by both Gram-negative and Gram-positive bacteria. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002014	furosemide drug pathway	http://purl.obolibrary.org/obo/PW_0002121	diuretic drug pathway		The pharmacokinetics and pharmacodynamics pathway of furosemide - a blocker of luminal sodium-potassium-chloride symporter used for the treatment of hypertension and edema. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002015	furosemide pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002014	furosemide drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of furosemide. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002016	furosemide pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002014	furosemide drug pathway		The pathway of furosemide-target interaction and of the biochemical or physiological responses to drug. The drug blocks the luminal sodium-potassium-chloride symporter in the thick ascending limb of the loop of Henle. Furosemide is used in the treatment of hypertension and edema.  Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002017	acute intermittent porphyria pathway	http://purl.obolibrary.org/obo/PW_0001980	hepatic porphyria pathway		A rather common autosomal dominant porphyria resulting from defects in hydroxymethybilane synthase in the heme biosynthetic pathway.
http://purl.obolibrary.org/obo/PW_0002018	glycerol kinase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001644	inborn error of carbohydrate metabolism pathway		A rare metabolic disease due to alterations in the glycerol metabolic pathway resulting from defects in the glycerol kinase enzyme.
http://purl.obolibrary.org/obo/PW_0002019	glutathione synthase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001645	inborn error of amino acid metabolism pathway		A condition resulting from alterations in the glutathione biosynthesis pathway.
http://purl.obolibrary.org/obo/PW_0002021	Krabbe disease pathway	http://purl.obolibrary.org/obo/PW_0002300	nervous system lysosomal storage disease pathway		An autosomal recessive metabolic disorder caused by a deficiency of galactosylceramidase leading to intralysosomal accumulation of galactolipids such as galactosylceramides and psychosine.
http://purl.obolibrary.org/obo/PW_0002022	fosinopril drug pathway	http://purl.obolibrary.org/obo/PW_0001228	ACE inhibitor drug pathway		The pharmacokinetics and pharmacodynamics of fosinopril - an angiotensin converting enzyme (ACE) inhibitor used for the treatment of hypertension. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002023	fosinopril pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002022	fosinopril drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of fosinopril, an ACE inhibitor. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002024	fosinopril pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002022	fosinopril drug pathway		The pathway of fosinopril-target interaction and of the biochemical or physiological responses to drug. The drug is an ACE inhibitor used for the treatment of hypertension. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002025	forasartan drug pathway	http://purl.obolibrary.org/obo/PW_0001789	renin-angiotensin system drug pathway		The pharmacokinetics and pharmacodynamics pathway of forasartan, an angiotensin II receptor type 1 antagonist used in the treatment of hypertension. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002026	forasartan pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002025	forasartan drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of forasartan. The drug is an antagonist of angiotensin II receptor type 1. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002027	forasartsn pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002025	forasartan drug pathway		The pathway of forasartan-target interaction and of the biochemical or physiological responses to drug. The drug is an antagonist of the angiotensin II receptor type 1. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002028	fluoxetine drug pathway	http://purl.obolibrary.org/obo/PW_0002115	selective serotonin uptake inhibitor drug pathway		The pharmacokinetics and pharmacodynamics pathway of fluoxetine, an antidepressant used in the treatment of major depressive disorders. The drug is a selective serotonin reuptake inhibitor. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002029	fluoxetine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002028	fluoxetine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of fluoxetine. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002030	fluoxetine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002028	fluoxetine drug pathway		The pathway of fluoxetine-target interaction and of the biochemical or physiological responses to drug. The drug is used in the treatment of major depressive disorders and its effect results from selective inhibition of serotonin reuptake. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002031	flecainide drug pathway	http://purl.obolibrary.org/obo/PW_0002336	antiarrhythmic drug pathway		The pharmacokinetics and pharmacodynamics pathway of flecainide, a drug used in the treatment of cardiac arrhythmias. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002032	flecainide pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002031	flecainide drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of flecainide. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002033	flecainde pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002031	flecainide drug pathway		The pathway of flecainide-target interaction and of the biochemical or physiological responses to drug. The drug is an antiarrhythmic agent that acts by blocking sodium and possibly other channels in cardiomyocytes. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002034	fentanyl drug pathway	http://purl.obolibrary.org/obo/PW_0002443	opioid drug pathway		The pharmacokinetics and pharmacodynamics pathway of fentanyl, a potent opioid analgesic used to treat sudden, severe pain. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002035	fentanyl pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002034	fentanyl drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of fentanyl, a potent opioid analgesic. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002036	fentanyl pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002034	fentanyl drug pathway		The pathway of fentonyl-target interaction and of the biochemical or physiological responses to drug. The drug is a synthetic opioid analgesic acting as a strong inhibitor of mu receptors. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002037	famotidine drug pathway	http://purl.obolibrary.org/obo/PW_0000921	alimentary tract and metabolism drug pathway		The pharmacokinetics and pharmacodynamics pathway of famotidine - a histamine H2 receptor antagonist used in the treatment of acid disorders. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002038	famotidine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002037	famotidine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of famotidine. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002039	famotidine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002037	famotidine drug pathway		The pathway of famotidine-target interaction and of the biochemical or physiological responses to drug. The drug is a histamine H2 receptor antagonist used in the treatment of acid disorders. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002040	etodolac drug pathway	http://purl.obolibrary.org/obo/PW_0001170	musculo-skeletal system drug pathway		The pharmacokinetics and pharmacodynamics pathway of etodolac, a non-steroidal anti-inflammatory drug used in the treatment of mild to moderate pain. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002041	etodolac pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002040	etodolac drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of etodolac. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002042	etodolac pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002040	etodolac drug pathway		The pathway of etodolac-target interaction and of the biochemical or physiological responses to drug. The drug is a cyclooxygenase (COX) inhibitor with a preference for COX-2 enzyme. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002043	etacryninc acid drug pathway	http://purl.obolibrary.org/obo/PW_0002121	diuretic drug pathway		The pharmacokinetics and pharmacodynamics pathway of etacrinic acid, a loop diuretic used  in the treatment of high blood pressure.  Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002044	etacrynic acid pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002043	etacryninc acid drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of etacrynic acid. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002045	etacrynic acid pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002043	etacryninc acid drug pathway		The pathway of etacrynic acid-target interaction and of the biochemical or physiological responses to drug. The drug acts by inhibiting sodium-potassium-chloride contransport in the ascending loop of Henle. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002046	esmolol drug pathway	http://purl.obolibrary.org/obo/PW_0001737	adrenergic beta receptor selective antagonist drug pathway		The pharmacokinetics and pharmacodynamics pathway of esmolol, a selective beta adrenergic type 1 receptor antagonist used in the treatment of hypertension and several other conditions involving a faster than normal heart rate. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002047	esmolol pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002046	esmolol drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of esmolol. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002048	esmolol pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002046	esmolol drug pathway		The pathway of esmolol-target interaction and of the biochemical or physiological responses to drug. The drug is a selective antagonist of beta adrenergic type 1 receptor. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002049	escitalopram drug pathway	http://purl.obolibrary.org/obo/PW_0002115	selective serotonin uptake inhibitor drug pathway		The pharmacokinetics and pharmacodynamics pathway of escitalopram, an antidepressant used in the treatment of major depressive disorders. The drug is a selective serotonin reuptake inhibitor. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002050	escitalopram pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002049	escitalopram drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of escitalopram. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002051	escitalopram pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002049	escitalopram drug pathway		The pathway of escitalopram-target interaction and of the biochemical or physiological responses to drug. The drug is used in the treatment of major depressive disorders and its effect results from selective inhibition of serotonin reuptake. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002052	erythromycin drug pathway	http://purl.obolibrary.org/obo/PW_0000996	anti-infective drug pathway		The pharmacokinetics and pharmacodynamics of erythromycin, an antibiotic that inhibits bacterial growth and used for the treatment of several bacterial infections. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002053	erythromycin pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002052	erythromycin drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination of erythromycin - an antibiotic that interferes with bacterial growth. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002054	erythromycin pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002052	erythromycin drug pathway		The pathway of ertthromycin-target interaction and of the biochemical or physiological responses to drug. The drug interferes with bacterial growth via incompletely understood mechanisms. It is used for the treatment of several bacterial infections. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002055	eptifibatide drug pathway	http://purl.obolibrary.org/obo/PW_0002150	antiplatelet drug pathway		The pharmacokinetics and pharmacodynamics pathway of eptifibatide, a platelet aggregation inhibitor. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002056	eptifibatide pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002055	eptifibatide drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of eptifibatide, a platelet aggregation inhibitor. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002057	eptifibatide pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002055	eptifibatide drug pathway		The pathway of eftifibatide-interaction and of the biochemical or physiological responses to drug. The platelet aggregation inhibitor belongs to glycoprotein IIb/IIIa inhibitor class. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002058	eprosartan drug pathway	http://purl.obolibrary.org/obo/PW_0001789	renin-angiotensin system drug pathway		The pharmacokinetics and pharmacodynamics pathway of eprosartan, an angiotensin II receptor type 1 antagonist used in the treatment of hypertension. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002059	eprosartan pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002058	eprosartan drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of eprosartan. The drug is an antagonist of angiotensin II receptor type 1. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002060	eprosartan pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002058	eprosartan drug pathway		The pathway of eprosartan-target interaction and of the biochemical or physiological responses to drug. The drug is an antagonist of the angiotensin II receptor type 1. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002061	mitochondria transport pathway	http://purl.obolibrary.org/obo/PW_0000103	transport pathway		The transport of mitochondria to sites of high energy demand, such as neurons and cardiomyocytes. Mitochondrial distribution at synaptic terminals and active growth cones is crucial for the proper function of neurons. Impaired transport and other aspects of mitochondrial dysfunction are involved in the pathology of major neurodegenerative disorders.
http://purl.obolibrary.org/obo/PW_0002062	altered mitochondria dynamics pathway	http://purl.obolibrary.org/obo/PW_0001961	mitochondria dynamics pathway		Defects in mitochondrial dynamics are associated with the pathology of major neurodegenerative disorders.
http://purl.obolibrary.org/obo/PW_0002063	disulfiram drug pathway	http://purl.obolibrary.org/obo/PW_0000923	nervous system drug pathway		The pharmacokinetics and pharmacodynamics pathway of disulfiram, a drug used in the treatment of chronic alcoholism and also cocaine dependence. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002064	disulfiram pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002063	disulfiram drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of disulfiram. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002065	disulfiram pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002063	disulfiram drug pathway		The pathway of disulfiram-target interaction and of the biochemical or physiological responses to drug. The drug inhibits the enzyme acetaldehyde dehydrogenase and also appears to prevent the breakdown of dopamine. Disulfiram is used in the treatment of chronic alcoholism and also cocaine dependence. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002066	disopyramide drug pathway	http://purl.obolibrary.org/obo/PW_0002336	antiarrhythmic drug pathway		The pharmacokinetics and pharmacodynamics pathway of disopyramide, a drug used in the treatment of arrhythmia. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002067	disopyramide pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002066	disopyramide drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of disopyramide. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002068	disopyramide pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002066	disopyramide drug pathway		The pathway of disopyramide-target interaction and of the biochemical or physiological responses to drug. The drug is a sodium channel blocker used in the treatment of arrhythmia. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002069	dipyridamole drug pathway	http://purl.obolibrary.org/obo/PW_0002150	antiplatelet drug pathway		The pharmacokinetics and pharmacodynamics pathway of dipyridamole, a drug that inhibits the formation of blood clots via inhibition of platelet aggregation. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002070	dipyridamole pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002069	dipyridamole drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of dipyridamole. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002071	dipyridamole pharmacodyamics pathway	http://purl.obolibrary.org/obo/PW_0002069	dipyridamole drug pathway		The pathway of dipyridamole-target nteraction and of the biochemical or physiological responses to drug. Dipyridamole inhibits he formation of blood clots via inhibition of platelet aggregation. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002072	lactose biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001363	lactose metabolic pathway		Those reactions involved in the synthesis of lactose, the major sugar in milk.
http://purl.obolibrary.org/obo/PW_0002073	altered mitochondria transport pathway	http://purl.obolibrary.org/obo/PW_0002062	altered mitochondria dynamics pathway		A mitochondria transport pathway that deviates from what its normal could should be. Impaired transport and other aspects of mitochondrial dysfunction are involved in the pathology of major neurodegenerative disorders.
http://purl.obolibrary.org/obo/PW_0002074	altered mitochondria fusion pathway	http://purl.obolibrary.org/obo/PW_0002062	altered mitochondria dynamics pathway		A mitochondria fusion pathway that deviates from what its normal could should be.
http://purl.obolibrary.org/obo/PW_0002075	altered mitochondria fission pathway	http://purl.obolibrary.org/obo/PW_0002062	altered mitochondria dynamics pathway		A mitochondria fission pathway that deviates from what its normal could should be.
http://purl.obolibrary.org/obo/PW_0002076	diltiazem drug pathway	http://purl.obolibrary.org/obo/PW_0001893	non-dihydropyridine calcium channel blocker drug pathway		The pharmacokinetics and pharmacodynamics pathway of diltiazem- a benzothiazepine L-type calcium channel blocker used in the treatment of hypertension and other cardiovascular conditions. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002077	diltiazem pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002076	diltiazem drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of diltiazem, an L-type calcium channel blocker used for the treatment of cardiovascular conditions. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002078	diltiazem pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002076	diltiazem drug pathway		The pathway of diltiazem-target interaction and of the biochemical or physiological responses to drug. The drug is an L-type calcium channel blocker used in the treatment of hypertension and other cardiovascular conditions. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002079	diflunisal drug pathway	http://purl.obolibrary.org/obo/PW_0001546	analgesic and/or antipyretic drug pathway		The pharmacokinetics and pharmacodynamics pathway of diflunisal,  a non-steroidal anti-inflammatory drug that inhibits cyclooxygenase enzymes and is used in the treatment of inflammation and pain. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002080	diflunisal pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002079	diflunisal drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of diflunisal. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002081	diflunisal pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002079	diflunisal drug pathway		The pathway of diflunisal-target interaction and of the biochemical or physiological responses to drug. Diflunisal is an inhibitor of cyclooxygenase enzymes used in the treatment of pain and inflammation. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002082	didanosine drug pathway	http://purl.obolibrary.org/obo/PW_0000996	anti-infective drug pathway		The pharmacokinetics and pharmacodynamics pathway of didanosine - an antiretroviral drug used in the treatment of HIV infection. It is a reverse transcriptase inhibitor. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002083	didanosine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002082	didanosine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of didanosine, a drug used for the treatment of HIV. Didanosine triphosphate is the active form of the drug which is intracellularly metabolized. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002084	didanosine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002082	didanosine drug pathway		The pathway of didanosine-target interaction and of the biochemical or physiological responses to drug. Didanosine is a drug used for the treatment of HIV infection. Didanosine, in its active triphosphate form, inhibits HIV-1 reverse transcriptase activity. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002085	diclofenac drug pathway	http://purl.obolibrary.org/obo/PW_0001170	musculo-skeletal system drug pathway		The pharmacokinetics and pharmacodynamics pathway of diclofenac, a non-steroidal anti-inflammatory drug used to treat arthritis and other joint diseases.
http://purl.obolibrary.org/obo/PW_0002086	diclofenac pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002085	diclofenac drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of diclofenac. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002087	diclofenac pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002085	diclofenac drug pathway		The pathway of diclofenac-target interaction and of the biochemical or physiological responses to drug. The drug is used for the treatment of various joint diseases and in pain management. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002088	desipramine drug pathway	http://purl.obolibrary.org/obo/PW_0002113	non-selective monoamine reuptake inhibitor drug pathway		The pharmacokinetics and pharmacodynamics pathway of desipramine, an antidepressant used in the treatment of depression and attention deficit disorder. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002089	desipramine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002088	desipramine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of desipramine. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002090	desipramine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002088	desipramine drug pathway		The pathway of desipramine-target interaction and of the biochemical or physiological responses to drug. The drug is used in the treatment of major depression and its effect results from inhibition of norepinephrine and to a lesser extent serotonin neurotransmitter reuptake. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002091	galactosemias pathway	http://purl.obolibrary.org/obo/PW_0001646	inborn error of brain metabolic pathway		A group of inherited enzyme deficiencies that affect galactose metabolism and manifest as elevated galactose levels in the blood.
http://purl.obolibrary.org/obo/PW_0002092	galactosemia pathway	http://purl.obolibrary.org/obo/PW_0002091	galactosemias pathway		A galactosemia resulting from defects in the galactose-1-phosphate uridylyltransferase enzyme GALT.
http://purl.obolibrary.org/obo/PW_0002093	GALE deficiency pathway	http://purl.obolibrary.org/obo/PW_0002091	galactosemias pathway		A galactosemia resulting from defects in the UDP-galactose-4-epimerase enzyme GALE.
http://purl.obolibrary.org/obo/PW_0002094	galactokinase deficiency pathway	http://purl.obolibrary.org/obo/PW_0002091	galactosemias pathway		A galactosemia resulting from defects in the galactokinase enzyme GALK1.
http://purl.obolibrary.org/obo/PW_0002095	GABA aminotransferase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001645	inborn error of amino acid metabolism pathway		A condition caused by alterations in gamma aminobutyric acid metabolism due to defects in the 4-aminobutyrate aminotransferase enzyme.
http://purl.obolibrary.org/obo/PW_0002096	neuromuscular manifestation of disease pathway	http://purl.obolibrary.org/obo/PW_0000178	neurological disorder pathway		Those symptoms associated with conditions affecting the muscles, neuromuscular junctions or peripheral nerves.
http://purl.obolibrary.org/obo/PW_0002097	muscle hypotonia disorder pathway	http://purl.obolibrary.org/obo/PW_0002096	neuromuscular manifestation of disease pathway		A disorder manifested by a diminished skeletal muscle tone.
http://purl.obolibrary.org/obo/PW_0002098	fumaric aciduria pathway	http://purl.obolibrary.org/obo/PW_0002097	muscle hypotonia disorder pathway		A severe autosomal recessive metabolic disorder resulting from defects in the fumarate hydratase enzyme and manifesting in early-onset hypotonia, psychomotor and brain abnormalities.
http://purl.obolibrary.org/obo/PW_0002099	inborn error of fructose metabolism pathway	http://purl.obolibrary.org/obo/PW_0001644	inborn error of carbohydrate metabolism pathway		Those diseases that are caused by inborn errors of fructose metabolism.
http://purl.obolibrary.org/obo/PW_0002100	fructose-1,6-bisphosphatase deficiency pathway	http://purl.obolibrary.org/obo/PW_0002099	inborn error of fructose metabolism pathway		An autosomal recessive condition resulting from alterations in fructose metabolism due to defects in the enzyme fructose-1,6-bisphosphatase.
http://purl.obolibrary.org/obo/PW_0002101	hereditary fructose intolerance syndrome pathway	http://purl.obolibrary.org/obo/PW_0002099	inborn error of fructose metabolism pathway		An autosomal recessive disorder resulting from alterations in fructose metabolism and due to defects in the fructose-1-phosphate aldolase enzyme.
http://purl.obolibrary.org/obo/PW_0002103	Fabry disease pathway	http://purl.obolibrary.org/obo/PW_0002301	sphingolipidosis pathway		An X-linked inherited metabolic disorder resulting from alterations in lipid metabolic pathways. It is due to defects in alpha-galactosidase leading to accumulation of glycosphingolipids in blood vessels.
http://purl.obolibrary.org/obo/PW_0002104	dystonia pathway	http://purl.obolibrary.org/obo/PW_0001611	movement disorder pathway		Movement disorders classified by patterns of inheritance and age of onset.
http://purl.obolibrary.org/obo/PW_0002105	dopa responsive dystonia pathway	http://purl.obolibrary.org/obo/PW_0002104	dystonia pathway		A condition resulting from alterations in the metabolism of tetrahydrobiopterin (BH4), an essential cofactor for the activity of many enzymes. Diet and supplements, such as administration of L-Dopa, may diminish the outcomes of the condition.
http://purl.obolibrary.org/obo/PW_0002106	desmosterolosis pathway	http://purl.obolibrary.org/obo/PW_0001643	inborn error of lipid metabolism pathway		A rare autosomal recessive disorder likely resulting from alteration in cholesterol metabolism. Desmosterol, a precursor of cholesterol, is present in elevated amounts.
http://purl.obolibrary.org/obo/PW_0002107	cyclophosphamide drug pathway	http://purl.obolibrary.org/obo/PW_0002367	antineoplastic drug pathway		The pharmacokinetics and pharmacodynamics pathway of  cyclophosphamide, an alkylating agent used in the treatment of certain cancer types. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002108	cyclophosphamide pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002107	cyclophosphamide drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of cyclophosphamide. It is a prodrug that has to be converted to its metabolite - 4-hydroxy cyclophosphamide, to exhibit chemotherapeutic activity. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002109	cyclophosphamide pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002107	cyclophosphamide drug pathway		The pathway of cyclophosphamide-target interaction and of the biochemical or physiological responses to drug. The alkylating drug is used for the treatment of several cancer types but its toxicity can have severe adverse effects. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002110	cimetidine drug pathway	http://purl.obolibrary.org/obo/PW_0000921	alimentary tract and metabolism drug pathway		The pharmacokinetics and pharmacodynamics pathway of cimetidine - a histamine H2 receptor antagonist used in the treatment of acid disorders. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002111	cimetidine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002110	cimetidine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of cimetidine. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002112	cimetidine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002110	cimetidine drug pathway		The pathway of cimetidine-target interaction and of the biochemical or physiological responses to drug. The drug is a histamine H2 receptor antagonist used for the treatment of various acid disorders. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002113	non-selective monoamine reuptake inhibitor drug pathway	http://purl.obolibrary.org/obo/PW_0002114	antidepressant drug pathway		The pharmacokinetics and pharmacodynamics of non- selective monoamine reuptake inhibitor drugs.
http://purl.obolibrary.org/obo/PW_0002114	antidepressant drug pathway	http://purl.obolibrary.org/obo/PW_0000923	nervous system drug pathway		The pharmacokinetics and pharmacodynamics of compounds used to treat various forms of depression. Some are non-selective monoamine reuptake inhibitors, others are selective serotonin reuptake inhibitors. The category also includes monoamine oxidase inhibitors and drug classified as others.
http://purl.obolibrary.org/obo/PW_0002115	selective serotonin uptake inhibitor drug pathway	http://purl.obolibrary.org/obo/PW_0002114	antidepressant drug pathway		The pharmacokinetics and pharmacodynamics of selective serotonin uptake  inhibitor drugs.
http://purl.obolibrary.org/obo/PW_0002116	citalopram drug pathway	http://purl.obolibrary.org/obo/PW_0002115	selective serotonin uptake inhibitor drug pathway		The pharmacokinetics and pharmacodynamics pathway of citalopram, an antidepressant used in the treatment of major depressive disorders. The drug is a selective serotonin reuptake inhibitor. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002117	citalopram pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002116	citalopram drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of citalopram. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002118	citalopram pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002116	citalopram drug pathway		The pathway of citalopram-target interaction and of the biochemical or physiological responses to drug. The drug is used in the treatment of major depressive disorders and its effect results from selective inhibition of serotonin reuptake. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002119	histamine signaling pathway, immunological	http://purl.obolibrary.org/obo/PW_0002120	histamine signaling pathway		Histamine signaling is important for the central and to some extent the peripheral nervous systems and is also involved in the immune responses. Histamine signaling engages four G-protein coupled receptors (GPCR). In the immune system/inflammatory it involves receptors H2 and H4. H2 couples to Galphas.
http://purl.obolibrary.org/obo/PW_0002120	histamine signaling pathway	http://purl.obolibrary.org/obo/PW_0001162	chemical compound signaling pathway		Histamine is a nitrogenous compound derived from histidine whose signaling plays important roles in the nervous and immune systems.
http://purl.obolibrary.org/obo/PW_0002121	diuretic drug pathway	http://purl.obolibrary.org/obo/PW_0000920	cardiovascular system drug pathway		The pharmacokinetics and pharmacodynamics of drugs that increase water excretion and are used in the treatment of hypertension, heart failure and certain kidney disorders. They are further categorized by type. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002122	chlorthalidone drug pathway	http://purl.obolibrary.org/obo/PW_0002121	diuretic drug pathway		The pharmacokinetics and pharmacodynamics pathway of chlorothalidone - a blocker of sodium -chloride symporter in the distal convoluted tubule of the nephron. The drug is used for the treatment of hypertension and also as an adjuvant drug for treating edema. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002123	chlorthalidone pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002122	chlorthalidone drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of chlorthalidone. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002124	chlorthalidone pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002122	chlorthalidone drug pathway		The pathway of chlorthalidone-target interaction and of the biochemical or physiological responses to drug. The drug blocks the sodium-chloride symporter and is used in the treatment of hypertension and as an adjuvant for treating edema. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002125	captopril drug pathway	http://purl.obolibrary.org/obo/PW_0001228	ACE inhibitor drug pathway		The pharmacokinetics and pharmacodynamics of captopril - an angiotensin converting enzyme (ACE) inhibitor. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002126	captopril pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002125	captopril drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of captopril, an ACE inhibitor. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002127	captopril pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002125	captopril drug pathway		The pathway of captopril-target interaction and of the biochemical or physiological responses to drug. The drug is an ACE inhibitor used for the treatment of hypertension and also for other cardiovascular and kidney diseases. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002128	candesartan drug pathway	http://purl.obolibrary.org/obo/PW_0001789	renin-angiotensin system drug pathway		The pharmacokinetics and pharmacodynamics pathway of candsartan, an angiotensin II receptor type 1 antagonist used in the treatment of hypertension. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002129	candesartan pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002128	candesartan drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of candesartan. The drug is an antagonist of angiotensin II receptor type 1. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002130	candesartan pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002128	candesartan drug pathway		The pathway of candesartan-target interaction and of the biochemical or physiological responses to drug. The drug is an antagonist of the angiotensin II receptor type 1. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002131	capecitabine drug pathway	http://purl.obolibrary.org/obo/PW_0002367	antineoplastic drug pathway		The pharmacokinetics and pharmacodynamics pathway of capecitabine, an agent used in the treatment of several cancers. Capecitabine is a prodrug that is enzymatically converted to 5-fluorouracil which inhibits the activity of thymidylate synthase necessary for the de novo DNA synthesis. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002132	capecitabine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002131	capecitabine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of capecitabine. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002133	capecitabine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002131	capecitabine drug pathway		The pathway of capecitabine-target interaction and of the biochemical or physiological responses to drug. Capecitabine  is used in the treatment of numerous cancers. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002134	bupranolol drug pathway	http://purl.obolibrary.org/obo/PW_0001738	adrenergic beta receptor non-selective antagonist drug pathway		The pharmacokinetics and pharmacodynamics pathway of buoranolol - a non-selective adrenergic beta receptor blocker, used for the treatment of hypertension and other cardiovascular conditions. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002135	bupranolol pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002134	bupranolol drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of bupranolol. The drug is a non-selective adrenergic beta receptor blocker. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002136	bupranolol pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002134	bupranolol drug pathway		The pathway of buopranolol-target interaction and of the biochemical or physiological responses to drug. The drug is non-selective blocker of adrenergic receptor beta. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002137	presequence pathway of mitochondrial protein import	http://purl.obolibrary.org/obo/PW_0001962	mitochondrial protein import pathway		A classical pathway of mitochondrial protein import that delivers matrix resident and some of the inner membrane proteins. The precursor proteins are synthesized with an amino terminal peptide extension - the presequence. Translocase complexes, chaperones and processing enzymes cooperate in the process.
http://purl.obolibrary.org/obo/PW_0002138	carrier pathway of mitochondrial protein import	http://purl.obolibrary.org/obo/PW_0001962	mitochondrial protein import pathway		The carrier pathway delivers many of the inner mitochondrial membrane proteins. These proteins are synthesized without a presequence.
http://purl.obolibrary.org/obo/PW_0002139	intermembrane space assembly pathway of mitochondrial protein import	http://purl.obolibrary.org/obo/PW_0001962	mitochondrial protein import pathway		The mitochondrial intermembrane space assembly pathway (MIA) delivers the resident proteins of this mitochondrial localization.
http://purl.obolibrary.org/obo/PW_0002140	beta-barrel pathway of mitochondrial protein import	http://purl.obolibrary.org/obo/PW_0001962	mitochondrial protein import pathway		The mitochondrial protein import thereby beta-barrel proteins of the outer mitochondrial membrane are sorted and assembled.
http://purl.obolibrary.org/obo/PW_0002141	alpha-helical insertion pathway of mitochondrial protein import	http://purl.obolibrary.org/obo/PW_0001962	mitochondrial protein import pathway		The mitochondrial protein import thereby alpha-helical proteins of the outer mitochondrial membrane are sorted and assembled.
http://purl.obolibrary.org/obo/PW_0002142	inborn error of urea cycle pathway	http://purl.obolibrary.org/obo/PW_0001646	inborn error of brain metabolic pathway		A rare congenital disorder resulting from alterations in the urea cycle pathway. The neonatal form exhibits several phenotypes and can result in death.
http://purl.obolibrary.org/obo/PW_0002143	citrullinemia pathway	http://purl.obolibrary.org/obo/PW_0002142	inborn error of urea cycle pathway		The condition represents a group of disorders due to argininosuccinate synthase deficiency. The enzyme is a component of the urea cycle pathway.
http://purl.obolibrary.org/obo/PW_0002145	argininosuccinic aciduria pathway	http://purl.obolibrary.org/obo/PW_0002142	inborn error of urea cycle pathway		A rare autosomal recessive disorder resulting from alterations in the urea cycle pathway and due to defects in the argininosuccinate lyase enzyme.
http://purl.obolibrary.org/obo/PW_0002146	direct thrombin inhibitor drug pathway	http://purl.obolibrary.org/obo/PW_0002151	anticoagulant drug pathway		The pharmacokinetics and pharmacodynamics pathway of drugs that reduce or prevent the formation of blood clots by directly inhibiting thrombin. Thrombin is a serine protease involved in coagulation-related reactions. The drugs are further classified depending on how they interact with thrombin. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002147	bivalirudin drug pathway	http://purl.obolibrary.org/obo/PW_0002146	direct thrombin inhibitor drug pathway		The pharmacokinetics and pharmacodynamics pathway of bivalirudin, a direct thrombin inhibitor. Bivalirudin binds to both the catalytic site and anion-binding exosite of thrombin and as classified as a bivalent inhibitor. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002148	bivalirudin pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002147	bivalirudin drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of bivalirudin, a bivalent direct thrombin inhibitor. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002149	bivalirudin pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002147	bivalirudin drug pathway		The pathway of bivalirudin-target interaction and of the biochemical or physiological responses to drug. The drug is a bivalent direct thrombin inhibitor. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002150	antiplatelet drug pathway	http://purl.obolibrary.org/obo/PW_0001651	antithrombotic drug pathway		The pharmacokinetics and pharmacodynamics pathway of drugs that decrease platelet aggregation and inhibit blood clot formation. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002151	anticoagulant drug pathway	http://purl.obolibrary.org/obo/PW_0001651	antithrombotic drug pathway		The pharmacokinetics and pharmacodynamics pathway of drugs that prevent the coagulation of blood. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002152	thrombolytic drug pathway	http://purl.obolibrary.org/obo/PW_0001651	antithrombotic drug pathway		The pharmacokinetics and pharmacodynamics of drugs that can dissolve blood clots. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002153	bumetanide drug pathway	http://purl.obolibrary.org/obo/PW_0002121	diuretic drug pathway		The pharmacokinetics and pharmacodynamics pathway of bumetanide - a blocker of luminal sodium-potassium-chloride symporter used for the treatment of heart failure.  Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002154	bumetanide pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002153	bumetanide drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of bumetanide. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002155	bumetanide pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002153	bumetanide drug pathway		The pathway of bumetanide-target interaction and of the biochemical or physiological responses to drug. The drug blocks the luminal sodium-potassium-chloride symporter in the thick ascending limb of the loop of Henle. Bumetanide is used in the treatment of heart failure.  Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002156	bisoprolol drug pathway	http://purl.obolibrary.org/obo/PW_0001737	adrenergic beta receptor selective antagonist drug pathway		The pharmacokinetics and pharmacodynamics pathway of bisoprolol, a selective beta adrenergic type 1 receptor antagonist used in the treatment of hypertension and several other conditions involving a faster than normal heart rate. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002157	bisoprolol pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002156	bisoprolol drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of bisoprolol. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002158	bisoprolol pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002156	bisoprolol drug pathway		The pathway of bisoprolol-target interaction and of the biochemical or physiological responses to drug. The drug is a selective antagonist of beta adrenergic type 1 receptor. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002159	sensory organ drug pathway	http://purl.obolibrary.org/obo/PW_0000754	drug pathway		The pharmacokinetics and pharmacodynamics of compounds used in the treatment of conditions affecting the sensory organs. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002160	betaxolol drug pathway	http://purl.obolibrary.org/obo/PW_0002159	sensory organ drug pathway		The pharmacokinetics and pharmacodynamics pathway of betaxolol, a selective beta adrenergic type 1 receptor antagonist used in the treatment of hypertension and glaucoma. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002161	betaxolol pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002160	betaxolol drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of betaxolol. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002162	betaxolol pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002160	betaxolol drug pathway		The pathway of betaxolol-target interaction and of the biochemical or physiological responses to drug. The drug is a selective antagonist of beta adrenergic type 1 receptor used in the treatment of hypertension and glaucoma. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002163	moexipril drug pathway	http://purl.obolibrary.org/obo/PW_0001228	ACE inhibitor drug pathway		The pharmacokinetics and pharmacodynamics of moexipril - an angiotensin converting enzyme (ACE) inhibitor. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002164	moexipril pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002163	moexipril drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of moexipril, an ACE inhibitor. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002165	moexipril pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002163	moexipril drug pathway		The pathway of moexipril-target interaction and of the biochemical or physiological responses to drug. The drug is an ACE inhibitor used for the treatment of hypertension and congestive heart failure. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002166	17-alpha-hydroxylase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001478	congenital adrenal hyperplasia pathway		A form of congenital hyperplasia resulting from defects in the CYP17A1 gene.
http://purl.obolibrary.org/obo/PW_0002167	21-alpha-hydroxylase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001478	congenital adrenal hyperplasia pathway		A form of congenital hyperplasia resulting from defects in the CYP21A2 gene.
http://purl.obolibrary.org/obo/PW_0002168	11-beta-hydroxylase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001478	congenital adrenal hyperplasia pathway		A form of congenital hyperplasia resulting from defects in the CYP11B1 gene.
http://purl.obolibrary.org/obo/PW_0002169	acebutolol drug pathway	http://purl.obolibrary.org/obo/PW_0001737	adrenergic beta receptor selective antagonist drug pathway		The pharmacokinetics and pharmacodynamics pathway of acebutolol, a selective beta adrenergic type 1 receptor antagonist used in the treatment of hypertension and arrhythmias. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002170	acebutolol pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002169	acebutolol drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of acebutolol. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002171	acebutolol pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002169	acebutolol drug pathway		The pathway of acebutolol-target interaction and of the biochemical or physiological responses to drug. The drug is a selective antagonist of beta adrenergic type 1 receptor. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002172	alendronate drug pathway	http://purl.obolibrary.org/obo/PW_0001621	nitrogenous bisphosphonate drug pathway		The pharmacokinetics and pharmacodynamics pathway of alendronate - a nitrogenous bisphosphonate drug used to treat bone diseases. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002173	alendronate pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002172	alendronate drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of alendronate, a nitrogenous bisphosphonate drug. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002174	alendronate pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002172	alendronate drug pathway		The pathway of alendronate-target interaction and of the biochemical or physiological responses to drug. Alendronate is a nitrogenous bisphosphonate drug used to treat bone diseases. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002175	pamidronate drug pathway	http://purl.obolibrary.org/obo/PW_0001621	nitrogenous bisphosphonate drug pathway		The pharmacokinetics and pharmacodynamics pathway of pamidronate - a nitrogenous bisphosphonate drug used to treat bone diseases. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002176	pamidronate pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002175	pamidronate drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of pamidronate, a nitrogenous bisphosphonate drug. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002177	pamidronate pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002175	pamidronate drug pathway		The pathway of pamidronate-target interaction and of the biochemical or physiological responses to drug. Pamidronate is a nitrogenous bisphosphonate drug used to treat bone diseases. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002180	genetic skin disease pathway	http://purl.obolibrary.org/obo/PW_0002178	skin disease pathway		Those skin diseases that contain a genetic component, usually resulting from inborn error of metabolism.
http://purl.obolibrary.org/obo/PW_0002181	prolidase deficiency pathway	http://purl.obolibrary.org/obo/PW_0002180	genetic skin disease pathway		A rare autosomal recessive disorder resulting from alterations in collagen metabolism and due to defects in the prolidase PEPD gene. The condition is manifested in skin ulcers and mental retardation.
http://purl.obolibrary.org/obo/PW_0002182	esomeprazole drug pathway	http://purl.obolibrary.org/obo/PW_0000918	proton pump inhibitor drug pathway		The pharmacokinetics and pharmacodynamics pathway of esomeprazole, a proton pump inhibitor. It is administered for the treatment of acid-related disorders. The drug inhibits the hydrogen potassium ATPase in the parietal cells of the stomach. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002183	esomeprazole pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002182	esomeprazole drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of esomeprazole, a compound in the class of proton pump inhibitors used in the treatment of acid-related disorders. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002184	esomeprazole pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002182	esomeprazole drug pathway		The pathway of esomeprazole-target interaction and of the biochemical or physiological responses to drug. Esomeprazole is a compound in the class of proton pump inhibitors used in the treatment of acid-related disorders. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002186	chlorothiazide drug pathway	http://purl.obolibrary.org/obo/PW_0002121	diuretic drug pathway		The pharmacokinetics and pharmacodynamics pathway of chlorothiazide, a drug used in the treatment of high blood pressure.  Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002187	chlorothiazide pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002186	chlorothiazide drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of chlorothiazide. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002188	chlorothiazide pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002186	chlorothiazide drug pathway		The pathway of chlorothiazide-target interaction and of the biochemical or physiological responses to drug. The drug reduces sodium reabsorption in the distal convoluted tubule of kidney nephron. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002189	buprenorphine drug pathway	http://purl.obolibrary.org/obo/PW_0002443	opioid drug pathway		The pharmacokinetics and pharmacodynamics pathway of buprenorphine, a semi-synthetic opioid and a mixed partial agonist opioid receptor modulator used to treat opioid addiction and to control moderate to acute pain. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002190	buprenorphine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002189	buprenorphine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of buprenorphine. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002191	buprenorphine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002189	buprenorphine drug pathway		The pathway of buprenorphine-target interaction and of the biochemical or physiological responses to drug. The drug is a non-selective, mixed agonist-antagonist opioid receptor modulator. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002192	bupivacaine drug pathway	http://purl.obolibrary.org/obo/PW_0002243	anesthetic drug pathway		The pharmacokinetics and pharmacodynamics pathway of bupivacaine, a drug used as a local anesthetic. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002193	bupivacaine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002192	bupivacaine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of bupivacaine. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002194	bupivacaine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002192	bupivacaine drug pathway		The pathway of bupivacaine-target interaction and of the biochemical or physiological responses to drug. It acts mainly as a voltage-gated sodium channel blocker. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002195	bendroflumethiazide drug pathway	http://purl.obolibrary.org/obo/PW_0002121	diuretic drug pathway		The pharmacokinetics and pharmacodynamics pathway of bendroflumethiazide, a drug used in the treatment of high blood pressure.  Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002196	bendroflumethiazide pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002195	bendroflumethiazide drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of bendroflumethiazide. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002197	bendroflumethiazide pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002195	bendroflumethiazide drug pathway		The pathway of bendroflumethiazide-target interaction and of the biochemical or physiological responses to drug. The drug reduces sodium reabsorption in the distal convoluted tubule of kidney nephron. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002198	azithromycin drug pathway	http://purl.obolibrary.org/obo/PW_0000996	anti-infective drug pathway		The pharmacokinetics and pharmacodynamics of azithromycin, an antibiotic that inhibits bacterial growth and used for the treatment of several bacterial infections and a number of sexually transmitted infections. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002199	azithromycin pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002198	azithromycin drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination of azithromycin - an antibiotic that interferes with bacterial growth. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002200	azithromycin pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002198	azithromycin drug pathway		The pathway of azithromycin-target interaction and of the biochemical or physiological responses to drug. The drug interferes with bacterial growth and is used for the treatment of several bacterial infections and a number of sexually transmitted infections. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002201	azathioprine drug pathway	http://purl.obolibrary.org/obo/PW_0002369	immunosuppressant drug pathway		The pharmacokinetics and pharmacodynamics pathway of azathioprine, an immunosupressive drug used in organ transplantation and autoimmune diseases. It is a prodrug for mercaptopurine, thus inhibiting DNA synthesis.  Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002202	azathioprine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002201	azathioprine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of azathioprine, a meracptopurine prodrug. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002203	azathioprine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002201	azathioprine drug pathway		The pathway of azathioprine-target interaction and of the biochemical or physiological responses to drug. It is an immunosupressive drug that inhibits DNA synthesis. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002204	2-aminoadipic 2-oxoadipic aciduria pathway	http://purl.obolibrary.org/obo/PW_0001645	inborn error of amino acid metabolism pathway		An inherited condition resulting from alterations in lysine metabolism. Mutations in the DHTKD1 gene, encoding an enzyme involved in the lysine degradation pathway, have been associated with the condition.
http://purl.obolibrary.org/obo/PW_0002205	2-hydroxyglutaric aciduria pathway	http://purl.obolibrary.org/obo/PW_0001646	inborn error of brain metabolic pathway		An autosomal recessive neurometabolic disorder with several phenotypes and due to mutations in the L2HGDH gene (the L-type), D2HGDH and IDH2 genes (the D-type). A combined L- and D-type has also been observed and has been attributed to mutations in the SLC25A1 gene.
http://purl.obolibrary.org/obo/PW_0002206	ethylmalonic encephalopathy pathway	http://purl.obolibrary.org/obo/PW_0001646	inborn error of brain metabolic pathway		An autosomal recessive metabolic disorder affecting the brain and peripheral vessels and manifested in infancy. Genetic studies identify defects in the ETHE1 gene, a mitochondrial resident gene product, thus pointing to implications in many aspects of mitochondrial metabolism and homeostasis.
http://purl.obolibrary.org/obo/PW_0002207	autonomic nervous system disease pathway	http://purl.obolibrary.org/obo/PW_0001412	nervous system disease pathway		Conditions of the parasympathetic and sympathetic divisions of the autonomic nervous system.
http://purl.obolibrary.org/obo/PW_0002208	dopamine beta-hydroxylase deficiency pathway	http://purl.obolibrary.org/obo/PW_0002207	autonomic nervous system disease pathway		A condition resulting from alterations in the pathways of norepinephrine and epinephrine biosynthesis due to defects in the dopamine beta-hydroxylase gene (DBH). DBH catalyzes the conversion of dopamine to norepinephrine, in turn the precursor to epinephrine.
http://purl.obolibrary.org/obo/PW_0002209	dimethylglycine dehydrogenase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001645	inborn error of amino acid metabolism pathway		An autosomal recessive disorder resulting in alterations in glycine, choline and folate metabolism and due to mutations in DMGDH gene.
http://purl.obolibrary.org/obo/PW_0002210	dihydropyrimidine dehydrogenase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001776	inborn error of purine-pyrimidine metabolism pathway		An autosomal recessive disorder resulting from alterations in pyrimidine degradation pathway due to mutations in dihydropyrimidine gene (DPYD). DPYD catalyzes the initial and rate-limiting step in pyrimidine bases (uracil and thymine) catabolism.
http://purl.obolibrary.org/obo/PW_0002211	dihydropyrimidinase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001776	inborn error of purine-pyrimidine metabolism pathway		An autosomal recessive disorder resulting from alterations in pyrimidine degradation pathway due to mutations in dihydropyrimidinase gene (DPYS). DPYS catalyzes the second step in pyrimidine bases (uracil and thymine) catabolism.
http://purl.obolibrary.org/obo/PW_0002212	D-glycericacidemia pathway	http://purl.obolibrary.org/obo/PW_0001644	inborn error of carbohydrate metabolism pathway		A very rare autosomal recessive condition resulting from alterations in glycerolipid metabolism due to defects in the glycerate kinase (GLYCTK) gene.
http://purl.obolibrary.org/obo/PW_0002213	inborn error of renal tubular transport pathway	http://purl.obolibrary.org/obo/PW_0001589	inborn error of metabolism pathway		Conditions resulting from genetic defects in the selective or non-selective transport pathways of kidney tubules.
http://purl.obolibrary.org/obo/PW_0002214	cystinuria pathway	http://purl.obolibrary.org/obo/PW_0002213	inborn error of renal tubular transport pathway		An autosomal condition resulting from impaired epithelial transport of cystine and dibasic amino acids in the proximal renal tubule. It is further classified based on differences in the genetic basis of the disorder.
http://purl.obolibrary.org/obo/PW_0002215	guanidinoacetate methyltransferase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001611	movement disorder pathway		An autosomal recessive condition resulting from alterations in creatine metabolism due to mutations in the GAMT gene.
http://purl.obolibrary.org/obo/PW_0002216	erythropoietic porphyria pathway	http://purl.obolibrary.org/obo/PW_0001784	porphyria pathway		An autosomal recessive condition due to defects in the uroporphyrinogen III synthase gene.
http://purl.obolibrary.org/obo/PW_0002217	cystinosis pathway	http://purl.obolibrary.org/obo/PW_0001630	lysosomal storage disease pathway		A condition resulting from alterations in the transport of cystine across the lysosomal membrane due to defects in the lysosomal cystine transporter, cystinosin (CTNS).
http://purl.obolibrary.org/obo/PW_0002218	ocular nonnephropathic cystinosis pathway	http://purl.obolibrary.org/obo/PW_0002217	cystinosis pathway		A variant of the classic nephropathic cystinosis type.
http://purl.obolibrary.org/obo/PW_0002220	carbamoyl phosphate synthetase I deficiency pathway	http://purl.obolibrary.org/obo/PW_0002142	inborn error of urea cycle pathway		An autosomal recessive disorder resulting from alterations in the urea cycle pathway and due to defects in the hepatic mitochondrial enzyme carbamoyl phosphate synthetase 1.
http://purl.obolibrary.org/obo/PW_0002221	aprotinin drug pathway	http://purl.obolibrary.org/obo/PW_0001652	antihemorrhagic drug pathway		The pharmacokinetics and pharmacodynamics pathway of aprotinin, an antifibrinolytic inhibitor of trypsin and other serine proteases, used to reduce bleeding during surgery. Once withdrawn from the market, it has been reintroduced. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002222	aprotinin pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002221	aprotinin drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of aprotinin. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002223	aprotinin pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002221	aprotinin drug pathway		The pathway of aprotinin-target interaction and of the biochemical or physiological responses to drug. Aprotinin is a serine protease inhibitor of trypsin, chymotrypsin and others. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002224	arbekacin drug pathway	http://purl.obolibrary.org/obo/PW_0000996	anti-infective drug pathway		The pharmacokinetics and pharmacodynamics of arbekacin, an antibiotic used for the treatment of infections caused by multi-resistant bacteria. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002225	arbekacin pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002224	arbekacin drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of arbekacin. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002226	arbekacin pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002224	arbekacin drug pathway		The pathway of arbekacin-target interaction and of the biochemical or physiological responses to drug. Arbekacin inhibits protein synthesis by irreversibly binding to bacterial 30S ribosomal subunit. The drug is used for the treatment of infections caused by multi-resistant bacteria. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002227	argatrobran drug pathway	http://purl.obolibrary.org/obo/PW_0002146	direct thrombin inhibitor drug pathway		The pharmacokinetics and pharmacodynamics pathway of argatroban, a direct thrombin inhibitor. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002228	argatrobran pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002227	argatrobran drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of argatroban, a direct thrombin inhibitor. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002229	argatroban pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002227	argatrobran drug pathway		The pathway of argatroban-target interaction and of the biochemical or physiological responses to drug. The drug is a direct thrombin inhibitor. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002230	atenolol drug pathway	http://purl.obolibrary.org/obo/PW_0001737	adrenergic beta receptor selective antagonist drug pathway		The pharmacokinetics and pharmacodynamics pathway of atenotolol, a selective beta adrenergic type 1 receptor antagonist used in the treatment of hypertension. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002231	atenolol pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002230	atenolol drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of atenolol. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002232	atenolol pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002230	atenolol drug pathway		The pathway of atenolol-target interaction and of the biochemical or physiological responses to drug. The drug is a selective antagonist of beta adrenergic type 1 receptor. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002233	gastrointestinal disease pathway	http://purl.obolibrary.org/obo/PW_0001697	digestive system disease pathway		The various conditions affecting any segment of the gastrointestinal tract resulting from alterations in one or several pathways.
http://purl.obolibrary.org/obo/PW_0002234	folic acid deficiency pathway	http://purl.obolibrary.org/obo/PW_0001584	avitaminosis pathway		A condition resulting from inadequate levels of folic acid in the diet and manifested as various forms of anemia. In certain tissues, the condition is indistinguishable from vitamin B deficiency.
http://purl.obolibrary.org/obo/PW_0002235	malabsorption syndrome pathway	http://purl.obolibrary.org/obo/PW_0002366	intestinal disease pathway		The group of syndromes resulting from failure of normal intestinal absorption of nutrients.
http://purl.obolibrary.org/obo/PW_0002236	hereditary folate malabsorption pathway	http://purl.obolibrary.org/obo/PW_0002235	malabsorption syndrome pathway		An autosomal recessive condition likely due to alterations in folate transport and exhibiting the symptoms of folate deficiency.
http://purl.obolibrary.org/obo/PW_0002237	penbutolol drug pathway	http://purl.obolibrary.org/obo/PW_0001738	adrenergic beta receptor non-selective antagonist drug pathway		The pharmacokinetics and pharmacodynamics pathway of penbutolol - a non-selective adrenergic beta receptor blocker, used in the treatment of high blood pressure. Penbutolol is a sympathomimetic drug. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002238	penbutolol pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002237	penbutolol drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of penbutolol. The drug is a non-selective adrenergic beta receptor blocker. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002239	penbutolol pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002237	penbutolol drug pathway		The pathway of penbutolol-target interaction and of the biochemical or physiological responses to drug. The drug is non-selective blocker of adrenergic receptor beta. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002240	oxeprenolol drug pathway	http://purl.obolibrary.org/obo/PW_0001738	adrenergic beta receptor non-selective antagonist drug pathway		The pharmacokinetics and pharmacodynamics pathway of oxeprenolol - a non-selective adrenergic beta receptor blocker, used for the treatment of angina, high blood pressure and abnormal heart rhythms. The drug has some intrinsic sympathomimetic properties. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002241	oxeprenolol pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002240	oxeprenolol drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of oxeprenolol. The drug is a non-selective adrenergic beta receptor blocker. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002242	oxeprenolol pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002240	oxeprenolol drug pathway		The pathway of oxeprenolol-target interaction and of the biochemical or physiological responses to drug. The drug is non-selective blocker of adrenergic receptor beta. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002243	anesthetic drug pathway	http://purl.obolibrary.org/obo/PW_0000923	nervous system drug pathway		The pharmacokinetics and pharmacodynamics of compounds used to cause reversible loss of sensation and generally administered to facilitate surgery.
http://purl.obolibrary.org/obo/PW_0002244	prilocaine drug pathway	http://purl.obolibrary.org/obo/PW_0002243	anesthetic drug pathway		The pharmacokinetics and pharmacodynamics pathway of prilocaine, a drug used as a local anesthetic. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002245	prilocaine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002244	prilocaine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of prilocaine. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002246	prilocaine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002244	prilocaine drug pathway		The pathway of prilocaine-target interaction and of the biochemical or physiological responses to drug. The drug exerts its effects by blocking the voltage-gated sodium channels. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002247	ropivacaine drug pathway	http://purl.obolibrary.org/obo/PW_0002243	anesthetic drug pathway		The pharmacokinetics and pharmacodynamics pathway of ropivacaine, a drug used as a local anesthetic. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002248	ropivacaine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002247	ropivacaine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of ropivacaine. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002249	ropivacaine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002247	ropivacaine drug pathway		The pathway of ropivacaine-target interaction and of the biochemical or physiological responses to drug. The drug exerts its effects by blocking the voltage-gated sodium channels. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002250	torasemide drug pathway	http://purl.obolibrary.org/obo/PW_0002121	diuretic drug pathway		The pharmacokinetics and pharmacodynamics pathway of torasemide, a diuretic drug mainly used in the management of edema associated with congestive heart failure. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002251	torasemide pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002250	torasemide drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of torasemide. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002252	torasemide pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002250	torasemide drug pathway		The pathway of torasemide-target interaction and of the biochemical or physiological responses to drug. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002253	multiple carboxylase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001645	inborn error of amino acid metabolism pathway		Autosomal recessive conditions resulting from alterations in biotin metabolism.
http://purl.obolibrary.org/obo/PW_0002254	biotinidase deficiency pathway	http://purl.obolibrary.org/obo/PW_0002253	multiple carboxylase deficiency pathway		A late onset form of multiple carboxylase deficiency due to defects in the biotin recycling biotinidase enzyme.
http://purl.obolibrary.org/obo/PW_0002255	holocarboxylase synthetase deficiency pathway	http://purl.obolibrary.org/obo/PW_0002253	multiple carboxylase deficiency pathway		The neonatal form of multiple carboxylase deficiency due to defects in holocarboxylase synthetase, the enzyme catalyzing the covalent attachment of biotin to biotin-dependent carboxylases.
http://purl.obolibrary.org/obo/PW_0002256	reteplase drug pathway	http://purl.obolibrary.org/obo/PW_0002152	thrombolytic drug pathway		The pharmacokinetics and pharmacodynamics pathway of reteplase - one of several recombinant tissue plasminogen activators. Plasminogen is a key player in the fibrinolytic cascade pathway of blood clots breakdown. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002257	reteplase pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002256	reteplase drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of reteplase, one of several recombinant tissue plasminogen activators. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002258	reteplase pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002256	reteplase drug pathway		The pathway of reteplase-target interaction and of the biochemical or physiological responses to drug. Reteplase is one of several recombinant tissue plasminogen activators. Reteplase is used to treat heart attack. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002259	nadolol drug pathway	http://purl.obolibrary.org/obo/PW_0001738	adrenergic beta receptor non-selective antagonist drug pathway		The pharmacokinetics and pharmacodynamics pathway of nadolol - a non-selective adrenergic beta receptor blocker, used in the treatment of high blood pressure. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002260	nadolol pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002259	nadolol drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of nadolol. The drug is a non-selective adrenergic beta receptor blocker. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002261	nadolol pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002259	nadolol drug pathway		The pathway of nadolol-target interaction and of the biochemical or physiological responses to drug. The drug is non-selective blocker of adrenergic receptor beta. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002262	pindolol drug pathway	http://purl.obolibrary.org/obo/PW_0001738	adrenergic beta receptor non-selective antagonist drug pathway		The pharmacokinetics and pharmacodynamics pathway of pindolol - a non-selective adrenergic beta receptor blocker, used in the treatment of high blood pressure. Pindolol is a sympathomimetic drug. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002263	pindolol pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002262	pindolol drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of pindolol. The drug is a non-selective adrenergic beta receptor blocker. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002264	pindolol pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002262	pindolol drug pathway		The pathway of pindolol-target interaction and of the biochemical or physiological responses to drug. The drug is non-selective blocker of adrenergic receptor beta. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002265	teniposide drug pathway	http://purl.obolibrary.org/obo/PW_0002367	antineoplastic drug pathway		The pharmacokinetics and pharmacodynamics pathway of teniposide, a drug used to treat childhood leukemia. The drug inhibits DNA synthesis. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002266	teniposide pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002265	teniposide drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of teniposide. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002267	teniposide pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002265	teniposide drug pathway		The pathway of teniposide-target interactions and of the biochemical or physiological responses to drug. The drug is used in the treatment of certain cancers and its mode of action is believed to be inhibition of DNA synthesis. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002268	zoledronate drug pathway	http://purl.obolibrary.org/obo/PW_0001621	nitrogenous bisphosphonate drug pathway		The pharmacokinetics and pharmacodynamics pathway of zoledronate - a nitrogenous bisphosphonate drug used to treat bone diseases. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002269	zoledronate pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002268	zoledronate drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of zoledronate, a nitrogenous bisphosphonate drug. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002270	zoledronate pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002268	zoledronate drug pathway		The pathway of zoledronate-target interaction and of the biochemical or physiological responses to drug. Zoledronate is a nitrogenous bisphosphonate drug used to treat bone diseases. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002271	eplerenone drug pathway	http://purl.obolibrary.org/obo/PW_0002121	diuretic drug pathway		The pharmacokinetics and pharmacodynamics pathway of eplrenone, a drug used as an adjunct in the management of chronic heart failure. enetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002272	eplerenone pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002271	eplerenone drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of eplerenone. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002273	eplerenone pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002271	eplerenone drug pathway		The pathway of eplerenone-target interaction and of the biochemical or physiological responses to drug. Eplerenone is an antagonist of the mineralocorticoid receptor and indicated for the reduction of cardiovascular death risk in people with heart failure.  Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002274	3-methylglutaconic aciduria type 1 pathway	http://purl.obolibrary.org/obo/PW_0001589	inborn error of metabolism pathway		A rare autosomal recessive condition resulting from alterations in leucine metabolism.
http://purl.obolibrary.org/obo/PW_0002275	3-methylglutaconic aciduria type 3 pathway	http://purl.obolibrary.org/obo/PW_0001611	movement disorder pathway		A syndrome consisting of early-onset bilateral optic atrophy associated with later-onset spasticity and cognitive deficit.
http://purl.obolibrary.org/obo/PW_0002276	adenylosuccinate lyase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001776	inborn error of purine-pyrimidine metabolism pathway		An autosomal recessive condition resulting from alteration in the de novo purine biosynthetic pathway.
http://purl.obolibrary.org/obo/PW_0002277	alkaptonuria pathway	http://purl.obolibrary.org/obo/PW_0001645	inborn error of amino acid metabolism pathway		An autosomal recessive condition resulting from alterations in the metabolism of phenylalanine and tyrosine.
http://purl.obolibrary.org/obo/PW_0002278	fenoprofen drug pathway	http://purl.obolibrary.org/obo/PW_0001170	musculo-skeletal system drug pathway		The pharmacokinetics and pharmacodynamics pathway of fenoprofen, a non-steroidal anti-inflammatory drug used  in the treatment of rheumatoid arthritis and mild pain. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002279	fenoprofen pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002278	fenoprofen drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of fenoprofen. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002280	fenoprofen pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002278	fenoprofen drug pathway		The pathway of fenoprofen-target interaction and of the biochemical or physiological responses to drug. The drug is used in the treatment of rheumatoid arthritis and mild pain.  Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002281	various drug pathway	http://purl.obolibrary.org/obo/PW_0000754	drug pathway		One of the subgroups of the Therapeutic Chemical  Classification System developed by WHO for grouping drugs acting as antidotes, chelators, detoxifying agents, and others. The pharmacokinetics and pharmacodynamics of such agents. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002282	naloxone drug pathway	http://purl.obolibrary.org/obo/PW_0002281	various drug pathway		The pharmacokinetics and pharmacodynamics of naloxone, a medication used to reverse the effects opioids overdose. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002283	naloxone pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002282	naloxone drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of naloxone. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002284	naloxone pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002282	naloxone drug pathway		The pathway of naloxone-target interaction and of the biochemical or physiological responses to drug. Naloxone is a mu-opioid receptor competitive antagonist. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002285	porphyrin metabolic pathway	http://purl.obolibrary.org/obo/PW_0000190	porphyrin and chlorophyll metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of porphyrins. Porphyrins represent a group of heterocyclic macrocycle organic compounds. Many are naturally occurring and one best example is the red blood cell heme pigment.
http://purl.obolibrary.org/obo/PW_0002286	cilostazol drug pathway	http://purl.obolibrary.org/obo/PW_0002150	antiplatelet drug pathway		The pharmacokinetics and pharmacodynamics pathway of cilostazol, a platelet aggregation inhibitor. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002287	cilostazol pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002286	cilostazol drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of cilostazol, a platelet aggregation inhibitor. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002288	cilostazol pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002286	cilostazol drug pathway		The pathway of cilostazol-interaction and of the biochemical or physiological responses to drug. The drug is a selective inhibitor of phosphodiesterase type 3. The increase in cyclic AMP (cAMP) and subsequent increase in active protein kinase A (PKA) leads to inhibition of platelet aggregation. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002289	malonic aciduria pathway	http://purl.obolibrary.org/obo/PW_0001589	inborn error of metabolism pathway		A rare inherited metabolic condition due to alterations in the activity of malonyl-CoA decarboxylase.
http://purl.obolibrary.org/obo/PW_0002290	hyperargininemia pathway	http://purl.obolibrary.org/obo/PW_0002142	inborn error of urea cycle pathway		A rare autosomal condition resulting from alterations in the urea cycle pathway and due to defects in the arginase enzyme.
http://purl.obolibrary.org/obo/PW_0002291	carnitine metabolic pathway	http://purl.obolibrary.org/obo/PW_0000132	metabolic pathway of other amino acids		Those metabolic reactions involved in the synthesis, utilization and/or degradation of carnitine. Carnitine is derived from lysine and methionine and is important for fatty acid transport into the mitochondrial matrix.
http://purl.obolibrary.org/obo/PW_0002292	carnitine biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0002291	carnitine metabolic pathway		Those metabolic reactions involved in the synthesis of carnitine. It involves the amino acids lysine and methionine and it largely occurs in the kidney and liver.
http://purl.obolibrary.org/obo/PW_0002293	carnitine degradation pathway	http://purl.obolibrary.org/obo/PW_0002291	carnitine metabolic pathway		Those metabolic reactions resulting in the breakdown of carnitine.
http://purl.obolibrary.org/obo/PW_0002294	AICA-ribosuria pathway	http://purl.obolibrary.org/obo/PW_0001589	inborn error of metabolism pathway		A condition resulting from alterations in the de novo purine biosynthetic pathway and due to defects in the enzyme catalyzing the final steps.
http://purl.obolibrary.org/obo/PW_0002295	antiepileptic drug pathway	http://purl.obolibrary.org/obo/PW_0000923	nervous system drug pathway		The pharmacokinetics and pharmacodynamics of compounds used in the treatment of epilepsy or seizure. Some can also act as mood stabilizers.
http://purl.obolibrary.org/obo/PW_0002296	fosphenytoin drug pathway	http://purl.obolibrary.org/obo/PW_0002295	antiepileptic drug pathway		The pharmacokinetics and pharmacodynamics pathway of fosphenytoin, a drug used in the treatment of acute convulsive epileptic seizure. Fosphenytoin is a water-soluble phenytoin prodrug. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002297	fosphenytoin pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002296	fosphenytoin drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of fosphenytoin, a prodrug used for the treatment of epilepsy. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002298	fosphenytoin pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002296	fosphenytoin drug pathway		The pathway of fosphenytoin-target interaction and of the biochemical or physiological responses to drug. Fosphenytoin is a water-soluble phenytoin prodrug used for the treatment of epilepsy. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002299	glycine N-methyltransferase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001645	inborn error of amino acid metabolism pathway		A condition due to defects in glycine N-methyltransferase (GNMT). As a component of methionine, homocysteine and folate metabolism among others, the defective enzyme potentially disrupts many metabolic pathways.
http://purl.obolibrary.org/obo/PW_0002300	nervous system lysosomal storage disease pathway	http://purl.obolibrary.org/obo/PW_0001646	inborn error of brain metabolic pathway		The lysosomal storage disease pathways affecting the nervous system.
http://purl.obolibrary.org/obo/PW_0002301	sphingolipidosis pathway	http://purl.obolibrary.org/obo/PW_0002300	nervous system lysosomal storage disease pathway		A group of inherited metabolic disorders resulting in abnormal accumulation of sphingolipids in the central nervous system and also visceral organs due to defects in their degradation pathway.
http://purl.obolibrary.org/obo/PW_0002302	familial hypercholanemia pathway	http://purl.obolibrary.org/obo/PW_0002102	inborn error of steroid metabolism pathway		A condition characterized by elevated serum bile acid concentration that can be due to defects in any of several genes.
http://purl.obolibrary.org/obo/PW_0002303	indometacin drug pathway	http://purl.obolibrary.org/obo/PW_0001546	analgesic and/or antipyretic drug pathway		The pharmacokinetics and pharmacodynamics pathway of indometacin, a non-steroidal anti-inflammatory drug that inhibits cyclooxygenase enzymes and is used in the treatment of inflammation and pain and to reduce fever. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002304	indometacin pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002303	indometacin drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of indometacin. The drug is used in the treatment of pain and inflammation and to reduce fever. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002305	indometacin pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002303	indometacin drug pathway		The pathway of indometacin-target interaction and of the biochemical or physiological responses to drug. Indometcin is an inhibitor of cyclooxygenase enzymes used in the treatment of pain and inflammation and to reduce fever. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002306	glutaric aciduria type I pathway	http://purl.obolibrary.org/obo/PW_0001645	inborn error of amino acid metabolism pathway		An autosomal recessive condition resulting from alterations in several metabolic pathways due to defects in the GCDH gene.
http://purl.obolibrary.org/obo/PW_0002307	levobunolol drug pathway	http://purl.obolibrary.org/obo/PW_0002159	sensory organ drug pathway		The pharmacokinetics and pharmacodynamics pathway of levobunolol, a non-selective beta adrenergic receptor antagonist used in the treatment of glaucoma. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002308	levobunolol pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002307	levobunolol drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of levobunolol. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002309	levobunolol pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002307	levobunolol drug pathway		The pathway of levobunolol-target interaction and of the biochemical or physiological responses to drug. The drug is a non-selective antagonist of beta adrenergic used in the treatment of glaucoma. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002310	doxepin drug pathway	http://purl.obolibrary.org/obo/PW_0002113	non-selective monoamine reuptake inhibitor drug pathway		The pharmacokinetics and pharmacodynamics pathway of desipramine, an antidepressant used in the treatment of depression, anxiety disorders, insomnia. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002311	doxepin pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002310	doxepin drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of doxepin. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002312	doxepin pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002310	doxepin drug pathway		The pathway of doxepin-target interaction and of the biochemical or physiological responses to drug. The drug is used in the treatment of depression, anxiety disorders, insomnia. Its effects result from inhibition of serotonin and norepinephrine neurotransmitter reuptake. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002313	indometacin drug pathway	http://purl.obolibrary.org/obo/PW_0001170	musculo-skeletal system drug pathway		The pharmacokinetics and pharmacodynamics pathway of indometacin, a non-steroidal anti-inflammatory drug that inhibits cyclooxygenase enzymes. It is commonly used to reduce fever, pain and swelling in wide range of conditions. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002314	indometacin pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002313	indometacin drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of indometacin. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002315	indometacin pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002313	indometacin drug pathway		The pathway of indometacin-target interaction and of the biochemical or physiological responses to drug. Indometacin is an inhibitor of cyclooxygenase enzymes and commonly used to reduce fever, pain and swelling in a wide range of conditions. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002316	psychostimulant drug pathway	http://purl.obolibrary.org/obo/PW_0000923	nervous system drug pathway		The pharmacokinetics and pharmacodynamics pathway of psychoactive drugs that can induce an improvement in the  mental or physical activity. While such drugs are used as prescription medicine they can also be abused and some substances in this category are illicit.
http://purl.obolibrary.org/obo/PW_0002317	caffeine drug pathway	http://purl.obolibrary.org/obo/PW_0002316	psychostimulant drug pathway		The pharmacokinetics and pharmacodynamics pathway of caffeine, a psychostimulant of the methylxanthine class. It can confer some protective effects against some conditions. It is largely considered safe but the pure powdered caffeine, available as dietary supplement, can be lethal in higher amounts. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002318	caffeine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002317	caffeine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of caffeine, a widely used stimulant of the central nervous system. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002319	caffeine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002317	caffeine drug pathway		The pathway of caffeine-target interaction and of the biochemical or physiological responses to drug. Caffeine is an antagonist of adenosine receptors of all types. As such, it stimulates vasomotor and respiratory centers and also promotes neurotransmitter release. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002320	trichlormethiazide drug pathway	http://purl.obolibrary.org/obo/PW_0002121	diuretic drug pathway		The pharmacokinetics and pharmacodynamics pathway of trichlormethiazide, a drug used in the treatment of high blood pressure.  Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002321	trichlormethiazide pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002320	trichlormethiazide drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of trichlormethiazide. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002322	trichlormethiazide pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002320	trichlormethiazide drug pathway		The pathway of trichlormethiazide-target interaction and of the biochemical or physiological responses to drug. The drug is thought to block reabsorption of chloride and possibly sodium in the ascending loop of Henle. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002323	3-hydroxy-3-methylglutaryl-CoA lyase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001645	inborn error of amino acid metabolism pathway		A rare autosomal condition resulting from alterations in several metabolic pathways and due to defects in the HMGCL gene.
http://purl.obolibrary.org/obo/PW_0002324	aromatic L-amino acid decarboxylase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001645	inborn error of amino acid metabolism pathway		An autosomal recessive condition resulting from alterations in neurotransmitter metabolism and due to defects in the AADC gene.
http://purl.obolibrary.org/obo/PW_0002325	vitamin K antagonist drug pathway	http://purl.obolibrary.org/obo/PW_0002151	anticoagulant drug pathway		The pharmacokinetics and pharmacodynamics pathway of drugs that prevent the coagulation of blood acting as vitamin K inhibitors . Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002326	heparin group drug pathway	http://purl.obolibrary.org/obo/PW_0002151	anticoagulant drug pathway		The pharmacokinetics and pharmacodynamics pathway of heparin group drugs that reduce or prevent the formation of blood clots by activating the antithrombin III (AT) thrombin inhibitor. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002327	heparin drug pathway	http://purl.obolibrary.org/obo/PW_0002326	heparin group drug pathway		The pharmacokinetics and pharmacodynamics pathway of heparin, a naturally occurring anticoagulant produced by basophils and mast cells. Heparin, and its low molecular weight derivative, bind to and activates the thrombin enzyme inhibitor antithrombin III. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002328	heparin pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002327	heparin drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of heparin. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002329	heparin pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002327	heparin drug pathway		The pathway of heparin-target interaction and of the biochemical or physiological responses to drug. Heparin is a naturally occurring anticoagulant that binds to and activates the thrombin inhibitor antithrombin III (AT). Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002330	enoxaparin drug pathway	http://purl.obolibrary.org/obo/PW_0002326	heparin group drug pathway		The pharmacokinetics and pharmacodynamics pathway of enoxaparin, a low molecular weight heparin derivative. The drug is an anticoagulant that activates the thrombin inhibitor antithrombin III (AT). Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002331	enoxaparin pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002330	enoxaparin drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of enoxaparin. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002332	enoxaparin pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002330	enoxaparin drug pathway		The pathway of enoxaparin-target interaction and of the biochemical or physiological responses to drug. Enoxaparin is a low molecular weight heparin derivative anticoagulant that binds to and activates the thrombin inhibitor antithrombin III (AT). Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002333	phenytoin drug pathway	http://purl.obolibrary.org/obo/PW_0002336	antiarrhythmic drug pathway		The pharmacokinetics and pharmacodynamics pathway of fosphenytoin, an anti-seizure medication also used for certain heart arrhythmias. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002334	phenytoin pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002333	phenytoin drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of phenytoin. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002335	phenytoin pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002333	phenytoin drug pathway		The pathway of phenytoin-target interaction and of the biochemical or physiological responses to drug. The drug is used as an anti-seizure medication and also for certain heart arrhythmias. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002336	antiarrhythmic drug pathway	http://purl.obolibrary.org/obo/PW_0000920	cardiovascular system drug pathway		The pharmacokinetics and pharmacodynamics pathway of drugs used in the treatment of arrythmias.  Some beta receptor and channel blockers may also act as antiarrhythmic agents. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002337	mexiletine drug pathway	http://purl.obolibrary.org/obo/PW_0002336	antiarrhythmic drug pathway		The pharmacokinetics and pharmacodynamics pathway of mexiletine, a drug used in the treatment of cardiac arrhythmias. Mexiletine is a non-selective voltage-gated sodium channel blocker of the Class IB antiarrhythimc drugs. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002338	mexiletine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002337	mexiletine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of mexiletine. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002339	mexiletine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002337	mexiletine drug pathway		The pathway of mexiletine-target interaction and of the biochemical or physiological responses to drug. The drug is a non-selective voltage-gated sodium channel blocker  antiarrhythmic agent. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002340	muscular disease pathway	http://purl.obolibrary.org/obo/PW_0001593	musculoskeletal disease pathway		Those conditions, acquired, familial or congenital, affecting the skeletal muscle and/or smooth muscle.
http://purl.obolibrary.org/obo/PW_0002341	muscle hypertonia disorder pathway	http://purl.obolibrary.org/obo/PW_0002096	neuromuscular manifestation of disease pathway		A disorder manifested by abnormal increase in skeletal or smooth muscle tone.
http://purl.obolibrary.org/obo/PW_0002342	muscle spasticity disorder pathway	http://purl.obolibrary.org/obo/PW_0002341	muscle hypertonia disorder pathway		A form of muscle hypertonia associated with upper motor neuron dysfunction.
http://purl.obolibrary.org/obo/PW_0002343	methylenetetrahydrofolate reductase deficiency pathway	http://purl.obolibrary.org/obo/PW_0002342	muscle spasticity disorder pathway		A rather common condition resulting from alterations in folate metabolism and due to defects in methylenetetrahydrofolate reductase (MTHFR) gene.
http://purl.obolibrary.org/obo/PW_0002344	etoposide drug pathway	http://purl.obolibrary.org/obo/PW_0002367	antineoplastic drug pathway		The pharmacokinetics and pharmacodynamics pathway of etoposide, a cytotoxic anticancer drug in the topoisomerase inhibitor class. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002345	etoposide pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002344	etoposide drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of etoposide. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002346	etoposide pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002344	etoposide drug pathway		The pathway of etoposide-target interactions and of the biochemical or physiological responses to drug. Etoposide is a cytotoxic anticancer drug in the topoisomerase inhibitor class. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002347	cholesterol ester storage disease pathway	http://purl.obolibrary.org/obo/PW_0001643	inborn error of lipid metabolism pathway		An autosomal recessive condition due to defects in the acid lipase gene.
http://purl.obolibrary.org/obo/PW_0002348	lornoxicam drug pathway	http://purl.obolibrary.org/obo/PW_0001546	analgesic and/or antipyretic drug pathway		The pharmacokinetics and pharmacodynamics pathway of lornoxicam, a non-steroidal anti-inflammatory drug with analgesic, anti-inflammatory and antipyretic properties Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002349	lornoxicam pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002348	lornoxicam drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of lornoxicam. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002350	lornoxicam pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002348	lornoxicam drug pathway		The pathway of lornoxicam-target interaction and of the biochemical or physiological responses to drug. The drug is used to relieve various types of pain. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002351	trastuzumab drug pathway	http://purl.obolibrary.org/obo/PW_0002370	monoclonal antibody drug pathway		The pharmacokinetics and pharmacodynamics pathway of trastuzumab, a monoclonal antibody that interferes with the epidermal growth factor receptor 2, overexpressed in certain cancer types. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002352	trastuzumab pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002351	trastuzumab drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of trastuzumab. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002353	trastuzumab pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002351	trastuzumab drug pathway		The pathway of trastuzumab-target interaction and of the biochemical or physiological responses to drug. The drug interferes with the epidermal growth factor receptor 2, overexpressed in certain cancer types. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002354	antiparasitic drug pathway	http://purl.obolibrary.org/obo/PW_0000754	drug pathway		The pharmacokinetics and pharmacodynamics of compounds used as antiparasitic agents. Genetic variations can result in changes in drug availability.
http://purl.obolibrary.org/obo/PW_0002355	artemether drug pathway	http://purl.obolibrary.org/obo/PW_0002354	antiparasitic drug pathway		The pharmacokinetics and pharmacodynamics pathway of artemether, an antimalarial agent. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002356	artemether pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002355	artemether drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of artemether. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002357	artemether pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002355	artemether drug pathway		The pathway of artemether-target interactions and of the biochemical or physiological responses to drug. Artemether is used to treat malaria.  Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002358	neurodevelopmental disorder pathway	http://purl.obolibrary.org/obo/PW_0000240	neuropsychiatric disease pathway		A group of mental disorders whose onset is in the developmental period.
http://purl.obolibrary.org/obo/PW_0002359	AGAT deficiency pathway	http://purl.obolibrary.org/obo/PW_0002358	neurodevelopmental disorder pathway		An autosomal recessive condition characterized by developmental delay and mental retardation due to defects in the GATM gene.
http://purl.obolibrary.org/obo/PW_0002360	Fanconi syndrome pathway	http://purl.obolibrary.org/obo/PW_0002213	inborn error of renal tubular transport pathway		Condition resulting from genetic defects in the selective or non-selective transport functions of the kidney tubules.
http://purl.obolibrary.org/obo/PW_0002361	remifentanil drug pathway	http://purl.obolibrary.org/obo/PW_0002443	opioid drug pathway		The pharmacokinetics and pharmacodynamics pathway of remifentanil, a synthetic opioid analgesic used in general anesthesia.  Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002362	remifentanil pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002361	remifentanil drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of remifentanil. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002363	remifentanil pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002361	remifentanil drug pathway		The pathway of remifentanil-target interaction and of the biochemical or physiological responses to drug. The drug is a synthetic opioid analgesic used in general anesthesia. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002364	mitochondrial encephalomyopathy pathway	http://purl.obolibrary.org/obo/PW_0001669	mitochondrial disease pathway		A heterogeneous group of disorders triggered  by alterations in mitochondria metabolism and resulting in dysfunction in muscle and nervous system.
http://purl.obolibrary.org/obo/PW_0002365	mitochondrial neurogastrointestinal encephalopathy syndrome pathway	http://purl.obolibrary.org/obo/PW_0002366	intestinal disease pathway		A severe autosomal recessive disorder due to defects in the p53-inducible ribonucleotide reductase RRM2B.
http://purl.obolibrary.org/obo/PW_0002366	intestinal disease pathway	http://purl.obolibrary.org/obo/PW_0002233	gastrointestinal disease pathway		Conditions affecting any segment of the intestine.
http://purl.obolibrary.org/obo/PW_0002367	antineoplastic drug pathway	http://purl.obolibrary.org/obo/PW_0000919	antineoplastic and immunomodulatory drug pathway		The pharmacokinetics and pharmacodynamics pathway of drugs used in the treatment of various cancers. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002368	immunostimulant drug pathway	http://purl.obolibrary.org/obo/PW_0000919	antineoplastic and immunomodulatory drug pathway		The pharmacokinetics and pharmacodynamics pathway of drugs used as immunostimulants. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002369	immunosuppressant drug pathway	http://purl.obolibrary.org/obo/PW_0000919	antineoplastic and immunomodulatory drug pathway		The pharmacokinetics and pharmacodynamics pathway of drugs used as immunosupressants. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002370	monoclonal antibody drug pathway	http://purl.obolibrary.org/obo/PW_0002367	antineoplastic drug pathway		The pharmacokinetics and pharmacodynamics pathway of monoclonal antibodies used in the treatment of various types of cancer.  Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002371	cetuximab drug pathway	http://purl.obolibrary.org/obo/PW_0002370	monoclonal antibody drug pathway		The pharmacokinetics and pharmacodynamics pathway of cetuximab, a chimeric (mouse/human) monoclonal antibody that interferes with the epidermal growth factor receptor (EGFR) and used for the treatment of certain cancer types. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002372	cetuximab pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002371	cetuximab drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of cetuximab. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002373	cetuximab pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002371	cetuximab drug pathway		The pathway of cetuxiumab-target interaction and of the biochemical or physiological responses to drug. The drug interferes with the epidermal growth factor receptor (EGFR) and is used for the treatment of certain cancer types. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002374	panitumumab drug pathway	http://purl.obolibrary.org/obo/PW_0002370	monoclonal antibody drug pathway		The pharmacokinetics and pharmacodynamics pathway of panitumumab, a human monoclonal antibody that interferes with the epidermal growth factor receptor (EGFR) and used for the treatment of certain cancer types. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002375	panitumumab pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002374	panitumumab drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of panitumumab. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002376	panitumumab pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002374	panitumumab drug pathway		The pathway of panitumumab-target interaction and of the biochemical or physiological responses to drug. The drug interferes with the epidermal growth factor receptor (EGFR) and is used for the treatment of certain cancer types. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002377	hydroflumethiazide drug pathway	http://purl.obolibrary.org/obo/PW_0002121	diuretic drug pathway		The pharmacokinetics and pharmacodynamics pathway of hydroflumethiazide, a drug used in the treatment of high blood pressure.  Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002378	hydroflumethiazide pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002377	hydroflumethiazide drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of hydroflumethiazide. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002379	hydroflumethiazide pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002377	hydroflumethiazide drug pathway		The pathway of hydroflumethiazide-target interaction and of the biochemical or physiological responses to drug. The drug reduces sodium reabsorption in the distal convoluted tubule of kidney nephron. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002380	hawkinsinuria pathway	http://purl.obolibrary.org/obo/PW_0001645	inborn error of amino acid metabolism pathway		An autosomal dominant condition resulting from alterations in amino acid metabolism due to defects in the 4-hydroxyphenylpyruvate dioxygenase (HPD) gene.
http://purl.obolibrary.org/obo/PW_0002381	sialic acid storage disease pathway	http://purl.obolibrary.org/obo/PW_0002300	nervous system lysosomal storage disease pathway		Autosomal recessive neurodegenrative disorder resulting from alterations in lysosomal membrane transport due to defects in the SLC17A5 gene.
http://purl.obolibrary.org/obo/PW_0002382	dobutamine drug pathway	http://purl.obolibrary.org/obo/PW_0000920	cardiovascular system drug pathway		The pharmacokinetics and pharmacodynamics pathway of dobutamine, a drug used in the treatment of heart failure. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002383	dobutamine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002382	dobutamine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of dobutamine. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002384	dobutamine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002382	dobutamine drug pathway		The pathway of dobutamine-target interaction and of the biochemical or physiological responses to drug. The drug is an agonist of beta 1 adrenergic receptor used in the treatment of heart failure. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002385	clomipramine drug pathway	http://purl.obolibrary.org/obo/PW_0002113	non-selective monoamine reuptake inhibitor drug pathway		The pharmacokinetics and pharmacodynamics pathway of clomipramine, an antidepressant used in the treatment of obsessive compulsive disorder, panic disorder, major depressive disorder. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002386	clomipramine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002385	clomipramine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of clomipramine. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002387	clomipramine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002385	clomipramine drug pathway		The pathway of clomipramine-target interaction and of the biochemical or physiological responses to drug. The drug is categorized as a non-selective monoamine reuptake inhibitor. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002388	fructosuria pathway	http://purl.obolibrary.org/obo/PW_0002099	inborn error of fructose metabolism pathway		An autosomal recessive condition resulting from alterations in fructose metabolism and associated with defects in the ketohexokinase (KHK) gene.
http://purl.obolibrary.org/obo/PW_0002389	felbamate drug pathway	http://purl.obolibrary.org/obo/PW_0002295	antiepileptic drug pathway		The pharmacokinetics and pharmacodynamics pathway of felbamate - an anticonvulsant used in the treatment of epilepsy. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002390	felbamate pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002389	felbamate drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of felbamate. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002391	felbamate pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002389	felbamate drug pathway		The pathway of felbamate-target interaction and of the biochemical or physiological responses to drug. It is used for the treatment of severe epilepsy due to its adverse effects, particularly hepatic failure. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002392	tioguanine drug pathway	http://purl.obolibrary.org/obo/PW_0002367	antineoplastic drug pathway		The pharmacokinetics and pharmacodynamics pathway of tioguanine, a drug used to treat several leukemia types, ulcerative colitis and some autoimmune diseases. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002393	tioguanine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002392	tioguanine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of tioguanine. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002394	tioguanine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002392	tioguanine drug pathway		The pathway of teniposide-target interactions and of the biochemical or physiological responses to drug. The drug is used in the treatment of several leukemia types, ulcerative colitis and some autoimmune diseases. Derivatives of tioguanine exert several cytotoxic effects. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002395	cellular trafficking cycle pathway	http://purl.obolibrary.org/obo/PW_0000004	regulatory pathway		The endocytosis and the exocytosis pathway that delivers, takes up and recycles cellular material. Efficient coupling between exocytosis and endocytosis pathways is essential for synaptic transmission.
http://purl.obolibrary.org/obo/PW_0002396	exocytosis pathway	http://purl.obolibrary.org/obo/PW_0002395	cellular trafficking cycle pathway		The exocytosis pathway whereby cellular material is delivered in the extracellular space outside the cell. There are two main types of exocytosis: calcium-triggered, regulated and constitutive. They are also represented in the more specific protein exocytosis pathway.
http://purl.obolibrary.org/obo/PW_0002397	constitutive exocytosis pathway	http://purl.obolibrary.org/obo/PW_0002396	exocytosis pathway		A signal-independent exocytic pathway employed by all cell types.
http://purl.obolibrary.org/obo/PW_0002398	regulated exocytosis pathway	http://purl.obolibrary.org/obo/PW_0002396	exocytosis pathway		A signal-dependent exocytic pathway employed by particular cell types. For instance, the release of hormones and neurotransmitters by neuroendocrine cells is mediated by regulated exocytosis.
http://purl.obolibrary.org/obo/PW_0002400	degradative endosome sorting pathway	http://purl.obolibrary.org/obo/PW_0002399	endosomal sorting pathway		The lysosome is the final destination of endosomal degradative and autophagy pathways. Fusion of late endosomes and mature autophagosome with the lysosome form the endolysosome or autolysosome, respectively, where cargo is actively degraded.
http://purl.obolibrary.org/obo/PW_0002401	chaperone mediated autophagy pathway	http://purl.obolibrary.org/obo/PW_0002402	cellular autophagy pathway		Chaperone-mediated autophagy is a specific and selective pathway whereby chaperone complexes recognize substrates bearing a recognition sequence forming a chaperone/substrate complex recognized by translocators.
http://purl.obolibrary.org/obo/PW_0002402	cellular autophagy pathway	http://purl.obolibrary.org/obo/PW_0000276	non-apoptotic cell death pathway		Cellular autophagy involves the mechanisms whereby dysfunctional components, proteins or organelles, are targeted to the lysosomes for destruction. Three main pathways are known: macroautophagy generally referred to as autophagy, microautophagy and chaperone-mediated autophagy. A fourth is the autophagy pathway for the removal of damaged mitochondria whose features are both shared with regular autophagy and distinct.
http://purl.obolibrary.org/obo/PW_0002403	altered cellular autophagy	http://purl.obolibrary.org/obo/PW_0002402	cellular autophagy pathway		A cellular autophagy pathway that deviates from what its normal course should be. Altered cellular autophagy has been associated with a range of human conditions and disorders.
http://purl.obolibrary.org/obo/PW_0002404	altered chaperone mediated autophagy	http://purl.obolibrary.org/obo/PW_0002403	altered cellular autophagy		Chaperone mediated autophagy declines with aging and can also be due to alterations in protein stability and gene structure. Altered chaperone mediated autophagy has been associated with conditions such as neurodegenerative diseases.
http://purl.obolibrary.org/obo/PW_0002405	microautophagy pathway	http://purl.obolibrary.org/obo/PW_0002402	cellular autophagy pathway		A form of autophagy whereby the cytoplasmic material is directly engulfed in the lysosome.
http://purl.obolibrary.org/obo/PW_0002406	endosome export pathway	http://purl.obolibrary.org/obo/PW_0002399	endosomal sorting pathway		The endosome export pathway delivers cargo to the trans Golgi network (TGN) or the plasma membrane via the retrograde and recycling pathways, respectively. An important cargo sorting system for the export pathway, primarily via the retrograde, but also the recycling pathways, is the retromer complex.
http://purl.obolibrary.org/obo/PW_0002407	retrograde export pathway	http://purl.obolibrary.org/obo/PW_0002406	endosome export pathway		The retrograde export pathway is major route to recycle components of the secretory apparatus and to diverge from lysosomal degradation components derived from endocytosis.
http://purl.obolibrary.org/obo/PW_0002408	recycling export pathway	http://purl.obolibrary.org/obo/PW_0002406	endosome export pathway		The recycling export pathway routes receptors and other proteins back to the plasma membrane.
http://purl.obolibrary.org/obo/PW_0002410	altered cellular trafficking cycle pathway	http://purl.obolibrary.org/obo/PW_0002395	cellular trafficking cycle pathway		Any alteration in the proceedings of endocytosis or exocytosis.
http://purl.obolibrary.org/obo/PW_0002411	altered endocytosis pathway	http://purl.obolibrary.org/obo/PW_0002410	altered cellular trafficking cycle pathway		Any alteration of an aspect pertinent to endocytosis pathway.
http://purl.obolibrary.org/obo/PW_0002412	altered endosomal sorting pathway	http://purl.obolibrary.org/obo/PW_0002415	altered endosomal pathway		Alterations in the endosomal sorting pathway can dramatically impact on the proper delivery of cargo. Defects in retromer function have been linked to human conditions such as the neurodegenerative Alzheimer's and Parkinson's diseases.
http://purl.obolibrary.org/obo/PW_0002413	altered endosome export pathway	http://purl.obolibrary.org/obo/PW_0002412	altered endosomal sorting pathway		Alterations in the endosome export pathway can dramatically impact on cellular fate. Defects in retromer function have been linked to human conditions such as the neurodegenerative Alzheimer's and Parkinson's diseases.
http://purl.obolibrary.org/obo/PW_0002415	altered endosomal pathway	http://purl.obolibrary.org/obo/PW_0002414	endosomal pathway		Any alteration of an aspect pertinent to endosomal pathway. Defects in endosomal sorting and export have been associated with human conditions such as neurodegenerative diseases.
http://purl.obolibrary.org/obo/PW_0002416	phosphatidylserine metabolic pathway	http://purl.obolibrary.org/obo/PW_0000354	glycerophospholipid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of phosphatidylserine, an essential component of the membrane, also with roles in signaling.
http://purl.obolibrary.org/obo/PW_0002417	phosphatidylinositol metabolic pathway	http://purl.obolibrary.org/obo/PW_0000354	glycerophospholipid metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of phosphatidylinositol (PtdIns). Phosphorylation of PtdIns can occur at the 3, 4, and/or 5 position of the inositol ring using one or multiple phosphate groups. These phosphorylated forms of PtdIns are known as phosphoinositides.
http://purl.obolibrary.org/obo/PW_0002418	phosphoinositide metabolic pathway	http://purl.obolibrary.org/obo/PW_0002417	phosphatidylinositol metabolic pathway		Reversible phosphorylation of phosphatidylinositol at the 3, 4, and/or 5 position of the inositol ring with one or more phosphate groups by the action of phosphatidylinositol kinases and phosphatases gives rise to several different phosphoinositides (PIs) whose various distribution is important to cellular membrane identity. PIs are involved in various transport and trafficking, signaling and metabolic pathways. As such, alteration of PIs metabolism is implicated in a wide range of human diseases.
http://purl.obolibrary.org/obo/PW_0002421	altered phosphoinositide metabolic pathway	http://purl.obolibrary.org/obo/PW_0002420	altered phosphatidylinositol metabolic pathway		Phosphoinositides are involved in a wide range of biological processes and alterations in their metabolism have been associated with a spectrum of human conditions.
http://purl.obolibrary.org/obo/PW_0002422	synaptic differentiation pathway	http://purl.obolibrary.org/obo/PW_0001251	regulatory pathway pertinent to the brain		Chemical synapses require the induction and assembly of pre- and postsynaptic structures.
http://purl.obolibrary.org/obo/PW_0002423	synaptic vesicle cycle pathway	http://purl.obolibrary.org/obo/PW_0001251	regulatory pathway pertinent to the brain		The cycle of synaptic vesicle exocytosis and neurotransmitter release and the subsequent endocytosis and recycling of synaptic vesicles at nerve terminals.
http://purl.obolibrary.org/obo/PW_0002424	synaptic vesicle endocytosis pathway	http://purl.obolibrary.org/obo/PW_0002423	synaptic vesicle cycle pathway		The endocytosis of synaptic vesicles, their recycling and refilling for another round of exocytosis. Two recycling pathways are documented: a fast endocytosis, also referred to as 'kiss-and-run' which is thought to be clathrin-independent, and a slower route, that is clathrin-dependent.
http://purl.obolibrary.org/obo/PW_0002425	synaptic vesicle exocytosis pathway	http://purl.obolibrary.org/obo/PW_0002423	synaptic vesicle cycle pathway		The release pathway of neurotransmitter-filled synaptic vesicles.
http://purl.obolibrary.org/obo/PW_0002426	altered regulatory pathway pertinent to the brain	http://purl.obolibrary.org/obo/PW_0001251	regulatory pathway pertinent to the brain		Any alteration in the proceedings regulatory pathways important for brain function.
http://purl.obolibrary.org/obo/PW_0002427	altered synaptic vesicle cycle pathway	http://purl.obolibrary.org/obo/PW_0002426	altered regulatory pathway pertinent to the brain		Alterations in any of the various aspects pertinent to the release, endocytosis or trafficking/recycling of synaptic vesicles.
http://purl.obolibrary.org/obo/PW_0002428	altered synaptic vesicle endocytosis pathway	http://purl.obolibrary.org/obo/PW_0002427	altered synaptic vesicle cycle pathway		Alterations in any of the mechanisms underlying the endocytosis of synaptic vesicles.
http://purl.obolibrary.org/obo/PW_0002429	synaptic vesicle trafficking pathway	http://purl.obolibrary.org/obo/PW_0002423	synaptic vesicle cycle pathway		Prior to exocytosis and following endocytosis, synaptic vesicles go through several trafficking steps that prepare them for neurotransmitter release.
http://purl.obolibrary.org/obo/PW_0002430	retromer-mediated pathway	http://purl.obolibrary.org/obo/PW_0002399	endosomal sorting pathway		The retromer complex is an important system for the selective cargo sorting for the endosome export pathways, primarily via the retrograde, but also the recycling pathway.
http://purl.obolibrary.org/obo/PW_0002431	altered retromer-mediated pathway	http://purl.obolibrary.org/obo/PW_0002430	retromer-mediated pathway		Alterations in retromer-mediated pathway can affect both the sorting and the export pathways subsequent to sorting. Defects in retromer function have been linked to human conditions such as the neurodegenerative Alzheimer's and Parkinson's diseases.
http://purl.obolibrary.org/obo/PW_0002432	clathrin-dependent synaptic vesicle endocytosis	http://purl.obolibrary.org/obo/PW_0002424	synaptic vesicle endocytosis pathway		Clathrin-dependent endocytosis is a major route for synaptic vesicle endocytosis.
http://purl.obolibrary.org/obo/PW_0002433	altered clathrin-dependent synaptic vesicle endocytosis	http://purl.obolibrary.org/obo/PW_0002432	clathrin-dependent synaptic vesicle endocytosis		Alterations in any of the mechanisms underlying the clathrin-dependent endocytosis of synaptic vesicles.
http://purl.obolibrary.org/obo/PW_0002434	other antithrombotic drug pathway	http://purl.obolibrary.org/obo/PW_0001651	antithrombotic drug pathway		The pharmacokinetics and pharmacodynamics pathway of drugs that reduce or prevent the formation of blood clots.  They are further classified depending on the blood clotting processes they affect. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002435	fondaparinux drug pathway	http://purl.obolibrary.org/obo/PW_0002434	other antithrombotic drug pathway		The pharmacokinetics and pharmacodynamics pathway of fondaparinux, a synthetic pentasaccharide factor Xa inhibitor. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002436	fondaparinux pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002435	fondaparinux drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of fondaparinux. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002437	fondaparinux pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002435	fondaparinux drug pathway		The pathway of fondaparinux-target interaction and of the biochemical or physiological responses to drug. Fondaparinux is a synthetic pentasaccharide factor Xa inhibitor. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002438	congenital limb deformities pathway	http://purl.obolibrary.org/obo/PW_0001593	musculoskeletal disease pathway		Congenital structural deformities caused by alterations in a number of pathways.
http://purl.obolibrary.org/obo/PW_0002439	congenital hemidysplasia with ichthyosiform erythroderma and limb defects pathway	http://purl.obolibrary.org/obo/PW_0002438	congenital limb deformities pathway		An X-linked dominant disorder with a range of phenotypes and reduced activities of several enzymes in a number of metabolic pathways.
http://purl.obolibrary.org/obo/PW_0002440	levobupivacaine drug pathway	http://purl.obolibrary.org/obo/PW_0002243	anesthetic drug pathway		The pharmacokinetics and pharmacodynamics pathway of levobupivacaine, a drug used as a local anesthetic. It is the S-enantiomer of bupivacaine compared to which, it has a longer duration of action and is associated with less vasodilation. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002441	levobupivacaine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002440	levobupivacaine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of levobupivacaine. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002442	levobupivacaine phgarmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002440	levobupivacaine drug pathway		The pathway of levobupivacaine-target interaction and of the biochemical or physiological responses to drug.  It is the S-enantiomer of bupivacaine compared to which, it has a longer duration of action and is associated with less vasodilation. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002443	opioid drug pathway	http://purl.obolibrary.org/obo/PW_0001546	analgesic and/or antipyretic drug pathway		The pharmacokinetics and pharmacodynamics of compounds used to alleviate pain and which act on the nervous system in a way similar to opiate. They can be natural opiates, like morphine or codeine, endogenous opioid peptide, like endorphins, semi- or fully synthetic opioids, or drugs that chemically are not of the opioid class but act as agonists of opioid receptors. Others can act as antagonists or mixed agonists/antagonists. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002444	oxycodone drug pathway	http://purl.obolibrary.org/obo/PW_0002443	opioid drug pathway		The pharmacokinetics and pharmacodynamics pathway of oxycodone, a semi-synthetic opioid and a narcotic analgesic indicated for relief of moderate to severe pain. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002445	oxycodone pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002444	oxycodone drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of oxycodone. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002446	oxycodone pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002444	oxycodone drug pathway		The pathway of oxycodone-target interaction and of the biochemical or physiological responses to drug. It is thought to act on different opioid receptors in different situations. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002447	hydromorphone drug pathway	http://purl.obolibrary.org/obo/PW_0002443	opioid drug pathway		The pharmacokinetics and pharmacodynamics pathway of hydromorphone, a derivative of the morphine family and a potent analgesic opioid drug and a narcotic. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002448	hydromorphone pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002447	hydromorphone drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of hydromorphone. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002449	hydromorphone pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002447	hydromorphone drug pathway		The pathway of hydromorphone-target interaction and of the biochemical or physiological responses to drug. The drug is a mu-receptor agonist whose major effects are on the central nervous system and gastrointestinal tract. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002450	hydrocodone drug pathway	http://purl.obolibrary.org/obo/PW_0002443	opioid drug pathway		The pharmacokinetics and pharmacodynamics pathway of hydrocodone, a narcotic analgesic synthesized from codeine and used for relief of moderate to severe pain. It is also used as an antitussive to treat cough. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002451	hydrocodone pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002450	hydrocodone drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of hydrocodone. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002452	hydrocodone pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002450	hydrocodone drug pathway		The pathway of hydrocodone-target interaction and of the biochemical or physiological responses to drug. It primarily acts on the mu-opioid receptor. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002453	oxymorphone drug pathway	http://purl.obolibrary.org/obo/PW_0002443	opioid drug pathway		The pharmacokinetics and pharmacodynamics pathway of oxymorphone, a semi-synthetic opioid analgesic. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002454	oxymorphone pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002453	oxymorphone drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of oxymorphone. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002455	oxymorphone pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002453	oxymorphone drug pathway		The pathway of oxymorphone-target interaction and of the biochemical or physiological responses to drug. It acts on the mu-opioid receptor and to a lesser extent, the delta receptor. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002456	salicylic acid drug pathway	http://purl.obolibrary.org/obo/PW_0002459	dermatological drug pathway		The pharmacokinetics and pharmacodynamics pathway of salicylic acid derived from salicin, an anti-inflammatory agent produced in willow bark. It is best known for its use in anti-acne products. As a drug, it is used in the treatment of pain and inflammation and to reduce fever. Its salts and esters are known as salicylates. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002457	salicylic acid pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002456	salicylic acid drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of salicylic acid. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002458	salicylic acid pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002456	salicylic acid drug pathway		The pathway of salicylic acid-target interaction and of the biochemical or physiological responses to drug. Salicylic acid is used in the treatment of pain and inflammation and to reduce fever. Salts and esters of salicylic acid are known as salicylates. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002459	dermatological drug pathway	http://purl.obolibrary.org/obo/PW_0000754	drug pathway		The pharmacokinetics and pharmacodynamics of compounds used for the treatment of conditions related to skin, hair and nails. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002460	sodium salicylate drug pathway	http://purl.obolibrary.org/obo/PW_0001546	analgesic and/or antipyretic drug pathway		The pharmacokinetics and pharmacodynamics pathway of sodium salicylate, a sodium salt of salicylic acid, used as an analgesic and antipyretic drug. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002461	sodium salicylate pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002460	sodium salicylate drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of sodium salicylate. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002462	sodium salicylate pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002460	sodium salicylate drug pathway		The pathway of salicylic acid-target interaction and of the biochemical or physiological responses to drug. Sodium salicylate is used as an analgesic and antipyretic. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002463	carbamazepine drug pathway	http://purl.obolibrary.org/obo/PW_0002295	antiepileptic drug pathway		The pharmacokinetics and pharmacodynamics pathway of carbamazepine, a drug used in the treatment of epilepsy and neuropathic pain. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002464	carbamazepine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002463	carbamazepine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of carbamazepine. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002465	carbamazepine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002463	carbamazepine drug pathway		The pathway of carbamazepine-target interaction and of the biochemical or physiological responses to drug. Carbamazepine is used in the treatment of epilepsy and neuropathic pain. The drug stabilizes the inactivated state of voltage-gated sodium channels and can also act as a GABA receptor agonist. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002466	apparent mineralocorticoid excess syndrome pathway	http://purl.obolibrary.org/obo/PW_0002102	inborn error of steroid metabolism pathway		An autosomal recessive condition resulting from alterations in steroid metabolism due to defects in HSD11B2 gene.
http://purl.obolibrary.org/obo/PW_0002467	Glut1 deficiency syndrome pathway	http://purl.obolibrary.org/obo/PW_0001644	inborn error of carbohydrate metabolism pathway		A hereditary, usually autosomal dominant condition, resulting from alterations in glucose transport, affecting the nervous system and exhibiting a wide phenotypic variability.
http://purl.obolibrary.org/obo/PW_0002468	felodipine drug pathway	http://purl.obolibrary.org/obo/PW_0001894	dihydropyridine calcium channel blocker drug pathway		The pharmacokinetics and pharmacodynamics pathway of felodipine, a calcium channel blocker used for the treatment of high blood pressure. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002469	felodipine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002468	felodipine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of felodipine. The drug is a calcium channel blocker used in the treatment of high blood pressure.  Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002470	felodipine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002468	felodipine drug pathway		The pathway of felodipine-target interaction and of the biochemical or physiological responses to drug. The drug is a calcium channel blocker used for the treatment of high blood pressure.  Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002471	hypermethioninemia pathway	http://purl.obolibrary.org/obo/PW_0001645	inborn error of amino acid metabolism pathway		A condition resulting from alterations in the methionine cycle/metabolism.
http://purl.obolibrary.org/obo/PW_0002472	other antidepressant drug pathway	http://purl.obolibrary.org/obo/PW_0002114	antidepressant drug pathway		The pharmacokinetics and pharmacodynamics of compounds used to treat various forms of depression.
http://purl.obolibrary.org/obo/PW_0002473	venlafaxine drug pathway	http://purl.obolibrary.org/obo/PW_0002472	other antidepressant drug pathway		The pharmacokinetics and pharmacodynamics pathway of venlafaxine, a drug used in the treatment of major depressive, anxiety and panic disorders. The drug inhibits the reuptake of key neurotransmitters such as serotonin, epinephrine and dopamine. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002474	venlafaxine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002473	venlafaxine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of venlafaxine. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002475	venlafaxine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002473	venlafaxine drug pathway		The pathway of venlafaxiine-target interaction and of the biochemical or physiological responses to drug. The drug inhibits the reuptake of key neurotransmitters such as serotonin, epinephrine and dopamine. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002476	rosiglitazone drug pathway	http://purl.obolibrary.org/obo/PW_0000723	anti-diabetic drug pathway		The pharmacokinetics and pharmacodynamics pathway of rosiglitazone, an anti-diabetic drug. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug. In several countries the drug was withdrawn from the market due to its side effects.
http://purl.obolibrary.org/obo/PW_0002477	rosiglitazone pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002476	rosiglitazone drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of rosiglitazone, an anti-diabetic drug. Genetic variations can result in changes in the availability of the drug. In several countries the drug was withdrawn from the market due to its side effects.
http://purl.obolibrary.org/obo/PW_0002478	rosiglitazone pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002476	rosiglitazone drug pathway		The pathway of rosiglitazone-target interaction and of the biochemical or physiological responses to drug. Genetic variations can cause differences in the response of the organism to the drug.  In several countries rosiglitazone was withdrawn from the market due to its side effects.
http://purl.obolibrary.org/obo/PW_0002479	biliary tract disease pathway	http://purl.obolibrary.org/obo/PW_0001697	digestive system disease pathway		The various conditions affecting any part of the biliary tract including the bile ducts,  resulting from alterations in one or several pathways.
http://purl.obolibrary.org/obo/PW_0002480	cholestasis pathway	http://purl.obolibrary.org/obo/PW_0002479	biliary tract disease pathway		A condition where bile cannot flow from the liver to the duodenum which can be mechanical in nature as in blockage of the duct system or metabolic, resulting from alterations in bile formation due to genetic or environmental factors.
http://purl.obolibrary.org/obo/PW_0002481	congenital bile acid synthesis defect pathway	http://purl.obolibrary.org/obo/PW_0002102	inborn error of steroid metabolism pathway		Autosomal recessive disorders resulting from alterations in bile acid synthesis due to defects in one or several enzymes. Type 1 is due to mutations in the HSD3B7 gene, type 2 is due to mutations in the AKR1D1 gene, type 3 is due to mutations in the CYP7B1 gene.
http://purl.obolibrary.org/obo/PW_0002482	chloroprocaine drug pathway	http://purl.obolibrary.org/obo/PW_0002243	anesthetic drug pathway		The pharmacokinetics and pharmacodynamics pathway of chloroprocaine, a drug used as a local anesthetic. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002483	chloroprocaine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002482	chloroprocaine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of chloroprocaine. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002484	chloroprocaine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002482	chloroprocaine drug pathway		The pathway of chloroprocaine-target interaction and of the biochemical or physiological responses to drug. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002485	prednisolone drug pathway	http://purl.obolibrary.org/obo/PW_0002459	dermatological drug pathway		The pharmacokinetics and pharmacodynamics of prednisolone - a synthetic glucocorticoid used to treat a wide range of inflammatory and autoimmune conditions, and also allergic reactions. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002486	prednisolone pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002485	prednisolone drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of prednisolone, a synthetic glucocorticoid. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002487	prednisolone pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002485	prednisolone drug pathway		The pathway of prednisolone-target interaction and of the biochemical or physiological responses to drug. used to treat a wide range of inflammatory and autoimmune conditions, and also allergic reactions. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002489	melatonin signaling pathway	http://purl.obolibrary.org/obo/PW_0001162	chemical compound signaling pathway		Melatonin, in human and other organisms derived from tryptophan, is a monoamine with antioxidant properties and involved in the synchronization of the circadian rhythms. Melatonin signals through three receptors types of which two are present in humans and other mammals. They are G protein coupled receptors (GPCR).
http://purl.obolibrary.org/obo/PW_0002490	glycine signaling pathway	http://purl.obolibrary.org/obo/PW_0000456	Inhibitory synaptic transmission pathway		Glycine signaling is primarily inhibitory. The glycine receptor is ligand-gated ion channel that exerts its effects via chloride currents.
http://purl.obolibrary.org/obo/PW_0002491	leukotriene C4 synthase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001589	inborn error of metabolism pathway		An autosomal recessive condition resulting from alteration in leukotriene C4 synthesis due to defects in the LTC4 synthase gene.
http://purl.obolibrary.org/obo/PW_0002492	phenindione drug pathway	http://purl.obolibrary.org/obo/PW_0002325	vitamin K antagonist drug pathway		The pharmacokinetics and pharmacodynamics pathway of phenindione. The drug is used as anticoagulant that antagonizes the vitamin K dependent clotting pathway. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002493	phenindione pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002492	phenindione drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of phenindione.  Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002494	phenindione pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002492	phenindione drug pathway		The pathway of phenindione-target interaction and of the biochemical or physiological responses to drug. Phenindione is used as anticoagulant that antagonizes the vitamin K dependent clotting pathway. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002495	dicoumarol drug pathway	http://purl.obolibrary.org/obo/PW_0002325	vitamin K antagonist drug pathway		The pharmacokinetics and pharmacodynamics pathway of dicoumarol. Dicoumarol is a naturally occurring anticoagulant that antagonizes the vitamin K dependent clotting pathway. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002496	dicoumarol pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002495	dicoumarol drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of dicoumarol.  Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002497	dicoumarol pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002495	dicoumarol drug pathway		The pathway of dicoumarol-target interaction and of the biochemical or physiological responses to drug.  Dicoumarol is a naturally occurring anticoagulant that antagonizes the vitamin K dependent clotting pathway. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002498	adrenergic beta receptor agonist drug pathway	http://purl.obolibrary.org/obo/PW_0000920	cardiovascular system drug pathway		The pharmacokinetics and pharmacodynamics pathway of adrenergic beta receptors agonists. The drugs can be either selective or non-selective. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002499	adrenergic beta receptor selective agonist drug pathway	http://purl.obolibrary.org/obo/PW_0002498	adrenergic beta receptor agonist drug pathway		The pharmacokinetics and pharmacodynamics pathway of selective adrenergic beta receptors agonists. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002500	adrenergic beta receptor non-selective agonist drug pathway	http://purl.obolibrary.org/obo/PW_0002498	adrenergic beta receptor agonist drug pathway		The pharmacokinetics and pharmacodynamics pathway of non-selective adrenergic beta receptors agonists. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002501	isoprenaline drug pathway	http://purl.obolibrary.org/obo/PW_0002500	adrenergic beta receptor non-selective agonist drug pathway		The pharmacokinetics and pharmacodynamics pathway of isoprenaline, a non-selective beta adrenergic agonist used for the treatment of heart block and slow heart rate. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002502	isoprenaline pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002501	isoprenaline drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of isoprenaline. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002503	isoprenaline pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002501	isoprenaline drug pathway		The pathway of isoprenaline-target interaction and of the biochemical or physiological responses to drug. The drug is a non-selective beta adrenergic agonist used for the treatment of heart block and slow heart rate.  Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002504	adrenal gland disease pathway	http://purl.obolibrary.org/obo/PW_0001547	endocrine system disease pathway		Those conditions resulting from alterations in one or several pathways and affecting the adrenal glands. The adrenal glands are the site of synthesis for a variety of hormones.
http://purl.obolibrary.org/obo/PW_0002505	adrenoleukodystrophy pathway	http://purl.obolibrary.org/obo/PW_0002504	adrenal gland disease pathway		An X-linked disorder resulting from disturbances in the metabolism of very long chain fatty acids due to defects in the ABCD1 gene.
http://purl.obolibrary.org/obo/PW_0002506	carnitine-acylcarnitine translocase deficiency	http://purl.obolibrary.org/obo/PW_0001643	inborn error of lipid metabolism pathway		A rare autosomal recessive condition resulting from alteration in long-fatty acid oxidation and due to defects in the SLC25A20 gene.
http://purl.obolibrary.org/obo/PW_0002507	mycophenolic acid drug pathway	http://purl.obolibrary.org/obo/PW_0002369	immunosuppressant drug pathway		The pharmacokinetics and pharmacodynamics of mycophenolic acid - an immunosuppressant drug used to prevent rejection in organ transplantation. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002508	mycophenolic acid pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002507	mycophenolic acid drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of mycophenolic acid. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002509	mycophenolic acid pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002507	mycophenolic acid drug pathway		The pathway of mycophenolic acid-target interaction and of the biochemical or physiological responses to drug. Mycophenolic acid is used as an immunosuppressant to prevent organ rejection in transplantation. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002510	catecholamine degradation pathway	http://purl.obolibrary.org/obo/PW_0000443	catecholamine metabolic pathway		Those metabolic reactions involved in the degradation of catecholamines. Epinephrine, norepinephrine and dopamine are among the most abundant.
http://purl.obolibrary.org/obo/PW_0002511	dopamine degradation pathway	http://purl.obolibrary.org/obo/PW_0002510	catecholamine degradation pathway		Those metabolic reactions involved in the degradation of dopamine. Dopamine degradation can be initiated by two enzymes. Dopamine can spontaneously oxidize and in the process, radicals are being produced. Storage of newly synthesized dopamine or degradation of excess cytosolic dopamine prevents oxidation of dopamine.
http://purl.obolibrary.org/obo/PW_0002512	epinephrine degradation pathway	http://purl.obolibrary.org/obo/PW_0002510	catecholamine degradation pathway		Those metabolic reactions involved in the degradation of epinephrine.
http://purl.obolibrary.org/obo/PW_0002513	norepinephrine degradation pathway	http://purl.obolibrary.org/obo/PW_0002510	catecholamine degradation pathway		Those metabolic reactions involved in the degradation of norepinephrine.
http://purl.obolibrary.org/obo/PW_0002514	tiaprofenic acid drug pathway	http://purl.obolibrary.org/obo/PW_0001170	musculo-skeletal system drug pathway		The pharmacokinetics and pharmacodynamics pathway of tiaprofenic acid, a non-steroidal anti-inflammatory drug used  to treat pain, especially arthritic. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002517	thyroid-stimulating hormone biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001757	peptide and protein hormone metabolic pathway		Those metabolic reactions involved in the synthesis of thyroid-stimulating hormone (TSH). TSH is a pituitary hormone that stimulates the thyroid gland to produce thyroxine (T4) and then triiodothyronine (T3). T3 is the active thyroid hormone that stimulates cellular metabolism.
http://purl.obolibrary.org/obo/PW_0002518	thyrotropin-releasing hormone biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001757	peptide and protein hormone metabolic pathway		Those metabolic reactions involved in the synthesis of thyrotropin-releasing hormone (TRH). TRH is a tripeptidal hormone produced in the hypothalamus that stimulates the release of thyroid-stimulating hormone and prolactin from the anterior pituitary.
http://purl.obolibrary.org/obo/PW_0002519	somatostatin biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001757	peptide and protein hormone metabolic pathway		Somatostatin, known as growth hormone-inhibiting hormone, is a peptide hormone that regulates cell proliferation, neurotransmission and the endocrine system.
http://purl.obolibrary.org/obo/PW_0002520	thyroglobulin processing pathway	http://purl.obolibrary.org/obo/PW_0001757	peptide and protein hormone metabolic pathway		Thyroglobulin, produced by the follicular cells of thyroid gland is used to produce the thyroid hormones via a number of steps. Thyroglobulin contains some 100-120 tyrosine residues, of which only a small fraction is used to produce thyroid hormones. Usually there are 5 to 6 molecules of either thyroxine (T4) and triiodothyronine (T3) derived from each molecule of thyroglobulin.
http://purl.obolibrary.org/obo/PW_0002522	flurbiprofen drug pathway	http://purl.obolibrary.org/obo/PW_0002159	sensory organ drug pathway		The pharmacokinetics and pharmacodynamics pathway of flurbiprofen, a non-steroidal anti-inflammatory drug used  in the treatment of arthritis and dental pain and also as a pre-operative solution. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002523	flurbiprofen pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002522	flurbiprofen drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of flurbiprofen. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002524	flurbiprofen pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002522	flurbiprofen drug pathway		The pathway of flurbiprofen-target interaction and of the biochemical or physiological responses to drug. The drug is used in the treatment of arthritis and dental pain and also as a pre-operative solution.  Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002525	ethylmorphine drug pathway	http://purl.obolibrary.org/obo/PW_0002443	opioid drug pathway		The pharmacokinetics and pharmacodynamics pathway of ethylmorphine, an opiate narcotic analgesic mostly used to treat dry cough and as an ophtalmologic agent. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002526	ethylmorphine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002525	ethylmorphine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of ethylmorphine. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002527	ethylmorphine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002525	ethylmorphine drug pathway		The pathway of ethylmorphine-target interaction and of the biochemical or physiological responses to drug. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002528	magnesium salicylate drug pathway	http://purl.obolibrary.org/obo/PW_0001546	analgesic and/or antipyretic drug pathway		The pharmacokinetics and pharmacodynamics pathway of magnesium salicylate, used as an analgesic and antipyretic drug. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002531	hereditary central nervous system demyelinating disease pathway	http://purl.obolibrary.org/obo/PW_0001646	inborn error of brain metabolic pathway		Inherited conditions characterized by a loss of myelin in the central nervous system.
http://purl.obolibrary.org/obo/PW_0002532	metachromatic leukodystrophy pathway	http://purl.obolibrary.org/obo/PW_0002531	hereditary central nervous system demyelinating disease pathway		An autosomal recessive condition resulting from alterations in cerebroside metabolism due to defects in the cerebroside sulfatase enzyme.
http://purl.obolibrary.org/obo/PW_0002533	cocaine drug pathway	http://purl.obolibrary.org/obo/PW_0002243	anesthetic drug pathway		The pharmacokinetics and pharmacodynamics pathway of cocaine, a drug of few medical uses, mostly as a local anesthetic during surgery. Cocaine is highly addictive due to its effects on the reward system in the brain. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002534	cocaine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002533	cocaine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of cocaine, a drug of limited medical uses. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002535	cocaine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002533	cocaine drug pathway		The pathway of cocaine-target interaction and of the biochemical or physiological responses to drug. Cocaine has few medical uses, mostly as local anesthetic during surgery. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002536	lidocaine drug pathway	http://purl.obolibrary.org/obo/PW_0002336	antiarrhythmic drug pathway		The pharmacokinetics and pharmacodynamics pathway of lidocaine, an important class 1b antiarrhythmic drug also used as a local anesthetic. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002537	lidocaine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002536	lidocaine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of lidocaine. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002538	lidocaine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002536	lidocaine drug pathway		The pathway of lidocaine-target interaction and of the biochemical or physiological responses to drug. Lidocaine is an important class 1b antiarrhythmic drug also used as a local anesthetic. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002539	oxybuprocaine drug pathway	http://purl.obolibrary.org/obo/PW_0002243	anesthetic drug pathway		The pharmacokinetics and pharmacodynamics pathway of oxybuprocaine, a drug used as a local anesthetic, particularly in ophtalmology and otolaryngology. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002540	oxybuprocaine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002539	oxybuprocaine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of oxybuprocaine. Genetic variations can result in changes in the availability of the drug.  Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002541	oxybuprocaine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002539	oxybuprocaine drug pathway		The pathway of oxybuprocaine-target interaction and of the biochemical or physiological responses to drug. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002542	dihydromorphine drug pathway	http://purl.obolibrary.org/obo/PW_0002443	opioid drug pathway		The pharmacokinetics and pharmacodynamics pathway of dihydromorphine, a semi-synthetic opioid used for the management of moderate to severe pain. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002543	dihydromorphine pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002542	dihydromorphine drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of dihydrolmorphine. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002544	dihydromorphine pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002542	dihydromorphine drug pathway		The pathway of dihydromorphine-target interaction and of the biochemical or physiological responses to drug. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002545	acid-base imbalance pathway	http://purl.obolibrary.org/obo/PW_0001472	metabolic disease pathway		A disturbance that leads to changes in the body's normal balance of acids and bases resulting in deviation from the normal  pH range. The imbalance is due to changes in renal or ventilation function. The changes can lead to an excess of acid, acidosis or acidaemia, or to an excess of vases, alkalosis or alkalemia.
http://purl.obolibrary.org/obo/PW_0002546	acidosis pathway	http://purl.obolibrary.org/obo/PW_0002545	acid-base imbalance pathway		Those metabolic changes resulting in an excess of acids in the system causing a decrease in the normal pH range.
http://purl.obolibrary.org/obo/PW_0002547	alkalosis pathway	http://purl.obolibrary.org/obo/PW_0002545	acid-base imbalance pathway		Those metabolic changes resulting in an excess of bases in the system causing an increase in the normal pH range.
http://purl.obolibrary.org/obo/PW_0002548	lactic acidosis pathway	http://purl.obolibrary.org/obo/PW_0002546	acidosis pathway		An acidosis caused by alteration in lactic acid metabolism.
http://purl.obolibrary.org/obo/PW_0002549	succinyl-CoA:3-oxoacid transferase deficiency pathway	http://purl.obolibrary.org/obo/PW_0002546	acidosis pathway		An acidosis caused by alteration in the ketone bodies metabolic pathway due to defects in the 3-oxoacid CoA transferase 1 enzyme.
http://purl.obolibrary.org/obo/PW_0002551	levacetylmethadol drug pathway	http://purl.obolibrary.org/obo/PW_0002443	opioid drug pathway		The pharmacokinetics and pharmacodynamics pathway of levacetylmethadol, a synthetic opioid, similar in structure to methadone, used for the treatment and management of opioid dependence.  Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002552	levacetylmethadol pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002551	levacetylmethadol drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of levacetylmethadol. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002553	levacetylmethadol pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002551	levacetylmethadol drug pathway		The pathway of levacetylmethadol-target interaction and of the biochemical or physiological responses to drug. The drug acts as a mu-receptor agonist. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002554	levorphanol drug pathway	http://purl.obolibrary.org/obo/PW_0002443	opioid drug pathway		The pharmacokinetics and pharmacodynamics pathway of levorphanol, an opioid used for the treatment of moderate to severe pain. Primarily an agonist of the mu opioid receptor, levorphanol acts as an agonist or antagonist for several other receptors. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002555	levorphanol pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002554	levorphanol drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of levorphanol. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002556	levorphanol pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002554	levorphanol drug pathway		The pathway of levorphanol-target interaction and of the biochemical or physiological responses to drug. The drug acts primarily as a mu-receptor agonist, but it can be an agonist or antagonist for several other receptors. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002557	familial lipoprotein lipase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001643	inborn error of lipid metabolism pathway		An inherited condition resulting from alteration in lipid metabolism due to defects in lipase or apolipoprotein functions.
http://purl.obolibrary.org/obo/PW_0002558	heroin drug pathway	http://purl.obolibrary.org/obo/PW_0002443	opioid drug pathway		The pharmacokinetics and pharmacodynamics pathway of heroin, an opioid painkiller and a narcotic. Chemically is 3,6-diacetyl ester of morphine. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002559	heroin pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002558	heroin drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of heroin. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002560	heroin pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002558	heroin drug pathway		The pathway of heroin-target interaction and of the biochemical or physiological responses to drug. Heroin is an opioid painkiller and a narcotic. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002561	cystathioninuria pathway	http://purl.obolibrary.org/obo/PW_0001840	hyperhomocysteinemia pathway		An autosomal recessive condition resulting from alterations in the transsulfuration pathway of homocysteine metabolism.
http://purl.obolibrary.org/obo/PW_0002562	glutathionuria disease pathway	http://purl.obolibrary.org/obo/PW_0001645	inborn error of amino acid metabolism pathway		An inherited condition resulting from alterations in glutathione metabolism.
http://purl.obolibrary.org/obo/PW_0002563	ornithine translocase deficiency pathway	http://purl.obolibrary.org/obo/PW_0002142	inborn error of urea cycle pathway		An inherited condition resulting from alterations in the urea cycle pathway.
http://purl.obolibrary.org/obo/PW_0002564	phytanic acid degradation pathway	http://purl.obolibrary.org/obo/PW_0000739	fatty acid alpha degradation pathway		Those metabolic reactions involved in the oxidation of phytanic acid, a branched chain fatty acid. Phytanic acid alpha-oxidation in the peroxisome results in pristanic acid, which can then follow a beta degradation pathway.
http://purl.obolibrary.org/obo/PW_0002565	carnosinemia pathway	http://purl.obolibrary.org/obo/PW_0001646	inborn error of brain metabolic pathway		An inherited condition resulting from alterations in carnosine metabolism due to defects in the enzyme carnosinase and manifested in neurological disorders.
http://purl.obolibrary.org/obo/PW_0002566	adenine phoshoribosyltransferase deficiency pathway	http://purl.obolibrary.org/obo/PW_0002567	urolithiasis pathway		An autosomal recessive disorder leading to the formation of urinary stones.
http://purl.obolibrary.org/obo/PW_0002567	urolithiasis pathway	http://purl.obolibrary.org/obo/PW_0001700	urologic disease pathway		Conditions leading to the formation of stones in any part of the urinary tract.
http://purl.obolibrary.org/obo/PW_0002568	mercaptolactate-cysteine disulfiduria pathway	http://purl.obolibrary.org/obo/PW_0001645	inborn error of amino acid metabolism pathway		An autosomal condition resulting from alterations in cysteine metabolism due to defects in the enzyme mercaptopyruvate sulfurtransferase.
http://purl.obolibrary.org/obo/PW_0002569	3-hydroxyisobutyric aciduria pathway	http://purl.obolibrary.org/obo/PW_0001645	inborn error of amino acid metabolism pathway		A rare condition resulting from possible alterations in amino acid metabolism for which the causative genes are a matter of debate.
http://purl.obolibrary.org/obo/PW_0002570	diphenoxylate drug pathway	http://purl.obolibrary.org/obo/PW_0000921	alimentary tract and metabolism drug pathway		The pharmacokinetics and pharmacodynamics of diphenoxylate, a drug of the phenulpiperidine sries used for the treatment of diarrhea. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002571	diphenoxylate pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002570	diphenoxylate drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of diphenoxylate. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002572	diphenoxylate pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002570	diphenoxylate drug pathway		The pathway of diphenoxylate-target interaction and of the biochemical or physiological responses to drug. Diphenoxylate is used for the treatment of diarrhea. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002573	hypoglycemia pathway	http://purl.obolibrary.org/obo/PW_0001602	glucose metabolism disease pathway		A condition resulting from alterations in glucose metabolism and homeostasis leading to abnormally low blood glucose levels.
http://purl.obolibrary.org/obo/PW_0002574	carnitine palmitoyltransferase I deficiency pathway	http://purl.obolibrary.org/obo/PW_0002573	hypoglycemia pathway		An autosomal recessive disorder resulting from alterations in long chain fatty acid oxidation due to defects in the carnitine palmitoyltransferase 1A (CPT1A) enzyme.
http://purl.obolibrary.org/obo/PW_0002575	dopamine oxidation pathway	http://purl.obolibrary.org/obo/PW_0000409	dopamine metabolic pathway		The reactions thereby dopamine can spontaneously oxidize under aerobic conditions. In the process, radicals are being formed that can potentially exert noxious effects. Oxidation of dopamine gives rise to three quinone species that can form adducts with proteins or be precursor to the neuromelanin pigment (NM). NM, which accumulates with age, but is diminished in Parkinson disease patients may confer protective roles, particularly as a metal chelator.
http://purl.obolibrary.org/obo/PW_0002576	3-methylcrotonyl CoA carboxylase 1 deficiency pathway	http://purl.obolibrary.org/obo/PW_0002142	inborn error of urea cycle pathway		An inheritied condition resulting from alterations in the degradation of branched-chain amino acid due to defects in the alpha subunit of methylcrotonyl CoA carboxylase (MCCC1). MCCC is a biotin-requiring enzyme in the mitochondria.
http://purl.obolibrary.org/obo/PW_0002577	3-methylcrotonyl CoA carboxylase 2 deficiency pathway	http://purl.obolibrary.org/obo/PW_0002142	inborn error of urea cycle pathway		An inheritied condition resulting from alterations in the degradation of branched-chain amino acid due to defects in the beta subunit of methylcrotonyl CoA carboxylase (MCCC2). MCCC is a biotin-requiring enzyme in the mitochondria.
http://purl.obolibrary.org/obo/PW_0002579	altered brain-derived neurotrophic factor signaling pathway	http://purl.obolibrary.org/obo/PW_0002578	altered neurotrophic factor signaling pathway		A brain-derived neurotrophic factor (BDNF) signaling pathway that deviates from what it normal course should be. Impaired BDNF signaling contributes to the pathogenesis of conditions such as Huntington Disease (HD) and depression.
http://purl.obolibrary.org/obo/PW_0002580	nicotinamide adenine dinucleotide metabolic pathway	http://purl.obolibrary.org/obo/PW_0000135	metabolic pathway of cofactors, vitamins, nutrients		Those metabolic reactions involved in the synthesis and utilization of nicotinamide adenine dinucleotide (NAD). There are several routes leading to NAD biosynthesis from various sources. NAD, in addition to its well known role as a cofactor in redox reactions, also serves as a substrate for several classes of enzymes.
http://purl.obolibrary.org/obo/PW_0002581	nicotinamide adenine nucleotide utilization pathway	http://purl.obolibrary.org/obo/PW_0002580	nicotinamide adenine dinucleotide metabolic pathway		Those metabolic reactions involved in the utilization of nicotinamide adenine dinucleotide (NAD). NAD, in addition to its well known role as a cofactor in redox reactions, also serves as a substrate for several classes of enzymes. These include the sirtuin deacetylases, the adenosine diphosphate (ADP)-ribose transferases/poly(ADP-ribose) polymerases, and the cyclic ADP-ribose (cADPR) synthases.
http://purl.obolibrary.org/obo/PW_0002582	ADP-ribosylation pathway, mono and poly-ribosylation	http://purl.obolibrary.org/obo/PW_0002581	nicotinamide adenine nucleotide utilization pathway		Mono- and poly-ADP-ribosylation of proteins is carried out by members of the PARP family. Proteins with particular domains or modules are involved in the recognition of modified proteins while others reverse the modification. Protein ADP-ribosylation plays important roles in DNA damage repair, cell-cycle, transcription and cell death pathways.
http://purl.obolibrary.org/obo/PW_0002583	ADP-ribosylation pathway, cyclic ribosylation	http://purl.obolibrary.org/obo/PW_0002581	nicotinamide adenine nucleotide utilization pathway		Cyclic ADP-ribosylation leads to the formation of second messengers with important roles in calcium signaling.
http://purl.obolibrary.org/obo/PW_0002584	Sirtuin mediated pathway	http://purl.obolibrary.org/obo/PW_0002581	nicotinamide adenine nucleotide utilization pathway		Sirtuins belong to the class III deacetylases that carry out NAD-dependent deacetylation and other activities. They are sensors of NAD/NAM ratio and play important roles in cellular homeostasis.
http://purl.obolibrary.org/obo/PW_0002585	carvedilol drug pathway	http://purl.obolibrary.org/obo/PW_0001738	adrenergic beta receptor non-selective antagonist drug pathway		The pharmacokinetics and pharmacodynamics pathway of carvedilol - a non-selective adrenergic beta receptor blocker, used in the treatment of mild to severe congestive heart failure. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002586	carvedilol pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002585	carvedilol drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of carvedilol. The drug is a non-selective adrenergic beta receptor blocker. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002587	carvedilol pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002585	carvedilol drug pathway		The pathway of carvedilol-target interaction and of the biochemical or physiological responses to drug. The drug is non-selective blocker of adrenergic receptor beta belonging to the third generation of blockers. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002588	bone disease pathway	http://purl.obolibrary.org/obo/PW_0001593	musculoskeletal disease pathway		Those conditions affecting the skeletal system and elements associated with it, arising from deregulation in a number of pathways.
http://purl.obolibrary.org/obo/PW_0002589	chondrodysplasia punctata pathway	http://purl.obolibrary.org/obo/PW_0002590	osteochondrodysplasia pathway		A heterogeneous group of conditions with recessive, dominant, and X-linked forms.
http://purl.obolibrary.org/obo/PW_0002590	osteochondrodysplasia pathway	http://purl.obolibrary.org/obo/PW_0002588	bone disease pathway		Those conditions resulting from the abnormal development of cartilage and bone.
http://purl.obolibrary.org/obo/PW_0002591	X-linked dominant chondrodysplasia punctata 2 pathway	http://purl.obolibrary.org/obo/PW_0002589	chondrodysplasia punctata pathway		The better characterized form of chondrodysplasia punctata due to defects in the Ebp gene involved in the cholesterol biosynthetic pathway.
http://purl.obolibrary.org/obo/PW_0002592	vitamin K cycle pathway	http://purl.obolibrary.org/obo/PW_0001016	vitamin K metabolic pathway		The vitamin K cycle is an essential aspect of its metabolism. The carboxylation of glutamate residues in vitamin K-dependent (VKD) proteins, necessary for their function, requires a reduced form of vitamin K as a cofactor. The resulting oxidized compound is converted back to the reduced form via a two-step reduction reaction. Natural and synthetic antagonists block the cycle and thus, the VKD protein modification. VKD proteins include coagulation factors; antagonists are used as anti-coagulation, anti-thrombotic agents.
http://purl.obolibrary.org/obo/PW_0002593	dabigatran drug pathway	http://purl.obolibrary.org/obo/PW_0002146	direct thrombin inhibitor drug pathway		The pharmacokinetics and pharmacodynamics pathway of dabigatran, a direct thrombin inhibitor. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002594	dabigatran pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002593	dabigatran drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of dabigatran, a direct thrombin inhibitor. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002595	dabigatran pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002593	dabigatran drug pathway		The pathway of dabigatran-target interaction and of the biochemical or physiological responses to drug. The drug is a direct thrombin inhibitor. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002596	direct factors Xa inhibitor drug pathway	http://purl.obolibrary.org/obo/PW_0002151	anticoagulant drug pathway		The pharmacokinetics and pharmacodynamics pathway of drugs that reduce or prevent the formation of blood clots by directly inhibiting activated factor X (Xa). Factor X is a serine protease and essential component of coagulation cascade. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002597	apixaban drug pathway	http://purl.obolibrary.org/obo/PW_0002596	direct factors Xa inhibitor drug pathway		The pharmacokinetics and pharmacodynamics pathway of apixaban, a direct inhibitor of activated factor X (Xa) of the coagulation cascade. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002598	edoxaban drug pathway	http://purl.obolibrary.org/obo/PW_0002596	direct factors Xa inhibitor drug pathway		The pharmacokinetics and pharmacodynamics pathway of edoxaban, a direct inhibitor of activated factor X (Xa) of the coagulation cascade. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002599	rivaroxaban drug pathway	http://purl.obolibrary.org/obo/PW_0002596	direct factors Xa inhibitor drug pathway		The pharmacokinetics and pharmacodynamics pathway of rivaroxaban, a direct inhibitor of activated factor X (Xa) of the coagulation cascade. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002600	apixaban pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002597	apixaban drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of apixaban, a direct inhibitor of activated factor X (Xa) of the coagulation cascade. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002601	apixaban pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002597	apixaban drug pathway		The pathway of apixaban-target interaction and of the biochemical or physiological responses to drug. The drug is a direct inhibitor of activated factor X (Xa) of the coagulation cascade. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002602	edoxaban pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002598	edoxaban drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of edoxaban, a direct inhibitor of activated factor X (Xa) of the coagulation cascade. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002603	edoxaban pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002598	edoxaban drug pathway		The pathway of edoxaban-target interaction and of the biochemical or physiological responses to drug. The drug is a direct inhibitor of activated factor X (Xa) of the coagulation cascade. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002604	rivaroxaban pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002599	rivaroxaban drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of rivaroxaban, a direct inhibitor of activated factor X (Xa) of the coagulation cascade. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002605	rivaroxaban pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002599	rivaroxaban drug pathway		The pathway of rivaroxaban-target interaction and of the biochemical or physiological responses to drug. The drug is a direct inhibitor of activated factor X (Xa) of the coagulation cascade. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002606	protease mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000003	signaling pathway		Proteases, the vitamin K-dependent coagulation proteases in particular, can activate a specific class of G protein-coupled receptors harboring an internally tethered ligand. The four protease-activated receptors (PARs) are involved in numerous physiologically relevant processes and can also play a role in disease-related aspects. PARs can be cleaved at different sites by different proteases to elicit distinct signaling responses, referred to as biased signaling.
http://purl.obolibrary.org/obo/PW_0002607	protease mediated signaling via protease-activated receptor 1	http://purl.obolibrary.org/obo/PW_0002606	protease mediated signaling pathway		Protease-activated receptor 1 (PAR1/F2R) is primarily a target of coagulation factor 2, thrombin, but other proteases can prompt or disarm it. PAR1 signaling plays many roles in the immune, cardiovascular and nervous system.
http://purl.obolibrary.org/obo/PW_0002608	protease mediated signaling via protease-activated receptor 2	http://purl.obolibrary.org/obo/PW_0002606	protease mediated signaling pathway		Protease-activated receptor 2 (PAR2/F2RL1) is primarily a target of coagulation factor 10, but other proteases can prompt or disarm it. PAR2  signaling plays important roles in the cardiovascular and immune systems.
http://purl.obolibrary.org/obo/PW_0002609	protease mediated signaling via protease-activated receptor 4	http://purl.obolibrary.org/obo/PW_0002606	protease mediated signaling pathway		Protease-activated receptor 4 (PAR4/F2RL3) is primarily a target of coagulation factor 2, thrombin, but other proteases can prompt or disarm it. PAR4 signaling plays important roles in the inflammatory response.
http://purl.obolibrary.org/obo/PW_0002610	protease mediated signaling via protease-activated receptor 3	http://purl.obolibrary.org/obo/PW_0002606	protease mediated signaling pathway		Protease-activated receptor 3 (PAR3/F2RL2) is primarily a target of coagulation factor 2, thrombin, but other proteases can prompt or disarm it. PAR3 is thought to not signal autonomously and require heterodimerization with other PARs.
http://purl.obolibrary.org/obo/PW_0002611	altered hemostasis pathway	http://purl.obolibrary.org/obo/PW_0001538	altered cardiovascular system homeostasis pathway		Alterations in the hemostatic system can result in a series of pathological conditions. They are caused by alterations in the coagulation cascade and/or anticoagulant pathways that regulate it.
http://purl.obolibrary.org/obo/PW_0002612	altered natural anticoagulant pathway	http://purl.obolibrary.org/obo/PW_0001538	altered cardiovascular system homeostasis pathway		Alterations in the anticoagulant system are associated with various conditions.
http://purl.obolibrary.org/obo/PW_0002613	altered coagulation cascade pathway	http://purl.obolibrary.org/obo/PW_0002611	altered hemostasis pathway		Alterations in the coagulation cascade have been associated with several conditions. Deficiencies in factors F5 and F8, the essential cofactors of the intrinsic tenase and thrombinase complexes, lead to parahemophilia and hemophilia A, respectively.
http://purl.obolibrary.org/obo/PW_0002614	altered protein C anticoagulant pathway	http://purl.obolibrary.org/obo/PW_0002612	altered natural anticoagulant pathway		Mutations in protein C (Proc) and its cofactor, protein S (Pros1) are associated with several deficiencies.
http://purl.obolibrary.org/obo/PW_0002615	glyoxalase metabolic pathway	http://purl.obolibrary.org/obo/PW_0000063	glyoxylate and dicarboxylate metabolic pathway		The glyoxalase pathway is the main detoxifying  route to protect against the harmful effects of methylglyoxal (MG). The highly reactive dicarbonyl compound is primarily a by-product of glycolysis, but  it can also result as a by-product of fatty acid and protein metabolism. MG is also known as pyruvaldehyde or 2-oxopropanol.
http://purl.obolibrary.org/obo/PW_0002616	altered fibrinolysis pathway	http://purl.obolibrary.org/obo/PW_0001538	altered cardiovascular system homeostasis pathway		A fibrinolysis pathway that deviates from what its normal course should be. Several congenital and acquired disorders of fibrinolysis are reported.
http://purl.obolibrary.org/obo/PW_0002617	phosphoenolpyruvate carboxykinase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001644	inborn error of carbohydrate metabolism pathway		A condition resulting from alterations in the gluconeogenesis pathway due to defects in the cytosolic PCK1 gene.
http://purl.obolibrary.org/obo/PW_0002618	altered platelet-derived growth factor signaling pathway	http://purl.obolibrary.org/obo/PW_0000673	altered signaling pathway pertinent to development		Alterations in platelet-derived growth factor signaling are implicated in cancer development.
http://purl.obolibrary.org/obo/PW_0002619	altered oxidative stress response pathway	http://purl.obolibrary.org/obo/PW_0001545	altered stress response pathway		An oxidative stress response pathway that deviates from what its normal course should be. Alterations in stress response pathway are associated with cardiovascular and neurodegenerative diseases and various forms of cancer.
http://purl.obolibrary.org/obo/PW_0002620	altered cellular detoxification pathway	http://purl.obolibrary.org/obo/PW_0000263	altered regulatory pathway		A cellular detoxification pathway that deviates from what its normal course should be.
http://purl.obolibrary.org/obo/PW_0002621	altered nuclear factor, erythroid 2 like 2 signaling pathway	http://purl.obolibrary.org/obo/PW_0002620	altered cellular detoxification pathway		Deregulation of nuclear factor, erythroid 2 like 2 (Nfe2l2, also known as Nrf2) signaling pathway has been associated with several conditions, including neurodegeneration and cancer.
http://purl.obolibrary.org/obo/PW_0002622	endogenous antioxidant pathway	http://purl.obolibrary.org/obo/PW_0000124	cellular detoxification pathway		Several endogenous small proteins are involved in the antioxidant response. Subsequently they need to be reduced back for another round of response, The reductase enzymes catalyze the reaction in an NADPH-dependent manner. The expression of these and of NADPH-producing enzymes is under the control of nuclear factor, erythroid 2 like 2 signaling pathway.
http://purl.obolibrary.org/obo/PW_0002626	ferroptosis pathway	http://purl.obolibrary.org/obo/PW_0000276	non-apoptotic cell death pathway		Ferroptosis is a non-apoptotic form of programmed cell death that is triggered by conditions or molecules that inhibit the Gpx4 function. Loss of function of glutathione peroxidase GPX4 results in accumulation of lipid-based reactive oxygen species (ROS).
http://purl.obolibrary.org/obo/PW_0002627	bortezomib drug pathway	http://purl.obolibrary.org/obo/PW_0002367	antineoplastic drug pathway		The pharmacokinetics and pharmacodynamics pathway of bortezomib, a proteasome inhibitor used in the treatment of several cancer types. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002628	bortezomib pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002627	bortezomib drug pathway		The pathway of processing - absorption, distribution, metabolism or elimination - of bortezomib. Genetic variations can result in changes in the availability of the drug.
http://purl.obolibrary.org/obo/PW_0002629	bortezomib pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002627	bortezomib drug pathway		The pathway of bortezomib-target interaction and of the biochemical or physiological responses to drug. Bortezomib  is used in the treatment of several cancer types. Genetic variations can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0002630	paraquat response pathway	http://purl.obolibrary.org/obo/PW_0001434	toxin and toxicant response pathway		Paraquat, a chemical used as a herbicide and a powerful oxidant, is highly toxic to the mammalian system. Toxicity depends on delivery routes: the highest is via inhalation, followed by the oral route, with the dermal route being moderately toxic. It has been shown that there is a connection between paraquat use and Parkinson disease (PD) in farm workers.
http://purl.obolibrary.org/obo/PW_0002631	iron uptake pathway	http://purl.obolibrary.org/obo/PW_0000591	iron transport pathway		Several systems are involved in the uptake of iron. They require the action of ferric reductases as the form of iron crossing the membrane is the ferrous Fe(II).
http://purl.obolibrary.org/obo/PW_0002632	iron efflux pathway	http://purl.obolibrary.org/obo/PW_0000591	iron transport pathway		A single system is involved in the efflux of iron from many cell types. As the iron crossing the membrane is the ferrous Fe(II), several oxidases carry out the formation of ferric Fe(III) which can be bound by the transferrin carrier.
http://purl.obolibrary.org/obo/PW_0002634	iron-sulfur cluster protein biogenesis pathway	http://purl.obolibrary.org/obo/PW_0002633	iron utilization pathway		The steps involved in the assembly and delivery of iron-sulfur (Fe-S) clusters (ISC) to Fe-S proteins. The mitochondrial ISC and the connected cytosolic assembly (CIA) pathways provide for the biogenesis of all Fe-S proteins. The Fe-S proteins participate in a broad range of important cellular processes.
http://purl.obolibrary.org/obo/PW_0002635	mitochondrial iron-sulfur cluster protein biogenesis pathway	http://purl.obolibrary.org/obo/PW_0002634	iron-sulfur cluster protein biogenesis pathway		The mitochondrial pathway consists of the synthesis of [2Fe-2S] clusters on scaffold proteins, cluster transfer and formation of mitochondrial [2Fe-2S] proteins, and the synthesis of 4Fe-4S] clusters and the formation of [4Fe-4S] proteins. The first two steps are required for the mitochondrial export and the biogenesis of cytosolic and nuclear Fe-S proteins. This arm of the pathway is usually referred to as the 'core'.
http://purl.obolibrary.org/obo/PW_0002636	cytosolic iron-sulfur cluster protein assembly pathway	http://purl.obolibrary.org/obo/PW_0002634	iron-sulfur cluster protein biogenesis pathway		The cytosolic iron-sulfur cluster protein assembly pathway is dependent upon the core mitochondrial assembly and export pathways. The pathway is structurally distinct from the mitochondrial system.
http://purl.obolibrary.org/obo/PW_0002638	cofactor transport pathway	http://purl.obolibrary.org/obo/PW_0000103	transport pathway		The molecular aspects of transport and intracellular trafficking of cofactors and prosthetic groups.
http://purl.obolibrary.org/obo/PW_0002639	heme transport pathway	http://purl.obolibrary.org/obo/PW_0002638	cofactor transport pathway		Heme is a prosthetic group found in proteins important for many and diverse metabolic pathways. Import and export of heme into and from cells are important for proper heme homeostasis.
http://purl.obolibrary.org/obo/PW_0002640	acrolein response pathway	http://purl.obolibrary.org/obo/PW_0001434	toxin and toxicant response pathway		Acrolein is a reactive unsaturated aldehyde that is a dietary and environmental pollutant and can also be metabolically generated. It exerts severe toxic effects through production of DNA and protein adducts and disruption of important cellular pathways. Acrolein is thought to play a role in cardiovascular and neurodegenerative diseases, diabetes and immune disorders.
http://purl.obolibrary.org/obo/PW_0002670	hyaluronan metabolic pathway	http://purl.obolibrary.org/obo/PW_0000157	glycosaminoglycan metabolic pathway		The chemical reactions and pathways involving hyaluronan, the naturally occurring anionic form of hyaluronic acid, which is not sulfated and is not found covalently attached to proteins as a proteoglycan. This includes any member of a group of glycosaminoglycans, the repeat units of which consist of beta-1,4 linked D-glucuronyl-beta-(1,3)-N-acetyl-D-glucosamine.
http://purl.obolibrary.org/obo/PW_0002671	oncogene-induced cell senescence pathway	http://purl.obolibrary.org/obo/PW_0000277	cellular senescence pathway		A cellular senescence pathway associated with the dismantling of a cell as a response to oncogenic stress, such as the activation of the Ras oncogenic family, which can be caused by oncogenic mutations in RAS or RAF proteins, or by oncogenic mutations in growth factor receptors, such as EGFR, that act upstream of RAS/RAF/MAPK cascade.
http://purl.obolibrary.org/obo/PW_0002672	cellular response to heat stress pathway	http://purl.obolibrary.org/obo/PW_0000237	stress response pathway		Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a heat stimulus, a temperature stimulus above the optimal temperature for that organism. In response to exposure to elevated temperature, cells activate a number of cytoprotective mechanisms known collectively as the "heat shock response".
http://purl.obolibrary.org/obo/PW_0002709	organic cation transport pathway	http://purl.obolibrary.org/obo/PW_0001348	ion transport pathway		Those metabolic reactions involved in the the elimination of a variety of endogenous cationic substances, xenobiotics and their metabolites from the body, mediated by families of transporters.
http://purl.obolibrary.org/obo/PW_0002710	transcription-coupled nucleotide-excision repair pathway	http://purl.obolibrary.org/obo/PW_0000130	nucleotide excision repair pathway		The nucleotide-excision repair pathway that carries out preferential repair of DNA lesions on the actively transcribed strand of the DNA duplex. In addition, the transcription-coupled nucleotide-excision repair pathway is required for the recognition and repair of a small subset of lesions that are not recognized by the global genome nucleotide excision repair pathway. Pathway impairment is the underlying cause of a severe hereditary disorder, Cockayne syndrome, an autosomal recessive disease characterized by hypersensitivity to UV light.
http://purl.obolibrary.org/obo/PW_0002711	global genome nucleotide-excision repair pathway	http://purl.obolibrary.org/obo/PW_0000130	nucleotide excision repair pathway		The nucleotide-excision repair pathway in which DNA lesions are removed from non-transcribed strands and from transcriptionally silent regions over the entire genome.
http://purl.obolibrary.org/obo/PW_0002712	vesicle-mediated transport pathway	http://purl.obolibrary.org/obo/PW_0000103	transport pathway		A cellular transport pathway in which transported substances are moved in membrane-bounded vesicles; transported substances are enclosed in the vesicle lumen or located in the vesicle membrane. The pathway begins with a step that directs a substance to the forming vesicle, and includes vesicle budding and coating. Vesicles are then targeted to, and fuse with, an acceptor membrane.
http://purl.obolibrary.org/obo/PW_0002713	Interleukin-13 signaling pathway	http://purl.obolibrary.org/obo/PW_0000906	interleukin-2 family mediated signaling pathway		Interleukin-13, an interleukin-2 family member, is secreted predominantly by activated T helper cells and is a key mediator in the pathogenesis of allergic inflammation.
http://purl.obolibrary.org/obo/PW_0002714	tRNA modification pathway	http://purl.obolibrary.org/obo/PW_0001573	tRNA maturation pathway		The covalent alteration of one or more nucleotides within a tRNA molecule to produce a tRNA molecule with a sequence that differs from that encoded genetically. At least 92 distinct tRNA nucleotide base modifications have been found, made post-transcriptionally by a large group of disparate enzymes located in the nucleus, cytosol, and mitochondria.
http://purl.obolibrary.org/obo/PW_0002715	post-translational protein modification pathway	http://purl.obolibrary.org/obo/PW_0000432	protein modification pathway		Those pathways involved in the covalent altering of one or more amino acids in a protein after the protein has been completely translated and released from the ribosome.
http://purl.obolibrary.org/obo/PW_0002686	glycosaminoglycan biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000157	glycosaminoglycan metabolic pathway		Those metabolic reactions involved in the biosynthesis of glycosaminoglycans.
http://purl.obolibrary.org/obo/PW_0002687	hyaluronan biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0002686	glycosaminoglycan biosynthetic pathway		Those metabolic reactions involved in the biosynthesis of hyaluronan.
http://purl.obolibrary.org/obo/PW_0002688	hyaluronan degradation pathway	http://purl.obolibrary.org/obo/PW_0002670	hyaluronan metabolic pathway		Those metabolic reactions involved in the degradation of hyaluronan.
http://purl.obolibrary.org/obo/PW_0002689	keratan sulfate metabolic pathway	http://purl.obolibrary.org/obo/PW_0000157	glycosaminoglycan metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of keratan sulfate - a glycosaminoglycan found in the cornea, in cartilage, and in the nucleus pulposus and also as the accumulation product in Morquio's syndrome. It consists of repeating disaccharide units in specific linkage, each composed of a sulfated N-acetylglucosamine residue linked to one of galactose, which is usually sulfated. There are two forms, keratan sulfate I and keratan sulfate II, which differ in carbohydrate content and localization; the former occurs in the cornea and the latter in skeletal tissues.
http://purl.obolibrary.org/obo/PW_0002690	keratan sulfate degradation pathway	http://purl.obolibrary.org/obo/PW_0002689	keratan sulfate metabolic pathway		Those metabolic reactions involved in the degradation of keratan sulfate.
http://purl.obolibrary.org/obo/PW_0002691	heparan sulfate metabolic pathway	http://purl.obolibrary.org/obo/PW_0000157	glycosaminoglycan metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of heparan sulfate. Heparan sulfate is a glycosaminoglycan occurring in the cell membrane of most cells. It consists of repeating disaccharide units in specific linkage, each composed of a glucosamine residue linked to a uronic acid, either glucuronic acid or L-iduronic acid, which may be sulfated.
http://purl.obolibrary.org/obo/PW_0002692	heparan sulfate degradation pathway	http://purl.obolibrary.org/obo/PW_0002691	heparan sulfate metabolic pathway		Those metabolic reactions involved in the degradation of heparan sulfate.
http://purl.obolibrary.org/obo/PW_0002693	heparin metabolic pathway	http://purl.obolibrary.org/obo/PW_0000157	glycosaminoglycan metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of heparin. Heparin is similar to heparan sulfates but is of somewhat higher average Mr (6000-20000) and contains fewer N-acetyl groups and more N-sulfate and O-sulfate groups. It is found mainly as an intracellular component of mast cells.
http://purl.obolibrary.org/obo/PW_0002694	heparin degradation pathway	http://purl.obolibrary.org/obo/PW_0002693	heparin metabolic pathway		Those metabolic reactions involved in the degradation of heparin.
http://purl.obolibrary.org/obo/PW_0002695	heparin biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0002693	heparin metabolic pathway		Those metabolic reactions involved in the biosynthesis of heparin.
http://purl.obolibrary.org/obo/PW_0002742	mitochondrial calcium ion transport pathway	http://purl.obolibrary.org/obo/PW_0001139	calcium transport pathway		The events involved in the transport of a calcium ion (Ca2+) across a mitochondrial membrane, into or out of the mitochondrion.
http://purl.obolibrary.org/obo/PW_0002743	nucleotide degradation pathway	http://purl.obolibrary.org/obo/PW_0000012	nucleotide metabolic pathway		Those chemical reactions resulting in the breakdown of nucleotides, any nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the sugar moiety; these may be mono-, di- or triphosphates. This definition includes cyclic-nucleotides (nucleoside cyclic phosphates).
http://purl.obolibrary.org/obo/PW_0002744	nucleotide biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000012	nucleotide metabolic pathway		Those chemical reactions resulting in the formation of nucleotides, any nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the sugar moiety; these may be mono-, di- or triphosphates. This definition includes cyclic-nucleotides (nucleoside cyclic phosphates).
http://purl.obolibrary.org/obo/PW_0002745	nucleotide salvage pathway	http://purl.obolibrary.org/obo/PW_0000012	nucleotide metabolic pathway		Those reactions involved in converting nucleosides and free bases, generated by RNA and DNA breakdown, back into nucleotide monophosphates, allowing them to re-enter the pathways of nucleotide biosynthesis and interconversion.
http://purl.obolibrary.org/obo/PW_0002654	ethanol oxidation pathway	http://purl.obolibrary.org/obo/PW_0000005	carbohydrate metabolic pathway		Those metabolic reactions involved in oxidizing ethanol to acetaldehyde, which is oxidized to acetate. This is then condensed with coenzyme A to form acetyl-CoA.
http://purl.obolibrary.org/obo/PW_0002655	glucose metabolic pathway	http://purl.obolibrary.org/obo/PW_0000005	carbohydrate metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of glucose, also known as dextrose. It is an important source of energy for living organisms and is found free as well as combined in homo- and hetero-oligosaccharides and polysaccharides.
http://purl.obolibrary.org/obo/PW_0002656	DNA biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000875	deoxyribonucleotide metabolic pathway		Those reactions involved in the biosynthesis of DNA.
http://purl.obolibrary.org/obo/PW_0002657	fructose degradation pathway	http://purl.obolibrary.org/obo/PW_0002666	fructose metabolic pathway		Those metabolic reactions involved in the degradation of fructose.
http://purl.obolibrary.org/obo/PW_0002658	galactose degradation pathway	http://purl.obolibrary.org/obo/PW_0000042	galactose metabolic pathway		Those metabolic reactions involved in the degradation of galactose.
http://purl.obolibrary.org/obo/PW_0002659	proline degradation pathway	http://purl.obolibrary.org/obo/PW_0001258	hydrophobic amino acid degradation pathway		Those metabolic reactions involved in the degradation of proline.
http://purl.obolibrary.org/obo/PW_0002660	DNA strand elongation pathway	http://purl.obolibrary.org/obo/PW_0000098	DNA replication pathway		Those reactions involved in extending an existing DNA strand by activities including the addition of nucleotides to the 3' end of the strand.
http://purl.obolibrary.org/obo/PW_0002661	DNA replication initiation pathway	http://purl.obolibrary.org/obo/PW_0000098	DNA replication pathway		The pathway in which DNA-dependent DNA replication is started; it begins when specific sequences, known as origins of replication, are recognized and bound by the origin recognition complex, followed by DNA unwinding.
http://purl.obolibrary.org/obo/PW_0002662	glycerophospholipid degradation pathway	http://purl.obolibrary.org/obo/PW_0000354	glycerophospholipid metabolic pathway		Those metabolic reactions involved in the degradation of glycerophospholipids.
http://purl.obolibrary.org/obo/PW_0002663	choline degradation pathway	http://purl.obolibrary.org/obo/PW_0000212	choline metabolic pathway		Those metabolic reactions involved in the degradation of choline.
http://purl.obolibrary.org/obo/PW_0002664	deubiquitination pathway	http://purl.obolibrary.org/obo/PW_0000433	protein modification pathway via conjugation with ubiquitin and ubiqutin-like molecules		A pathway of protein modification via removal of conjugated ubiquitin.
http://purl.obolibrary.org/obo/PW_0002665	fat-soluble vitamin metabolic pathway	http://purl.obolibrary.org/obo/PW_0000135	metabolic pathway of cofactors, vitamins, nutrients		Those metabolic reactions involving the fat-soluble vitamins. These include vitamins A, D, E and K.
http://purl.obolibrary.org/obo/PW_0002666	fructose metabolic pathway	http://purl.obolibrary.org/obo/PW_0000041	fructose and mannose metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of fructose.
http://purl.obolibrary.org/obo/PW_0002667	fructose biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0002666	fructose metabolic pathway		Those metabolic reactions involved in the biosynthesis of fructose.
http://purl.obolibrary.org/obo/PW_0002668	retinoic acid biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001004	retinoic acid metabolic pathway		The reactions involved in the biosynthesis of retinoic acid (RA).
http://purl.obolibrary.org/obo/PW_0002653	sulfur amino acid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000132	metabolic pathway of other amino acids		The chemical reactions and pathways involving the breakdown, interconversion and synthesis of amino acids containing sulfur, comprising cysteine, homocysteine, methionine and selenocysteine. Only plants and microorganisms employ all processes.
http://purl.obolibrary.org/obo/PW_0002102	inborn error of steroid metabolism pathway	http://purl.obolibrary.org/obo/PW_0001589	inborn error of metabolism pathway		Those disorders resulting from alterations in steroid metabolic pathways due to inborn genetic mutations.
http://purl.obolibrary.org/obo/PW_0002696	chondroitin sulfate metabolic pathway	http://purl.obolibrary.org/obo/PW_0000157	glycosaminoglycan metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of chondroitin sulfate. Chondroitin is a mucopolysaccharide occurring in sulfated form in various animal tissues (such as cartilage).
http://purl.obolibrary.org/obo/PW_0002697	chondroitin sulfate degradation pathway	http://purl.obolibrary.org/obo/PW_0002696	chondroitin sulfate metabolic pathway		Those metabolic reactions involved in the degradation of chondroitin sulfate.
http://purl.obolibrary.org/obo/PW_0002698	dermatan sulfate metabolic pathway	http://purl.obolibrary.org/obo/PW_0000157	glycosaminoglycan metabolic pathway		Those metabolic reactions involved in the synthesis, utilization and/or degradation of dermatan sulfate - a mucopolysaccharide found primarily in skin but also in tendons, lungs, heart valves and blood vessels.
http://purl.obolibrary.org/obo/PW_0002699	dermatan sulfate degradation pathway	http://purl.obolibrary.org/obo/PW_0002698	dermatan sulfate metabolic pathway		Those metabolic reactions involved in the degradation of dermatan sulfate.
http://purl.obolibrary.org/obo/PW_0002700	hypusinylation pathway	http://purl.obolibrary.org/obo/PW_0002715	post-translational protein modification pathway		Cytosolic eukaryotic translation initiation factor 5A (eIF5A) undergoes a unique two-step post-translational modification at Lysine 50 via deoxyhypusine to form hypusine. eIF5A is the only protein known to undergo hypusinylation.
http://purl.obolibrary.org/obo/PW_0002716	glycogen storage disease type II pathway	http://purl.obolibrary.org/obo/PW_0001991	glycogen storage disease pathway		A type of glycogen storage disease pathway involving mutations in lysosomal alpha-glucosidase (GAA).
http://purl.obolibrary.org/obo/PW_0002717	regulation of mitotic cell cycle pathway	http://purl.obolibrary.org/obo/PW_0000086	cell cycle pathway, mitotic		Those pathways involved in modulating the rate or extent of progress through the mitotic cell cycle.
http://purl.obolibrary.org/obo/PW_0002718	mitochondrial translation initiation pathway	http://purl.obolibrary.org/obo/PW_0000580	translation initiation pathway		The series of events preceding formation of the peptide bond between the first two amino acids of a protein in a mitochondrion. This includes the formation of a complex of the ribosome, mRNA, and an initiation complex that contains the first aminoacyl-tRNA.
http://purl.obolibrary.org/obo/PW_0002719	mitochondrial translation termination pathway	http://purl.obolibrary.org/obo/PW_0000582	translation termination pathway		The series of events resulting in the release of a polypeptide chain from the ribosome in a mitochondrion, usually in response to a termination codon (note that mitochondria use variants of the universal genetic code that differ between different taxa).
http://purl.obolibrary.org/obo/PW_0002721	melanin biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000052	tyrosine metabolic pathway		The metabolic reactions and pathways resulting in the formation of melanins, pigments largely of animal origin. High molecular weight polymers of indole quinone, they are irregular polymeric structures and are divided into three groups: allomelanins in plants and fungi, and eumelanins and pheomelanins in animals.
http://purl.obolibrary.org/obo/PW_0002722	protein O-linked glycosylation pathway	http://purl.obolibrary.org/obo/PW_0002715	post-translational protein modification pathway		Those pathways involved in the post-translational addition of a carbohydrate or carbohydrate derivative unit to a protein via the hydroxyl group of peptidyl-serine, peptidyl-threonine, peptidyl-hydroxylysine, or peptidyl-hydroxyproline, or via the phenol group of peptidyl-tyrosine, forming an O-glycan.
http://purl.obolibrary.org/obo/PW_0002723	ion homeostasis pathway	http://purl.obolibrary.org/obo/PW_0000355	homeostasis pathway		Those pathways involved in the maintenance of an internal steady state of ions within an organism or cell.
http://purl.obolibrary.org/obo/PW_0002724	mitochondrial tRNA modification pathway	http://purl.obolibrary.org/obo/PW_0002714	tRNA modification pathway		The covalent alteration of one or more nucleotides within a mitochondrial tRNA molecule to produce a mitochondrial tRNA molecule with a sequence that differs from that encoded genetically.
http://purl.obolibrary.org/obo/PW_0002725	protein repair pathway	http://purl.obolibrary.org/obo/PW_0001756	peptide and protein metabolic pathway		Those pathways involved in restoring a protein to its original state after damage by such things as oxidation or spontaneous decomposition of residues.
http://purl.obolibrary.org/obo/PW_0002726	rRNA modification pathway	http://purl.obolibrary.org/obo/PW_0001574	rRNA maturation pathway		The covalent alteration of one or more nucleotides within an rRNA molecule to produce an rRNA molecule with a sequence that differs from that encoded genetically.
http://purl.obolibrary.org/obo/PW_0002731	cell division pathway	http://purl.obolibrary.org/obo/PW_0000085	pathway pertinent to DNA replication and repair, cell cycle, maintenance of genomic integrity, RNA and protein biosynthesis		The series of events resulting in division and partitioning of components of a cell to form more cells; this may or may not be accompanied by the physical separation of a cell into distinct, individually membrane-bounded daughter cells.
http://purl.obolibrary.org/obo/PW_0002732	propionyl-CoA degradation pathway	http://purl.obolibrary.org/obo/PW_0000738	fatty acid beta degradation pathway		Those metabolic reactions involved in the breakdown of propionyl-CoA.
http://purl.obolibrary.org/obo/PW_0002734	nucleotide sugar transport pathway	http://purl.obolibrary.org/obo/PW_0000055	nucleotide sugar metabolic pathway		Those reactions involved in the directed movement of a nucleotide, any compound consisting of a nucleoside esterified with (ortho) phosphate, into, out of or within a cell.
http://purl.obolibrary.org/obo/PW_0002675	altered cobalamin metabolic pathway	http://purl.obolibrary.org/obo/PW_0000429	altered metabolic pathway of cofactors, vitamins, nutrients		A cobalamin (Cbl) metabolic pathway that deviates from what its normal course should be. Cbl deficiency results in hyperhomocysteinemia (due to defects in the conversion of homocysteine to methionine which requires Cbl as a cofactor) and increased levels of methylmalonic acid. Symptoms of Cbl deficiency are bone marrow promegaloblastosis (megaloblastic anemia) due to the inhibition of DNA synthesis (specifically purines and thymidine) and neurological symptoms.
http://purl.obolibrary.org/obo/PW_0002676	altered biotin metabolic pathway	http://purl.obolibrary.org/obo/PW_0000429	altered metabolic pathway of cofactors, vitamins, nutrients		A biotin metabolic pathway that deviates from what its normal course should be.
http://purl.obolibrary.org/obo/PW_0002677	agmatine biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001234	biogenic amine biosynthetic pathway		Those metabolic reactions involved in the synthesis of agmatine, which is the decarboxylation product of the amino acid arginine and is an intermediate in polyamine biosynthesis. It is synthesized in the brain, stored in synaptic vesicles, accumulated by uptake, released by membrane depolarization, and hydrolyzed by agmatinase to putrescine. Agmatine binds to several target receptors in the brain and has been proposed as a novel neuromodulator. It has the potential to serve in the coordination of the early and repair phase pathways of arginine in inflammation.
http://purl.obolibrary.org/obo/PW_0002678	glycogen storage disease type XV pathway	http://purl.obolibrary.org/obo/PW_0001991	glycogen storage disease pathway		A type of glycogen storage disease pathway involving glycogenin 1.
http://purl.obolibrary.org/obo/PW_0002679	glycogen storage disease type 0 pathway	http://purl.obolibrary.org/obo/PW_0001991	glycogen storage disease pathway		A type of glycogen storage disease pathway involving glycogen synthase 1.
http://purl.obolibrary.org/obo/PW_0002680	NADPH regeneration pathway	http://purl.obolibrary.org/obo/PW_0002580	nicotinamide adenine dinucleotide metabolic pathway		Those metabolic reactions involved in the generation of a pool of NADPH by the reduction of NADP+.
http://purl.obolibrary.org/obo/PW_0002681	very long-chain fatty acid beta degradation pathway	http://purl.obolibrary.org/obo/PW_0000738	fatty acid beta degradation pathway		Fatty acid degradation via beta oxidation, acting on very long-chain fatty acids having an aliphatic tail containing more than 22 carbons.
http://purl.obolibrary.org/obo/PW_0002682	muscle contraction pathway	http://purl.obolibrary.org/obo/PW_0001140	calcium/calcium-mediated signaling pathway		A pathway in which force is generated within muscle tissue, resulting in a change in muscle geometry. Force generation involves a calcium-triggered chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis.
http://purl.obolibrary.org/obo/PW_0002683	striated muscle contraction pathway	http://purl.obolibrary.org/obo/PW_0002682	muscle contraction pathway		A pathway in which force is generated within striated muscle tissue, resulting in a change in muscle geometry. Force generation involves a calcium-triggered chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. Striated muscle contains repeating units (sarcomeres) of the contractile myofibrils that are arranged in registry throughout the cell, resulting in transverse or oblique striations observable by light microscope.
http://purl.obolibrary.org/obo/PW_0002684	smooth muscle contraction pathway	http://purl.obolibrary.org/obo/PW_0002682	muscle contraction pathway		A pathway in which force is generated within smooth muscle tissue, resulting in a change in muscle geometry. Force generation involves a calcium-triggered chemo-mechanical energy conversion step that is carried out by the actin/myosin complex activity, which generates force through ATP hydrolysis. Smooth muscle differs from striated muscle in the much higher actin/myosin ratio, the absence of conspicuous sarcomeres and the ability to contract to a much smaller fraction of its resting length.
http://purl.obolibrary.org/obo/PW_0000406	metabolic pathway pertinent to the brain	http://purl.obolibrary.org/obo/PW_0000002	classic metabolic pathway		
http://purl.obolibrary.org/obo/PW_0000541	signaling pathway involving second messengers	http://purl.obolibrary.org/obo/PW_0000003	signaling pathway		
http://purl.obolibrary.org/obo/PW_0000959	lipid signaling pathway	http://purl.obolibrary.org/obo/PW_0000003	signaling pathway		
http://purl.obolibrary.org/obo/PW_0000997	nucleoside and nucleotide mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000003	signaling pathway		
http://purl.obolibrary.org/obo/PW_0001251	regulatory pathway pertinent to the brain	http://purl.obolibrary.org/obo/PW_0000004	regulatory pathway		
http://purl.obolibrary.org/obo/PW_0000066	C5-branched dibasic acid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000005	carbohydrate metabolic pathway		
http://purl.obolibrary.org/obo/PW_0000391	altered Ras superfamily mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0001541	altered G protein mediated signaling pathway		
http://purl.obolibrary.org/obo/PW_0001029	substance dependence pathway	http://purl.obolibrary.org/obo/PW_0000013	disease pathway		
http://purl.obolibrary.org/obo/PW_0001308	respiratory system disease pathway	http://purl.obolibrary.org/obo/PW_0000013	disease pathway		
http://purl.obolibrary.org/obo/PW_0001547	endocrine system disease pathway	http://purl.obolibrary.org/obo/PW_0000013	disease pathway		
http://purl.obolibrary.org/obo/PW_0001699	urogenital disease pathway	http://purl.obolibrary.org/obo/PW_0000013	disease pathway		
http://purl.obolibrary.org/obo/PW_0001701	skin and connective tissue disease pathway	http://purl.obolibrary.org/obo/PW_0000013	disease pathway		
http://purl.obolibrary.org/obo/PW_0000344	cerebrovascular disease pathway	http://purl.obolibrary.org/obo/PW_0001412	nervous system disease pathway		
http://purl.obolibrary.org/obo/PW_0000347	cardiovascular abnormalities pathway	http://purl.obolibrary.org/obo/PW_0000020	cardiovascular system disease pathway		
http://purl.obolibrary.org/obo/PW_0001118	altered energy metabolic pathway	http://purl.obolibrary.org/obo/PW_0000262	altered metabolic pathway		
http://purl.obolibrary.org/obo/PW_0000272	neuron-to-neuron signaling pathways	http://purl.obolibrary.org/obo/PW_0000059	signaling pathway pertinent to the brain and nervous system		
http://purl.obolibrary.org/obo/PW_0000389	altered signaling pathway pertinent to the brain and nervous system	http://purl.obolibrary.org/obo/PW_0000264	altered signaling pathway		
http://purl.obolibrary.org/obo/PW_0001536	sensory system signaling pathway	http://purl.obolibrary.org/obo/PW_0000059	signaling pathway pertinent to the brain and nervous system		
http://purl.obolibrary.org/obo/PW_0000098	DNA replication pathway	http://purl.obolibrary.org/obo/PW_0000085	pathway pertinent to DNA replication and repair, cell cycle, maintenance of genomic integrity, RNA and protein biosynthesis		
http://purl.obolibrary.org/obo/PW_0001552	altered cell cycle pathway, mitotic	http://purl.obolibrary.org/obo/PW_0001551	altered cell cycle pathway		
http://purl.obolibrary.org/obo/PW_0001955	bacterial DNA replication pathway	http://purl.obolibrary.org/obo/PW_0000098	DNA replication pathway		
http://purl.obolibrary.org/obo/PW_0001313	transcription pathway via transcription factor mediated signaling	http://purl.obolibrary.org/obo/PW_0000100	transcription pathway		
http://purl.obolibrary.org/obo/PW_0001068	altered translation pathway	http://purl.obolibrary.org/obo/PW_0000290	altered pathway pertinent to DNA replication and repair, cell cycle, maintenance of genomic integrity, RNA and protein biosynthesis		
http://purl.obolibrary.org/obo/PW_0000545	altered transport pathway	http://purl.obolibrary.org/obo/PW_0000263	altered regulatory pathway		
http://purl.obolibrary.org/obo/PW_0000680	altered extrinsic apoptotic pathway	http://purl.obolibrary.org/obo/PW_0000287	altered apoptotic cell death pathway		
http://purl.obolibrary.org/obo/PW_0001541	altered G protein mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000264	altered signaling pathway		
http://purl.obolibrary.org/obo/PW_0002669	selenocysteine biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000133	selenoamino acid metabolic pathway		
http://purl.obolibrary.org/obo/PW_0000429	altered metabolic pathway of cofactors, vitamins, nutrients	http://purl.obolibrary.org/obo/PW_0000262	altered metabolic pathway		
http://purl.obolibrary.org/obo/PW_0000148	alkaloid biosynthetic pathway I	http://purl.obolibrary.org/obo/PW_0000147	metabolic pathway of secondary metabolites		
http://purl.obolibrary.org/obo/PW_0000149	alkaloid biosynthetic pathway II	http://purl.obolibrary.org/obo/PW_0000147	metabolic pathway of secondary metabolites		
http://purl.obolibrary.org/obo/PW_0000150	stilbene, coumarine and lignin biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000147	metabolic pathway of secondary metabolites		
http://purl.obolibrary.org/obo/PW_0000257	polyketide sugar biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000147	metabolic pathway of secondary metabolites		
http://purl.obolibrary.org/obo/PW_0000525	Ras mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000158	Ras family mediated signaling pathway		
http://purl.obolibrary.org/obo/PW_0001540	altered Ras family mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000391	altered Ras superfamily mediated signaling pathway		
http://purl.obolibrary.org/obo/PW_0001548	diabetes complication pathway	http://purl.obolibrary.org/obo/PW_0000176	diabetes mellitus pathway		
http://purl.obolibrary.org/obo/PW_0000393	altered mTOR signaling pathway	http://purl.obolibrary.org/obo/PW_0000359	altered energy homeostasis pathway		
http://purl.obolibrary.org/obo/PW_0001209	altered folate mediated one-carbon metabolic pathway	http://purl.obolibrary.org/obo/PW_0001189	altered folate metabolic pathway		
http://purl.obolibrary.org/obo/PW_0000601	altered p38 MAPK signaling pathway	http://purl.obolibrary.org/obo/PW_0000422	altered stress-regulated MAPK signaling pathway		
http://purl.obolibrary.org/obo/PW_0000635	altered Wnt/calcium signaling pathway	http://purl.obolibrary.org/obo/PW_0000600	altered Wnt signaling, non-canonical pathway		
http://purl.obolibrary.org/obo/PW_0000510	altered insulin-like growth factor signaling pathway	http://purl.obolibrary.org/obo/PW_0000511	altered peptide and protein hormone signaling pathway		
http://purl.obolibrary.org/obo/PW_0000671	altered cell adhesion signaling pathway	http://purl.obolibrary.org/obo/PW_0000648	cell adhesion signaling pathway		
http://purl.obolibrary.org/obo/PW_0000673	altered signaling pathway pertinent to development	http://purl.obolibrary.org/obo/PW_0000650	signaling pathway pertinent to development		
http://purl.obolibrary.org/obo/PW_0001169	altered calcium/calcium-mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0001140	calcium/calcium-mediated signaling pathway		
http://purl.obolibrary.org/obo/PW_0001196	altered phosphatase mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000652	phosphatase mediated signaling pathway		
http://purl.obolibrary.org/obo/PW_0001198	altered kinase mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0001193	kinase mediated signaling pathway		
http://purl.obolibrary.org/obo/PW_0001492	altered photosignal transduction pathway	http://purl.obolibrary.org/obo/PW_0001008	photosignal transduction pathway		
http://purl.obolibrary.org/obo/PW_0001493	altered vitamin and vitamin metabolites signaling pathway	http://purl.obolibrary.org/obo/PW_0001012	vitamin and vitamin metabolites signaling pathway		
http://purl.obolibrary.org/obo/PW_0001505	altered mechanotransduction pathway	http://purl.obolibrary.org/obo/PW_0001502	mechanotransduction pathway		
http://purl.obolibrary.org/obo/PW_0001543	altered signaling pathway pertinent to immunity	http://purl.obolibrary.org/obo/PW_0000818	signaling pathway pertinent to immunity		
http://purl.obolibrary.org/obo/PW_0001563	altered non-apoptotic cell death pathway	http://purl.obolibrary.org/obo/PW_0001559	altered programmed cell death pathway		
http://purl.obolibrary.org/obo/PW_0001551	altered cell cycle pathway	http://purl.obolibrary.org/obo/PW_0001317	cell cycle pathway		
http://purl.obolibrary.org/obo/PW_0000326	altered protein degradation pathway	http://purl.obolibrary.org/obo/PW_0000325	protein degradation pathway		
http://purl.obolibrary.org/obo/PW_0001780	hyperoxaluria pathway	http://purl.obolibrary.org/obo/PW_0000300	kidney disease pathway		
http://purl.obolibrary.org/obo/PW_0000422	altered stress-regulated MAPK signaling pathway	http://purl.obolibrary.org/obo/PW_0000421	altered mitogen activated protein kinase pathway		
http://purl.obolibrary.org/obo/PW_0000420	altered c-Jun N-terminal kinase MAPK signaling pathway	http://purl.obolibrary.org/obo/PW_0000422	altered stress-regulated MAPK signaling pathway		
http://purl.obolibrary.org/obo/PW_0000418	altered ubiquitin, ubiquitin-like degradation pathway	http://purl.obolibrary.org/obo/PW_0000417	ubiquitin, ubiquitin-like/proteasome degradation pathway		
http://purl.obolibrary.org/obo/PW_0000334	connexin signaling pathway	http://purl.obolibrary.org/obo/PW_0000332	cell-cell signaling pathway		
http://purl.obolibrary.org/obo/PW_0000338	altered cadherins mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000333	cadherin mediated signaling pathway		
http://purl.obolibrary.org/obo/PW_0000339	altered connexins mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0000334	connexin signaling pathway		
http://purl.obolibrary.org/obo/PW_0000994	altered classical cadherin signaling pathway	http://purl.obolibrary.org/obo/PW_0000988	classical cadherin signaling pathway		
http://purl.obolibrary.org/obo/PW_0000345	cerebral arterial diseases pathway	http://purl.obolibrary.org/obo/PW_0000344	cerebrovascular disease pathway		
http://purl.obolibrary.org/obo/PW_0000348	congenital heart defects pathway	http://purl.obolibrary.org/obo/PW_0000347	cardiovascular abnormalities pathway		
http://purl.obolibrary.org/obo/PW_0002419	altered glycerophospholipid metabolic pathway	http://purl.obolibrary.org/obo/PW_0000483	altered lipid metabolic pathway		
http://purl.obolibrary.org/obo/PW_0000476	cardiovascular system homeostasis pathway	http://purl.obolibrary.org/obo/PW_0000355	homeostasis pathway		
http://purl.obolibrary.org/obo/PW_0000361	altered oxygen homeostasis pathway	http://purl.obolibrary.org/obo/PW_0001833	altered inorganic chemical homeostasis pathway		
http://purl.obolibrary.org/obo/PW_0001500	altered vitamin homeostasis	http://purl.obolibrary.org/obo/PW_0001006	vitamin homeostasis		
http://purl.obolibrary.org/obo/PW_0001538	altered cardiovascular system homeostasis pathway	http://purl.obolibrary.org/obo/PW_0000476	cardiovascular system homeostasis pathway		
http://purl.obolibrary.org/obo/PW_0000364	altered leptin system pathway	http://purl.obolibrary.org/obo/PW_0000511	altered peptide and protein hormone signaling pathway		
http://purl.obolibrary.org/obo/PW_0000381	multidrug resistance-associated protein mediated transport pathway	http://purl.obolibrary.org/obo/PW_0000380	transport pathway for the elimination of drugs, endogenous or exogenous compounds and metabolites		
http://purl.obolibrary.org/obo/PW_0000382	multidrug resistance protein mediated transport pathway	http://purl.obolibrary.org/obo/PW_0000380	transport pathway for the elimination of drugs, endogenous or exogenous compounds and metabolites		
http://purl.obolibrary.org/obo/PW_0000390	altered Reelin signaling pathway	http://purl.obolibrary.org/obo/PW_0000669	altered glycoprotein signaling pathway		
http://purl.obolibrary.org/obo/PW_0000395	altered dopamine signaling pathway	http://purl.obolibrary.org/obo/PW_0000394	dopamine signaling pathway		
http://purl.obolibrary.org/obo/PW_0002578	altered neurotrophic factor signaling pathway	http://purl.obolibrary.org/obo/PW_0000571	neurotrophic factor signaling pathway		
http://purl.obolibrary.org/obo/PW_0001190	altered hydrophobic amino acid metabolic pathway	http://purl.obolibrary.org/obo/PW_0001074	hydrophobic amino acid metabolic pathway		
http://purl.obolibrary.org/obo/PW_0000437	amino acid neurotransmitter metabolic pathway	http://purl.obolibrary.org/obo/PW_0000407	neurotransmitter metabolic pathway		
http://purl.obolibrary.org/obo/PW_0000447	peptide neurotransmitter metabolic pathway	http://purl.obolibrary.org/obo/PW_0000407	neurotransmitter metabolic pathway		
http://purl.obolibrary.org/obo/PW_0001165	lipid neurotransmitter metabolic pathway	http://purl.obolibrary.org/obo/PW_0000407	neurotransmitter metabolic pathway		
http://purl.obolibrary.org/obo/PW_0000604	altered Erk5 MAPK signaling pathway	http://purl.obolibrary.org/obo/PW_0000603	Erk5 MAPK signaling pathway		
http://purl.obolibrary.org/obo/PW_0000428	altered molybdenum cofactor biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0000429	altered metabolic pathway of cofactors, vitamins, nutrients		
http://purl.obolibrary.org/obo/PW_0000445	excitatory neurotransmitter metabolic pathway	http://purl.obolibrary.org/obo/PW_0000437	amino acid neurotransmitter metabolic pathway		
http://purl.obolibrary.org/obo/PW_0000446	inhibitory neurotransmitter metabolic pathway	http://purl.obolibrary.org/obo/PW_0000437	amino acid neurotransmitter metabolic pathway		
http://purl.obolibrary.org/obo/PW_0001238	indoleamine and related compounds biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001234	biogenic amine biosynthetic pathway		
http://purl.obolibrary.org/obo/PW_0000466	amine and amino acid-derived hormone signaling pathway	http://purl.obolibrary.org/obo/PW_0000465	hormone signaling pathway		
http://purl.obolibrary.org/obo/PW_0000467	peptide and protein hormone signaling pathway	http://purl.obolibrary.org/obo/PW_0000465	hormone signaling pathway		
http://purl.obolibrary.org/obo/PW_0000500	tyrosine-based hormone signaling pathway	http://purl.obolibrary.org/obo/PW_0000466	amine and amino acid-derived hormone signaling pathway		
http://purl.obolibrary.org/obo/PW_0000511	altered peptide and protein hormone signaling pathway	http://purl.obolibrary.org/obo/PW_0000509	altered hormone signaling pathway		
http://purl.obolibrary.org/obo/PW_0000786	altered steroid hormone signaling pathway	http://purl.obolibrary.org/obo/PW_0000785	altered lipid hormone signaling pathway		
http://purl.obolibrary.org/obo/PW_0000785	altered lipid hormone signaling pathway	http://purl.obolibrary.org/obo/PW_0000509	altered hormone signaling pathway		
http://purl.obolibrary.org/obo/PW_0000886	interleukin-19 signaling pathway	http://purl.obolibrary.org/obo/PW_0000513	interleukin-10 family mediated signaling pathway		
http://purl.obolibrary.org/obo/PW_0000887	interleukin-20 signaling pathway	http://purl.obolibrary.org/obo/PW_0000513	interleukin-10 family mediated signaling pathway		
http://purl.obolibrary.org/obo/PW_0000889	interleukin-24 signaling pathway	http://purl.obolibrary.org/obo/PW_0000513	interleukin-10 family mediated signaling pathway		
http://purl.obolibrary.org/obo/PW_0000890	interleukin-26 signaling pathway	http://purl.obolibrary.org/obo/PW_0000513	interleukin-10 family mediated signaling pathway		
http://purl.obolibrary.org/obo/PW_0000891	interleukin-28A signaling pathway	http://purl.obolibrary.org/obo/PW_0000513	interleukin-10 family mediated signaling pathway		
http://purl.obolibrary.org/obo/PW_0000892	interleukin-28B signaling pathway	http://purl.obolibrary.org/obo/PW_0000513	interleukin-10 family mediated signaling pathway		
http://purl.obolibrary.org/obo/PW_0000893	interleukin-29 signaling pathway	http://purl.obolibrary.org/obo/PW_0000513	interleukin-10 family mediated signaling pathway		
http://purl.obolibrary.org/obo/PW_0000902	interleukin-11 signaling pathway	http://purl.obolibrary.org/obo/PW_0000514	interleukin-6 family mediated signaling pathway		
http://purl.obolibrary.org/obo/PW_0000904	ciliary neurotrophic factor signaling pathway	http://purl.obolibrary.org/obo/PW_0000514	interleukin-6 family mediated signaling pathway		
http://purl.obolibrary.org/obo/PW_0001347	altered cholesterol transport pathway	http://purl.obolibrary.org/obo/PW_0001346	cholesterol transport pathway		
http://purl.obolibrary.org/obo/PW_0001353	altered ion transport pathway	http://purl.obolibrary.org/obo/PW_0001348	ion transport pathway		
http://purl.obolibrary.org/obo/PW_0000558	glucose conversion pathway	http://purl.obolibrary.org/obo/PW_0000555	glucose utilization pathway		
http://purl.obolibrary.org/obo/PW_0001519	glucose reduction pathway	http://purl.obolibrary.org/obo/PW_0000555	glucose utilization pathway		
http://purl.obolibrary.org/obo/PW_0001147	eicosanoid signaling pathway via peroxisome proliferator-activated receptor gamma	http://purl.obolibrary.org/obo/PW_0000565	eicosanoid signaling pathway		
http://purl.obolibrary.org/obo/PW_0000880	altered corticosteroid signaling pathway	http://purl.obolibrary.org/obo/PW_0000566	corticosteroid signaling pathway		
http://purl.obolibrary.org/obo/PW_0000787	altered sex steroids signaling pathway	http://purl.obolibrary.org/obo/PW_0000786	altered steroid hormone signaling pathway		
http://purl.obolibrary.org/obo/PW_0001832	altered metal homeostasis pathway	http://purl.obolibrary.org/obo/PW_0001833	altered inorganic chemical homeostasis pathway		
http://purl.obolibrary.org/obo/PW_0000621	altered phosphatidylinositol 3-kinase signaling pathway	http://purl.obolibrary.org/obo/PW_0000620	altered signaling pathway involving second messengers		
http://purl.obolibrary.org/obo/PW_0000632	bone cancer pathway	http://purl.obolibrary.org/obo/PW_0000605	cancer pathway		
http://purl.obolibrary.org/obo/PW_0000964	altered phosphatidylinositol 3-kinase class I signaling pathway	http://purl.obolibrary.org/obo/PW_0000621	altered phosphatidylinositol 3-kinase signaling pathway		
http://purl.obolibrary.org/obo/PW_0000630	liver cancer pathway	http://purl.obolibrary.org/obo/PW_0000625	digestive system cancer pathway		
http://purl.obolibrary.org/obo/PW_0000628	intestinal cancer pathway	http://purl.obolibrary.org/obo/PW_0000627	gastrointestinal cancer pathway		
http://purl.obolibrary.org/obo/PW_0001222	forkhead class C signaling pathway	http://purl.obolibrary.org/obo/PW_0000647	forkhead signaling pathway		
http://purl.obolibrary.org/obo/PW_0001223	forkhead class P signaling pathway	http://purl.obolibrary.org/obo/PW_0000647	forkhead signaling pathway		
http://purl.obolibrary.org/obo/PW_0001197	altered serine/threonine-specific phosphatase mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0001196	altered phosphatase mediated signaling pathway		
http://purl.obolibrary.org/obo/PW_0000672	altered cell-extracellular matrix signaling pathway	http://purl.obolibrary.org/obo/PW_0000671	altered cell adhesion signaling pathway		
http://purl.obolibrary.org/obo/PW_0000702	respiratory tract cancer pathway	http://purl.obolibrary.org/obo/PW_0000701	thoracic cancer pathway		
http://purl.obolibrary.org/obo/PW_0001306	altered steroid biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001152	steroid biosynthetic pathway		
http://purl.obolibrary.org/obo/PW_0000881	altered glucocorticoid signaling pathway	http://purl.obolibrary.org/obo/PW_0000880	altered corticosteroid signaling pathway		
http://purl.obolibrary.org/obo/PW_0001314	altered transcription pathway via transcription factor mediated signaling	http://purl.obolibrary.org/obo/PW_0001313	transcription pathway via transcription factor mediated signaling		
http://purl.obolibrary.org/obo/PW_0000810	endogenous small interfering RNA pathway	http://purl.obolibrary.org/obo/PW_0000809	small non-coding RNA pathway		
http://purl.obolibrary.org/obo/PW_0000819	signaling pathway in the innate immune response	http://purl.obolibrary.org/obo/PW_0000818	signaling pathway pertinent to immunity		
http://purl.obolibrary.org/obo/PW_0000820	signaling pathway in the adaptive immune response	http://purl.obolibrary.org/obo/PW_0000818	signaling pathway pertinent to immunity		
http://purl.obolibrary.org/obo/PW_0000849	glutamate signaling pathway via group I metabotropic glutamate receptor	http://purl.obolibrary.org/obo/PW_0000847	glutamate signaling pathway via metabotropic glutamate receptor		
http://purl.obolibrary.org/obo/PW_0000850	glutamate signaling pathway via group II or III glutamate receptor	http://purl.obolibrary.org/obo/PW_0000847	glutamate signaling pathway via metabotropic glutamate receptor		
http://purl.obolibrary.org/obo/PW_0001111	tocilizumab pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0000928	tocilizumab drug pathway		
http://purl.obolibrary.org/obo/PW_0001112	tocilizumab pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0000928	tocilizumab drug pathway		
http://purl.obolibrary.org/obo/PW_0000977	chemokine (C-X-C motif) ligand 7 signaling pathway	http://purl.obolibrary.org/obo/PW_0000971	CXC chemokine ELR(+) subgroup mediated signaling pathway		
http://purl.obolibrary.org/obo/PW_0000984	chemokine (C-X-C motif) ligand 13 signaling pathway	http://purl.obolibrary.org/obo/PW_0000972	CXC chemokine ELR(-) subgroup mediated signaling pathway		
http://purl.obolibrary.org/obo/PW_0000985	chemokine (C-X-C motif) ligand 14 signaling pathway	http://purl.obolibrary.org/obo/PW_0000972	CXC chemokine ELR(-) subgroup mediated signaling pathway		
http://purl.obolibrary.org/obo/PW_0000986	chemokine (C-X-C motif) ligand 16 signaling pathway	http://purl.obolibrary.org/obo/PW_0000972	CXC chemokine ELR(-) subgroup mediated signaling pathway		
http://purl.obolibrary.org/obo/PW_0000995	altered E-cadherin signaling pathway	http://purl.obolibrary.org/obo/PW_0000994	altered classical cadherin signaling pathway		
http://purl.obolibrary.org/obo/PW_0001001	adenosine triphosphate signaling via the P2X ligand-gated ion channel	http://purl.obolibrary.org/obo/PW_0000999	adenosine triphosphate signaling pathway		
http://purl.obolibrary.org/obo/PW_0001501	altered vitamin A homeostasis	http://purl.obolibrary.org/obo/PW_0001500	altered vitamin homeostasis		
http://purl.obolibrary.org/obo/PW_0001116	vitamin A and metabolites signaling pathway	http://purl.obolibrary.org/obo/PW_0001012	vitamin and vitamin metabolites signaling pathway		
http://purl.obolibrary.org/obo/PW_0001056	Herpes simplex virus infection pathway	http://purl.obolibrary.org/obo/PW_0001028	infectious disease pathway		
http://purl.obolibrary.org/obo/PW_0001057	Epstein-Barr virus infection pathway	http://purl.obolibrary.org/obo/PW_0001028	infectious disease pathway		
http://purl.obolibrary.org/obo/PW_0001326	altered mitochondrial translation pathway	http://purl.obolibrary.org/obo/PW_0001960	altered mitochondria homeostasis pathway		
http://purl.obolibrary.org/obo/PW_0001256	hydrophobic amino acid biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001254	amino acid biosynthetic pathway		
http://purl.obolibrary.org/obo/PW_0001258	hydrophobic amino acid degradation pathway	http://purl.obolibrary.org/obo/PW_0001257	amino acid degradation pathway		
http://purl.obolibrary.org/obo/PW_0001255	hydrophilic amino acid biosynthetic pathway	http://purl.obolibrary.org/obo/PW_0001254	amino acid biosynthetic pathway		
http://purl.obolibrary.org/obo/PW_0001259	hydrophilic amino acid degradation pathway	http://purl.obolibrary.org/obo/PW_0001257	amino acid degradation pathway		
http://purl.obolibrary.org/obo/PW_0001078	cysteine and methionine metabolic pathway	http://purl.obolibrary.org/obo/PW_0001077	amino acid metabolic pathway (KEGG)		
http://purl.obolibrary.org/obo/PW_0001494	altered vitamin A and metabolites signaling pathway	http://purl.obolibrary.org/obo/PW_0001493	altered vitamin and vitamin metabolites signaling pathway		
http://purl.obolibrary.org/obo/PW_0001166	endocannabinoid metabolic pathway	http://purl.obolibrary.org/obo/PW_0001165	lipid neurotransmitter metabolic pathway		
http://purl.obolibrary.org/obo/PW_0001181	altered fibroblast growth factor 23 signaling pathway	http://purl.obolibrary.org/obo/PW_0001179	fibroblast growth factor 23 signaling pathway		
http://purl.obolibrary.org/obo/PW_0001184	altered phosphate homeostasis pathway	http://purl.obolibrary.org/obo/PW_0001182	phosphate homeostasis pathway		
http://purl.obolibrary.org/obo/PW_0001187	calcium/calmodulin dependent kinase 1 signaling pathway	http://purl.obolibrary.org/obo/PW_0001186	calcium/calmodulin dependent kinase signaling cascade		
http://purl.obolibrary.org/obo/PW_0001188	calcium/calmodulin dependent kinase 4 signaling pathway	http://purl.obolibrary.org/obo/PW_0001186	calcium/calmodulin dependent kinase signaling cascade		
http://purl.obolibrary.org/obo/PW_0001208	altered folate cycle metabolic pathway	http://purl.obolibrary.org/obo/PW_0001207	folate cycle metabolic pathway		
http://purl.obolibrary.org/obo/PW_0001199	altered serine/threonine-specific kinase mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0001198	altered kinase mediated signaling pathway		
http://purl.obolibrary.org/obo/PW_0001537	altered tyrosine-specific protein kinase mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0001198	altered kinase mediated signaling pathway		
http://purl.obolibrary.org/obo/PW_0001459	amphotericin B drug pathway	http://purl.obolibrary.org/obo/PW_0001202	genito-urinary system and sex hormones drug pathway		
http://purl.obolibrary.org/obo/PW_0001232	arylamine metabolic pathway	http://purl.obolibrary.org/obo/PW_0001229	xenobiotic metabolic pathway		
http://purl.obolibrary.org/obo/PW_0001389	glutamate degradation pathway IX	http://purl.obolibrary.org/obo/PW_0001263	glutamic acid/glutamate degradation pathway		
http://purl.obolibrary.org/obo/PW_0001351	altered non-metal ion transport pathway	http://purl.obolibrary.org/obo/PW_0001353	altered ion transport pathway		
http://purl.obolibrary.org/obo/PW_0001352	altered metal ion transport pathway	http://purl.obolibrary.org/obo/PW_0001353	altered ion transport pathway		
http://purl.obolibrary.org/obo/PW_0001368	trichothecene metabolic pathway	http://purl.obolibrary.org/obo/PW_0001365	toxic secondary metabolite metabolic pathway		
http://purl.obolibrary.org/obo/PW_0001398	terpene and terpenoid degradation pathway	http://purl.obolibrary.org/obo/PW_0001397	terpene and terpenoid metabolic pathway		
http://purl.obolibrary.org/obo/PW_0001496	sensory system disease pathway	http://purl.obolibrary.org/obo/PW_0001412	nervous system disease pathway		
http://purl.obolibrary.org/obo/PW_0001938	Kelley-Seegmiller syndrome pathway	http://purl.obolibrary.org/obo/PW_0001441	gout pathway		
http://purl.obolibrary.org/obo/PW_0001460	amphotericin B pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0001459	amphotericin B drug pathway		
http://purl.obolibrary.org/obo/PW_0001461	amphotericin B pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0001459	amphotericin B drug pathway		
http://purl.obolibrary.org/obo/PW_0001544	altered heterotrimeric G protein mediated signaling pathway	http://purl.obolibrary.org/obo/PW_0001541	altered G protein mediated signaling pathway		
http://purl.obolibrary.org/obo/PW_0001549	diabetic angiopathy pathway	http://purl.obolibrary.org/obo/PW_0001548	diabetes complication pathway		
http://purl.obolibrary.org/obo/PW_0001585	vitamin A deficiency pathway	http://purl.obolibrary.org/obo/PW_0001584	avitaminosis pathway		
http://purl.obolibrary.org/obo/PW_0001668	3-hydroxyacyl-CoA dehydrogenase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001589	inborn error of metabolism pathway		
http://purl.obolibrary.org/obo/PW_0001700	urologic disease pathway	http://purl.obolibrary.org/obo/PW_0001699	urogenital disease pathway		
http://purl.obolibrary.org/obo/PW_0002178	skin disease pathway	http://purl.obolibrary.org/obo/PW_0001701	skin and connective tissue disease pathway		
http://purl.obolibrary.org/obo/PW_0002179	connective tissue disease pathway	http://purl.obolibrary.org/obo/PW_0001701	skin and connective tissue disease pathway		
http://purl.obolibrary.org/obo/PW_0001752	pyruvate decarboxylase deficiency pathway	http://purl.obolibrary.org/obo/PW_0001751	inborn error of pyruvate metabolism pathway		
http://purl.obolibrary.org/obo/PW_0001753	pyruvate dehydrogenase E1 deficiency pathway	http://purl.obolibrary.org/obo/PW_0001752	pyruvate decarboxylase deficiency pathway		
http://purl.obolibrary.org/obo/PW_0001754	pyruvate dehydrogenase E2 deficiency pathway	http://purl.obolibrary.org/obo/PW_0001752	pyruvate decarboxylase deficiency pathway		
http://purl.obolibrary.org/obo/PW_0001755	pyruvate dehydrogenase E3 deficiency pathway	http://purl.obolibrary.org/obo/PW_0001752	pyruvate decarboxylase deficiency pathway		
http://purl.obolibrary.org/obo/PW_0002420	altered phosphatidylinositol metabolic pathway	http://purl.obolibrary.org/obo/PW_0002419	altered glycerophospholipid metabolic pathway		
http://purl.obolibrary.org/obo/PW_0002515	tiaprofenic acid pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002514	tiaprofenic acid drug pathway		
http://purl.obolibrary.org/obo/PW_0002516	tiaprofenic acid pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002514	tiaprofenic acid drug pathway		
http://purl.obolibrary.org/obo/PW_0002529	magnesium salicylate pharmacokinetics pathway	http://purl.obolibrary.org/obo/PW_0002528	magnesium salicylate drug pathway		
http://purl.obolibrary.org/obo/PW_0002530	magnesium salicylate pharmacodynamics pathway	http://purl.obolibrary.org/obo/PW_0002528	magnesium salicylate drug pathway		
http://purl.obolibrary.org/obo/PW_0002623	glutathione antioxidant pathway	http://purl.obolibrary.org/obo/PW_0002622	endogenous antioxidant pathway		
http://purl.obolibrary.org/obo/PW_0002624	thioredoxin antioxidant pathway	http://purl.obolibrary.org/obo/PW_0002622	endogenous antioxidant pathway		
http://purl.obolibrary.org/obo/PW_0002625	peroxiredoxin antioxidant pathway	http://purl.obolibrary.org/obo/PW_0002622	endogenous antioxidant pathway		
http://purl.obolibrary.org/obo/PW_0000001	pathway				A pathway is a set of inter-connected  reactions and interactions whose delineation and scope are used as a model for exploring and studying, describing and understanding the working of and relationships between biomolecules within a context.
http://purl.obolibrary.org/obo/PW_0000024	inflammatory response pathway				Inflammation is the cellular response of the innate immune system to infection or injury. Sensing of infection by pattern recognition receptors triggers signaling cascades leading to the expression of mediator genes such as the pro-inflammatory cytokines.
http://purl.obolibrary.org/obo/PW_0000034	electron transport chain pathway				Those metabolic reactions whereby the electrons, derived from the oxidation of glucose and lipids or the degradation of amino acids, are passed to oxygen via a series of series of spatially separated complexes. The energy derived generates an electrochemical gradient that drives the synthesis of ATP. The coupling between the electron transport chain, also known as the respiratory chain, and the ATP biosynthetic pathway is known as oxidative phosphorylation. Under certain circumstances the two may be uncoupled.
http://purl.obolibrary.org/obo/PW_0000035	ATP biosynthetic pathway				Those metabolic reactions involved in the synthesis of adenosine triphosphate (ATP). ATP synthesis is coupled to the electron transfer or respiratory chain pathway which generates an electrochemical gradient that drives the phosphorylation of ADP. The coupling of the two pathways is called oxidative phosphorylation. Under certain circumstances however, the two may be uncoupled.
http://purl.obolibrary.org/obo/PW_0000038	Sterol, vitamin K, vitamine E and cartenoids  biosynthesis				OBSOLETE. Originally found at KEGG, the term has since been deleted.
http://purl.obolibrary.org/obo/PW_0000044	Duplicated Glutamate Metabolism term				OBSOLETE. Duplicated term. Use PW:0000027.
http://purl.obolibrary.org/obo/PW_0000060	long term potentiation				Long-term potentiation (LTP) is a strengthening of the synapse that can last from hours to days and months. It is thought to underlie information storage and constitute the cellular basis of learning and memory. LTP engages numerous cascades of events on either side of the synapse and is accompanied by changes in gene expression.
http://purl.obolibrary.org/obo/PW_0000061	long term depression				Long term depression is a weakening of a synapse that lasts hours to days. It results from either strong synaptic stimulation (as in the cerebellum) or to weak synaptic stimulation (as in the hippocampus), and engages several cascades.
http://purl.obolibrary.org/obo/PW_0000079	Duplicated Selenoamino acid metabolism term				OBSOLETE. Duplicated term. Use PW:0000133
http://purl.obolibrary.org/obo/PW_0000080	Duplicated term - Selenoamino acid metabolism				OBSOLETE. Duplicated term. Use PW:0000133
http://purl.obolibrary.org/obo/PW_0000084	Duplicated glutathione metabolism term				OBSOLETE. Duplicated term. Use PW:0000134
http://purl.obolibrary.org/obo/PW_0000087	G1 phase pathway				The series of events underlying the progression of the early cell cycle into the G phase and under the control of D-type cyclins together with Cdk4 and Cdk6. The formation of the pre-initiation replication complex takes place during this phase.
http://purl.obolibrary.org/obo/PW_0000088	G1/S transition pathway				The series of events underlying the transition from G1 into S phase and under the control of Cyclin E/A - Cdk2 and cyclin D-Cdk4/Cdk6 complexes and their regulators. Genetic alterations of this important transition point are frequent in human cancers.
http://purl.obolibrary.org/obo/PW_0000089	S phase pathway				The series of events underlying duplication of the hereditary material of the cell, forming two copies of each chromosome.
http://purl.obolibrary.org/obo/PW_0000090	G2 phase pathway				The series of events underlying the second 'gap' phase of the mitotic cell cycle - an interval between the completion of DNA synthesis and the beginning of mitosis, during which protein synthesis occurs.
http://purl.obolibrary.org/obo/PW_0000091	G2/M transition pathway				The series of events underlying the transition from the G2 phase into mitosis.
http://purl.obolibrary.org/obo/PW_0000092	M phase pathway				The series of events underlying mitosis (M phase), in turn comprised of several phases, involving nuclear division and cytokinesis and resulting in the formation of two daughter cells.
http://purl.obolibrary.org/obo/PW_0000093	M/G1 transition pathway				The series of events underlying progression out of mitosis and division into two daughter cells. It requires the inactivation of cyclinB-cdc2 by ubiquitin-dependent proteolysis.
http://purl.obolibrary.org/obo/PW_0000094	cell cycle checkpoint pathway				Those pathways involved in the control of cell cycle progression as well as its precision and fidelity.
http://purl.obolibrary.org/obo/PW_0000145	Metabolism of complex carbohydrates				OBSOLETE. Originally found at KEGG, the term has since been deleted
http://purl.obolibrary.org/obo/PW_0000155	phospholipid metabolic pathway				Those metabolic reactions involved in the synthesis, utilization and/or degradation of phospholipids - lipids containing phosphorus, including those with a glycerol backbone or a backbone of sphingosine or related substances. Phospholipids are the major form of lipid in the cell membrane.
http://purl.obolibrary.org/obo/PW_0000175	familial combined hyperlipidemia pathway				A possible subset of the metabolic syndrome, characterized  by features such as hypertriglyceridemia, age-dependent changes in plasma total cholesterol, overproduction of triglyceride-rich lipoproteins. Several metabolic and possibly other pathways deviate from their normal functioning.
http://purl.obolibrary.org/obo/PW_0000189	folate mediated one-carbon metabolic pathway				Folate mediated one-carbon metabolism represents the one-carbon transfer reactions important for de novo purine and thymidylate biosynthesis and for the remethylation of methionine in the methionine cycle and homocysteine metabolism. The methionine cycle also produces the major methyl donor for proteins, nucleic acids, lipids and other small molecules. The folate mediated one-carbon transfer and the folate cycle pathways are part of folate metabolism.
http://purl.obolibrary.org/obo/PW_0000193	N-Glycan degradation pathway				Those metabolic reactions involved in the degradation of N-Glycans. N-Glycans are found attached to the R-group nitrogen of asparagine.
http://purl.obolibrary.org/obo/PW_0000210	SMAD dependent signaling pathways				The core intracellular  signaling cascade mediated  by the TGF-beta superfamily. SMAD proteins function by carrying signals from the cell surface to the nucleus. There are eight vertebrate SMAD proteins and they are activated  by two types of  TGF-beta receptors in response to TGF cytokines binding.There are two known SMAD-dependent TGF-beta signaling pathways. SMAP pathways can also be activated via NGF signalign pathways
http://purl.obolibrary.org/obo/PW_0000231	Rap1 pathways				A very close relative of Ras, Rap1 mediated pathway  appears to control diverse processes such as modulation of growth and differentiation, secretion, integrin linked cell adhesion, morphogenesis.
http://purl.obolibrary.org/obo/PW_0000252	monoterpenoid biosynthetic pathway				Those metabolic reactions involved in the synthesis of monoterpenoid. Terpenoids are a large class of naturally-occurring organic chemicals. They are derived from five-carbon units and are modifed in manifold ways.
http://purl.obolibrary.org/obo/PW_0000362	the ion channels pathway				The acute hypoxic response is mediated through the activity of excitable cells via oxygen-sensing ion channels.
http://purl.obolibrary.org/obo/PW_0000399	remethylation pathway of homocysteine metabolism - cobalamin dependent				The predominant route of homocysteine remethylation to methionine that requires the 5-methyl tetrahydrofolate 1 carbon donor and as such, engages folate metabolism.
http://purl.obolibrary.org/obo/PW_0000400	transsulfuration pathway of homocysteine metabolism				The transulfuration pathway is one of the two routes of homocysteine metabolism. It allows for the transfer of sulfur from methionine to cysteine. 70% of cysteine is then converted to glutathione and the remainder ends up as either taurine or pyruvate and sulfate.
http://purl.obolibrary.org/obo/PW_0000401	remethylation pathway of homocysteine metabolism - cobalamin independent, betaine dependent				The route of homocysteine remethyation to methionine that mainly occurs in the liver and requires betaine as the methyl donor.
http://purl.obolibrary.org/obo/PW_0000474	coagulation cascade pathway				The coagulation cascade is the series of events proceeding via the tissue factor (extrinsic) or the contact activation (intrinsic) pathway and converging in the formation of fibrin clots. Several anticoagulation systems are in place to modulate the pathway. The coagulation cascade and the complement pathway of immune responses are connected in a cross talk.
http://purl.obolibrary.org/obo/PW_0000475	hemostasis pathway				Hemostasis is the response to blood vessel injury to prevent blood loss via platelet-mediated primary homeostasis and the secondary homeostasis of coagulation. The latter is a complex cascade which is triggered by the innate immune response and inflammation.
http://purl.obolibrary.org/obo/PW_0000477	natural anticoagulant pathway				The endogenous routes of inhibiting the coagulation cascade, collectively known as the natural anticoagulant pathways.
http://purl.obolibrary.org/obo/PW_0000481	fibrinolysis pathway				The steps leading to the activation of plasminogen and the subsequent breaking down of a fibrin clot - the product of the coagulation cascade.
http://purl.obolibrary.org/obo/PW_0000488	antigen processing pathway				Antigen processing pathway engages the proteosomal machinery in the cytosol, ER specific proteases as well as chaperones for loading the HMC class I molecules with the 8-10 amino acid peptides
http://purl.obolibrary.org/obo/PW_0000502	complement system pathway				The complement system is an important effector of innate and also of humoral adaptive immunity. It consists of three biochemical cascades that are differently initiated but share similar late steps and effector functions. The complement pathway and the coagulation cascade are connected in a cross talk.
http://purl.obolibrary.org/obo/PW_0000508	platelet aggregation pathway				The pathway involving the attachment of platelets to one another and leading to the formation of a thrombus. Platelet attachment can be induced by a variety of agents.
http://purl.obolibrary.org/obo/PW_0000574	pentose phosphate pathway - non-oxidative phase				The non-oxidative (circular) phase of the pentose phosphate pathway involves conversion of ribulose-5-phosphate to ribose-5-phosphate, important in the synthesis of nucleotides and nucleic acids, or of 3 or 6 carbon sugars.
http://purl.obolibrary.org/obo/PW_0000580	translation initiation pathway				Translation initiation is the first, the rate-limiting and the most regulated step of translation. It involves the formation of a scanning- competent small ribosomal subunit. Upon finding the initiation codon, scanning is stopped, the large 60S subunit joins, and an elongation-competent 80S ribosome is formed.
http://purl.obolibrary.org/obo/PW_0000581	translation elongation pathway				Translation elongation involves sampling of aminoacyl-tRNAs until a cognate tRNA is found followed by peptidyl transfer and translocation reactions. The iterative step continues until a stop codon is read or other events stall the ribosome.
http://purl.obolibrary.org/obo/PW_0000582	translation termination pathway				Translation termination occurs when a stop codon is read, followed by splitting of the ribosomal subunits and their recycling. Ribosome recycling also happens in the case of aberrantly stalled ribosomes due to features of the mRNA, absence of a stop codon or its premature presence. In these cases mRNA surveillance mechanisms trigger appropriate mRNA decay pathways.
http://purl.obolibrary.org/obo/PW_0000592	iron storage pathway				The main storage system for iron is represented by ferritin. The iron entering the cell is in its ferrous Fe(II) form. It is oxidized to the stored ferric Fe(III) by the oxidase activity of ferritin heavy chain. Neuromelanin pigment, abundant in the dopaminergic neurons of the substantia nigra, is known as a metal chelator and is the storage form of iron in these cells.
http://purl.obolibrary.org/obo/PW_0000636	protein exocytosis pathway				The protein exocytosis pathway involves trafficking of protein-containing vesicles to their final destination. It consists of several steps: budding, transport mediated by microtubule and actin associated molecular motors, tethering/docking and fusion with target membrane. Members of the Arf and Rab family of Ras superfamily are involved in the control of exit from Golgi and exocytic route, respectively. These are two main types of protein exocytosis which also represented in the more general exocytosis thereby material is delivered outside the cell.
http://purl.obolibrary.org/obo/PW_0000660	hematopoiesis pathway				Hematopoiesis refers to the formation of blood cellular components. All components are derived from the hematopoietic stem cells residing in the marrow. A great amount of new blood cells needs to be produced daily to maintain steady-state levels of circulation.
http://purl.obolibrary.org/obo/PW_0000674	insulin secretion pathway				Insulin secretion by pancreatic beta-cells is an important aspect of glucose homeostasis. A major component of glucose-stimulated insulin secretion is represented by the route dependent on the ATP-sensitive potassium channels. However, other contributions are also likely to promote insulin secretion.
http://purl.obolibrary.org/obo/PW_0000675	glucagon secretion pathway				Glucagon is secreted by pancreatic alpha cells; the mechanisms of its release in response to low glucose levels are poorly understood.
http://purl.obolibrary.org/obo/PW_0000825	antigen processing and presentation pathway				The pathways of antigen processing and presentation assure the generation of peptides that have the structural attributes necessary for the association with and their placement near major histocompatibility complex (MHC) molecules. Protein antigens present in vesicular compartments generate class II peptides, those in cytosol, class I.
http://purl.obolibrary.org/obo/PW_0001066	ribosome biogenesis pathway				The pathway of ribosome biogenesis starts with the transcription of rRNA precursors, and involves the co-transciptional events of pre-rRNA processing and the assembly of pre-ribosomal particles. The maturation of pre-40S and pre-60S particles follows independent routes. Once in the cytoplasm, additional steps yield the mature, translation-competent ribosome. Alterations in the pathway result in specific phenotypes collectively known as ribosomopathies.
http://purl.obolibrary.org/obo/PW_0001072	synaptic vesicle cycle pathway				The cycle of synaptic vesicle exocytosis and neurotransmitter release and the subsequent endocytosis and recycling of synaptic vesicles at nerve terminals.
http://purl.obolibrary.org/obo/PW_0001076	special amino acid metabolic pathway				Those metabolic reactions involving special amino acids. The special amino acids include cysteine whose side chain contains a sulfhydryl group, glycine whose side chain is a hydrogen atom and proline whose side chain bends to form a ring and hose rigidity limits the folding abilities of proteins around proline residues.
http://purl.obolibrary.org/obo/PW_0001157	ether lipid metabolic pathway				Those metabolic reactions involved in the synthesis, utilization and/or degradation of ether lipids. On these molecules one or more of the carbon atoms of glycerol is bonded to an alkyl group via an ether linkage.
http://purl.obolibrary.org/obo/PW_0001159	aminoacyl-tRNA biosynthetic pathway				Aminoacyl-tRNA, or transfer RNA (tRNA) carries amino acids to ribosomes and is part of the translation pathway. tRNAs are specific for the amino acids with which they are associated. Their synthesis involves adenylation of the amino acid followed by its transfer; both steps require ATP.
http://purl.obolibrary.org/obo/PW_0001207	folate cycle metabolic pathway				The folate cycle metabolic pathway sums up the uptake and transport of folates, the processing and interconversion reactions of folate compounds. The folate cycle and the folate mediate one-carbon transfer pathways are part of folate metabolism.
http://purl.obolibrary.org/obo/PW_0001274	RNA polymerase II transcription initiation pathway				RNA polymerase II and a set of general and specific transcription factors assemble as a large pre-initiation complex which undergoes a series of transformations before transcription proceeds. Promoter recognition and subsequent initiation of transcription are dependent upon the presence of these transcription factors. Activators and repressors impact upon transcription at these early stages.
http://purl.obolibrary.org/obo/PW_0001294	eicosanoid signaling pathway				Eicosanoids, derived from omega-3 or omega-6 fatty acids, are represented by the leukotriene and prostanoid classes of which the latter is represented by several families. Some can act as endogenous ligands for members of the peroxisomal proliferator-activated nuclear receptors (PPARs). Once activated, PPARs heterodimerize with the retinoid X receptor (RXR) and modulate the expression of target genes.
http://purl.obolibrary.org/obo/PW_0001324	mitochondrial aminoacyl-tRNA biosynthetic pathway				Aminoacyl-tRNA, or transfer RNA (tRNA) carries amino acids to ribosomes and is part of the translation pathway. tRNAs are specific for the amino acids with which they are associated. Their synthesis involves adenylation of the amino acid followed by its transfer; both steps require ATP. There are 22 tRNA genes encoded by the mitochondrial genome. Mutations in these genes have been implicated in a number of disorders and may affect various steps of tRNA biosynthesis.
http://purl.obolibrary.org/obo/PW_0001331	RNA polymerase II transcription elongation pathway				RNA polymerase II transcription elongation commences when the nascent transcript reaches about 25 residues. Some general transcription factors are released and the RNA polymerase II carries out elongation of the pre-mRNA transcript and proofreading. Various regulators control early elongation, proximal promoter pausing and full elongation proceedings. Nascent mRNA processing, splicing and alternative splicing are co-occurring.
http://purl.obolibrary.org/obo/PW_0001332	RNA polymerase II transcription termination pathway				Termination of transcription is important for partitioning the genome and maintaining adequate expression of neighboring genes.
http://purl.obolibrary.org/obo/PW_0001480	kinin signaling pathway				The active kinin peptides generated by the kallikrein-kinin cascade - bradykinin, kallidin and their C-terminal processed metabolites, signal via two G-protein coupled (GPCR) receptors. The two receptors employ similar signaling pathways but also exhibit distinct patterns. Type 1 receptor is inducible, type 2 is ubiquitous and can form heterodimers with angiotensin II receptors.
http://purl.obolibrary.org/obo/PW_0001528	prostacyclin signaling pathway				Prostacyclin is one of several families of prostanoids, eicosanoids derived from omega-3 or omega-6 fatty acids. Prostacyclin, also known as prostaglandin I2 signaling engages one receptor to mediate a vasodilator effect and modulate immune responses.
http://purl.obolibrary.org/obo/PW_0001570	RNA polymerase I transcription initiation pathway				Initiation of transcription from the bipartite rDNA repeats requires the assembly of the Pol I preinitiation complex (PIC) and subsequent recruitment of the polymerase.
http://purl.obolibrary.org/obo/PW_0001571	RNA polymerase I transcription elongation pathway				Subunits of Pol I have elongation and hydrolysis capabilities. However, additional trans-acting factors are involved in Pol I elongation steps.
http://purl.obolibrary.org/obo/PW_0001572	RNA polymerase I transcription termination pathway				Termination of transcription by the polymerase I system requires the recruitment of specific factors to particular DNA elements.
http://purl.obolibrary.org/obo/PW_0001734	adrenergic beta receptor drug pathway - beta agonist				The pharmacokinetics and pharmacodynamics pathway of adrenergic beta receptors drugs - beta-agonists. Adrenergic beta receptors, in response to epinephrine or norepinephrine couple to the Gs alpha subunit of heterotrimeric G protein to elicit several responses. Beta-agonists are used to stimulate these responses. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.
http://purl.obolibrary.org/obo/PW_0001961	mitochondria dynamics pathway				The interplay of mitochondria fission and fusion and mitochondria trafficking to properly respond to cellular needs. Mitochondria tend to form reticular networks, regulated through the coordination of fission, fusion and redistribution.
http://purl.obolibrary.org/obo/PW_0001998	mitochondria fission pathway				The events leading to fission of mitochondria. Fission allows mitochondria to divide and grow and also to isolate and remove defective organelles.
http://purl.obolibrary.org/obo/PW_0001999	mitochondria fusion pathway				The events leading to fusion of mitochondria.
http://purl.obolibrary.org/obo/PW_0002020	nervous system lysosomal storage disease pathway				The lysosomal storage disease pathways affecting the nervous system.
http://purl.obolibrary.org/obo/PW_0002144	carbamoyl phosphate synthase I deficiency pathway				An autosomal recessive disorder resulting from alterations in the urea cycle pathway and due to defects in the hepatic mitochondrial enzyme carbamoyl phosphate synthetase 1.
http://purl.obolibrary.org/obo/PW_0002185	lysine metabolic pathway				Those metabolic reactions involved in the synthesis, utilization and/or degradation of lysine, an essential amino acid.
http://purl.obolibrary.org/obo/PW_0002219	urea cycle disease pathway				Conditions resulting from alterations in the urea cycle pathway.
http://purl.obolibrary.org/obo/PW_0002399	endosomal sorting pathway				The endosomal system is at the crossroads of endocytosis and secretory pathways. As the endosome goes through the maturation process various trafficking events are initiated. Material internalized from the plasma membrane or synthesized is sorted along two routes: a degradative pathway to the lysosome or an export pathway. Cargo delivery to the plasma membrane is via the recycling export pathway while delivery to the trans Golgi network (TGN) is via the retrograde export pathway. An important system for selective cargo sorting is the retromer.
http://purl.obolibrary.org/obo/PW_0002409	endosome maturation pathway				Early to late endosome maturation pathway is a state of flux associated with changes in component composition, such as particular Rab proteins and lipids such as phosphoinositides, increase in the number of intraluminal vesicles, luminal acidification and movement along microtubules. Along this continuum, sorting and trafficking of cargo takes place.
http://purl.obolibrary.org/obo/PW_0002414	endosomal pathway				In the endosomal pathway, endosomal maturation couples to sorting of material and its appropriate delivery or degradation, promoted by specific transport along and dynamics of cytoskeleton and associated molecular motors.
http://purl.obolibrary.org/obo/PW_0002521	thyroid hormone biosynthetic pathway				The major thyroid hormones thyroxine (T4) or tetraidothyronine and triiodothyronine (T3) are the major thyroid hormones produced via processing of thyroglobulin precursor. T3 is the active hormone and is derived from T4 by the action of deiodinases.
http://purl.obolibrary.org/obo/PW_0002550	malonic aciduria pathway				A rare acidosis resulting from defects in malonyl-CoA decarboxylase enzyme.
http://purl.obolibrary.org/obo/PW_0002633	iron utilization pathway				Heme and iron-sulfur cluster (ISC) biosynthetic pathways are the major routes of iron utilization.
http://purl.obolibrary.org/obo/PW_0002637	mitochondrial iron-sulfur cluster export pathway				The core mitochondrial iron-sulfur assembly and export pathways are crucial for the assembly of cytosolic and nuclear Fe-S proteins. Despite knowledge of the export system, the  species that is actually transported remains to be determined. The exported molecule is usually termed X-S.
http://purl.obolibrary.org/obo/PW_0002735	RNA polymerase I promoter clearance pathway				The series of events mediating the transition from the initiation to the elongation phases of transcription by RNA polymerase I, generally including a conformational change from the initiation conformation to the elongation conformation. Promoter clearance often involves breaking contact with transcription factors involved only in the initiation phase and making contacts with elongation specific factors.
http://purl.obolibrary.org/obo/PW_0002736	RNA polymerase II promoter clearance pathway				The series of events mediating the transition from the initiation to the elongation phases of transcription by RNA polymerase II, generally including a conformational change from the initiation conformation to the elongation conformation. Promoter clearance often involves breaking contact with transcription factors involved only in the initiation phase and making contacts with elongation specific factors.
http://purl.obolibrary.org/obo/PW_0002737	fatty-acyl-CoA biosynthetic pathway				The chemical reactions resulting in the formation of a fatty-acyl-CoA, any derivative of coenzyme A in which the sulfhydryl group is in thioester linkage with a fatty-acyl group.
http://purl.obolibrary.org/obo/PW_0002738	nucleosome assembly pathway				The events involved in the aggregation, arrangement and bonding together of a nucleosome, the beadlike structural units of eukaryotic chromatin composed of histones and DNA.
http://purl.obolibrary.org/obo/PW_0002739	insulin receptor recycling pathway				The pathway that results in the return of an insulin receptor to an active state at the plasma membrane. An active state is when the receptor is ready to receive an insulin signal. Internalized insulin receptors can be dephosphorylated and recycled to the plasma membrane or sorted to lysosomes for protein degradation.
http://purl.obolibrary.org/obo/PW_0002740	wax biosynthetic pathway				The chemical reactions resulting in the formation of wax by plants and animals, which includes C16 and C18 fatty acids.
http://purl.obolibrary.org/obo/PW_0002741	very-low-density lipoprotein assembly pathway				Those metabolic reactions involved in the two-step aggregation and arrangement of proteins and lipids in the liver to form a very-low-density lipoprotein particle.
http://purl.obolibrary.org/obo/PW_0002720	xylulose 5-phosphate biosynthetic pathway				Those metabolic reactions and pathways resulting in the formation of xylulose 5-phosphate.
http://purl.obolibrary.org/obo/PW_0002727	mitotic telophase pathway				The series of events underlying mitotic telophase, which follows anaphase, during which the chromosomes arrive at the poles of the cell and the division of the cytoplasm starts.
http://purl.obolibrary.org/obo/PW_0002728	mitotic prophase pathway				The series of events underlying mitotic prophase, which is the first stage of mitosis, during which chromosomes condense and the two daughter centrioles and their asters migrate toward the poles of the cell.
http://purl.obolibrary.org/obo/PW_0002729	mitotic prometaphase pathway				The series of events underlying mitotic prometaphase in higher eukaryotes, which follows mitotic prophase, during which the nuclear envelope is disrupted and breaks into membrane vesicles, and the spindle microtubules enter the nuclear region. Kinetochores mature on each centromere and attach to some of the spindle microtubules. Kinetochore microtubules begin the process of aligning chromosomes in one plane halfway between the poles.
http://purl.obolibrary.org/obo/PW_0002730	mitotic metaphase/anaphase transition pathway				The series of events underlying the progression of a cell from metaphase to anaphase during mitosis, triggered by the activation of the anaphase promoting complex by Cdc20/Sleepy homolog, which results in the degradation of cyclin B and securin.
http://purl.obolibrary.org/obo/PW_0002733	translation initiation complex formation pathway				Joining of the large ribosomal subunit with the translation preinitiation complex, with release of IF2/eIF2 and IF3/eIF3 or IF5B/eIF5B. This leaves the functional ribosome at the AUG, with the methionyl/formyl-methionyl-tRNA positioned at the P site.
http://purl.obolibrary.org/obo/PW_0002673	mitotic metaphase pathway				The series of events underlying mitotic metaphase, the cell cycle phase following prophase or prometaphase, during which chromosomes become aligned via spindle fibers on the equatorial or metaphase plate of the cell. Such an organization helps to ensure that later, when the chromosomes are separated, each new nucleus that is formed receives one copy of each chromosome. 
http://purl.obolibrary.org/obo/PW_0002674	mitotic anaphase pathway				The series of events underlying mitotic anaphase, following metaphase, during which the chromosomes separate and migrate towards the poles of the spindle at the opposite sides of the cell. The movement of the chromosomes is facilitated by a combination of kinetochore movement along the spindle microtubules and through the physical interaction of polar microtubules.
http://purl.obolibrary.org/obo/PW_0002703	hepoxilin biosynthetic pathway				
http://purl.obolibrary.org/obo/PW_0000000	term zero				
http://purl.obolibrary.org/obo/PW_0000207	central obesity with hypertension pathway				
http://purl.obolibrary.org/obo/PW_0000222	UDP-N-acetylgalactosamine biosynthetic pathway				
http://purl.obolibrary.org/obo/PW_0000223	UDP-N-acetylglucosamine biosynthetic pathway				
http://purl.obolibrary.org/obo/PW_0000430	killed term				
http://purl.obolibrary.org/obo/PW_0000431	another killed term				
http://purl.obolibrary.org/obo/PW_0000496	exogenous pathway				
http://purl.obolibrary.org/obo/PW_0000497	endogenous pathway				
http://purl.obolibrary.org/obo/PW_0000649	<new term>				
http://purl.obolibrary.org/obo/PW_0000695	<new term>				
http://purl.obolibrary.org/obo/PW_0001325	mitochondrial ribosome biogenesis pathway				
http://purl.obolibrary.org/obo/PW_0001575	RNA polymerase III transcription initiation pathway				
http://purl.obolibrary.org/obo/PW_0001576	RNA polymerase III transcription elongation pathway				
http://purl.obolibrary.org/obo/PW_0001577	RNA polymerase III transcription termination pathway				
http://purl.obolibrary.org/obo/PW_0001698	liver disease pathway				
http://purl.obolibrary.org/obo/PW_0001736	adrenergic beta receptor agonist drug pathway				
http://purl.obolibrary.org/obo/PW_0001934	Nonketotic hyperglycinemia disease pathway				
http://purl.obolibrary.org/obo/PW_0001937	<new term>				
http://purl.obolibrary.org/obo/PW_0002685	mitotic sister chromatid segregation pathway				
http://purl.obolibrary.org/obo/pw#part_of	part_of